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Abstract: 
Title: Proteomic Characterisation of Clonal Populations from a Human Lung 
Carcinoma Cell Line  
Author: Shane Kelly 
Lung cancer is the leading cause of cancer related deaths worldwide. Although 
treatment strategies have improved, overall survival has not significantly increased. 
Studies have revealed a heterogeneous subclonal architecture to lung cancer, which 
contributes to the persistence of the disease by allowing the tumour to metastasise to 
distant sites, utilising the different phenotypic characteristics of the heterogeneous 
population.  
The DLKP cell line was established from a lymph node metastasis of a primary 
lung tumour and is described as a poorly differentiated squamous lung carcinoma cell 
line. This cell line is comprised of three distinct subpopulations: DLKP-SQ, DLKP-M 
and DLKP-I, each with well-defined phenotypes. In vitro studies have shown DLKP-M 
to be extremely invasive relative to DLKP-SQ, whereas the latter cell line shows high 
anoikis resistance relative to DLKP-M. As the cells originate from the same tumour, 
these varied phenotypic characteristics make DLKP a particularly useful model for the 
study of cellular heterogeneity in lung cancer.  
Quantitative label-free LC-MS/MS was used to analyse the DLKP cell line and 
its subpopulations at a proteomic level. This resulted in a cohort of significantly 
differentially expressed proteins between the cell lines. From this, three differentially 
expressed proteins; Shootin-1 (highly expressed in DLKP-SQ), MARCKS (highly 
expressed in DLKP-M), and Desmoglein-3 (highly expressed in DLKP-I) were chosen 
for a series of follow up studies. The expression patterns for these proteins were 
validated, and functional cell-based assays were carried out to establish the role of each 
protein in their respective clone. MARCKS and Desmoglein-3 were found to reduce cell 
motility in vitro upon transient protein knockdown using siRNA. Co-
immunoprecipitation of Desmoglein-3 revealed a potential interaction with 
mitochondrial proteins, a novel finding in lung cancer. Shootin-1, a relatively 
uncharacterised protein, was also found to reduce cell motility upon protein knockdown. 
Shootin-1 was also found to have novel potential binding partners, such as 
Semenogelin-1. Shootin-1 and Desmoglein-3 expression were affected by co-culture of 
the clonal subpopulations, highlighting the heterogeneous nature of the original DLKP 
cell line and the influences this has on protein expression. 
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1.1. Lung Development 
The primary function of the lungs is to exchange carbon dioxide in the 
cardiovascular system with oxygen in the external environment. This organ also carries 
out important secondary processes such as the regulation of blood pressure, and the 
filtering of blood for gas bubbles and blood clots. The entire inner surface of the lung is 
exposed to the external environment, and therefore faces many challenges when dealing 
with associated problems which arise from this. These include temperature changes, 
irritation by allergens, and constant bombardment of particulate matter. As a result, the 
lungs are a complex system comprised of multiple cell lineages, capable of carrying out 
all the functions of the lungs while dealing with the challenges mentioned above.  
The lungs are an unnecessary organ in utero; however they must be developed 
to such an extent that they function immediately following birth. The development of 
the lung is a complex multistage process which involves growth factors, transcription 
factors and the extracellular matrix. Lung development can be divided into five main 
stages. 
The embryonic stage of lung development begins with the appearance of a 
groove in the ventral lower pharynx. A bud develops in the ventral wall of the foregut 
and is known as the true lung primordium. The location of this bud is determined by 
signals from the surrounding mesenchyme, in particular from fibroblast growth factors 
(Al Alam et al. 2015). This bud undergoes further subdivision into the two main bronchi 
and the asymmetry of the bronchi present in adults is developed at this stage.  
The pseudoglandular stage takes place from the 6th to the 16th week of prenatal 
lung development. Epithelial tubes lined with cuboidal epithelial cells undergo repeated 
branching to form primordial airways, and the lungs resemble exocrine glands at this 
stage. Separation occurs between the epithelium and the mesoderm by the development 
of a basement membrane. The bronchial tree is coated by cuboidal epithelial cells, 
which are the precursors of the ciliated epithelium and secretory cells. Neuroendocrine 
cells are the first type of cells to differentiate from the lung epithelium early on during 
this stage. They grow in clusters known as neuroepithelial bodies (NEBs) and are 
usually found at junctions of broncioalveolar ducts and airway bifurcations (Linnoila 
2006, Song et al. 2012). This is followed by the development of ciliated cells, then 
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mucus secreting cells, and submucosal glands. At this stage, basal cells begin to 
differentiate; however mature basal cells are the last mature cell type to appear in the 
epithelium.  
The canalicular stage (16th week-26th week) is characterised by the development 
of basic structures of the gas-exchanging parts of the lungs, vascularisation, and the 
formation of primordial alveoli called the terminal saccules. Invasion of capillaries into 
the mesenchyme occurs at this stage, and forms the foundation for the later exchange of 
gases. Differentiation of type I and type II alveolar epithelial cells (pneumocytes) occurs 
during this stage and arise from the undifferentiated cuboidal epithelial cells. From the 
cubic type II pneumocytes develop the flattened type I pneumocytes, and this is the 
beginning of alveolar epithelium development (Desai, Brownfield and Krasnow 2014). 
The saccular stage (26th week – Birth) is the time during which alveolar ducts 
and air sacs are developed. These air sacs develop on the terminal bronchioli which are 
the last subdivision of the passages which supply air to the lungs. Capillaries bulge into 
the thin epithelial lining of these sacs which are lined by type I and type II 
pneumocytes. Type I cells are numerous, covering ~95% of the alveolar surface. Type I 
cells are squamous and unable to replicate, and are involved in the process of gas 
exchange between alveoli and blood. Type II cells are scattered across the alveolar 
surface and represent ~ 5% of the total surface cell population. They function to secrete 
pulmonary surfactant which is critical to reduce the surface tension within alveoli 
allowing the lungs to expand, and to reduce fluid accumulation and keep epithelial 
surfaces dry (Wright 2004). In the event of damage to the epithelium, type II cells can 
differentiate into type I to compensate. 
The alveolar stage ranges from the later stages of fetal development up to 
approximately 8 years of age. At birth, roughly one third of the alveoli in the lungs are 
fully developed. The remaining underdeveloped alveoli are present in their beginning 
forms; however these will continue to enlarge and expand until completion at 
approximately 3 years of age. New alveoli continue to be generated and increase up to 
10 years of age. 
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1.1.1. Epithelial Cells of the Lung: 
There are a number of different cell types in the developed lung which arise 
from what is believed to be a common stem cell. The upper respiratory airway is 
classified as the ciliated pseudostratified columnar epithelium, and is so called due to 
the multiple cell types which comprise this epithelial layer. Though several cell types 
are present in this layer, they all make contact with the basal layer, and it is therefore 
classified as pseudostratified. There are three main epithelial cells which make up this 
layer: Goblet cells; ciliated cells; and basal cells. 
Goblet cells and ciliated cells are terminally differentiated epithelial cell types. 
They are located in the upper respiratory airways and work together to protect and clean 
the lung from environmental particulate matter as well as microorganisms such as 
fungal spores, bacteria and viruses. Goblet cells are columnar epithelial cells and are so 
called due to their shape which resembles a wine goblet. They contain membrane-bound 
mucous granules and their primary function is to secrete mucous as a method of 
maintaining the lung. The mucous helps to trap particles and pathogens which enter the 
airway, and also functions to maintain moisture in the epithelial layer. Goblet cells work 
together with ciliated cells, which are also columnar epithelial cells containing cilia 
protrusions. They sweep the mucous secretions of the goblet cells which have trapped 
undesirable matter and move it up and out of the airway towards the mouth, where it is 
swallowed or expelled from the body (Stannard and O'Callaghan 2006). 
Basal cells are small cuboidal cells which are attached to the basal lamina. It 
was originally thought these cells have a primary role in adhering columnar epithelial 
cells to the basal lamina. Basal cells attach to the goblet and ciliated cells through 
desmosomes, and they also attach directly to the basal lamina through hemi-
desmosomes. Both goblet and ciliated cells do not form desmosomal structures with the 
basal lamina, therefore it was thought that basal cells serve to anchor the ciliated 
pseudostratified columnar epithelium to the basal lamina through these interactions 
(Evans and Plopper 1988).  
Basal cells are also known to be a stem cell population of the lung epithelium. 
These cells differentiate and mature last during the pseudoglandular stage of lung 
development as previously mentioned; therefore it is clear that they are not the 
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precursors of the other epithelial cell types. However, studies have shown that they have 
the ability to differentiate into other epithelial cell types under certain circumstances. A 
number of these studies examined the role of basal cells in denuded sections of the 
upper airway in rat tracheas. They found that basal cells are capable of proliferating and 
restoring a fully differentiated mucociliary and functional epithelium (Randell et al. 
1991, Hajj et al. 2007, Rock, Randell and Hogan 2010).  
Club cells are found in the small airways (bronchioles) of the lung and are 
known as exocrine cells. They function to protect the ciliated epithelium through the 
secretion of various substances such as glycosaminoglycans, and others similar to the 
surfactant secreted by type II alveolar cells. Club cells have been found to be associated 
with neuroendocrine cells. After the induced death of club cells by naphthalene injury, 
the only remaining club cells were found to be located bear neuroepithelial bodies 
(NEBs) at the broncioalveolar duct junction. These cells were found to have the ability 
to restore damaged lung epithelium, and the study led to the hypothesis that NEBs aid in 
club cell regeneration through paracrine signalling, and maintain a stem cell niche in 
this way (Reynolds et al. 2000a, Reynolds et al. 2000b). 
Neuroendocrine cells are known as Pulmonary Neuroendocrine cells (PNECs) 
when they are present in the lung. As previously mentioned, these are the first type cells 
to differentiate in the developing lung. Here, they appear as solitary cells or in clusters 
as neuroepithelial bodies (NEBs). They are a distinct cell population of airway epithelial 
cells which display both endocrine and paracrine secretory mechanisms associated with 
nerve fibres. They synthesise and secrete a number of bioactive substances such as 
serotonin, calcitonin gene-related peptide and the mitogen bombesin (Van Lommel 
2001). PNECs acting via their secretions are thought to function as local regulators of 
lung growth and differentiation, and bombesin has been shown to be involved in lung 
maturation (Aguayo et al. 1994).  
PNECs have been found to share morphological features with cells of the 
nervous system and also cells from neuroendocrine carcinomas such as small cell lung 
carcinoma (Gu et al. 2014). A common protein expressed in neuronal cells and PNECs 
is ASH1, which is known to be essential for neuronal cell commitment and 
differentiation.  Selectively expressed by PNECs, this protein has been has been found 
to be expressed by a range of lung cancers with neuroendocrine features (Westerman et 
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al. 2002). Inhibition of ASH1 expression has been shown to suppress growth of lung 
cancer cells which express it, potentially highlighting it as a therapeutic target (Osada et 
al. 2005).  
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1.2. Lung Cancer 
Lung cancer is the fourth most common cancer in Ireland with approximately 
2000 new cases diagnosed each year, and is the leading cause of cancer related death in 
this country (www.ncri.ie). In the United States, there were approximately 221,200 new 
cases of lung cancer diagnosed, and accounts for 13% all new cancers. Each year, more 
people die of lung cancer than of colon, breast, and prostate cancers combined. 
Lung cancer is the abnormal growth of cells in one or both of the lungs. The 
abnormal cells are termed ‘cancerous’, and are caused by DNA damage which trigger 
the cells to divide continuously. Lung cancer cells usually originate in the epithelial 
lining of the lung and grow abnormally fast relative to non-cancerous cells and do not 
undergo apoptosis like healthy cells. Highly proliferative cancer cells eventually 
become so abundant they form tumours within the lung tissue. The increasing mass of 
these tumours restrict the ability of the lungs to provide the bloodstream with 
oxygenated blood, eventually resulting in death. In addition, cancerous cells can 
metastasise to other parts of the body, forming new tumours and significantly 
contributing to disease progression.  
Lung cancer is classified based on histological grading by microscopic 
analysis. The classification of lung cancer type is crucial to predict the outcome of the 
disease and to determine the proper management and therapeutic strategies. Two broad 
classes of lung cancer have been distinguished: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC). These two classes refer to primary lung cancer 
types and both behave quite differently. SCLC accounts for approximately 12% of all 
lung cancers, and is so called because the cancer cells are small. SCLC makes up 
approximately 13-15% of lung cancer cases worldwide and is characterised as being 
highly malignant with rapid growth and widespread metastasis. Treatment for this type 
of cancer is usually chemotherapy combined with radiotherapy. Over 70% of patients 
who present with SCLC have already developed secondary metastasis and despite 
extensive research over the last 30 years, no significant improvement in disease 
outcome has been achieved with the 5-year survival rate at < 7% (Jemal et al. 2010).  
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NSCLC makes up 87% of all lung cancers and this type is further subdivided 
into three subtypes of primary lung cancer which all behave in a similar way: 
Adenocarcinoma (AD); squamous cell carcinoma (SCC); and large cell carcinoma 
(LCLC). NSCLC is usually treated by surgical resection or a combination of surgery 
and chemotherapy depending on the stage of the disease, of which there are four. The 
five year survival rate ranges from 65% for Stage 1 to 7% for Stage 4.  This form of 
lung cancer is the leading cause of cancer death, and many patients are beyond the 
curable stage at diagnosis. 
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1.2.1. Classification of Lung Cancer 
Carcinomas may be described as well-differentiated, moderately-differentiated 
and poorly differentiated, and these classifications are based on microscopic evaluation 
of the cells by a histopathologist. Differentiation refers to how developed the cancer 
cells are within a tumour with regard to their morphology and growth rate, and how 
well they resemble their tissue of origin. Well-differentiated cells resemble normal 
surrounding cells, spreading and growing at a relatively slow rate. Tumours of this type 
tend to grow slowly and have a better prognosis. Poorly-differentiated cells bear 
minimal resemblance to the cells from which they arose and grow at a much faster rate. 
These tumour types are the most aggressive and have a poor prognosis. Moderately-
differentiated tumours have features which are intermediate to the differentiation 
categories mentioned above. Differentiation classification refers to the staging system 
mentioned previously with Stage 1 being well-differentiated, Stage 2 being moderately-
differentiated and Stage 3-4 being poorly differentiated. 
As previously mentioned, there are two broad classes of lung cancer: SCLC 
and NSCLC. Within NSCLC there are three further subtypes: Adenocarcinoma; 
Squamous cell carcinoma; and Large cell carcinoma.  
 
1.2.1.1. Non-Small Cell Carcinoma 
Adenocarcinoma (AD) accounts for approximately 40% of lung cancer cases 
and is the most common form with ~500,000 cases presented annually. The tumour type 
is described as highly heterogeneous and is highly associated with smoking, now the 
leading form of cancer caused by this habit.  AD is usually located around the periphery 
of the lungs relative to other cancers of the lung, and it is thought this development is 
related to the deep inhalation of tobacco smoke into the lungs. However, it is also the 
subtype which is presented most commonly in people who do not smoke. This cancer 
starts in early versions of glandular cells which would normally secrete substances such 
as mucin. This mucin is used as a marker in poorly-differentiated AD to verify the 
presence of these cancerous cells (Travis et al. 2013). AD does not respond well to 
chemotherapy or radiotherapy, and is therefore usually treated by resection or 
lobectomy. 
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Squamous cell carcinoma (SCC) is the second-most common type of cancer 
and accounts for about 30% of all cases of non-small cell lung cancer. Most cases of 
SCC begin in the central area of the lungs and are referred to epidermoid carcinomas. 
Typically arising from the bronchus, these tumour types invade the surrounding lung 
parenchyma and can extend into the chest wall (Miyazaki et al. 2011). Tumours can be 
very large and tend to undergo central necrosis. Cavitation is a frequent finding in 
primary lung SCC but can also be encountered in metastatic SCC and this process is 
secondary to tumour necrosis. In other instances, SCC can have a central scar with 
peripheral growth of tumour. SCC is characterised by intercellular bridging and the 
keratinisation of individual cells, depending on the degree of differentiation. Four 
subtypes are recognised: papillary, small-cell, clear-cell, and basaloid (Perez-Moreno et 
al. 2012). This slow growing tumour type can take many years become invasive, and the 
most common sites of metastasis are regional lymph nodes, adrenal glands, brain, bone 
and liver. SCC has a better prognosis than AD if they are at the same stage of 
development (Chansky et al. 2009). 
 
Large cell Carcinoma (LCC) is the least common form of lung tumour and 
account for approximately 10-15% of all lung cancers. They are malignant epithelial 
tumours with large nuclei, abundant cytoplasm and well defined cell borders. Most 
LCCs grow without evidence of glandular or papillary differentiation, and have no 
distinguishing features which can be discerned by light microscopic examination. Risk 
of LCC increases in those with a history of tobacco smoking, with a relative risk of 2.3 
compared to never-smokers which increases to 3.6 if smoking duration is > 40 years 
(Kenfield et al. 2008). Tumours of LCC generally start in the outer regions of the lung 
and grow rapidly. This causes fluid to develop in the lining of the lung which can result 
in what is known as a pleural effusion. Diagnosis of LCC is performed using a 
‘diagnosis of exclusion’ method, where the tumour demonstrates none of the 
morphological features of AD, SCC or SCLC (Travis et al. 2013). Another clinically 
relevant subtype of LCC is large cell neuroendocrine carcinoma (LCNEC) which 
displays immunohistochemical and morphological features common to both 
neuroendocrine tumours and LCCs. Diagnosis of this subtype is critical as it has a much 
poorer prognosis compared to other forms of NSCLC (Fernandez and Battafarano 
2006). 
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1.2.1.2. Small Cell Lung Cancer 
Small cell carcinoma is a type of aggressive and malignant cancer which most 
commonly arises in the lung. It is also known as oat cell carcinoma due to its 
appearance under the microscope of cells with a flat shape and very little cytoplasm. It 
is a cancer which accounts for approximately 13-15% of all lung cancers and in this 
form is described as a highly aggressive neuroendocrine malignancy (Nishino et al. 
2011). The majority of patients present with the metastatic form of the disease upon 
diagnosis, therefore surgical resection of rarely an option. The lung is the most common 
site of origin of small cell carcinoma in the body and more than 95% of cases occur in 
that location. Small cell carcinomas which develop outside of the lung in areas such as 
prostate, cervix and oesophagus are extremely rare (Walenkamp, Sonke and Sleijfer 
2009).  
There are two categories of SCLC: small cell lung carcinoma (SCLC) and combined 
small cell lung carcinoma (c-SCLC) 
 
Small Cell Lung Carcinomas are a highly aggressive form of lung cancer and 
are considered a subtype of neuroendocrine tumours. SCLC is separate from NSCLC as 
it has unique presentation, imaging appearance, treatment and prognosis. Tumours with 
this classification are characterised as an epithelial malignancy made up of small tumour 
cells with ill-defined borders, scant cytoplasm and finely granular nuclear chromatin 
without obvious nucleoli. SCLC cells are associated with the secretion of a variety of 
substances such as serotonin, calcitonin and bombesin peptides (Alexander et al. 1988). 
For this reason SCLC is regarded as a neuroendocrine tumour because of its ability to 
synthesize various hormone peptides that can act as paracrine and autocrine growth 
factors, similar to PNECs of the lung.  
The distinctive appearance of SCLC makes diagnosis of this subtype reliable, 
and a panel of immunohistochemical markers such as pancytokeratin as well as 
chromogranin and synaptophysin (neuroendocrine markers) can be used to confirm 
suspected SCLC (Miskovic et al. 2015). SCLC is rarely operable at the time of 
diagnosis and treatment is usually a combination of chemotherapy and radiotherapy. It 
is an extremely aggressive subtype with survival measured in months with a five year 
 12 
 
survival rate of < 5%. The highly metastatic nature of SCLC results in approximately 
two-thirds of patients presenting with distant metastases usually in the liver, bone, brain, 
lung and adrenal gland. Studies have shown that metastasis to the liver, brain and 
pleural and/or pericardial fluid are associated with particularly poor prognosis 
(Nakazawa et al. 2012). The amount of SCLCs presenting without evidence of 
metastasis is extremely rare occurring in < 5% of cases. 
c-SCLC or combined small cell lung carcinoma is a classification reserved for 
small cell carcinoma tumours which are found to additionally possess an additional 
component consisting of any non-small cell histological type. A NSCLC component can 
be one or more differentiated forms of lung cancer such as AD, SCC and LCC 
identified by histopathological examination. It is a relatively rare form of cancer and is 
thought to make up approximately 30% of SCLC cases (Wagner et al. 2009). As SCLC 
is the most aggressive form of lung cancer, it is recommended that all malignant lung 
tumours which are found to contain any proportion of SCLC cells should be classified 
as c-SCLC. Treatment for c-SCLC has traditionally been similar to SCLC and is usually 
a combination of chemotherapy and radiotherapy. However, studies have shown that 
surgery in combination with the above treatments can improve the outcomes of patients 
with stage 1 c-SCLC (Ihde 1984, Hage et al. 1998). 
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1.2.2. Causes of Lung Cancer 
The cellular and molecular changes which give rise to lung cancer have 
become better understood over the past 25 years. Cancer cells contain many genetic and 
epigenetic abnormalities, and there is now a greater understanding of the role played by 
these factors in relation to the development of this disease. Numerous studies have 
identified changes in the expression of tumour suppressor genes, abnormal alterations in 
growth-stimulatory signalling pathways and overexpression of oncogenes. In addition, 
the external factors which contribute to acquired gene alterations and DNA damage 
which lead to the development of lung cancer have been extensively studied.  
1.2.2.1. Proto-Oncogenes 
Continued improvements in genetic technology have led to a greater 
understanding of the molecular changes involved in the development of lung cancer. It 
is thought that numerous mutations in diverse gene types lead to the development of 
lung cancer and drive the malignant phenotype. Though these numerous mutations may 
lead to the development of the disease, it has been found that proto-oncogenes play a 
crucial role in the metastatic phenotype. Proto-oncogenes are mutated genes which are 
overexpressed at a high level. Investigations into these genes have led to the concept of 
‘oncogene addiction’, where tumour cells become dependent on overexpressed proteins 
as a result of genetic mutations (Weinstein 2002). Targeting such a proto-oncogene can 
profoundly inhibit the proliferation of cancer cells and increase overall patient survival 
(Weinstein and Joe 2008).  
Epidermal growth factor receptor (EGFR) is a proto-oncogene associated with 
the malignant phenotype of lung cancer. It is overexpressed in 65% of Adenocarcinoma, 
84% in Large cell carcinoma and has minimal expression in Small cell lung carcinoma 
(Bunn and Franklin 2002). The mutated version of EGFR and other proto-oncogenes are 
thought to drive the malignant phenotype of lung cancer. EGFR inhibitors such as 
gefitinib and erolitinib have shown a 67% response rate, increasing overall survival 
compared to wild-type EGFR, and outperforming conventional chemotherapeutic 
treatment (Jackman et al. 2009). 
Ras genes (HRAS, KRAS and NRAS) code for proteins involved in guanosine 
triphosphate (GTP) binding, and approximately 20-25% of cases of NSCLC patients 
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have been found to present with KRAS mutations (Campos-Parra et al. 2015). 
Mutations of KRAS lead to constitutively activated proteins locked in the GTP-bound 
“on” state which in turn results in the continued activation of the MAPK and 
PI3K/AKT7/mTOR pathways, ultimately leading to increased proliferation and 
resistance to apoptosis (Shaw et al. 2011). The majority of mutations in the KRAS 
proto-oncogene in NSCLC occur at codon-12 with single point amino acid mutation 
being the most frequent. KRAS mutant tumours are independent of the EGFR signalling 
pathway and are therefore unaffected by EGFR inhibitors such as gefitinib, and they are 
also resistant to chemotherapy. Mutations in EGFR and KRAS are usually mutually 
exclusive, and patients who are positive for KRAS mutations have a low response rate 
to EGFR inhibitors at < 5% (Suda, Tomizawa and Mitsudomi 2010). 
The Myc family of proteins have been found to be potent proto-oncogenes, 
mutated and persistently overexpressed in various cancers. c-Myc plays an essential role 
as a transcription regulator and plays a critical role in the regulation of processes such as 
cell-cycle control, apoptosis, protein synthesis and cell adhesion (Dang 2012). 
Abnormal overexpression of c-Myc is often found in SCLCs, and less frequently in 
NSCLCs (Bergh 1990).  Mitogenic signalling pathways such as Wnt and EGF (via the 
MAPK/ERK pathway) activate c-Myc with a resulting upregulation of many genes such 
as those involved in cell proliferation. Constitutive overexpression of c-Myc through 
mutation drives the proliferation of cancer cells and contributes to the progression of the 
disease (Zhang et al. 2012). 
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1.2.2.2. Tumour Suppressor Genes 
In contrast to proto-oncogenes, loss of function of tumour suppressor genes 
(TSGs) plays an equally important role in the development of lung cancer. TSGs are 
genes which protect cell from starting down the road towards a cancerous phenotype. 
These genes usually code for proteins which have a dampening effect on the regulation 
of the cell cycle, or may even promote apoptosis. It has been proposed that TSGs fall 
into two broad categories: gatekeeper genes and caretaker genes (Kinzler and 
Vogelstein 1997). Gatekeeper genes regulate the cell cycle and control how cells 
progress through division. Caretaker genes maintain the integrity of the genome and are 
involved in the repair of DNA damage. Loss of function in these TSGs requires both 
alleles of a gene to be damaged or mutated and is referred to as the ‘two-hit model’ 
(Knudson 1971). This model proposes that for the effect of a mutation in a TSG to be 
manifested and lead to a cancerous phenotype, both copies of the gene must undergo 
mutation as the remaining copy of the gene can still produce a functional version of the 
protein, though there are exceptions to his rule. In contrast, proto-oncogenes need only 
undergo a mutation in a single allele as they are gain of function mutations. 
One of the most common TSGs which have undergone loss of function 
mutations in a wide variety of cancers is p53. It is mutated in 30-50% of human cancers 
(Hollstein et al. 1991, Freed-Pastor and Prives 2012) with high prevalence in lung 
cancer. It was originally believed to be a proto-oncogene; however these early data were 
based on findings from experimental overexpression using cDNA cloned from a 
mutated version of p53. Subsequently, wild-type p53 was found to suppress growth, and 
it was reclassified as a TSG (Michalovitz, Halevy and Oren 1990). Mutations in the 
TP53 gene are reported in 70% of SCLCs and 50% of NSCLCs, resulting in the 
synthesis of full-length p53 protein which is unable to bind directly to DNA and 
activate anti-proliferative and pro-apoptotic target genes (Toyooka, Tsuda and Gazdar 
2003). P53 mutations are significantly higher in smokers than in non-smokers and the 
most prominent carcinogens in tobacco smoke such as polycyclic aromatic 
hydrocarbons has been found to form DNA adducts in the coding region of the TP53 
gene (Abedi-Ardekani et al. 2011). 
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P16 and RB (cyclin-dependent kinase inhibitor 2A and retinoblastoma protein 
respectively) are well accepted TSGs which are mutated in lung cancers, with both 
alleles frequently inactivated in the diseased state.  Alterations in both these genes have 
been reported within subtypes of lung cancer, with mutated versions of RB expressed in 
85% of SCLC and 25% of NSCLC, and mutated P16 expressed in < 10% of SCLC and 
60% of NSCLCs (Mori et al. 1990, Okamoto et al. 1995). Both proteins are involved in 
cell cycle regulation, decelerating the progression of cells transitioning from G1 phase 
of growth to synthesis (S) phase. Studies indicate that p16 and RB are inactivated in 
lung cancer cells, and the signalling pathways are estimated to be disturbed in 50-80% 
of lung cancers (Kelley et al. 1995). Loss of function of these genes has been shown to 
play a significant role in lung carcinogenesis through the unrestrained progression of the 
cell cycle. 
 
1.2.2.3. Tobacco Smoke 
Smoking of tobacco is by far the leading cause of lung cancer, responsible for 
~90% of all lung cancer cases. It is estimated that approximately 1.25 billion people 
smoke cigarettes on a daily basis and 40% of patients with newly diagnosed lung cancer 
are still smokers. Tobacco smoke is an aerosol containing 4000 substances, of which 50 
are known carcinogens including benzene, formaldehyde, lead, and polycyclic aromatic 
hydrocarbons (Abedi-Ardekani et al. 2011). It is thought that smoking will cause 
roughly 10 million deaths per annum by the year 2030, and one quarter of these deaths 
will be as a result of lung cancer (Lemjabbar-Alaoui et al. 2006). Smoking has been 
linked with aberrant methylation of both p53 and p16 causing silencing of the tumour 
suppressor genes. It is thought that analysis of promoter methylation on TSGs may 
provide a useful biomarker for the identification of groups with elevated risk of lung 
cancer such as smokers (Jarmalaite et al. 2003). Only 20% of smoker develop lung 
cancer, therefore it is logical to conclude that some people are more susceptible to the 
effects of tobacco related carcinogens than others. 
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1.2.2.4. Environmental Carcinogens 
Radon is a naturally occurring radioactive gas which results from the 
breakdown of uranium in rocks and soil. Alpha-particles emitted by radon are highly 
effective at damaging tissues. Charged alpha-particles are attracted to dust due to their 
charged state, and can become lodged in the epithelial tissues of the lung if inhaled. 
This can lead to gene mutations, chromosome aberrations and eventually the 
development of lung cancer. Radon is recognised as the second most common cause of 
cancer in the United States causing about 21,000 deaths each year (Choi and Mazzone 
2014).  
Asbestos is a naturally occurring mineral which has been widely used as a 
building and fireproofing material due to its intrinsic properties, however it is now 
know to be a potent carcinogen. Asbestos fibres can become lodged deep in the lung 
and cause irritation and scarring. This eventually leads to the development of lung 
cancer. Asbestos fibres can penetrate into the outer lining of the lung and chest wall 
(known as the pleura), and lead to development of cancer there known as mesothelioma. 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
1.3. Cancer Metastasis 
Cancer metastasis is a complex multistep process whereby malignant cells 
spread from the primary tumour site to distant organs of the body setting up secondary 
tumour sites. Approximately 90% of all cancer deaths are the result of complications 
arising from metastasis, and it is rare for death to occur from the effects of a primary 
tumour alone (Wirtz, Konstantopoulos and Searson 2011). Metastasising cancer cells 
travel via the bloodstream, the lymphatic system or invade adjoining tissue by direct 
extension. The processes of invasion and metastasis are poorly understood, and there 
are currently no therapies available which effectively target invading tumour cells.   
The ability of cells to undergo metastasis is preceded by the acquisition of an 
invasive phenotype by tumour cells. Malignant cells must be able to breach the 
extracellular matrix (ECM) and escape the tumour environment. This is a prerequisite 
phenotypic characteristic required for the initiation of the metastatic cascade which then 
allows tumour cells to move from the primary site to a distant location. In lung cancer 
metastasis, this cascade involves a number of fundamental mechanisms such as cell 
motility, angiogenesis, and degradation of the ECM, and cell-cell adhesion (See Figure 
1.1.)  
 
 
Figure 1.1: The steps involved in metastatic cascade resulting in the development of 
secondary tumours. (Wirtz, Konstantopoulos and Searson 2011) 
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The metastatic cascade involves the following critical steps which allow cells 
from a primary tumour site to set up a secondary tumour at a distant site in the body. 
Firstly, the cells must invade the surrounding tissue to escape the primary tumour site. 
The cell then must undergo trans-endothelial migration into lymph or blood vessels 
which is referred to as intravasation. Survival of the cells in these vessels is difficult due 
to the shear stresses involved, and if successful they will be translocated to distant sites. 
Next, the cells must leave the vessel through extravasation and survive the 
microenvironment of the new distant tissue type. Finally, the cells must undergo 
proliferation in order to set up a secondary tumour or metastasis (van Zijl, Krupitza and 
Mikulits 2011). 
Fortunately, metastasis is thought to be an inefficient process, and studies 
suggest that less than 0.02% of tumour cells in circulation have the ability to form 
metastases (Chambers, Groom and MacDonald 2002). Tumour cells encounter 
significant obstacles once they have left the primary site, and subsequent colonisation is 
very limited due to incompatibility of distant sites with tumour cell proliferation. 
However, the ability of cancer cells to acquire a metastatic phenotype is one of the most 
critical and dangerous determining factors of tumour progression.  
Healthy cells are programmed to be anchorage dependant, and to undergo 
apoptosis if detached or damaged. In cancer cells, the accumulation of genetic changes 
causes this regulatory process to be disrupted, leading to tumour development. A 
tumour which has not yet developed an invasive phenotype is termed ‘carcinoma in 
situ’. This form of carcinoma has a good prognosis and is usually treatable. However, if 
tumour cells start down the path of the metastatic cascade, the resulting metastases 
dramatically decrease the chances of survival.  
A major problem which hinders the understanding of metastasis is how 
individual tumour cells acquire all the individual properties which are required for the 
metastatic phenotype. One possible solution to this problem is the existence of a multi-
faceted biological program which allows carcinoma cells to attain a number of the 
characteristics to set them down the metastatic cascade path. This biological program is 
a process known as epithelial to mesenchymal transition (EMT). 
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1.3.1. Epithelial to Mesenchymal Transition (EMT) 
Epithelial cells are closely packed cells connected to each other via adherens 
junctions, gap junctions and tight junctions. They are polarised with apico-basal polarity 
and usually interact with the basement membrane via their basal surface. Mesenchymal 
cells lack polarisation, have spindle-like morphology and connect to each other only 
through focal points. EMT describes a transition process by which epithelial cells lose 
their polarity and undergo biochemical changes which allows them to develop a 
mesenchymal phenotype. These phenotypic characteristics include enhanced migratory 
ability, invasiveness, resistance to apoptosis and increased production of ECM 
components (Kalluri and Weinberg 2009). This is a natural process which is known to 
be involved in embryonic development and wound healing processes (Kong et al. 
2011). 
The transition of epithelial cells in lung cancer to mesenchymal cells is thought 
to be a critical step in the development of metastasis. The acquisition of invasiveness is 
firstly demonstrated by the breaching of the basement membrane that confines the 
epithelial compartment. This step is thought to be the critical step heralding the 
initiation of a multi-step process leading to metastatic spread of malignant cells with life 
threatening consequences (Hanahan and Weinberg 2011).  
Carcinoma cells in primary tumours undergoing EMT lose cell-cell adhesion, 
and a key step in this process is the reduction or loss of expression of E-cadherin, 
crucial to the progression of epithelial tumours to develop into metastatic cancers. The 
reduction or loss of expression of E-cadherin is usually seen to coincide with the gain of 
expression of N-cadherin which is a marker for mesenchymal cells (Nakajima et al. 
2004). This is known as the ‘cadherin switch’, and is a hallmark of EMT. Several other 
interconnected pathways and signalling molecules have been identified which are 
involved in the process of EMT such as receptor tyrosine kinases, GTPases, β-catenin 
and Integrins. In addition, transcription factors such as Slug, Snail and Twist have all 
been implicated in inducing EMT in epithelial cells and have each been shown to be 
highly expressed in metastatic cells (Talmadge and Fidler 2010). 
The central regulator of EMT has been shown to be transforming growth 
factor- β (TGF- β) which is an important suppressor of endothelial cell proliferation. It 
can serve as a positive regulator of tumour progression and metastasis, and in vitro 
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studies have shown it can induce EMT in certain types of cancer cells (Oft, Heider and 
Beug 1998, Song 2007). A number of pathways have been identified as mediators of 
TGF- β induced EMT. One pathway involves SMAD proteins, in which TGF-β induces 
SMAD-mediated signalling facilitating cell motility. Autocrine production of TGF-β 
can further amplify the EMT program via SMAD signalling.  Signalling pathways that 
mediate the action of β-catenin have been found to also cooperate with SMAD inducing 
an EMT. Studies have collectively demonstrated that the TGF-β/SMAD/β-catenin axis 
is an important inducer of EMT in cancer cells (Yang, Lin and Liu 2006). The 
identification of pathways which lead to EMT provides a new perspective on the 
plasticity of cells and possible therapeutic routes. 
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1.3.2. Invasion/Metastasis 
Once a cell undergoes EMT, it gains the ability to invade surrounding tissue. 
This involves the translocation of the cell through well-defined tissue boundaries and 
further through different types of ECM barriers. In the case of lung cancer, the cell must 
pass through the basement membrane to escape the primary tumour site within the lung. 
A number of proteins and processes are involved in this including: Matrix 
metalloproteinases, cellular adhesion molecules and Actin cytoskeletal regulation. 
 
Matrix metalloproteinases (MMPs) are calcium dependant proteins which 
belong to the larger family of proteases. These enzymes are secreted in an inactive form 
as zymogens, are activated by the presence of other MMPs or serine proteases such as 
Kallikrein, Trypsin and Plasmin which remove the pro-peptide domain. MMPs are 
capable of degrading ECM proteins such as proteoglycans, fibronectin, collagen and 
laminin, and this ability significantly contributes to the invasive ability of malignant 
cancer cells. Studies have shown that MMP-10 is highly expressed in human NSCLC 
compared to normal lung tissues, rendering it a potential target for the development of 
novel therapeutics for lung cancer treatment (Gill et al. 2004).  
In addition to providing cancer cells with the means to degrade the ECM and 
escape the primary tumour site, subgroups of MMPs have also been shown to cause 
EMT in the first instance. Overexpression of ADAM10 has been shown to lead to the 
shedding of E-cadherin in epithelial cells, leading to the disruption of cell-cell adhesions 
and increasing migratory ability (Maretzky et al. 2005). In addition, the shedding of E-
cadherin induced by MMPs appear to contribute to EMT, as recent studies have 
implicated MMP-28 in the activation of TGF-β in lung carcinoma cells (Illman et al. 
2006, Song 2007) 
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Cellular adhesion molecules (CAMs) are proteins expressed on the surface of 
cells which are involved in cell-cell binding or adhesion. They are transmembrane 
proteins which are composed of three domains: and intracellular domain which interacts 
with the cytoskeleton, and transmembrane domain, and the extracellular domain which 
interacts with other CAMs. Circulating tumour cells need to interact with the 
endothelium of blood and lymph vessels in order to undergo extravasation and 
ultimately metastasise. Studies of tumour cell-endothelial adhesion have been thus far 
based on parallels with leukocyte-endothelial interactions during inflammation, and it is 
thought that the mechanisms involved are potentially very similar. Sub-families of 
calcium dependant CAMs have been identified as participants in cancer metastasis such 
as Selectins, Integrins, and Cadherins (Paschos, Canovas and Bird 2009).  
Selectins are vascular CAMs involved in adhesive interactions of 
leukocytes/platelets and the endothelium within the blood circulation. P-selectin 
glycoprotein ligand-1 (PSGL-1) is a Selectin protein expressed on the surface of white 
blood cells. The expression and activation of PSGL-1 on the surface of white blood 
cells being recruited to inflamed tissue allows the cell to interact with the endothelial 
cell surface of blood CAMs. This allows the cell to roll slowly along the wall until it 
reaches the site of inflammation, where it transmigrates into the tissue (Kang et al. 
2012). The majority of Selectin ligands consist of distinct glycoprotein structures 
carrying the tetrasaccharide structure Sialyl Lewisx (SLex) expressed on the cell surface 
(Kansas 1996) which is a modification required for its activation. During malignant 
transformation of epithelial cells, one of the major changes in Selectin proteins is the 
upregulation in expression of structures such as SLex. The enhanced expression of SLex 
is associated with progression and poor prognosis in various cancers including lung 
cancer (Kannagi et al. 2004). 
Integrins are one of the major families of CAMs. It is well established that they 
are ubiquitously expressed ECM receptors, and serve as the main link between cells and 
the ECM through adhesion processes. Integrins mediate cell-ECM interactions through 
collagen, Vitronectin, Fibronectin and Fibrinogen   (Humphries, Byron and Humphries 
2006). These transmembrane proteins bind extracellularly to the ECM and intracellulary 
to the Actin cytoskeleton, integrating both environments. In this role, Integrins 
transduce signals from the outside of the cell to the inside and vice versa, and regulate 
cell adhesion, cell migration, ECM remodelling, and differentiation (Hynes 2002). 
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Integrins can also modulate the signalling cascade elicited by growth factors such as 
TGF-β (Margadant and Sonnenberg 2010).  
Cadherins are calcium dependant cell surface glycoproteins which are capable 
of mediating cell-cell adhesion. The cadherin superfamily includes N/E-Cadherins, 
Proto-Cadherins, Desmogleins, and Desmocollins (Garrod and Chidgey 2008). These 
transmembrane proteins are concentrated at adherens junctions, particularly 
desmosomes, and are involved in cell-cell adhesion. Desmocollins are similar to E/N-
Cadherins in overall structure, whereas Desmogleins have extra cytoplasmic sequenced 
added on to the basic Cadherin structure. This allows them bind to mediator proteins 
such as Plakoglobin, which in turn links to the Keratin intermediate filament network 
(Andl and Stanley 2001). Behaving as CAMs, these proteins have additional roles as 
both receptors and ligands for other molecules. As previously mentioned, loss of E-
Cadherin expression is concomitant with a loss of cell-cell adhesion and is one of the 
primary steps involved in EMT (Nakajima et al. 2004). 
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Regulation of the Actin cytoskeleton is a key process involved in the normal 
function of numerous different types of cells and is highly associated with cell 
migration. Many naturally occurring cell types are migratory and are involved in 
various processes such as immune surveillance, tissue repair, and embryonic 
morphogenesis. Atypical regulation of the actin cytoskeleton has been found to 
contribute to the progression of many diseases including cancer with regard to 
migration and metastasis (Yamaguchi, Wyckoff and Condeelis 2005).  
The initial step in cell migration is the protrusion of the cell membrane, and 
these protrusions are referred to as lamellipodia, filopodia, or invadopodia depending on 
their shape and function. Lamellipodia are flat structures which form at the leading edge 
of a motile cell and their extension is generated by the polymerisation of Actin 
filaments pushing against the cell membrane. The filaments of Actin can exert force as 
they polymerise at the leading edge of a cell, and flow back towards the cell body. By 
Actin filaments coupling with focal adhesions, force is generated against the cell 
membrane causing traction and movement (Zimmermann et al. 2012). This mechanism 
which gives rise to cell motility is referred to as Actin Retrograde Flow (ARF). The cell 
velocity is determined by polymerization forces at the lamellipodium leading edge, 
contraction of the Actin gel by myosin motors, cell adhesion to the ECM substrate via 
CAMs such as the Integrins, and the process of ARF (Ji, Lim and Danuser 2008).  
In order for cells to migrate though the ECM barrier, they require the ability to 
attach to the ECM and move through it, as well as degrade it. Invasive cancer cells form 
Actin-rich protrusions which extend vertically from the ventral cell membrane, and are 
termed invadopodia. These structures are enriched with Actin regulatory proteins, 
CAMs, membrane remodelling proteins, and matrix degrading proteases (Baldassarre et 
al. 2003). Carcinoma cells migrating on ECM fibres extend invadopodial protrusions 
which attach to the ECM at the leading edge of the cells, and utilise these formations to 
migrate and invade through the stroma towards blood vessels in the process of 
metastasis. The formation of invadopodial structures has only been observed in highly 
invasive cancer cells, and is therefore implicated in tumour metastasis (Yamaguchi et al. 
2005, Weaver 2006). 
Regulation of the formation of protrusive structures is carried out by a number 
of Actin related proteins and complexes. One of these is known as the ARP 2/3 complex 
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and this plays a major role in the regulation of the Actin cytoskeleton. Many Actin 
related molecules sever pre-existing filaments and use the exposed ends as nucleation 
cores for Actin polymerisation, extending existing filaments. In contrast, ARP 2/3 
stimulates the polymerisation of new Actin filaments by creating new nucleation cores, 
encouraging Actin branching (Aguda, Burtnick and Robinson 2005). The nucleation 
activity of ARP 2/3 is activated by upstream regulators such as members of the Wiskott-
Aldrich syndrome family of proteins (WASP, N-WASP, WAVE, and WASH). These 
WASP proteins integrate multiple upstream signals to induce Actin polymerization 
through the Arp2/3 complex (Veltman and Insall 2010).  
The expression of WASP and ARP 2/3 proteins has been associated with 
malignant phenotypes of cancer cells, indicating their importance in metastasis. 
Immunohistochemical investigation of ARP 2/3 expression in colorectal tumours found 
that while no positive staining was found in normal colorectal tissue or surrounding 
stroma, significantly high staining for ARP 2/3 was found in invasive carcinomas. 
Positive staining for this protein was typically seen at the invasive front of the colorectal 
carcinoma, and higher intensity staining correlated with increased invasive depth 
(Otsubo et al. 2004).  Immunohistochemical staining of both WASP and ARP 2/3 
complexes in lung adenocarcinoma found that co-staining of both proteins is an 
independent risk factor for tumour recurrence.  They also concluded that WASP binds 
to ARP 2/3 in lung adenocarcinoma and drives the migratory phenotype through 
regulation of the actin cytoskeleton and the formation of protrusive and invasive 
structures (Semba et al. 2006). 
Cortactin (CTTN) is a monomeric scaffolding protein involved in the 
regulation of the Actin cytoskeleton. The protein is located diffusely in the cytoplasm in 
its inactive state, and here Src-kinase can bind to its Proline-rich region and 
phosphorylate the protein. Cortactin assists in the creation of new nucleation cores in 
ARP 2/3 mediated F-Actin branching.  It also binds and cross-links F-Actin filaments 
and stabilises existing interactions between ARP 2/3 complexes and F-Actin (Uruno et 
al. 2001). It is prominently expressed in cell protrusions such as lamellipodia and 
invadopodia which are essential structures required by cancer cells to achieve metastasis 
through migratory processes, and they have also been shown to be essential for the 
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degradation of the ECM through the localisation of proteolytic enzymes (Artym et al. 
2006).  
The development of invadopodia and podosomes is dependent on CTTN 
activity and the protein has been shown to be a key regulator in the formation of these 
structures in cancer cells. Examination of breast cancer cells found that inhibition of 
invadopodia formation was caused by the knockdown of CTTN by RNAi. 
Consequently, impeded development of invadopodial structures by CTTT depletion 
resulted in a block of ECM degradation due to failure of invadopodia formation 
(Bowden et al. 1999). In NSCLC, CTTN was found to be associated with poor 
prognosis and lymph node metastasis by immunohistochemistry. It was concluded that 
CTTN is involved in the progression of NSCLC (Noh et al. 2013). 
Key proteins involved in the regulation of the Actin cytoskeleton are associated 
with the malignant and invasive phenotypes in a variety of cancers. The mode of 
invasion that is involved with invadopodial structures requires a dynamic Actin 
cytoskeleton, and there is growing evidence that Actin-binding proteins have multiple 
roles in tumourigenic and metastatic processes.  Further investigation into how these 
proteins work together to promote the invasive phenotype may lead to a greater 
understanding of the migratory and metastatic phenotypes in cancers, and may present 
novel therapeutic routes of treatment.  
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1.4. Heterogeneity in Lung Tumours 
The poor outcome of lung cancer is due to a number of factors specific to the 
disease. These include the early metastatic spread, difficult detection of the onset of 
disease, and the development of drug resistance following treatment with 
chemotherapeutic agents. One major factor which makes lung cancer a particularly 
difficult disease to treat is the characteristic heterogeneity of lung tumours.  Functional 
and phenotypic heterogeneity of lung cancer cells has been long recognized, with 
experiments as early as the 1930s demonstrating that some but not other cells from 
mouse tumours could give rise to new tumours when transplanted (Marte 2013).  
Tumour heterogeneity refers to the observation that multiple cell types can be 
found within individual tumours, and that each subpopulation can show distinct 
morphological and phenotypic characteristics. These can include cellular morphology, 
gene expression, protein expression, metabolism, and metastatic potential (Marusyk and 
Polyak 2010). It is thought that this complex population of cells within a single tumour 
type can be explained by the cancer stem cell (CSC) theory. This theory proposes that 
within tumours, there are subsets of stem cell-like cancer cells with the ability to self-
renew and generate diverse tumour cells (Reya et al. 2001). These cells may be the 
source of intra-tumour heterogeneity which is a characteristic of lung cancer. The 
existence of CSC is supported by the fact that only a small population of lung 
adenocarcinoma cells (< 1.5%) possess clonal forming and tumourigenic ability (Kim et 
al. 2005, Carney et al. 1982). 
In addition to the CSC theory, genomic and chromosomal instability is thought 
to contribute to the heterogeneity found in tumours. In normally functioning lung 
epithelial cells, the genome is replicated with high fidelity, with mutations being 
routinely eliminated by thorough molecular checking mechanisms such as double-strand 
break repair, and mismatch repair. In cancerous cells, these checking mechanisms 
malfunction, and lead to a proliferation of mutations in the tumour cells. This eventually 
results in further carcinogenesis and tumour heterogeneity (Pailler et al. 2015). 
Diversity in subpopulations with the same tumour can be evident at a genetic 
level. Using next generation whole genome sequencing, it has been shown that 
heterogeneous somatic mutations and divergent allelic profiles are present in different 
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regions of micro-dissected samples from the same renal tumour. Genes associated with 
both good and bad prognoses were detected in different regions of the same tumour, 
reflecting the drastic subclonal diversity and heterogeneous nature of the tumour 
(Gerlinger et al. 2012). In lung cancer, analyses of samples from different regions of the 
same tumour are still lacking. One study conducted deep digital sequencing of tumour 
and adjacent normal tissue samples from 17 patients with NSCLC. Deep digital 
sequencing refers to a method in which multiple sequencing reads are carried out (100-
10,000 times) to reliably identify potential mutations. Deep digital sequencing of 
somatic mutations in lung cancers from both smokers and never-smokers revealed 
multi-clonal signatures, indicated by distinct variant allele frequency features. This 
suggested that at a genetic level NSCLC had a heterogeneous nature, consisting of 
subclonal populations (Govindan et al. 2012). 
Micro-environmental adaption of tumour cells is another factor which is 
thought to contribute to the heterogeneity of lung tumours. The immediate external 
tumour micro-environment area is made up of numerous cell types including stromal 
cells, fibroblasts, and immune cells. This results in the varying degrees of selective 
pressures such as oxygen availability, pH variations, and growth factors to name but a 
few (Albini et al. 2015). The surrounding microenvironment interacts with cancer cells 
to influence the development and progression of the neoplastic disease. For instance, 
secretion of Hepatocyte Growth Factor (HGF) by stromal fibroblasts under the 
stimulation of tumour-derived factors such as Interleukins strongly encourages tumour 
expansion and invasiveness by activating the MET oncogene pathway in NSCLC 
(Nakamura et al. 1997). Depending on the proximity of tumour cells to the stroma, these 
effects vary and induce the generation of subpopulations within a tumour with differing 
phenotypic abilities.  
A major route in the treatment of NSCLC is the targeting of tumour-driving 
pathways such as epidermal growth factor receptor (EGFR) by tyrosine kinase 
inhibitors (TKIs). This treatment is based on the oncogene addiction theory (Weinstein 
and Joe 2008), and has been shown to be successful in advanced NSCLC patients, 
conferring prolonged survival and limited adverse effects. However, it has been found 
that tumours which initially respond to TKIs eventually become refractory to therapy 
and regrow (Mok et al. 2009, Gainor and Shaw 2013). The role of tumour heterogeneity 
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has been shown to be a critical factor in the development of drug resistance in lung 
cancer. It is thought that tumour development is a process of clonal evolution as 
described in the CSC theory, with every tumour possessing subclones with diverse 
phenotypic abilities. This allows some cells to escape therapeutic intervention and then 
induce regrowth of the tumour. 
Tumour heterogeneity in lung cancer presents major challenges for the 
determination of appropriate treatments and indeed the diagnosis of the disease. 
Subpopulations within a tumour can survive through therapeutic intervention and cause 
re-growth of the tumour, severely compromising attempts at treatment. In addition, 
tumour heterogeneity may complicate the initial diagnosis and subsequent treatment 
regimen, as single biopsies of primary tumours, as is usual clinical practice, leads to a 
misleading characterisation of a heterogeneous lung tumour (Gerlinger et al. 2012). It is 
now recommended that multiple biopsies be taken of a tumour to mitigate the effects of 
intratumour heterogeneity. This may result in improved response to chemotherapy with 
more targeted therapies based on more detailed and accurate diagnoses (Hiley et al. 
2014). 
Despite the evidence for intratumour heterogeneity, the subject remains 
relatively poorly explored. It is thought that a more systemic approach is required for to 
characterise the extent of heterogeneity within tumours. An important factor to consider 
is to distinguish between cellular heterogeneity and clonal heterogeneity. Cellular 
heterogeneity refers to the differences between individual tumour cells, whereas clonal 
heterogeneity refers to differences which have been amplified by clonal expansion 
(Marusyk and Polyak 2010). Focusing on clonal heterogeneity eliminates some of the 
‘noise’ from variants of clones which did not clonally expand due to poor adaptation to 
the tumour microenvironment.  
A simplistic view of tumours as homogenous entities is not a true 
representation of the reality in the majority of lung cancers and cancers in general. 
Treating tumours as complex systems with subpopulations of interacting clones may 
provide a useful route to understanding the interactions in a tumour which leads 
expansion, EMT and subsequent metastasis. Unravelling the full extent of clonal 
interactions is unlikely; however this approach may uncover critical links which may 
aid in the elimination of tumours.  
 31 
 
1.4.1. The DLKP Cell Line and its Subpopulations 
The DLKP cell line presents a unique opportunity to study tumour 
heterogeneity in vitro. This cell line was derived from the lymph node metastasis of a 
primary lung tumour. Previous work determined that the DLKP cell line contains three 
morphologically distinct subpopulations (McBride et al. 1998a). These clonal 
subpopulations were termed: DLKP-SQ, DLKP-M, and DLKP-I. These cell lines can be 
used as a model system for the study of tumour heterogeneity in lung cancer, with 
respect to clonal heterogeneity. It also provides an in vitro model of invasion, due to the 
different phenotypic properties of the clones. Investigations into the phenotypes and 
proteomic profiles of the clonal subpopulations, as well as possible interactions between 
them, may reveal targets associated with those phenotypes, and add knowledge to the 
understanding of tumour heterogeneity in lung cancer. 
1.4.1.1. Origin  
The DLKP cell line was established by Dr Geraldine Grant (Law et al. 1992) 
during the course of routine primary culture of human lung tumours. The patient from 
which DLKP originated was a 52-year-old male who had smoked approximately 40 
cigarettes a day for most of his adult life. The DLKP cell line was derived from a 
tumour which was histologically diagnosed as a poorly differentiated squamous cell 
carcinoma. A subsequent review further described the tumour as ‘poorly differentiated 
and necrotic carcinoma without obvious keratinisation, but of a larger size and with 
more cytoplasm than typical oat small cell carcinoma’. Therefore the most appropriate 
diagnosis became ‘poorly differentiated non-small cell carcinoma’. Routine cell culture 
of DLKP revealed the presence of at least three morphologically distinct subpopulations 
which were ever-present. Isolation of these different cell types was achieved using a 
cloning procedure, and the three DLKP clonal subpopulations were established 
(McBride et al. 1998a).  
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1.4.1.2. Subclonal populations of the DLKP Cell Line 
The presence of morphologically distinct subpopulations with the DLKP cell 
line was confirmed by the establishment of three clonal subpopulations by McBride et 
al. 1998. It was found that the morphologies of the three individual clones are well 
defined, and remain so after approximately 20 passages in cell culture conditions. These 
clonal subpopulations were named based on their morphologies, and images of each cell 
line in monolayer are shown in Figure 1.2. The parental DLKP cell line is also included 
here. 
 
 
DLKP-SQ is named for its squamous-like morphology. These cells grow to a 
relatively large size when grown in monolayer and form distinct cell boundaries. They 
are found to predominate in the parental DLKP cell population, making up 
approximately 70% of the total cell population from microscopic observations 
(McBride et al. 1998). 
 
DLKP-M cells are named for their mesenchymal-like appearance in 
monolayer conditions. They are of intermediate size and have irregular elongated shapes 
with protruding outgrowths which extend from their ventral cell membrane. They grow 
in a scattered manner with cells extending across each other. In the parental DLKP cell 
line, they make up approximately 5% of the total cell population from microscopic 
observations (McBride et al. 1998). 
 
DLKP-I cells account for approximately 25% of the parental DLKP 
population. They grow in tightly packed groups with indistinct cell boundaries. They 
are named after their ‘intermediate’ properties in relation to DLKP-SQ and DLKP-M.  
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Figure 1.2: The three DLKP clonal subpopulations as they appear in monolayer: 
DLKP-SQ, DLKP-M, DLKP-I and DLKP. 
 
1.4.1.3. Characteristics of the DLKP Clones 
Follow-up studies carried out on the DLKP clones found that they displayed 
differences in the levels of in-vitro invasion, migration and anoikis resistance. The 
DLKP-SQ clone displays a poor invasive and migratory capacity, is anoikis resistant 
and displays low level expression of Integrin-αV. The DLKP-M clone displays a high 
invasive and migratory capacity but is anoikis sensitive (Keenan et al. 2012). The 
DLKP-I clone displays and intermediate level of invasive and migratory capacity, with 
an intermediate ability to resist anoikis. Both DLKP-I and DLKP-M display a high 
capacity to bind Fibronectin and Fitronectin, potentially explained by their higher 
expression of Integrin-αV relative to DLKP-SQ. The clones also show differences in 
expression of matrix-metalloproteinases (MMPs) which appear to correlate with the 
invasive profile of the clones, MMP2 is expressed in DLKP-I, while DLKP-M 
expressed MMP10, while DLKP-SQ appeared to express both as a lower level (Joyce 
H, PhD 2015).  
DLKP-SQ DLKP-M 
DLKP-I DLKP 
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1.4.1.4. The Inter-Conversion Model of DLKP 
The ratio of clones present within the DLKP parental cell line seems to be 
tightly controlled through a model of inter-conversion proposed in the previous study 
performed by McBride et al. 1998. The model proposed that DLKP-SQ may inter-
convert with DLKP-I, and DLKP-M may inter-convert with DLKP-I (See Figure 1.1). 
However, inter-conversion was not observed between DLKP-SQ and DLKP-M directly. 
It was therefore suggested that DLKP-I resembled a potential stem cell-like population 
in DLKP with its ability to interconvert and give rise to both DLKP-SQ and DLKP-M-
like cells. 
 
 
Figure 1.3: The inter conversion model of the DLKP clones as proposed by 
McBride et al. 1998. 
 
 
Previous attempts were made to identify specific markers for the DLKP clones 
using immunocytochemical methods however this was unsuccessful (McBride et al. 
1998a). To date, no markers have emerged that can allow for the differentiation between 
the individual DLKP clones. To identify proteins showing high expression in one of the 
clones relative to the others would be useful, as it may be involved in the phenotypic 
properties of that clone. Quantitative proteomic analysis could allow for the 
identification of proteins that are highly expressed in each of the clonal variants, and 
these could potentially act as markers for the clones. Also, identification of such 
proteins could provide the means to study the model of inter-conversion between the 
DLKP-SQ
DLKP-I
DLKP-M
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clones, as well as their potential involvement in cell invasion and migration. The 
phenotypic differences between the DLKP clones present a prime opportunity to 
investigate tumour heterogeneity in lung cancer in vitro.  
 
 
1.5. Proteomics 
Studies in genomics were hoped to provide the data necessary for the 
comprehensive analysis of an organism, however it was found that a genome is 
predominantly static, and changes very little in response to intra and extracellular 
influences. Transcriptomics was the next avenue of investigation, as both the genome 
and proteome are dynamically linked to it. These studies provided mRNA quantification 
at certain points in time; however a severe lack in correlation was found between 
mRNA expression and protein expression (Chen et al. 2002). This has led to the direct 
study of biological systems through proteomic techniques, as proteins have been 
described as the ultimate effectors in a cell (Souchelnytskyi 2005).  
Proteomics focuses on quantifying and identifying proteins, characterising 
expression levels in comparative analyses, discovering sub-cellular locations of certain 
proteins, and determining the roles of proteins of interest in relation to function and 
interactions. Expression-proteomics deals with quantitative comparisons of proteins that 
are changed between groups based on a sample set comparison. From this, proteins can 
be profiled based on the expression level changes which are present between groups in 
the comparison. This approach has been implemented extensively in the field of 
biomarker discovery, particularly in relation to cancer research. The use of quantitative 
proteomics can be used to compare normal vs. diseased state, and the identification of 
differentially expressed proteins can hypothetically be mapped back to the cause of the 
condition, or at least highlight proteins associated with the disease state. It is hoped that 
such an approach can lead to the development of diagnostic techniques which facilitate 
the early detection of said biomarkers, which may improve disease treatment and 
prognosis. This approach can also use the differentially expressed protein data to 
correlate with aspects of the disease state, leading to a greater understanding of the 
mechanisms involved. 
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Most proteomics research is focused on identifying differentially expressed 
proteins in a sample type by comparing its normal vs. diseased state. These samples can 
be tissues, bio-fluids, and cell lines to name but a few. Several protein profiling 
technologies have been developed which allow the quantitative analysis of sample types 
mentioned above, resulting in the identification of thousands of proteins. There have 
been major improvements in the speed, sensitivity and the resolution of mass 
spectrometry instrumentation, reproducible nano-HPLC and the associated advances 
in technologies for sample preparation and data analysis. 
 
1.5.1. Sample Preparation  
There are two main strategies employed when analyzing proteins using mass 
spectrometry. They are referred to as ‘top-down and ‘bottom-up’. Top-down methods 
analyse whole proteins, whereas bottom-up methods analyse the peptides generated 
from digested proteins (Armirotti and Damonte 2010). Bottom-up proteomics, or 
shotgun proteomics, is the most common method of sample preparation prior to mass 
spectrometric analysis. This method of identification characterises the amino acid 
sequence and post-translational modifications of a protein that has been enzymatically 
digested into its associated peptides. A crude protein sample is directly digested by 
adding an enzyme to the protein extract resulting in peptide formation. Numerous 
proteolytic enzymes are commercially available and differ in their cleavage sites of a 
protein. Trypsin has become the gold standard for protein digestion to peptides for 
bottom-up proteomics. Trypsin is a serine protease which cleaves proteins at the 
carboxyl side of arginine and lysine. These specific cleavage sites must be stated when 
sequence identification is searched for using protein databases.  
Generally, peptide samples are separated by liquid chromatography prior to 
mass spectrometry to allow the MS adequate time to retrieve high resolution data on 
each peptide entering the instrument. The use of peptides instead of proteins in mass 
spectrometry gives higher sensitivity allowing for accurate identifications. By 
comparing the mass spectra of the proteolytic peptides, as determined by MS, with 
theoretical mass spectra generated from in silico digestion of a protein database, 
peptides can be accurately identified with several peptide identifications assembled into 
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a protein identification. By relying on the analysis of peptides, which are more easily 
fractionated, ionized, and fragmented, shotgun proteomics can be more universally 
adopted for protein analysis. 
 
1.5.2. Reverse-phase HPLC 
Separation of peptides using HPLC is carried out using two phases: the mobile 
phase (liquid), and the stationary phase. The mobile phase contains the analytes, and 
permeates through the stationary phase at high pressure, separating analytes which can 
be subsequently analysed by mass spectrometry. The stationary phase is typically a 
tightly packed column filled with irregular or spherically shaped particles which 
functions to separate the analytes in a complex sample.  
In Reverse phase (RP) chromatography the stationary phase column in the 
analysis of peptides is composed of octadecylsilyl (C18) particles. Use of these particles 
takes advantage of the natural physiochemical properties of peptides which vary in their 
hydrophilic and hydrophobic properties. This method uses a polar mobile phase, and 
hydrophobic molecules (peptides) in this phase bind to the hydrophobic stationary phase 
(C18). By decreasing the polarity of the mobile phase over time, peptides can be eluted 
based on their hydrophobic interactions, which are reduced in strength by the decreasing 
polarity. Reverse phase LC columns are most suited for analysis of complex peptide 
mixtures (Tuli and Ressom 2009) with the most polar or hydrophilic peptides eluting 
from the stationary phase first and most non-polar hydrophobic peptides eluting towards 
the end of the HPLC separation. This allows good separation of peptides in a sample 
which can then be introduced into a mass spectrometer for analysis. 
Prior to mass spectrometric analysis, the separation mechanism employed is a 
version of high pressure liquid chromatography (HPLC). This updated version is 
referred to as nano-HPLC. This method offers several advantages over regular HPLC 
which include: low sample volumes, improved due to small droplet formation, high 
efficiency packed columns that can be operated with MS friendly solvent systems, 
reproducible delivery of solvents to nano-columns (Qian et al. 2006). 
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1.5.3. Protein Mass Spectrometry (MS) 
MS is an analytical technique which can be used for the fragmentation and 
detection of peptides, allowing their subsequent identification and quantification. A 
mass spectrometer is composed of three main parts, each with essential functions. There 
are: i) an ionization source which can convert eluting peptides into gas phase ions; ii) a 
mass analyser which separates ions based on their mass to charge ratios (m/z); iii) a 
detector which registers relative abundances of ions at discrete m/z values.  
1.5.3.1. Ionisation 
To analyse a peptide sample by mass spectrometry it must first be ionised and 
vaporised. The two commonly used techniques used for peptide ionisation are Matrix 
Assisted Laser Desorption Ionisation (MALDI), and ElectroSpray Ionisation (ESI). In 
MALDI, matrix absorbs laser energy and transfers it to the acidified peptide sample, 
where rapid laser heating causes desorption of matrix and peptide ions into the gas 
phase. ESI creates peptide ions by passing the peptide solution through a fine needle 
with a high electric potential across it. This electric potential produces charged droplets 
which shrink by evaporation resulting in increasing charge density. ESI produces 
multiply charged peptide ions at atmospheric pressure (Canas et al. 2006). This is 
carried out at the interface between the Nano-HPLC and the mass spectrometer.  
Peptides being separated by liquid chromatography can be continuously ionised with 
high efficiency and increased throughput. However this method of ionisation is not very 
tolerant of interfering compounds in the sample matrix such as salts, buffers, and 
detergents. 
 
1.5.3.2. Mass Analysis 
Mass analysers separate peptide ions based on their mass to charge ratio (m/z). 
The most common forms of these mass analysers are: time-of-flight (TOF), quadropole 
mass analysers (Q), and ion trap (IT).  A mass spectrometer can have various 
arrangements of ion source and mass analysers, some including just one mass analyser 
or more than one. These are referred to as hybrid instruments. The most important 
characteristics of mass analysers are their resolution, which refers to their ability to 
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differentiate between two close signals. Other key parameters of these components in 
proteomic analyses are sensitivity, mass accuracy and the ability to generate 
information-rich ion mass spectra from peptide fragments (Aebersold and Mann 2003). 
Instruments with ion trap analysers have high sensitivity, fast scan rates, high duty 
cycle, and multiple MS scans with high resolution and mass accuracy. In quantitative 
label-free LC-MS/MS a hybrid instrument can be used such as a LTQ XL Orbitrap 
(Thermo Scientific). 
Orbitrap is a high accuracy mass analyser which traps moving peptide ions in 
an electrostatic field and forces them to move in complex spiral patterns. Using 
mathematical algorithms, the m/z value of these ions can be determined. The Orbitrap 
can be coupled to other mass analyser such as a linear trap quadropole (LTQ) resulting 
in a hybrid system with high resolution and high mass accuracy along with faster scans 
and high sensitivity (Yates, Ruse and Nakorchevsky 2009).   
In mass spectrometric analysis, the mass-to-charge ratios (m/z) of ionised 
peptides are determined. Each particle measured has an m/z signature detectable by the 
mass spectrometer. This m/z measurement is computed by bioinformatic tools and 
converted into a mass for the associated peptide. Peptides in the sample can 
subsequently be identified by comparing its actual mass as determined by MS to 
theoretical peptide masses which are predicted from databases of compounds and 
molecules. 
 
Tandem mass spectrometry involves an instrument with MS/MS or MSn 
capabilities which can provide additional information about an ion. In short, precursor 
ions are scanned in the first mass analyser and an m/z identified. The precursor ion is 
then fragmented and the product ions are scanned in a second mass analyser. In terms of 
tandem mass spectrometry of peptides, the mass spectrometer scans peptide ions which 
enter it. The analyser then isolates ions of a particular peptide and subjects them 
to collision-induced dissociation (CID) and scans the produced fragments in a tandem 
mass spectrum. Peptide fragment ions are generally scanned in the first analyser, 
fragmented and subsequent amino acid ions are scanned in the second analyser.  
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1.5.4. Protein Identification 
Large sets of raw data generated from mass spectrometry analysis must be 
interrogated and converted to result files consisting of peptide and protein 
identifications. Data must be validated so that only information which will result in an 
identification are chosen and. Bioinformatics programs have the abilities to: set a 
threshold for only high resolution data to be accepted, assign charge states to ions, 
remove peaks below a certain intensity and merge MS/MS spectra that were derived 
from the same precursor ion (Cottrell 2011). The management of such large data sets 
has seen the introduction of various bioinformatics programs and algorithms to filter the 
raw data and convert data to protein identifications. 
 
1.5.4.1. Protein Identification algorithms and databases 
Sequest (MacCoss, Wu and Yates 2002) and MASCOT (Savitski, Nielsen and 
Zubarev 2005) are search engines used to process the data generated by MS. The 
software evaluates protein sequences from a database to calculate the list of peptides 
that could result from each, in silico. The intact mass of the peptide from a sample of 
interest is known from the mass spectrum, and Sequest uses this information to 
highlight candidate peptides sequences that could meaningfully be compared. For each 
candidate peptide, Sequest compares these theoretical spectra to the observed tandem 
mass spectrum by the use of cross correlation scoring. The candidate sequence with the 
best matching theoretical tandem mass spectrum is reported as the best identification for 
this spectrum. 
By using an appropriate scoring algorithm, the closest match or matches can be 
identified. If the "unknown" protein is present in the sequence database, then the aim is 
to pull out that precise entry. If the sequence database does not contain the unknown 
protein, then the aim is to pull out those entries which exhibit the closest homology, 
often equivalent proteins from related species. The sequence databases that can be 
searched on the public Mascot server are: 
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SwissProt: a high quality, curated protein database. Sequences are non-redundant, 
rather than non-identical, so fewer matches are achieved for an MS/MS search than 
what would be obtained from a comprehensive database, such as NCBInr. 
 
NCBInr:  a comprehensive, non-identical protein database maintained by NCBI for use 
with their search tools BLAST and Entrez. The entries have been compiled from 
GenBank CDS translations, PIR, SWISS-PROT, PRF, and PDB. 
 
1.5.5. Protein Quantification 
 
Quantitative proteomics comes in two forms: absolute and relative. Relative 
quantitation compares the levels of a specific protein in different samples with results 
being expressed as a relative fold change of protein abundance. Absolute quantitation is 
the determination of the exact amount or mass concentration of a protein, for example, 
in units of ng/mL of a plasma biomarker. 
Quantitative proteomics, as the name suggests, provides quantitative 
information (relative or absolute) on existing proteins within a sample set. Biological 
processes are mainly affected by the activity of proteins therefore it is useful to study 
these proteins directly. Obtaining accurate information on the behaviour of proteins is of 
the upmost importance as any change in response to external stimulation, or changes 
between sample sets in a proteomic comparison, may lead to the identification of 
proteins which control underlying mechanisms of potential interest. Though current 
quantitative proteomic techniques are far from characterising the entire proteome, there 
are a number of methods that are successful in determining quantitative information on 
proteins expression. 
Spectral counting as a means of quantifying peptides is based on the idea that 
the more of a protein is present in a sample, the more MS/MS spectra will be collected 
for peptides belonging to that protein. The relative abundance of that protein can be 
obtained by comparing the number of MS/MS spectra between sample sets. Although 
this method has the advantage of simultaneous quantification and identification, it 
depends on the quality of MS/MS generated 
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Peak intensity measurement (also called ‘signal intensity’ or ‘area under the 
curve’ (AUC)), is a method used to calculate the relative quantity of peptides in a label-
free quantitative analysis. In LC-MS, as peptides are eluted from the reverse phase 
column into the mass analyser, a particular mass to charge ratio (m/z) is recorded with a 
particular intensity, at a particular time. This results in a peptide of a particular charge 
and mass generating one mono-isotopic mass peak. It has been observed that the signal 
intensity of this peak correlates with ion concentration. The peak areas of identified 
peptides can therefore be extracted and calculated, and these peak areas increase 
linearly with increasing peptide concentration (Voyksner and Lee 1999). These peptides 
can be brought together to provide quantitative data on relative protein abundances 
between samples in a comparison. This method is applicable to data derived from high 
mass precision instruments, and uncouples quantification from the identification 
process. The accuracy of quantitative data can be further improved by the normalisation 
of peak areas. This method requires that all data is collected in data-dependent ‘Triple 
Play’ mode (allowing MS scan, and MS/MS scan). This AUC method of peptide 
quantification is used in this thesis to achieve quantitative proteomic profiles of the 
DLKP cell line and its subpopulations.  
 
1.6. Proteomic Profiling 
Proteomic profiling is a type of quantitative proteomics that identifies 
differences in protein expression across multiple samples. The quantitative analysis of 
protein levels is important for understanding the function of each protein and to provide 
insights into mechanisms of various biological processes and diseases. As previously 
mentioned, quantitative proteomics employs mass spectrometry to measure protein 
expression either in relative or absolute values. By gathering information about protein 
expression levels in a comparison between biological samples, proteomic profiles can 
be generated. Quantitative proteomic profiles can subsequently be exploited to target 
key proteins potentially involved in the known characteristics of each sample compared. 
Since the proteome of an organism is far too complex to be analysed in a single 
step, simplification of the sample is necessary prior to analysis.   Combined with the 
continued advances in mass spectrometry, gel-based quantitative proteomic profiling is 
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now a routine method for biomarker discovery using methods such as 2D-PAGE and 
2D-DIGE. There have been great advances made in mass spectrometry based methods 
of protein quantification available using labelled techniques such as SILAC, iTRAQ, 
and TMT. The recent development in proteomic profiling technology is what is referred 
to as the quantitative label-free LC-MS/MS method, which is the basis of the work 
presented in this thesis. 
 
1.6.1. Labelling techniques for Quantitative proteomic profiling 
 
1.6.1.1. Two-Dimensional Polyacrylamide Gel Electrophoresis (2D-PAGE) 
One of the earlier methods used for the separation of proteins is two-
dimensional polyacrylamide gel electrophoresis (2-D PAGE). The first step involves the 
separation of equal quantities of proteins across a sample set, based on their isoelectric 
point (pI). The pI of a protein is described as the pH at which its net charge is zero. 
Using this property, protein samples are separated on immobilised pH gradient (IPG) 
strips in the first dimension and rest at certain locations along the IPG strip depending 
on their pI. Following this, the IPG strips are incorporated into the top of a large 
polyacrylamide gel sheet and a charge is applied. Proteins migrate from the strip into 
the gel and are separated based on their size, using sodium dodecyl sulphate 
electrophoresis, in the second dimension. The result of this process is a 2-D gel which 
upon staining produces a series of spots, with each spot corresponding to a protein 
(O'Farrell 1975). Commonly used protein stains include Coomassie Brilliant Blue and 
silver nitrate colloidal stain, both of which are global protein stains. Subsequently, 
different polyacrylamide gel sheets representing separate samples can be compared 
using imaging software to look for abundance changes in matching protein spots. These 
can be picked and identified by mass spectrometry.  
This method is time consuming, labour intensive and results in poor 
reproducibility between gels. The inherent variability of this technique makes it difficult 
to distinguish between system variation and biological changes between samples being 
compared. This makes it hard to attribute protein abundance changes in a diseased state 
vs. normal conditions, resulting in a technique which is not very reliable (Marouga, 
David and Hawkins 2005). 
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1.6.1.2. Two-Dimensional Difference In-Gel Electrophoresis 2D-DIGE  
2D-DIGE is based on the same principle of 2D-PAGE however; it aims to 
overcome the problems associated with the latter technique. It incorporates the use of 
fluorescent dyes which can be used to provide quantitative information on protein 
abundance differences between samples. This highly sensitive method of minimal 
protein labelling uses three fluorescent dyes (Cy2, Cy3, and Cy5) which are covalently 
bound to protein samples just prior to co-electrophoresis. This method has an advantage 
over 2D-PAGE in that the Cy labelled sample set can be run together using co-
electrophoresis in both the first and second dimension. In addition, this method 
incorporates the use of a pooled sample internal standard which is included on all gels 
in the experiment. This allows normalisation of the resulting abundance data resulting in 
accurate reproducibility and protein comparisons between gels (Alban et al. 2003).  
Gel based proteomic techniques, in particular 2D-DIGE, have been 
successfully used as a tool for examining pathological processes such as in Alzheimer’s 
disease, as well identifying biomarkers in the saliva of lung cancer patients, and 
identifying proteins involved in radio-resistance in breast cancer (Souchelnytskyi 2005, 
Xiao et al. 2012, Duru et al. 2012). However, these techniques have drawbacks which 
limit the full potential of proteomic profiling. These include difficulties in 
accommodating hydrophobic proteins into the method, and an inability to achieve an 
entire representation of the proteome. Multiple proteins may be overlapping in one 
protein spot, which can lead to incorrect identification of a differentially expressed 
protein downstream. In addition, sample bottlenecks are a major limitation of 2D 
methodology due to the limited number of samples which can be analysed at any one 
time, and intensive image analysis required for data processing. In view of these 
limitations, many gel-free techniques have been developed which attempt to overcome 
these obstacles, and these techniques are centred on the use of mass spectrometry. 
 
1.6.1.3. Stable isotope labelling with amino acids in cell culture (SILAC) 
SILAC is an in vivo metabolic labelling technique where the isotopic labelling 
is performed when cells are in culture. Amino acids in growth medium are modified so 
they contain stable isotopic nuclei (e.g. deuterium, 13C and 2H), and two cell populations 
 45 
 
can be grown so that they remain identical, except one of them contains ‘light’ amino 
acid while the other contains ‘heavy’ amino acids. These modifications are incorporated 
into each newly synthesised peptide chain, and only amino acids which are essential to 
the organisms in the comparative experiment can be used (Ong et al. 2002).  These 
modifications result in a mass shift which can be readily distinguished by mass 
spectrometry analysis and relative quantitation is achieved by comparing heavy vs. light 
labelled cells. SILAC has the ability to compare up to five conditions in one experiment 
and is only limited by the availability of heavy forms of amino acids.  
SILAC has been successfully used as a method to study posttranslational 
modifications such as protein phosphorylation and methylation in mammalian cells, and 
to analyse the dynamics of signal-dependent phosphorylation events in plants (Gruhler 
and Kratchmarova 2008, Engelsberger et al. 2006), highlighting its diverse applications. 
Other advantages include its compatibility with cell culture, no requirement for affinity 
purification steps, and the ability to include a pooled internal control to find real protein 
abundance differences independent of variability from processing steps. The main 
drawback of SILAC are the limited availability of heavy amino acid types, limiting 
sample set size (up to 5-plex), and introduction of variability during the labelling 
process (Beynon and Pratt 2005). 
 
1.6.1.4. Isotope-Coded Affinity Tags (ICAT) 
ICAT is an in vitro chemical labelling technique which allows protein 
quantification by LC-MS analysis through the use of heavy or light isotopes 
(Monteoliva and Albar 2004). Chemical incorporation of isotope tags is performed after 
protein extraction, with control and test conditions being modified by with heavy and 
light ICAT reagent followed by Tryptic digestion. The ICAT reagent has three 
components: a biotin tag, an oxyethylene linker region, and a sulfhydryl-reactive 
iodoacetate group which modifies Cysteine residues in proteins (Gulcicek et al. 2005). 
ICAT labelled peptides are separated and analysed using LC-MS, with peptide pairs co-
eluting from different experimental conditions. Calculating the ratio of the areas under 
the curve for both peptides allows the relative abundance of that peptide to be 
determined, which corresponds to the protein level. 
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There are a number of limitations associated with the ICAT method. Similar to 
SILAC, the limited availability of isobaric tags limits the number of samples which can 
be included in an experiment. Labelling is also dependant on the presence of Cysteine 
residues, and therefore this method is unsuitable for proteins which lack these residues. 
(Monteoliva and Albar 2004). However, this can be turned into an advantage for 
experiments in which the goal is to enrich for proteins containing Cysteine residues. 
This method has been successfully implemented in the discovery of biomarkers and is 
able to detect and quantify low abundant proteins in complex mixtures (Gygi et al. 
2002). 
 
1.6.1.5. Isobaric Tag for Relative and Absolute Quantification (iTRAQ) 
iTRAQ is another method which uses isobaric tags for the simultaneous 
identification, both relative and absolute, of proteins in a comparative sample set. It 
utilizes labelled amine modifying chemistry with tandem mass spectrometry (MS/MS). 
This multiplexing technique allows up to eight samples (8-plex) to be analysed in a 
single experiment (Choe et al. 2007). iTRAQ tags react with all primary amines of 
peptides, which means that all peptides are labelled and information about their post-
translational modifications are retained. It requires the use of tandem-mass spectrometry 
with isobaric reporter ions being detected in the MS/MS scans.  
ITRAQ is based on the incorporation of different isobaric tags, during fragmentation in 
the second stage of MS/MS, tags are fragmented along with peptides. A reporter ion is 
released which is tag specific, and the ratio of signal intensities from these tags act as an 
indication of the relative proportions of that peptide between differentially labelled 
samples (Unwin 2010). The nature of the isobaric tags means that the same peptide 
from each of the samples in an experiment appears as a single peak in the mass 
spectrum. This reduces the data complexity associated with ICAT where heavy and 
light versions of each peptide need to be discerned (Fuller et al. 2010). 
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1.6.1.6. Tandem Mass Tags (TMT) 
TMTs are a recently developed method for the isobaric labelling of peptides 
which permits simultaneous determination of both the identity and relative abundances 
of peptide pairs from multiple samples. These tags are designed so that on analysis by 
collision-induced dissociation (CID), the TMT fragment is released to give rise to an 
ion with a specific mass-to-charge ratio. The TMT approach is similar in principle to 
other peptide isotope labelling techniques however offers some additional advantages. 
TMT tagged peptides have the same overall mass and co-migrate in chromatographic 
separations and, thus, will act as more precise reciprocal internal standards, which leads 
to more accurate quantification (Thompson, 2003). The TMT 10-plex technique allows 
for the simultaneous identification of proteins from 10 different samples and this 
method is compatible with samples derived from cells, tissues or biological fluids.  
 
1.6.2. Quantitative Label-Free Proteomics 
Quantitative label-free LC-MS/MS is a mass spectrometry based method which 
aims to measure the quantity of proteins in two or more biological samples without the 
use of labelling. It is an alternative to both gel based and labelling techniques, and seeks 
to overcome the drawbacks associated with those methods. Isotopic labelling of proteins 
or peptides is not always practical and has several disadvantages. Labelling with stable 
isotopes is an expensive technique and can be time-consuming and a very labour-
intensive method. Moreover, there may not be enough different isotopes to allow for 
simultaneous quantitation of proteins from multiple samples. The most current method 
of protein labelling is TMT however this relatively new technique only allows for 10-
plex labelling. As an alternative, many groups have presented methods of label-free 
peptide and protein quantification by comparing peptide signal intensities measured in 
sequential MS analyses. 
Quantitative label-free LC-MS/MS proteomic analysis is a popular current 
method of protein preparation whereby sample handling and potential contaminants are 
reduced allowing for high-throughput of samples. Quantitative label-free proteomics is 
based on the direct comparison of MS signal intensities between different peptides in a 
mass spectrometer (Zhu, Smith and Huang 2010). Quantitative proteomics is quickly 
becoming the method of choice for the analysis of complex samples due to its high 
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sensitivity and exceptional dynamic range. This technique involves the use of nano-high 
performance liquid chromatography (HPLC) with reverse phase chromatography prior 
to mass spectrometry analysis. Quantitative label-free LC-MS/MS was the main 
technique used in the discovery phase of the work presented in this thesis, and all 
subsequent work emerged from the proteomic data which was generated by it. Label-
free proteomics identifies proteins through a combination of bioinformatics and mass 
spectrometry. The label-free approach is based on the separate LC-MS/MS analysis of 
all samples, followed by retention time control and normalisation between the generated 
MS/MS spectra through the use of specific label-free analysis software programmes 
such as Progenesis LC-MS (Non-Linear Dynamics). Quantitative LC-MS/MS can be 
broken into two groups: peak intensity measurement based on precursor ion spectra, and 
spectral counting both of which are explained in Section 1.5.4.  
In order to provide a comprehensive overview of the basis of this quantitative 
proteomic profiling technique, what follows here is a short synopsis on each of the main 
elements involved. This will incorporate a brief outline of nano-HPLC coupled to mass 
spectrometry, the components which make this up and how proteins can be identified 
and quantified using this technology. The separation of complex samples is achieved 
through liquid chromatography prior to mass spectrometry. Liquid chromatography 
coupled to mass spectrometry (LC-MS) allows profiling of large numbers of peptides 
from complex mixtures and is an ideal method for comparing samples with different 
biological conditions. The introduction of nano-LC enables low flow separations and 
facilitate easy coupling to mass spectrometry to provide high resolution, sensitivity and 
selectivity for LC-MS proteomic applications (Gaspari and Cuda 2011). Quantitative 
label-free proteomics takes advantage of the robust and reproducible LC-MS technique 
in order to gather information from samples in sequential MS analyses. 
 As previously mentioned, mass spectrometric instruments have undergone 
extensive development in the last decade. Modern mass spectrometers allow high-
resolution sequencing, identification of post-translational modifications and have also 
significantly increased the number of protein identifications per run. Tandem mass 
spectrometry has also greatly advanced the field of mass spectrometry. It is this 
advancement which allows for peptide and subsequent amino acid identification, 
facilitating label-free quantitative accuracy. The development of ion trap-orbitrap MS 
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machinery allows high resolution, increased sensitivity compared to MS alone and 
provides a wider linear range of quantitation. The development of such state-of-the-art 
MS instruments has allowed for precision quantitation of biological samples thus 
enabling reliable quantitative label-free LC-MS/MS to be achieved.  
Increased numbers of protein databases, programs for quantitative raw data 
analysis, peptide search engines and protein scoring algorithms has provided great 
confidence in protein identifications and measurements. Data analysis programs are 
becoming more automated, user-friendly and accessible to researchers removing the 
need for bioinfomaticians to carry out in-depth interpretations of MS raw spectra and 
signal intensities. Current programs allow raw data files to be imported, basic filters to 
be applied such as choosing the genome of the sample being studied, and in a matter of 
minutes raw data will be converted to protein identification lists for each sample. 
Quantitative data analysis programs such as Progenesis, are slightly more complex, but 
advances in user friendly interfaces in these programs has enabled researchers to carry 
out their own differential analysis. Scoring algorithms such as Sequest and MASCOT 
give an indication of the confidence the program has in the peptide matches. Peptides 
can be filtered out of the data if their scoring or confidence is not high. Applying strict 
criteria and scoring thresholds to quantitative data analysis means only robust and 
strong protein candidates are presented. Increased confidence in protein identifications 
has thus given increased confidence to peptide and protein identifications obtained 
through quantitative label-free LC-MS/MS.  
Many groups have employed quantitative label-free proteomics to analyse 
samples and thus create proteomic profiles for biological states. The quantitative label-
free LC-MS/MS technique that is used for this thesis study was also employed by Linge 
et al. (2014) to investigate proteins involved in human breast cancer progression. 
Comparative label-free LC-MS/MS profiling was carried out using nano-LC coupled to 
a hybrid linear ion trap/ Orbitrap mass spectrometer. Label-free LC-MS quantitative 
analysis was carried out using Progenesis software, and MASCOT scoring criteria was 
applied to the data. This analysis revealed 45 proteins to be upregulated and 34 proteins 
to be downregulated when comparing the highly invasive to the poorly invasive breast 
cancer cell lines. Subsequent functional analyses of these deregulated proteins found 
RAD23B to have a key role in invasion and adhesion of breast cancer cells in vitro. This 
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study demonstrates that the utilisation of label-free quantitative LC-MS/MS to identify 
proteins is a valuable approach for characterising and profiling the phenotypes of 
various cell lines. 
A similar breast cancer quantitative label-free proteomics was performed by 
Dowling et al. (2014) to profile the proteome of serum from patients with advanced 
breast cancer. Nano LC-MS/MS analysis of patient serum samples identified a number 
of proteins involved in the complement and coagulation cascades to be upregulated in 
cancer serum samples. The elevated levels of such proteins were found to reflect the 
advanced stage of cancer where most tumour processes are in over-drive. Such proteins 
could be used as potential biomarkers for disease staging and patient prognosis in breast 
cancer. A quantitative proteomic approach is therefore a useful tool in identifying 
proteins associated with disease progression which contribute to the functional 
processes allowing carcinogenesis.  
Okayama et al. (2014) carried out proteomic analysis of proteins related to the 
prognosis of lung adenocarcinoma by employing shotgun proteomics. LC–MS/MS 
analysis of 21 cancerous tissue samples detected and identified a total of 875 proteins. 
Relative quantitative analysis revealed that 17 proteins were preferentially expressed in 
the poor prognosis group relative to the good prognosis group. Label-free protein 
relative quantification was performed using the Progenesis LC−MS software and 
scoring was achieved through the use of MASCOT. Among the 17 overexpressed 
proteins in the poor prognosis group, many of the proteins regulate cell adhesion and 
morphology and thus their overexpression might be involved in cancer progression. The 
results of this study strongly support the feasibility of a quantitative proteomic approach 
for identifying significant proteins associated with poor prognosis in cases of lung 
adenocarcinoma.  
Quantitative label-free LC-MS/MS was the main technique used in the 
discovery phase of the work presented in this thesis and all subsequent work flowed 
from the proteomic data which was generated by it. The above mentioned studies justify 
the use of quantitative mass spectrometry as a tool to profiling the DLKP lung 
carcinoma cell line and its subpopulations. Quantitative proteomics is quickly becoming 
the method of choice for the analysis of complex samples due to its high sensitivity, 
high reproducibility and accurate identifications.  
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1.7. Aims of Thesis 
 To identify differentially expressed proteins between the clonal subpopulations 
(DLKP-SQ, DLKP-I and DLKP-M) of a heterogeneous lung carcinoma cell 
line (DLKP) using quantitative label-free LC-MS/MS analysis, and interrogate 
the data to generate lists of the most significant differentially expressed protein 
targets. 
 
 To perform multiple analyses using various comparative proteomic 
experimental designs to highlight the strongest protein candidates associated 
with high expression in each clonal subpopulation compared to the other 
clones.   
 
 To determine potential individual protein markers for each clonal 
subpopulation based on their unique or high abundance in each cell line based 
on the quantitative LC-MS/MS analysis. Following this, validation studies will 
be carried out to support the use of the protein target as a marker for a clonal 
subpopulation within the DLKP cell line model.  
 
 To study the isolated clonal subpopulations with respect to their associated 
high abundance protein using functional cell-based assays, and to elucidate 
their role in relation to invasion and migration in cancer cells in vitro. Using 
these techniques may improve our understanding of the metastatic phenotype 
of the disease. 
 
 To investigate the potential binding partners of highly expressed proteins 
representing each clonal subpopulation. This may uncover unique protein 
interactions in this cell line model, and shed light on the role played by the 
protein targets in their respective cell lines.   
 
 To investigate the effects of co-culture of the clonal subpopulations in order to 
determine the effects on protein expression. The tumour microenvironment is 
heterogeneous in nature, and cell-cell interactions may play an important role 
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in how proteins are expressed and consequently on the phenotypic behaviour of 
the cells. 
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Chapter 2. Materials and Methods 
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2.1. Preparation of Materials for Cell Culture 
 
2.1.1. Ultrapure Water: 
Ultrapure water (UHP) was purified to a standard of 12-18 MΩ/cm resistance 
by a reverse osmosis system (Millipore MillI-RO 10 Plus, Elgastat UHP). 
 
2.1.2. Glassware: 
All glassware and lids pertaining to cell culture in any capacity were prepared 
as follows: Items were soaked in a 2% RBS-25 (Chemical Products R. Borghgraef S.A.) 
for 1 hour, after which they were scrubbed and rinsed using tap water. Following this 
they were washed in an industrial dishwasher using Neodisher detergent, which is an 
organic, phosphate-based acid detergent. Prior to sterilisation all items were rinsed 
twice with UHP. 
 
2.1.3. Sterilisation: 
Water, glassware and all thermo-stable solutions were sterilised by autoclaving 
at 121°C for 20 minutes at 15psi. Thermo-labile solutions were filtered through 0.22 μm 
sterile filters (Millipore, Millex-GV SLGV025BS). Low protein-binding filters were 
used for all protein-containing solutions. 
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2.2. Cell Culture 
All cell culture work was carried out in a class II laminar air-flow cabinet 
(Nuaire). The laminar air-flow cabinet was cleaned with 70% industrial methylated 
spirits (IMS) before and after use. Any items brought into the cabinet were also 
swabbed with IMS. At any time only one cell line was manipulated in the laminar air-
flow cabinet, and upon completion of work, 15 minutes clearance was given to 
eliminate any possibilities of cross-contamination between the various cell lines. The 
cabinet was cleaned weekly with Virkon (Antech International, P0550) and IMS. All 
cells were incubated at 37°C and where required, in an atmosphere of 5% CO2. Cells 
were fed with fresh media or sub-cultured every 2-3 days or as required in order to 
maintain active cell growth. 
Details of cell culture media and cell lines used in this study are shown in 
Table 2.1 and Table 2.2. Cell lines were maintained in T25; T75; and T175 flasks 
(Corning).  
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2.2.1. Cell Culture Media and Cell Lines: 
Media was stored in the dark at 4°C until one month before expiry. Complete 
medium was prepared by combining the components described in Table 2.1 . Complete 
media was stored at 4°C in the dark for up to one month. Aliquots of newly made cell 
culture media were taken and allowed to incubate at 37°C for up to 7 days to ensure 
sterility. Signs of contamination were assessed regularly by checking for turbidity in the 
growth media. 
Cell Line Passage Number Media 
DLKP 16 DMEM/F12 (D8437), 5% Fetal calf serum, 
Hyclone (A1011-1852). 
DLKP-SQ 32 DMEM/F12 (D8437), 5% Fetal calf serum, 
Hyclone (A1011-1852). 
DLKP-M 30 DMEM/F12 (D8437), 5% Fetal calf serum, 
Hyclone (A1011-1852). 
DLKP-I 30 DMEM/F12 (D8437), 5% Fetal calf serum, 
Hyclone (A1011-1852). 
Table 2.1: Details of media requirements for cell lines used in this study.  
 
 
2.2.2. Subculture of Adherent Cell Lines 
Exhausted cell culture medium was removed from the tissue culture flask and 
discarded into a sterile bottle. The flask was then rinsed out with 2 mL of PBS solution 
to ensure the removal of any residual media. Depending on the size of the flask, 2-5 mL 
of trypsin solution (0.25% (v/v) of Trypsin (Gibco, 043-05090) and 0.01% (v/v) of 
EDTA (Sigma, E9884) solution in PBS (Oxoid, BRI4a)) was then added. Cells were 
incubated at 37°C for approximately 5 minutes until all of the cells detached from the 
inside surface of the flask. This was monitored by microscopic observation. An equal 
volume of complete media was added to the flask to deactivate the Trypsin. The cell 
suspension was removed from the flask and placed in a sterile universal container 
(Sterilin, 128a) and centrifuged at 170 g for 5 minutes. The supernatant was then 
discarded from the universal and the pellet was suspended gently in fresh complete 
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medium. A cell count was performed as described in Section 2.2.3 and an aliquot of 
cells was used to seed a flask at the required density. All cell waste or media exposed to 
cells was autoclaved before disposal. 
 
Cell Line Details and Histology 
Invasion 
status 
DLKP 
(McBride et al. 
1998b) 
Poorly differentiated squamous 
cell lung carcinoma. 
Low 
invasive 
DLKP-SQ 
(McBride et al. 
1998b) 
Squamous subpopulation cloned 
from DLKP 
Low 
invasive 
DLKP-M 
(McBride et al. 
1998b) 
Mesenchymal-like 
subpopulation cloned from DLKP 
High 
invasive 
DLKP-I 
(McBride et al. 
1998b) 
Intermediate subpopulation 
cloned from DLKP 
High 
invasive 
Table 2.2: Cell lines used in this work with their details and invasive status. 
 
 
2.2.3. Cell Counting 
An aliquot of the cell suspension was then added to trypan blue (Gibco, 525) at 
a ratio of 1:1 (v/v). The mixture was incubated for 2-3 minutes at room temperature. An 
aliquot (10 μL) was then applied to the chamber of a glass coverslip-enclosed 
haemocytometer. For each of the four grids, cells in the 16 squares were counted. Non-
viable cells stained blue, while viable cells excluded the trypan blue dye. The average 
number of viable and dead cells per 16 squares was multiplied by a factor of 1 X 104 
(volume of the grid) and the relevant dilution factor to determine the average cell 
number per mL in the original cell suspension. Using the data for viable and non-viable 
cells, percentage viability was calculated. 
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2.2.4. Cryopreservation of Cells 
Cells for cryopreservation were harvested in the mid-log phase of growth and 
counted as described in Section 2.2.3. Cell pellets were resuspended in a suitable 
volume which of FCS which had been cooled to 4°C. An equal volume of filter 
sterilized solution of 10% (v/v) DMSO in serum was added drop-wise with mixing into 
the cell suspension. 1mL of cell suspension was then aliquoted into cryovials (Greiner, 
122278) and immediately placed on ice for 15 minutes. Following this, cryovials were 
transferred into the -20 °C freezer for 1 hour and then placed in at -80°C for four hours 
or overnight. The cryovials were then transferred to liquid nitrogen tank for long term 
storage (-196°C). 
 
2.2.5. Thawing of Cryopreserved Cells 
A volume of fresh complete culture medium pre-warmed to 37°C and 8 mL 
was added to a sterile universal. The cryopreserved cells were removed from the liquid 
nitrogen and thawed at 37°C as quickly as possible. The cells were removed from the 
vials and transferred into the pre-warmed aliquoted media in the universal. The resulting 
cell suspension was centrifuged at 170 g for 5 minutes. The supernatant was removed 
and the pellet was resuspended in the pre-warmed culture medium. This cell suspension 
was then transferred to a T-75 cm2 flask and allowed to attach and grow overnight in an 
incubator. The following day, the culture media was replaced with fresh complete 
culture medium to remove any non-viable cells and floating cells. 
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2.2.6. Mycoplasma Analysis of Cell Lines 
Mycoplasma testing was carried out for all cell lines for possible Mycoplasma 
contamination in house by Mr. Michael O’ Donoghue at the NICB. 
 
2.2.6.1. Indirect Staining Procedure for Mycoplasma Analysis 
Normal rat kidney fibroblast (NRK) cells were seeded onto sterile coverslips in 
sterile petri dishes (Greiner, 633 185) at a cell density of 2x103 cells/mL and were 
allowed to attach overnight at 37°C in a 5% CO2 humidified incubator. 1 mL of cell-
free supernatant from each test cell line was inoculated onto an NRK petri-dish and 
incubated as before until the cells reached 20-50% confluency. After this time, the 
waste medium was removed from the dishes, the coverslips (Chance Propper, 22 x 22 
mm) were washed twice with sterile PBS, once with a cold PBS/Carnoys (50/50) 
solution and fixed with 2 mL of Carnoys solution (acetic acid:methanol, 1:3) for 10 
minutes. The fixative was removed and dried coverslips were washed twice in deionised 
water and stained with 2 mL of Hoechst stain (BDH) (50ng/mL) for 10 minutes. From 
this point on, work proceeded without direct light to limit quenching of the fluorescent 
stain. The coverslips were rinsed three times in PBS. They were then mounted in 50% 
(v/v) glycerol in 0.05 M citric acid and 0.1 M disodium phosphate and examined using a 
fluorescent microscope with a UV filter. A Mycoplasma infection would be seen as 
small fluorescent bodies in and sometimes outside the cells. 
All cell lines used in this thesis are confirmed to be Mycoplasma free. 
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2.3. Western Blot Analysis 
2.3.1. Preparation of Whole Cell Protein Lysates 
Cells were grown to the desired confluency in monolayer culture flasks 
(T75/T175). Media was removed and cells were washed twice with sterile PBS. Excess 
PBS was removed and 500 μL of ‘2D lysis buffer’ was added directly to the monolayer 
of cells in a T75 flask, 1 mL for a T175 flask. 2-D lysis buffer contains 7 M urea (Sigma 
Aldrich, 208884), 2 M thiourea, 4% (w/v) (Sigma Aldrich, T8656), CHAPS (Sigma 
Aldrich, C3023), 40 mM DTT (Sigma Aldrich, D9163). The flask was incubated on ice 
for 5 minutes, and gently swirled regularly to ensure complete coverage of the 
monolayer by the lysis buffer. The cell lysate was scraped down to a corner of the flask 
using a P1000 tip and gently aspirated five times. The cell lysate was then transferred to 
a 1.7 mL Eppendorf tube and incubated at room temperature for 30 minutes after the 
addition of protease inhibitor (Thermo Fisher Scientific, 78430). This was centrifuged at 
18,620 g for 15 minutes at 4°C, and the supernatant was removed and stored at -80°C 
for future use. 
2.3.2. Protein Quantification 
Protein concentration was determined using the thiourea-compatible Quick 
Start Bradford Protein Assay Kit (Bio-Rad, 500-0201), containing 2 mg/mL of bovine 
serum albumin (BSA) solution as a known standard. Dilutions of BSA stock for 0.125, 
0.25, 0.5 and 1.0 mg/mL were prepared and used for generating a protein standard 
curve. Samples for quantification were diluted to reduce their concentration so as to fit 
within the range of the assay. Dilution factor was determined based on a visual test by 
mixing neat protein lysate with the assay reagent prior to sample preparation. 5 μL of 
protein standard dilutions, and prepared samples were added to a 96-well plate. 250 μL 
of thiourea-compatible Bradford protein assay reagent (Bio-Rad, 500-0205) was then 
added each protein containing well in the plate. After 5 minutes incubation, the 
absorbance was assessed at 595nm. All samples were assayed in triplicate. The 
concentration of the protein samples was determined from the plot of the absorbance at 
595nm versus the concentration of the protein standard. 
Protein concentration was assayed using the Pierce BCA Protein Assay Kit 
(Cat#23227), when lysis buffers were incompatible with the Bradford assay. 
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2.3.3. 1-D Gel Electrophoresis 
Proteins for analysis by Western blotting were resolved using 4-12% NuPAGE 
Bis-Tris Gels (Life Technologies, NP0322BOX) in XCell SureLock™ Mini-Cell (Life 
technologies, EI0001) running instrument. Protein samples were prepared for 1-D gel 
electrophoresis by taking the required volume to equalise the protein concentration 
across a sample set from the protein lysate sample preparation as described in Section 
2.3.2. Volumes of all samples were then equalised by the addition of PBS. Finally an 
equal volume of 2X loading buffer (Sigma, S3401) containing mercaptoethanol and 
bromophenol blue was added to each sample. The samples were heated at 95 °C for 5 
minutes on a heating block and allowed to cool to room temperature before being 
centrifuged. 10-40 μg of protein and 5 μL of molecular weight marker (Thermo, 26634) 
were loaded into the wells of a gel. The samples were electrophoretically separated at 
200 V and 45 mA using a 1X MOPS/SDS running buffer (Life Technologies, NP001) 
until the bromophenol blue dye reached the bottom of the gel. 
2.3.4. Western Blotting 
Once electrophoresis had been completed, the gel was equilibrated in a 1X tris-
glycine transfer buffer (Bio-Rad, 161-0734) containing 20% methanol for 
approximately 10 minutes. Five sheets of Whatman 3mm filter paper (Whatman, 
1001824) were soaked in freshly prepared transfer buffer. These were then placed on 
the cathode plate of a semi-dry blotting apparatus (Bio-Rad). Air pockets were then 
removed from between the filter paper by rolling with a clean pipette. PVDF membrane 
(GE Healthcare, 10600021) was activated by soaking in 100% methanol and 
equilibrated using the transfer buffer prepared earlier. This was placed over the filter 
paper on the cathode plate. Air pockets were once again removed. The gels were then 
placed onto the membrane, and five additional sheets of transfer buffer-soaked filter 
paper were placed on top of the gel. All air pockets removed and excess transfer buffer 
removed from the cathode plate. Proteins were transferred from the gel to the membrane 
at a current of 340 mA at 15 V for 23-30 minutes depending on the Mw of the protein 
under investigation. 
Following protein transfer, the PVDF membrane was blocked for two hours 
using 5% Marvel (Cadburys; Marvel skimmed milk) in TBS-T (a mixture of 1X tris-
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buffered saline (TBS) (Sigma, t5912) containing 0.05% Tween 20 (Sigma, P5927)). The 
membrane was washed with TBS-T prior to the addition of the primary antibody, 
prepared in 5% Marvel in TBS-T at recommended dilutions, and then incubated 
overnight at 4 °C. The membrane was then rinsed 3 times with TBS-T for a total of 30 
minutes. Relevant secondary antibody (1/2000 dilution of anti-mouse (Dako 
Cytomation, P0260) or anti-rabbit (Dako Cytomation, P0448) was added for 2 hours at 
room temperature. The membranes were again washed three times thoroughly in TBS-T 
for 30 minutes. 
 
All primary and secondary antibodies used for Western Blot analysis are shown below 
in Table 2.3. 
 
Antibody Dilution and 
Application 
Details 
Shootin-1  1:1000  Pierce: PA5-17167 
MARCKS 1:5000  Abcam: ab52616 
Desmoglein-3 1:2000  Abcam: ab78448 
Desmoglein-3 1:3000  Bio-Sciences: #326300 
Striatin-3 1:500  Pierce: MA1-46461 
Src-Substrate Cortactin 1:1000  Pierce: PA5-17273 
Semenogelin-1 1:500  Abcam: ab139405 
Junction Plakoglobin 1:1000  Pierce: PA5-17320 
Pyruvate Dehydrogenase E1 1:500  Abcam: ab168329 
Pyruvate Dehydrogenase E2 1:1000  Abcam: ab131200 
Beta-Actin 1:10,000  Abcam: ab20272 
Alpha Tubulin 1: 3000 Abcam: ab4074 
Secondary Antibodies Dilution and 
Application 
Details 
Anti-Mouse 1:2000  Dako: P0447 
Anti-Rabbit 1:2000  Dako: P0448 
Table 2.3: List of all antibodies used in this study for Western Blot along with their dilutions. 
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2.3.5. Enhanced Chemiluminescent Detection Using Autoradiographic Film 
Western Blots were developed using an enhanced chemiluminescence (ECL) 
kit (GE Life Sciences, RPN2106), which facilitated the detection of bound peroxidase-
conjugated secondary antibody. Following the final washing, membranes were 
subjected to ECL. The membrane was placed on a sheet of transparent plastic and 5 mL 
of a freshly prepared 1:1 (v/v) mixture of ECL reagent A and B was used to cover the 
membrane. The ECL reagent mixture was completely removed after a period of five 
minutes and the membrane was covered in a layer of transparent plastic. All excess air 
bubbles were removed. The membrane was then exposed to autoradiographic film (GE 
Life Sciences, 95017-681) for various times (from 10 seconds to 15 minutes depending 
on the intensity of the signal). The exposed autoradiographic film was developed for the 
appropriate time in developer solution (Kodak, LX24, diluted 1:5 in water) until clear 
bands developed. The film was then briefly washed in water and transferred to a fixative 
solution (Kodak, FX-40, diluted 1:5 in water) for 5 minutes. The film was washed with 
water for 5-10 minutes and left to dry at room temperature. 
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2.4. RNA Interference (RNAi) 
RNAi using small interfering RNA (siRNA) was carried out to transiently 
knockdown the expression of Shootin-1, MARCKS, and Desmoglein-3 at the protein 
level. Two independent siRNA molecules were used for each protein (Life 
Technologies). These siRNAs were 21-23 bps in length and were introduced to the cells 
via reverse transfection with Lipofectamine 2000 Transfection Reagent (Life 
Technologies, 13778075). 
 
2.4.1. Transfection Optimisation 
In order to determine the optimal conditions for siRNA transfection, cell 
concentrations required for RNAi transient transfections were first established for each 
cell line. Cell suspensions were prepared at 5X104, 7.5 X 104, 1X 105, 2.5 X 105, and 5 
X 105 cells per well, and were allowed to grow for 72 hours. This was carried out in 
order to determine which cell concentration allows the cells to be in late exponential 
phase at the end of the transfection (after 72 hours incubation), ensuring healthy 
proliferating cells will be used in the follow on functional assays. Transfections were 
optimised further to determine optimal transfection reagent volume required to 
efficiently transfect each cell type, and optimal the siRNA concentrations to achieve the 
greatest knockdown of specific targets.  
The general method used for siRNA transfection is as follows. Solutions of 
siRNA at their required concentrations were prepared in optiMEM (GibcoTM, 
31985047). Separately, a Lipofectamine 2000 solution was made up as a master mix 
using optiMEM with enough volume required for all transfection samples. Both of these 
solutions were incubated at room temperature for 12 minutes before being combined 
together. Each of the newly combined siRNA/Lipofectamine solutions were incubated 
at room temperature for a further 12 minutes. 100 μL of the siRNA/Lipofectamine 
solutions were added in a drop-wise fashion to each well of a 6-well plate, with each 
well containing 1 mL of a cell suspension at the required concentration. The plates were 
mixed gently and incubated at 37 °C for 6 hours. After this time, the transfection 
mixture was removed from the cells and the plates were fed with fresh complete 
medium.  
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2.4.2. siRNA Transfection for Functional Analyses 
Two pre-designed siRNAs were chosen for the protein targets and transfected 
into cells. For each set of siRNA transfections carried out a group of controls were 
always used which were: Non transfected cells-only control; Lipofectamine-only 
control cells; and a Negative siRNA transfected cells control. Negative siRNA are 
sequences that do not have homology to any genomic sequence. The Negative non-
targeting siRNA used in this study is commercially produced, and guarantees siRNA 
with a sequence that does not target any gene product. It has also been functionally 
proven to have no significant effects on cell proliferation, morphology and viability. 
For each set of experiments investigating the effect of siRNA, the cells 
transfected with target-specific siRNAs were compared to cells transfected with 
Negative siRNA. This takes into account of any effects due to the siRNA transfection 
procedure, reagents, and also any random effects of the Negative siRNA. Western blots 
were used to determine if siRNA had an efficient knock-down effect at a protein-level. 
All siRNA used in these experiments are shown in Table 2.4. 
 
 
Target siRNA Details siRNA 
Concentration 
Shootin-1 s33622; s33623, Ambion 20 nM 
MARCKS s8385; s8386, Ambion 20 nM 
Desmoglein-3 s4327; s4328, Ambion 10 nM 
Negative siRNA No. 1 4390843, Ambion As required 
Negative siRNA AllStars 1027280, Qiagen As required 
Kinesin (Kif11) s7903, Ambion 5 nM 
Table 2.4: siRNAs used in this study with their details and their required 
concentrations. 
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2.5. Functional Analyses 
2.5.1. Acid Phosphatase Assay 
Following an incubation period of 72 hours, media was removed from the 
plates. Each well on a 6-well plate was washed twice with 2 mL PBS. This was then 
removed and 2 mL of freshly prepared phosphatase substrate (10 mM p-nitrophenol 
phosphate (Sigma 104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 
(Sigma, X100), pH 5.5) was added to each well. The plates were then incubated in the 
dark at 37 °C for 2 hours. Colour development was monitored during this time. The 
enzymatic reaction was stopped by the addition of 1 mL of 1 M NaOH. A 150 μL 
aliquot of each sample (5 replicates) was transferred to a 96-well plate. The plate was 
read in a dual beam plate reader at 405 nm with a reference wavelength of 620 nm.  
 
2.5.2. Proliferation Assay 
Proliferation assays on transfection optimisation steps were carried out as 
described in Section 2.5.1. For functional analysis of proteins of interest, proliferation 
assays were performed using the cell counting method as described in Section 2.2.3 in 
order to assess cell viability in conjunction with proliferation. 
 
2.5.3. Invasion Assay  
2.5.3.1. Preparation of Inserts 
Matrigel (BD Biosciences, 354234) was diluted to a working stock of 1 mg/mL 
in serum- free DMEM. Aliquoted stocks were stored at -20°C. A volume of 100 μL of 
Matrigel was placed into each insert (BD Biosciences, 353097) (8.0 μm pore size, 24 
well format) and kept at 4°C for 24 hours. The insert and the plate were then incubated 
for one hour at 37°C to allow the proteins to polymerise. Cells were harvested and 
resuspended in culture media containing 5% FCS at 1×106 cells/mL. Excess media was 
removed from the inserts, and they were rinsed with 200 µL of culture media. A 100 μL 
volume of complete cell culture media was added to each insert. A 100 μL volume of 
cell suspension was added to each insert and 500 μL of culture media containing 5% 
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FCS was added to the well underneath the insert. Cells were incubated for 24 hours. 
Cell numbers seeded in each assay are shown in Table 2.5. 
Cell Line Cell Seed Number 
per Insert 
DLKP-SQ 1x105 cells 
DLKP-M 7.5x104 cells 
DLKP-I 1x105 cells 
Table 2.5: Seeding number for each cell line used for migration and 
invasion assays. 
 
 
2.5.3.2. Staining of Invaded Cells 
After the 24 hour incubation, the inside of the insert was wiped with a cotton 
swab dampened with PBS, while the outer side of the insert was stained with 0.25% 
crystal violet for 10 minutes and then rinsed in distilled water (dH2O) and allowed to 
dry. The inserts were viewed and photographed under the microscope.  
2.5.3.3. Counting of Invaded Cells 
To determine the total number of invading or migrating cells, the number of 
cells/field in 15 fields was counted at 200x magnification. The average number of cells 
per field was then multiplied by a conversion factor of 140 (growth area of membrane 
divided by field of viewed area at 200x magnification). All assays were subjected to 
statistical analysis using Student’s t-tests (2-tailed, 2-sample unequal variance). A 
minimum of 2 inserts were used per sample tested. 
 
2.5.4. Migration Assay 
Migration assays were carried out as described in Section 2.5.3 except inserts 
were not coated with Matrigel. Cell counts were also carried out as for invasion assays. 
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2.6. Immunostaining of Fixed Cells. 
2.6.1. Fixation of Cells Prior to Staining 
30 μL volumes of cells a concentration of 1×106 cells/mL were plated directly 
onto sterilised 10 well, 7 mm microscope slides (Erie Scientific Company, 465-68X) 
from actively growing cultures. Cells were allowed to attach overnight. After this time, 
slides were washed 3 times in PBS before fixation. Slides were submerged in a solution 
of 4% Paraformaldehyde for a maximum of 10 minutes before being permeabilzed with 
a 0.2% TritonX-100 (Sigma) in PBS solution for 10 minutes. After this process, cell 
slides were kept in cold PBS, never being allowed to dry out, and used for follow up 
staining procedures within 1 hour. 
 
2.6.2. Immunocytochemistry  
All immunocytochemical (ICC) staining was performed using the DAKO 
Autostainer (DAKO, S3800). The slides were immersed in wash buffer (DAKO, 
S3006). On the Autostainer slides were blocked for 10 minutes with 200 μL HRP Block 
(DAKO, S2023). Cells were washed with 1× wash buffer and 200 μL of primary 
antibody of interest was added to the slides for 20 minutes. Slides were washed again 
with 1× wash buffer and then incubated with 200 μL Real EndVision  DAKO, K4065) 
for 30 minutes. A positive control slide was included in each staining run. Each slide 
was also run with Negative Control Reagent (1× TBS/0.05% Tween-20), to allow 
evaluation of non-specific staining and allow better interpretation of specific staining at 
the antigen site. All slides were counterstained with haematoxylin (DAKO) for 5 
minutes, and rinsed with deionised water, followed by wash buffer. All slides were then 
dehydrated in graded alcohols (2 immersions x 3 minutes each in 70% IMS, 90% IMS 
and 100% IMS), and cleared in Xylene (2 immersions x 5 minutes), and mounted with 
coverslips using DPX mountant (Sigma, 44581). Slides were sealed with clear nail 
varnish. 
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2.6.3. Immunofluorescence 
Non-specific binding sites were blocked by incubating with 5% (v/v) normal 
serum (NS) in PBS for 30 minutes at room temp. The blocking serum was removed and 
the cells were incubated with the primary antibody of interest diluted in 1% v/v NS in 
PBS. This was incubated overnight at 4°C. Cells were washed 3× in PBS and secondary 
antibody (AlexoFluor, Thermo) which was diluted 1:1000 was added for 2 hours at RT. 
Secondary antibody was removed and cells were washed 3× in PBS. Finally, slides were 
counterstained using Dapi nuclear stain (Sigma, D9542). After washing 3× in PBS, 
slides were mounted with ProLong Gold mounting medium (P36930) and covered using 
a glass cover slip. Slides were sealed using clear nail varnish. Cells were viewed and 
photographed using a Nikon phase contrast microscope fitted with a mercury-vapour 
lamp.  
 
2.6.4. Co-Labelling of Cells Transfected Using RNAi 
Cells were set up for RNAi transfection as described in Section 2.4.2 with 
some modifications. In place of using 6-well plates to culture the cells during the 
transfection, the procedure was carried out using sterilized glass coverslips in their 
place. The glass coverslips were places in 30 mm tissue culture dishes and the 
transfection procedure was carried out. Coverslips were used as their thin profile allows 
better image quality when using confocal microscopy. 48 hours post-transfection, cell 
slides were scraped once using a P1000 tip to induce a migratory response prior to 
staining. Cells were stained 72 hours post transfection using an adapted version of the 
method described in Section 2.6.3. Slides were washed 3× in PBS and blocked using 
5% (v/v) normal serum in PBS to reduce non-specific interactions. After blocking, cells 
were stained with the primary antibody of interest overnight at 4°C, followed by 
washing 3× in PBS. Staining using fluorophore-conjugated secondary antibody was 
then carried out using an incubation time of 2 hours at RT.  Following another washing 
step, cells were stained using the F-Actin stain Phalloidin (Thermo, A12379) for 20 
minutes at RT. Cells were washed 5× in PBS before being mounted on glass slides with 
ProLong Gold mounting medium. Imaging was performed using confocal microscopy 
with the invaluable help of Dr Finbarr O’Sullivan. 
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Details of antibodies used in staining procedures are shown in Table 2.6. 
 
 
Antibody Dilution and Application Details 
Shootin-1 IF-1/5000; ICC-1/5000  Atlas: HPA037943 
MARCKS IF- 1/200  Abcam: ab52616 
Desmoglein-3 IF- 25μg/ml; ICC-25μg/ml Bio-Sciences: #326300 
Secondary Antibodies   
Anti-Mouse 1:2000 IF/ICC Thermo: A11001 
Anti-Rabbit 1:2000 IF/ICC Thermo: A11008 
Table 2.6: Details of antibodies used in cell staining methods. 
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2.7. Quantitative Label-Free LC-MS/MS Analysis 
2.7.1. Preparation of Protein from Cell Lines 
Cells for analysis by quantitative label-free LC-MS/MS were lysed to extract 
protein using the method described in Section 2.3.2. Quantification of protein 
concentrations of cell lysates was carried out with the Quick Start Bradford Protein 
Assay Kit (Bio-Rad, 500-0201) using the method described in Section 2.3.2. Following 
this, a buffer exchange step was performed in order to remove CHAPS detergent from 
the samples. 100 μg of protein from each sample (determined by Bradford assay) was 
placed into a clean Eppendorf and the protein was precipitated using a 2-D-clean-up kit 
(Bio-Rad, 163-2130), overnight in acetone at -20°C. Precipitated proteins were 
centrifuged for 15 minutes at 13,680 g at 4°C. The supernatant was discarded and the 
protein pellet was resuspended in 6M Urea, 2M Thiourea, 10 mM Tris, pH 8. 0.4% 
ProteaseMAX (Promega, V2071), a surfactant and Trypsin enhancer was added to 
improve protein solubility. The sample was sonicated and vortexed to ensure complete 
resuspension of precipitated proteins. 
 
2.7.2. Quantification of Protein for Digestion 
Quantification of buffer exchanged protein concentrations for each sample 
were determined with the Quick Start Bradford Protein Assay Kit (Bio-Rad, 500-0201) 
using a modified version of the method described in Section 2.3.2, and was performed 
prior to digestion and subsequent quantitative LC-MS/MS analysis. Accurate protein 
quantification at this stage is the foundation of a good label-free quantitative analysis to 
ensure protein concentrations can be precisely equalised across the entire sample set. 5 
μL of standards and samples were added to the 96-well plate, with five replicates for 
each condition to be assayed. 250 μL of thiourea-compatible Bradford protein assay 
reagent (Bio-Rad, 500-0205) was then added each protein containing well in the plate. 
After 5 minutes incubation, the absorbance was read at 595nm. Sample replicates were 
required to have a coefficient of variation (CV) of < 1.5%.  
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2.7.3. In-Solution Digest of Proteins for LC-MS/MS Analysis 
Preparation of individual protein samples for label-free LC-MS/MS analysis 
was carried out in accordance with the ProteaseMax Surfactant Trypsin enhancer in-
solution digestion protocol (Promega). For label-free LC-MS/MS analysis, 10 µg of 
each sample was prepared and volumes were normalised to 50 µL using 50 mM 
ammonium bicarbonate (Sigma-Aldrich, 09830). All samples were reduced for 20 
minutes with a final concentration of 5 mM Dithiothreitol in 50 mM ammonium 
bicarbonate at 56oC followed by alkylation for 15 minutes in the dark at room 
temperature using a final concentration of 15 mM Iodoacetamide in 50 mM ammonium 
bicarbonate. A volume of 0.1% (v/v) ProteaseMAX (Promega, V2071) was then added 
to each fraction. Finally, protein digestion was carried out using sequencing-grade 
Trypsin Gold (Promega, V5280) at a ratio of 1:20 (protease:protein) overnight at 37oC. 
Components and volumes required for this procedure are shown in Table 2.7. The 
enzymatic digestion was stopped by adding Trifluoroacetic acid (TFA) (Sigma-Aldrich, 
T6508) to a final volume of 0.1% (v/v).  
 
 
 
 
Component Volume (μL) 
10 μg of protein for digestion As required 
50 mM ammonium bicarbonate Up to 93.5 
0.5 M DTT 1 
0.55 M Iodoacetamide 2.7 
Trypsin (1μg/µL) 1.8 
1% ProteaseMAX Surfactant 1 
Final Volume 100 
Table 2.7: Components for in-solution digest prior to label-free     
LC-MS/MS analysis 
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2.7.4. C-18 spin column peptide concentration  
In order to concentrate the peptides in each sample after the digestion process 
(Section 2.7.3) samples were purified using Pierce C-18 spin columns (Thermo 
Scientific, #89870). Buffers were prepared as shown in Table 2.8. 
 
Buffer Components 
Activation Solution 50% Methanol 
Equilibration Solution 0.5% TFA in 5% ACN 
Sample Buffer 2% TFA in 20% ACN 
Wash Solution 0.5% TFA in 5% ACN 
Elution Buffer 70% ACN 
Table 2.8: Buffers required for C-18 peptide cleanup.  
  
All centrifugation steps were carried out at 1500 g for 1 minute. The spin 
column was prepared by gentle tapping until the resin was collected at the bottom after 
which it was placed into a collection tube. 200 μL of activation solution was used to 
rinse the column walls and to wet the resin, followed by centrifugation. Flow through 
was discarded and this step was repeated. Next, 200 μL of equilibration buffer was 
added and the column was centrifuged, flow-through discarded and the step repeated. 
Peptide samples were loaded into the resin bed of individual columns. The column was 
placed into a receiver tube and centrifuged. The flow-through was added to the resin 
bed once more to achieve maximum binding before re-centrifugation. The column was 
placed into a receiver tube and 200 μL of wash solution was added and centrifuged. The 
flow-through was discarded and the wash step was repeated. The column was placed 
into a new receiver tube. 20 μL of elution buffer was placed on top of the resin and 
centrifuged at 1500 g for 1 minute. This step was repeated with an additional 20 μL of 
elution buffer to yield a final volume of 40 μL of purified peptides. Samples were dried 
using a vacuum centrifuge (Maxi Dry Plus vacuum, MSC) until required. The resulting 
lyophilised peptides were re-suspended in 0.1% TFA in 2% acetonitrile with agitation 
and sonication prior to LC-MS/MS analysis. 
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2.7.5. LC-MS/MS Analysis 
An Ultimate 3000 NanoLC system (Thermo Fisher Scientific) coupled to an 
LTQ Orbitrap XL mass spectrometer from Thermo Fisher Scientific (Dublin, Ireland) 
was used for the nano LC-MS/MS analysis. Digested peptide samples (1 g) were 
loaded onto a C18 trap column (C18 PepMap, 300 m id × 5 mm, 5 m particle size, 
100 Å pore size; Thermo Fisher Scientific). Peptide trapping was carried out at a flow 
rate of 25 L/min in 0.1% TFA and 2% Acetonitrile (ACN) (Sigma-Aldrich, 34967) for 
5 minutes. The trap column was switched on-line with an analytical PepMap C18 
column (75 m id × 500 mm, 3 m particle, and 100 Å pore size; Thermo Fisher 
Scientific). Peptides were eluted using binary gradients of two solvent solutions A and 
B: Solvent A (2% ACN and 0.1% formic acid (Sigma-Aldrich, 94318) in LC-MS grade 
water (Sigma-Aldrich, product no. 39253); Solvent B (80% ACN and 0.08% formic 
acid in LC-MS grade water). 0%–25% of Solvent A was used for the first 240 min and 
25%–50% of Solvent B for the remaining 60 min, resulting in a 5 hour total elution 
gradient. The column flow rate was set to 350 nL/min. Data was acquired with Xcalibur 
software, version 2.0.7 (Thermo Fisher Scientific).  
 
Quantitative Label-Free MS: Separates the peptides using a 300 min linear 
gradient elution using Solvent A (0.1% formic acid) and Solvent B (0.08% formic acid, 
80% acetonitrile) starting with 2% Solvent B to 25% B over 240 min and 25%-50% B 
for 60 minutes at a flow rate of 350 nL/min.  
Qualitative MS Separates the peptides using a 60 min linear gradient elution 
using Solvent A (0.1% formic acid) and Solvent B (0.08% formic acid, 80% 
acetonitrile) starting with 2% Solvent B to 90% B over 60 min at a flow rate of 350 
nL/min.  
The MS was operated in data-dependent mode and externally calibrated. 
Survey MS scans were acquired in the Orbitrap in the 400–1800 m/z range with the 
resolution set to a value of 30,000 at m/z 400 and lock mass set to 445.120025 u. 
Collision induced dissociation (CID) fragmentation was carried out in the linear ion trap 
with up to three of the most intense ions per scan. Within 40s, a dynamic exclusion 
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window was applied. A normalised collision energy of 32%, an isolation window of 2 
m/z, and one microscan were used to collect suitable tandem mass spectra. 
 
2.7.6. Quantitative Profiling using Label-Free LC-MS/MS analysis 
The following two sections describe the analysis of LC-MS/MS data to generate 
quantitative protein identifications based on the experimental design chosen in the 
software. 
2.7.6.1. Detection of Differentially Expressed Peptides 
Progenesis QI for Proteomics label-free LC-MS software version 3.1 
(Nonlinear Dynamics, a Waters company) was used to process the MS data generated 
from the LC-MS/MS analysis. Data alignment was based on the LC retention time of 
each LC-MS sample, allowing for any drift in retention time given and adjusted 
retention time for all runs in the analysis. The sample run that yielded most features 
(i.e., peptide ions) was chosen to be the reference run. The retention times of all other 
runs were aligned to this reference run and peak intensities were normalised against it. 
Once alignments were complete, the following parameters were applied to filter out 
features which did not meet with the following criteria: (i) peptide features with 
ANOVA p < 0.05 between experimental groups, (ii) mass peaks (features) with charge 
states of +1, +2 and +3, and (iii) greater than one isotope per peptide. Comparative 
experimental designs were set up using the software, and differentially expressed 
peptides were subjected to the protein identification workflow. 
 
2.7.6.2. Protein Identification 
A MASCOT generic file was generated from all exported MS/MS spectra from 
Progenesis QI for Proteomics software after the comparative analysis was performed. 
The MASCOT generic file was used for peptide identification by importing the MS/MS 
data into Proteome Discoverer 1.4 (Thermo Fisher Scientific). The data was searched 
against a human FASTA database, downloaded from UniProKB/SwissProt in January 
2015. Using both MASCOT and Sequest (HT) search algorithms, the following search 
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parameters were set for protein identification: (i) MS/MS mass tolerance set at 0.6 Da; 
(ii) peptide mass tolerance set to 20 ppm; (iii) up to two missed cleavages were allowed; 
(iv) cysteine carbamidomethylation set as a fixed modification; (v) methionine 
oxidation set as a variable modification; (vi) MASCOT peptide ion score set to a 
minimum of 40; (vii) Sequest HT XCorr was set at 1.9 for +1 ions, 2.2 for +2 ions, and 
3.75 for +3 ions. Peptide identifications generated from Proteome Discoverer 1.4 were 
exported as a PepXML file and imported back into Progenesis QI software. 
Once the peptide identification information was re-imported into Progenesis QI 
software, newly identified proteins were reviewed and only those which passed the 
following criteria were considered confidently identified and statistically significant: (i) 
an ANOVA p-value of <0.05 between experimental groups; (ii) proteins with ≥2 
peptides contributing to the identification; (iii) a fold change between experimental 
groups of ≥2. Details on the experimental designs applied in Progenesis QI software, as 
well as the processing of the differentially expressed protein lists are described in 
Chapter 3.  
 
 
2.8. Immunoprecipitation 
2.8.1. Direct Immunoprecipitation 
This method is also known as traditional immunoprecipitation. Proteins were 
isolated from cell lines using a gentle lysis buffer (Thermo Fisher Scientific, #87787) to 
preserve protein complexes using the method described in Section 2.3.1. Protein 
extracts were quantified using the Pierce BCA Protein assay Kit (Cat #23227) which is 
compatible with the gentle lysis buffer. Samples were diluted to a concentration of 1 
mg/mL in a final volume of 1 mL using the gentle lysis buffer.  Protein-G agarose beads 
(Sigma, P3296) were washed x3 in PBS before being added to the 1 mL test aliquot of 
protein extract for pre-clearing. 60 μL of Protein-G beads were added to the sample 
using a cut P-1000 pipette tip to minimise damage to the beads. All samples were 
incubated for 4 hours at 4°C on a rocking platform for pre-clearing. Beads were 
removed by spinning at 1000 g for 1 minute at 4°C. Supernatants were removed to clean 
Eppendorf tubes and divided evenly to represent the test sample and the negative 
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control.  The primary antibody of interest was added to the test sample, and IgG 
matching the host species of the primary antibody was added to the negative control. 
Antibody/lysate mixtures were incubated at 4°C overnight on a rocking platform.  
The following day, in order to precipitate the antibody-antigen complex, newly 
prepared Protein- G agarose beads were added to the samples as before and incubated at 
4°C for 4 hours on a rocking platform. Beads were removed by spinning at 1000 g for 1 
minute at 4°C, and the supernatant was saved as the ‘unbound fraction’. The beads were 
then washed for 5 x 2-minute periods with gentle lysis buffer and pelleted at 1000 g 
between each wash for 1 minute. Following the final wash, the sample/bead solution 
was transferred to a spin column (Sigma, SC1000) before another centrifugation step as 
before.  70 μL of 2X Laemelli sample buffer was added to both sets of Protein-G beads 
before being heated to 95°C on a heating block. Samples were spun at 12000 g for 2 
minutes and eluted into fresh Eppendorf tubes. Elutions were made to a 1x 
concentration with PBS and were stored at -20°C until required.  
 
 
2.8.2. Cross-Linked Immunoprecipitation 
Cross Linked IP were carried out using the Pierce Co-Immunoprecipitation Kit 
(Thermo Fisher Scientific, #26149). 200 μL of AminoLink resin was added to a spin 
column, and spun down at 1000 g for 1 minute (all subsequent centrifugation steps were 
at this speed and duration). The resin was washed twice with 0.4 mL of Coupling 
Buffer, centrifuged and excess solution discarded. The primary antibody of interest was 
added to the resin, along with 200 mL of Coupling Buffer (same for negative control 
IgG). 3 μL of Reducing Agent (Sodium Cyanoborohydride) was added to the mixture 
antibody/resin, which was then incubated at RT for 90 minutes. This step is to facilitate 
cross-linking of the antibody to the resin. The resin was then centrifuged and washed 2 
times with 0.2 mL Coupling Buffer. Following this, 0.2 mL of Quenching Buffer was 
added to the suspension, centrifuged, and excess solution discarded. 0.4 mL of 
Quenching Buffer was then added to the gel/antibody complex, along with 3 μL of 
Reducing Agent. This suspension was incubated with end-over-end mixing, for 30 
minutes at room temperature, followed by centrifugation and discarding of any excess 
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solution. The gel was then washed 2 times with 0.2 mL Quenching Buffer, followed by 
6 washes in 0.4 mL Wash Solution, with centrifugation following each wash.  
The protein sample was prepared as described in Section 2.8.1, and added to 
the resin/antibody complex. This solution was incubated overnight at 4°C on a rocking 
platform. The following day, the sample was centrifuged, and excess solution discarded. 
The resin/antibody-antigen complex was then washed 3 times in 0.4 mL 
Immunoprecipitation Buffer, with centrifugation after each wash. The antigen/antibody 
complex was then eluted with the addition of 200 μL of a low pH Elution Buffer to the 
solution, followed by 5-minute incubation at room temperature. The low pH of the 
buffer was neutralised with the addition of 5 μL of a Tris-HCl, pH 9.5, solution. 
Elutions were made to a 1x concentration with PBS and were stored at -20°C until 
required. 
Both types of immunoprecipitation using direct and cross-linked methods are 
graphically displayed in Figure 2.1. 
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Figure 2.1: Traditional IP vs. Cross linked IP diagram. The advantage of 
cross linked IP is the antibody is not eluted with the target protein. Elimination 
of interfering heavy and light antibody chains and results in a clearer SDS gel 
for Western Blot analysis, or identification of proteins (www.piercenet.com) 
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2.8.3. 1-D Gel Electrophoresis of Co-Immunoprecipitated Proteins 
1-D gel electrophoresis was carried out as described in Section 2.3.3 using 4-
12% NuPAGE Bis-Tris Gels (Life Technologies, NP0321BOX) in XCell SureLock™ 
Mini-Cell (Life technologies, EI0001) running instrument). Following gel 
electrophoresis, the gel was either stained using Brilliant-blue G Colloidal Coomassie, 
or Western blot analysis was carried out as outlined in Section 2.3.4. 
2.8.4. Staining of Gels Using Brilliant Blue G- Colloidal Concentrate 
After electrophoresis, the gels were placed in a square petri dish (Sigma, 
Z617679) containing fixing solution (7% glacial acetic acid in 40% (v/v) methanol 
(ROMIL, HL109)) for 30 minutes. During this step a 1x working solution of Brilliant 
Blue G Colloidal Coomassie (Sigma, B2025) was prepared by combining 4 parts UHP 
to 1-part stain stock. Just prior to staining, a solution containing 4 parts of 1x working 
stock of Coomassie stain solution and 1-part methanol was made and thoroughly mixed. 
The gel was rinsed once with UHP water, and the Coomassie stain was poured over the 
gel. The gels were left to stain for 2 hours or overnight. To destain the background of 
the gel, UHP water was used with gentle rocking for 4 hours, or overnight.  
 
2.8.5. Excision of Protein Bands from 1-D Gels  
The stained gel was scanned and an image printed out for use as a map. The 
gel was rinsed 3x in LC-MS grade water and placed on a clean plastic plate which had 
been swabbed with 70% methanol. The work surface had also been cleaned with 70% 
methanol and great care was taken to reduce the probability of Keratin contamination 
from skin and hair. Each lane of the gel was sliced into thin sections, across the width of 
the lane using a scalpel, and cut into three smaller pieces. The approximate location of 
each gel slice was recorded on the image of the gel and an identifier was assigned to 
them. The pieces from each band were placed into individual wells of a polypropylene 
96-well plate (Greiner Bio One, 651201) with 50 μL of LC-MS grade water in each, and 
these locations were recorded on the gel map also. The plate was then stored at 4 °C 
covered in parafilm, prior to protein destaining and subsequent extraction and digestion. 
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2.8.6. In-Gel Digestion of Proteins 
2.8.6.1. Destaining of Gel Pieces 
Gel pieces were washed three times in a 96-well polypropylene plate using 100 
mM ammonium bicarbonate/acetonitrile (1:1, vol/vol) for 10 minutes each until the 
pieces were fully destained. 
2.8.6.2. In-Gel Digestion 
After destaining gel pieces, 50 μL of neat acetonitrile was then added to each 
well at room temperature until the pieces became dehydrated. The acetonitrile was 
removed and the gel pieces were dried. 50 μL of 10 mM DTT in 100 mM ammonium 
bicarbonate was added to cover the gel pieces and allowed to incubate for 30 minutes at 
56 °C. The DTT solution was removed and the gel pieces were cooled to room 
temperature. 50 μL of 55 mM Iodoacetamide in 100 mM ammonium bicarbonate was 
then added. The gel pieces were incubated for 20 minutes in the dark at room 
temperature. After reduction and alkylation, 50 μL of neat acetonitrile was added to 
each gel piece at room temperature to dehydrate them. After drying, the individual gel 
pieces were rehydrated in 10 μL of digestion buffer containing Trypsin (Promega, 
V5111). The digestion buffer was made fresh and consisted of 12.5 ng sequence-grade 
Trypsin/μL in 10% acetonitrile, 40 mM ammonium bicarbonate. Sufficient buffer was 
added to cover the dried gel pieces and the plate was incubated at 37 °C for 30 minutes. 
After this time, the pieces were checked to ensure that the buffer was absorbed. An 
additional 10-20 μL of ammonium bicarbonate buffer was added to cover the gel pieces 
and maintain moisture for the digestion. Digestion was carried out overnight at 37 °C. 
Peptides were extracted from the gel pieces twice using 50 μL of 1:2 (vol/vol) 5% TFA 
in acetonitrile (made fresh) for 15 minutes each at 37 °C with gentle agitation. The 
extracted peptides were transferred to a new 96-well plate and lyophilised using a Maxi 
Dry Plus vacuum (MSC). The plate was then stored at -20 °C, wrapped in parafilm, or 
the proteins were resuspended in 20 μL of 0.1% TFA containing 0.1% acetonitrile and 
analysed using LC-MS/MS. 
LC-MS/MS analysis and subsequent identification of proteins was performed 
as described in Section 2.7.5. 
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2.9. Gene Expression Assay 
2.9.1. RNA Extraction 
TRIzol Reagent (Thermo Fisher Scientific, 15596-026) was used for RNA 
extraction from cells in monolayer. 1 mL of TRIzol Reagent was added to each T75 
flask for RNA isolation. These samples were allowed to stand for 5 minutes on ice to 
allow complete lysis of the cells. The TRIzol/lysed cells solution was transferred to a 
clean Eppendorf tube, and 200 μL of chloroform (Sigma, C2432) was added. Samples 
were vortexed at high speed for 15 seconds and allowed to stand for 15 minutes at room 
temperature. The resulting mixtures were centrifuged at 13,684 g in a microcentrifuge 
for 15 minutes at 4ºC. The aqueous layer containing RNA was carefully removed to a 
clean fresh Eppendorf tube. To this 500 μL of ice-cold Isopropanol (Sigma, I9516) was 
added. The samples were mixed and incubated at room temperature for 10 minutes, and 
then centrifuged at 13,684 g for 30 minutes at 4ºC to pellet the precipitated RNA. 
Taking care not to disturb RNA pellet, the supernatant was removed and the pellet was 
subsequently washed by the addition of 750 μL of 75% of ethanol and vortexed. The 
samples were centrifuged at 7,500 g for 5 minutes at 4ºC. The supernatant was removed 
and the wash step was repeated. The RNA pellet was allowed to air-dry for 10 minutes 
and then re-suspended in 50 μL of RNase free water. 
2.9.2. Determination of DNA/RNA Quantity and Quality 
Purified RNA samples were quantified using the Nanodrop® ND-1000 
spectrophotometer (NanoDrop Technologies). Before applying the RNA/DNA sample, 
the pedestal was wiped down using a lint-free tissue dampened with UHP. The 
programme ‘RNA-40’ was selected on the NanoDrop software main screen to read the 
samples at 260nm, and the instrument was blanked with 2 μL of UHP. The 
concentration of RNA/DNA was calculated by software using the following formula:  
OD260 nm x Dilution factor x 40 = ng/μL RNA  
Samples were checked for quality (i.e. Phenol contamination) by assessing the 
A260/A280 and A260/A230 ratio values.  
An A260/A280 ratio ~2, and an A260/A230 of ~1.8-2.2 is indicative of a pure RNA. 
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2.9.3. High Capacity cDNA Reverse Transcription 
Reverse transcription of RNA to cDNA was carried out using the High 
Capacity cDNA reverse transcription kit (Applied Biosystems, 4368814) in accordance 
with the manufacturer’s specifications. A maximum of 2 μg of RNA was made up to 10 
μL in a 0.5 mL PCR tube using nuclease-free water. In a separate 0.5 mL PCR tube, the 
reverse transcription master mix was prepared. 10 μL of the RT master mix was added 
to the RNA sample and mixed using a pipette. The temperature profile for the reverse 
transcription reaction carried out using a bench top thermal cycler G-Storm GS1 PCR 
machine using the conditions shown in Table 2.9. 
 
 Step1 Step2 Step3 Step 4 
Temperature (°C) 25 37 85 4 
Time (min) 10 120 5 ∞ 
Table 2.9: Cycling conditions for reverse transcription. 
 
 
2.9.4. Real-Time PCR Gene Expression Assay 
RNA was extracted from cells as described in Section 2.9.1, and cDNA was 
synthesised from the RNA as described in Section 2.9.3. The PCR Master Mix used was 
TaqMan Fast Advanced Master Mix 2x (Thermo, 4444557). TaqMan assays used were 
Applied Biosystems TaqMan Gene Expression Assays (Thermo Fisher Scientific). The 
Real-Time PCR analysis was performed using a 7500 Fast Real-Time PCR system 
(Applied Biosystems). PCR reaction plates used were MicroAmp fast optical 96-well 
reaction plates (Applied Biosystems). 
Master Mix for each TaqMan assay was set up in PCR tubes, using the 
volumes shown in Table 2.10. Volumes shown are for 1 PCR reaction and were scaled 
up for multiple samples, with an additional 10% to allow for pipetting loss. A map was 
drawn up of the reaction plate and wells were designated for certain samples. cDNA 
was then pipetted in these wells as per Table 2.10 and control samples were added also. 
Master Mix was then added to the appropriate wells and the plate was covered and 
sealed with optical adhesive film. Each PCR was performed in triplicate and an 
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endogenous control was included. Comparison of the Ct value of a target gene with that 
of the endogenous control gene allows the gene expression level of the target gene to be 
normalized to the amount of input cDNA. As an additional control, water on its own 
was amplified as a negative control to rule out presence of any contaminating RNA or 
DNA. Plates were run on the 7500 Fast Real-Time PCR system using the conditions 
shown in Table 2.11. Details of TaqMan assays used in this study are shown in Table 
2.12. 
Data were analysed using a Relative Quantification ddCt study. A calibrator 
sample was selected and set to a value of one, allowing for the comparison of all other 
samples in relation to the calibrator. For the analysis of target gene and endogenous 
control amplification, the baseline was set to average, normalised fluorescent signal 
before detectable increase (usually 3-15 cycles) and the cycle threshold was set in the 
exponential part of the curve. The Ct standard error was ideally less than +/-0.161 
between replicate wells, and Ct errors with values greater than this were removed as 
outliers. The endogenous control was used automatically to normalise the data. When 
this was achieved for both the target and endogenous control, the relative quantity 
values for the run were generated and plotted relative to the calibrator sample. 
 
 
 
Component Volume μL/well 
Master Mix 10 
TaqMan Assay 1 
cDNA Template 2 
Nuclease free water 7 
Total volume 20 
Table 2.10: TaqMan assay components 
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Stage Temperature 
(°C) 
Time (Seconds) 
Polymerase Activation 95 20 
Denature PCR              
(40 cycles) 
95 3 
Anneal/Extend 60 30 
Table 2.11: Thermal cycling conditions for TaqMan assays 
 
 
Gene Catalogue Number 
Shootin-1 (Kiaa1598) hs01008867_m1 
MARCKS hs00158993_m1 
Desmoglein-3 hs00951897_m1 
Beta-Actin hs1060665_g1 
Table 2.12: TaqMan assays used in this study. 
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2.10. Overexpression of Targets 
2.10.1. Polymerase Chain Reaction  
The DreamTaqTM PCR Master Mix kit (Fermentas Life Sciences, #K1071) 
was the kit used to perform all PCR amplification reactions in accordance with the 
manufacturer’s specifications. DreamtaqTM PCR Master Mix was vortexed after 
thawing and placed on ice until further required. Each PCR reaction was made up to a 
volume of 50 μL using the components Table 2.13. A 25 μL reaction volume was made 
up in a thin walled PCR tube using a maximum concentration range of 1-100 ng of 
cDNA and 10 pg of forward and reverse PCR primer. Once all components have been 
added, 25 μL of the 2X DreamTaqTM PCR Master Mix was added to each sample 
creating a 50 μL reaction volume. 
Component Volume/Concentration 
DreamTaq 2x Master Mix 25 μL 
Forward Primer 0.1 – 1.0 μM 
Reverse Primer 0.1 – 1.0 μM 
Template cDNA 1 – 100 ng 
Nuclease Free Water To 50 μL 
Total Volume 50 μL 
Table 2.13: DreamTaq Components 
 
2.10.2. Gel Electrophoresis 
Visual analysis of PCR products can be carried out using gel electrophoresis. 
cDNA samples were diluted in nuclease free water and mixed with a 10x loading buffer.  
A 0.8% agarose gel in 50 mL 1 x TAE was made with 5 μL ethidium bromide (EtBr) 
(Sigma, E1510) added for staining the cDNA. A DNA ladder was added to one well of 
the gel to estimate the location of the PCR products. The gel was run for a sufficient 
time to ensure clear separation of the cDNA bands.  
2.10.3. PCR Purification  
All PCR product cDNAs were purified using the QIAGEN QIAquick PCR 
Purification kit (QIAGEN, 28104). Into the PCR mix, 5 volumes of Buffer PB was 
added and mixed by pipetting. A QIAquick spin column was placed into a 2 mL 
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collection tube and the sample was added and centrifuged at 16,060 g for 1 minute. The 
flow through was discarded and a wash step was performed by adding 750 μL of Buffer 
PE to the QIAquick column. After centrifugation at 16,060 g for 1 minute, flow through 
was discarded and the QIAquick column was placed back into the collection tube and 
spun for a further 1 minute at 16,060 g to dry the membrane. Before elution of the 
purified DNA, the QIAquick spin column was placed into a clean microcentrifuge tube. 
DNA was eluted by adding 30-50 μL of Buffer EB or water directly to the QIAquick 
membrane and incubating for 1 minute at room temperature followed by spinning at 
16,060 g for 1 minute. Quantification of DNA was determined using a NanoDrop 
spectrophotometer and measuring the OD260nm. Purified cDNA was stored at -20˚C 
until required. 
 
2.10.4. Restriction Enzyme Digestion 
Digestion reactions were set up in 0.5 mL PCR tubes at a reaction volume of 
20 μL. The reaction volume can vary depending on the amount of DNA required. 
Components required are shown in Table 2.14 for the digestion of 2 μg of DNA with 
two restriction enzymes in a volume of 20 μL. Enzymatic digestions are carried out at a 
temperature of 37 ˚C on a hot plate until complete digestion is achieved.  
Component Required for 20 μL 
cDNA 2 μg 
NEB Buffer (1-4) 10x 2 μL 
Restriction Enzymes 1U (0.5-1 μL)  
Nuclease Free Water To 20 μL 
Table 2.14: Restriction enzyme digestion components. 
 
 
2.10.5. Ligation  
The T4 DNA ligase kit from ROCHE (11635379001) was used for all ligation 
reactions. No more than a total of 1 μg of DNA is to be used in any given ligation 
reaction and a range of 1-5 Units of T4 DNA ligase enzyme. A range of ~80-150 ng of 
PcDNA3.1+ (V79020, Thermo Fisher scientific) vector backbone was used in all 
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ligations. The concentration of insert used was determined based on the fragment size 
and the amount/size of vector being used (Ligation Calculator), and all reactions were 
carried out in 20 μL volumes. 2 μL of 10x T4 DNA ligase reaction buffer (660 mM 
Tris-HCl, 50 mM MgCl2, 10 mM ATP, 50 mM EDTA, pH 7.5 at 25˚C) was added to 
the reaction mixture. Nuclease-free water was used to make up the reaction volume to 
19 μL prior to the addition of the T4 DNA ligase enzyme. Finally 1 μL (1 U) of T4 
DNA ligase enzyme was added to the reaction mixture creating a reaction volume of 20 
μL. This reaction was incubated overnight on ice water. This allows the ligation 
reaction to commence over a temperature gradient. Ligated samples were stored at -
20˚C. An identical reaction containing all components except the fragment to be 
inserted (no insert control) was set up in tandem to check for self-ligation of the vector. 
In addition, a no-enzyme control was also set up. 
2.10.6. Transformation of Competent Cells  
Competent cells used in this study were Subcloning Efficiency DH5αTM 
Competent cells (18265017, Thermo Fisher Scientific). A water bath was pre-heated to 
42°C while 50 μL of competent cells were transferred into clean Eppendorf tubes and 
kept on ice. ~5 μL of ligation product was added to the competent cells and stirred 
gently with a pipette tip. This mixture was left on ice for 30 min. The competent 
cells/DNA were heat-shocked by placing in the water bath at 42°C for 45 seconds. Cells 
were then immediately placed on ice for a further 3 min. 500 μL of pre-heated (37 °C) 
Super Optimal broth with catabolite repression media (supplied in kit) was added to the 
transformed competent cells. Cells were incubated for 2 hours at 37°C on a shaker 
platform. Contents were transferred into an Eppendorf tube and centrifuged at 3000 g 
for 4 min. All but 50 μL of SOC media was decanted from the bacterial pellet. The 
pellet was resuspended using a pipette and transferred onto a LB agar plate containing 
Ampicillin (A9518, Sigma) at a concentration of 50 μg/ml for selection of successfully 
transformed cells. Using a sterile microbiological spreader, the transformed competent 
cells were homogenously spread over the LB agar plate (Sigma, L2897). The plates 
were then sealed with parafilm and incubated at 37 ˚C for 16-24 hours. Controls in this 
process were: untransformed DH5α cells; S.O.C media alone; ligation mix with no 
ligation enzyme (Section 2.10.5). Healthy growing colonies after 24 hours were deemed 
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potentially successful transformants. These were inoculated into 5 mL of fresh LB 
media containing 50 μg/ml Ampicillin for selection. 
 
2.10.7. DNA mini-prep of plasmid DNA  
The QIAGEN QIAprep Spin Miniprep kit (QIAGEN, 27104) was used 
according to the manufacturer’s instructions for the isolation of plasmid DNA from a 
5mL culture. Cells were pelleted by centrifugation at 4000 g for 10 min. Cell pellets 
were resuspended in 250 μL of buffer P1 and transferred to a microcentrifuge tube. 250 
μL of buffer P2 was added to this solution and mixed gently by inversion. A 350 μL 
volume of buffer N3 was subsequently added to this solution and again mixed gently by 
inversion. This mixture was centrifuged for 10 min at 13,000 g. The decanted 
supernatant was applied to a QIAprep spin column and centrifuged for 60 seconds at 
13,000 g, and flow though was discarded. The column was washed by adding 500 μL of 
Buffer PB and centrifuged for 60 seconds at 13,000 g. A second wash was performed 
using 750 μL of Buffer PE and centrifuged for 60 seconds. The column was dried by an 
additional centrifugation step for 60 seconds to remove any remaining wash buffer. The 
spin column was then placed into a clean microcentrifuge tube. The DNA was eluted by 
adding 30-50 μL (depending on the desired DNA yield) of Buffer EB or water to the 
spin column. This was allowed to stand for 1 minute at room temperature (RT) before 
centrifugation at 16,060 g for 1 minute. The eluted DNA was reapplied to the spin 
column and centrifuged for an additional 60 seconds to collect any remaining plasmid 
DNA. Quantification of the eluted plasmid DNA was determined using a NanoDrop 
spectrophotometer by measuring at OD260nm. Plasmid was stored at -20˚C until 
required. 
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Chapter 3. Quantitative Proteomic Profiling of 
DLKP by Label-Free LC-MS/MS 
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3.1. Differential Protein Expression Analysis of DLKP and its Subpopulations 
Using Quantitative Mass Spectrometry Based Proteomics 
The DLKP cell line was established from a lymph node metastasis of a primary 
lung tumour and is described as a poorly differentiated squamous lung carcinoma cell 
line. This cell line was previously found to be comprised of three distinct 
subpopulations: DLKP-SQ, DLKP-M and DLKP-I, each with well-defined phenotypes 
(McBride et al. 1998a). Stark phenotypic differences between the subpopulations 
include the ability of the cells to migrate and invade in vitro (Joyce H, PhD, 2015), and 
the ability of cells to survive unattached to a surface or other cells (Keenan et al. 2012). 
These characteristics make DLKP a particularly useful model for studying cellular 
heterogeneity in poorly differentiated non-small cell carcinoma. 
Liquid chromatography coupled to mass spectrometry (LC-MS) is one of the 
most popular and comprehensive profiling techniques used to analyse proteins from 
complex biological material (Christin, Bischoff and Horvatovich 2011). Labelling 
technologies such as SILAC, iTRAQ, ICAT and 2D-DIGE have been the main 
technologies used in MS-based protein quantification for profiling experiments in 
proteomics. While these techniques have been successful for certain experimental 
setups, they also have inherent limitations. These can include: increased time and 
complexity of sample preparation; high cost of reagents; incomplete sample labelling 
which leads to confused data interpretation; sample number limitation: up to 10 samples 
maximum for TMT isobaric labelling (Murphy et al. 2014). More recently, label-free 
LC-MS/MS has become an attractive method to proteomic investigators for the 
quantitative analysis of proteins. This technique is becoming more widely employed as 
it overcomes many of the issues associated with labelled techniques. It is generally 
accepted that label-free quantitation estimates protein abundance more accurately than 
gel based methods, and has a higher sensitivity and larger dynamic range than labelling 
techniques (Neilson et al. 2011). Conversely, this technique requires highly 
reproducible HPLC to perform well, and powerful bioinformatics tools for data 
processing. With a high end nano-LC system coupled to a hybrid linear ion 
trap/Orbitrap mass spectrometer in-house, label-free quantification was the method of 
choice for the proteomic analysis of the DLKP cell line and its subpopulations to 
understand cellular heterogeneity in lung cancer. 
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3.1.1. Preparation of DLKP Cell Lines 
To identify proteins which may be used to characterise the DLKP cell lines, a 
comparative analysis was carried out using quantitative label-free mass spectrometry. 
The experimental design called for DLKP and clonal variants (DLKP-SQ, DLKP-M, 
DLKP-I) to be grown in biological triplicate with samples being taken at both 
exponential and stationary phases of growth. Both phases of growth were analysed 
separately in order to find highly differentially expressed proteins which were not 
growth phase dependent. Running two separate experiments would lead to strong 
protein identifications which could be used to characterise the DLKP clonal 
subpopulations. Previous optimisation had shown that the DLKP cell lines reach 
exponential phase at 72 hours and stationary phase 120 hours after seeding the cells at 
2.5x104cells/ml in a T75 flask, so these timepoints were used for both phases of growth. 
Extensive optimisation was carried out to determine the phases of growth for each cell 
line used in this study with both 72 and 120 hours representing exponential and 
stationary phases of growth respectively. Samples of each cell line were taken down 
within 6 passages of being thawed to reduce the chances of genetic drift due to 
prolonged time in culture. 
 Each cell line was grown in T75 cell culture flasks and seeded at a density of 
2.5x104cells/ml. Two flasks were designated for exponential phase and the other two for 
stationary phase. For exponential phase samples, one T75 flask was lysed using the 
method described in Section 2.3.1 after 72 hours and stored at -80°C. The remaining 
T75 flask was reseeded into two new flasks at a cell concentration of 2.5x104cells/ml 
once again. This process was repeated twice more until all three biological replicates 
were harvested. The same procedure was carried out for stationary phase samples, the 
only difference being that each sample harvest and reseeding step took place at 120 
hours.  
In parallel, combination cell lines were also set up and grown until exponential 
and stationary phase. These combination cell lines were set up in order to monitor how 
protein expression was affected when the DLKP clones were grown in co-culture. The 
same cell culture method as described above was carried out for these samples, however 
they initially consisted of 50/50 mixtures of each clone by cell number (1.25x104cell/ml 
of A + 1.25x104cell/ml of B). Alongside this, the DLKP cell line was reconstituted in 
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the proportions found previously (McBride et al. 1998a) with 70% DLKP-SQ, 25% 
DLKP-I and 5% DLKP-M and is referred to as “Remade”. A summary cell proportions 
used is shown in Table 3.1. 
 
DLKP-SQ DLKP-M DLKP-I Combination 
Cell Line 
1.25x104cell/ml 1.25x104cell/ml - SQ+M 
1.25x104cell/ml - 1.25x104cell/ml SQ+I 
- 1.25x104cell/ml 1.25x104cell/ml I+M 
1.75x104cell/ml 1.25x103cell/ml 6.25x103cell/ml DLKP Remade 
Table 3.1: Proportions of the DLKP clones which were used to make up the combination cell lines. 
 
 
3.1.2. Protein Preparation and Analysis by Quantitative Label-Free LC-MS/MS 
Equal protein concentrations were prepared as outlined in Section 2.7.2. This 
step is essential and is the foundation of an accurate quantitative label-free study. For 
the protein assay step, high precision was required, with samples requiring a coefficient 
of variance no greater than 1.5%, and the standard curve is required to have an R2 value 
of no less than 0.98. Following digestion of the protein samples as described in Section 
2.7.3, each sample was analysed using quantitative label-free LC-MS/MS as described 
in Section 2.7.6. 
All samples were analysed as one large group, directly after each other in order 
to reduce variability and retention time drift. To reduce potential bias incurred by 
running replicates from sample groups together as one block, samples were interleaved 
with those from other groups when being analysed using the label-free quantification 
method. 
 Data analysis was performed using Progenesis QI for Proteomics software. Raw 
MS files were imported into the software and aligned to each other based on a reference 
file chosen which was representative of the entire dataset. This file is chosen 
automatically by Progenesis software and is usually the file with the greatest number of 
peptide ions, which increases the chances of all other files to being strongly aligned to 
it. Once aligned, this matrix of sample files were analysed to detect features in each run. 
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Detected features were then filtered to only allow through those with an ANOVA p-
value of <0.05. This p-value was chosen to only allow through statistically significantly 
differentially expressed peptide features. DLKP and its clonal subpopulations come 
from the same origin but are essentially different cell types, so there will be inherent 
protein abundance differences. A tight filtering criterion ensures that only the most 
significant differences come through the analysis. From the list of features generated 
after filtering, a PCA (principal component analysis) plot can then be generated in the 
software. Plotting the abundance data in this way allows the separation of samples 
according to abundance variation, and is a useful tool for identifying run outliers (See 
Figure 3.1 and Figure 3.2). < 
The MS/MS data from this list of significant peptide features can then be 
exported from the software for protein identification. This is carried out by Proteome 
Discoverer 1.4 which searches the MS/MS information against the UniProt and 
SwissProt protein databases using MASCOT and Sequest algorithms (See Section 
2.7.6.2). Once completed, the search results are then re-imported back into Progenesis 
QI software and identified proteins are assigned to peptide features.  
A set of tight filtering criteria was applied to the data at this stage to select only 
the most statistically significant differentially expressed proteins. These filters were: ≥ 2 
peptides contributing to protein identifications, a change of ≥ 2 fold between 
experimental groups for any identified protein, an ANOVA value of <0.05 for a protein 
between experimental groups. The list of resulting proteins depends on the initial 
comparative experimental design setup in the Progenesis software. The software allows 
for any permutation of the samples comparison and those chosen in this analysis are 
described below. 
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3.1.3. Experimental Designs 
The LC-MS/MS data generated for the DLKP cell line and its clonal 
subpopulations resulted in a large dataset which could be arranged in any way for a 
comparative study using Progenesis software. Table 3.2 shows all the available samples 
for comparison. In the software, each biological triplicate for a given sample is grouped 
together as one to represent that cell line, and comparative studies are carried out on 
these.  
Name Exponential phase Stationary phase 
DLKP-SQ 3 3 
DLKP-M 3 3 
DLKP-I 3 3 
DLKP 3 3 
SQ+M 3 3 
SQ+I 3 3 
I+M 3 3 
Remade 3 3 
Table 3.2: Brief summary of the DLKP experimental design. 3 biological replicates for each 
cell line and combination cell lines were required, at both exponential and stationary phases 
of growth. This resulted in a total of 48 samples analysed by label-free LC-MS/MS. 
 
It was decided to analyse the data using two different methods in order to 
extract the maximum fold change information, and complete the most thorough 
comparative analyses using Progenesis software. These two strategies were termed: The 
Global Analysis; and the Two-Sample Analysis. 
The Global Analysis compares samples against each other as one large group. 
Using this method results in the availability of fold change data for a statistically 
significantly differentially expressed protein between the highest and lowest expressing 
cell lines. It also allows the expression profiles of a protein to be determined across 
multiple cell lines. However, it does not provide intermediary fold changes for a protein 
in cell lines which are not the highest and lowest expressers, nor does it provide 
statistical significance for these samples. For this reason, an additional experimental 
design was also used. 
The Two-Sample Analysis compares just two cell lines against each other in a 
one vs. one comparison. All samples are imported into Progenesis software, allowing 
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the software the full wealth of data for the software to draw upon. However in the 
experimental design itself, only two cell lines are compared against each other directly. 
All replicates for both cell lines in the experimental design are included. This method 
provides individual fold change data between two cell lines, along with their statistical 
significance. This information is lost in the global analysis, so by using both methods, 
the data can result in protein expression patterns and all associated fold changes. 
 
 
3.1.3.1. Global Comparison Experimental Design 
 The experimental designs for both exponential and stationary phases of growth 
were set up initially to compare the DLKP cell line and the clonal subpopulations, 
excluding the combination lines. These were compared initially using the global 
analysis method. Principal component analysis was carried out for both experiments in 
the Progenesis software and results are shown in Figure 3.1 and Figure 3.2. This tool 
performs statistical analysis on filtered data, and creates a graphical representation of 
the answers asked of the data by the experimental design. A number of details can be 
determined from this graphical representation: how tightly replicate samples cluster 
together, if there are outliers in groups, and how similar those groups are to each other. 
The PCA analysis was performed on statistically significant peptide features (ANOVA 
p < 0.05). 
Principal component analysis of the exponential phase global analysis (Figure 
3.1) shows that replicate samples cluster well into reasonably distinct groups based on 
the cell line. This indicates that sample preparation was uniform for each cell line, and 
growth in culture over three passages did not result in significant protein expression 
drift. The DLKP-SQ group clusters furthest away from the other cell lines, followed by 
DLKP-M. The principal component analysis for the stationary phase global analysis 
shows tighter clustering than during exponential phase. DLKP-M clusters furthest away 
compared to the other cell lines. In both phases of growth, good separation of the clones 
and DLKP cell line was found. 
Interestingly, DLKP-SQ and DLKP cluster closely together during stationary 
phase of growth but not as much during exponential phase. This suggests that as the 
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cells become more tightly packed and reach stationary phase, DLKP-SQ and DLKP 
become more similar to each other. This highlights the plastic nature of these cell types 
and may support the interconversion theory proposed by (McBride et al. 1998a) 
 
 
 
 
Figure 3.1: Principal component analysis for Exponential Phase global comparison of DLKP-SQ, 
DLKP-M, DLKP-I and DLKP cell lines only.  
 
 
 
 
 
Figure 3.2: Principal component analysis for Stationary Phase global comparison of DLKP-SQ, 
DLKP-M, DLKP-I and DLKP cell lines only.  
 
DLKP-SQ DLKP-M DLKP-I DLKP
 98 
 
3.1.3.2. Differentially Expressed Proteins: 
 In this global analysis, the experimental design compared; DLKP-SQ; DLKP-M; 
DLKP-I; and DLKP all against each other at once. Analysis was performed on protein 
results which were filtered using the tight criteria described previously (≥ 2 peptides 
contributing to protein identifications, a change of ≥ 2 fold between comparisons for 
any protein, an ANOVA p-value of <0.05 for a protein between experimental groups). 
The exponential phase experiment highlighted 127 significantly differentially expressed 
proteins and the stationary phase highlighted 203 significantly differentially expressed 
proteins (Table 3.3). Overlapping these two lists revealed 63 common proteins which 
were found in both independent experiments. To get an overview of the results from 
these analyses, a number of differentially expressed proteins from exponential and 
stationary phases are displayed in Table 3.4 and Table 3.5. The top 10 proteins with the 
highest abundance in each cell line are shown. Full lists are in Section 8.1 (Appendices 
on Disc). 
 
Comparison DLKP-SQ vs. DLKP-M vs. DLKP-I 
vs. DLKP 
Exponential 127 proteins 
Stationary 203 proteins 
Table 3.3: Displayed is the number of proteins which were shown to be statistically differentially 
expressed from a ‘Global Comparison’. Proteins were required to have a fold change ≥2 between two 
samples, and ANOVA p < 0.05, and ≥2 peptides contributing to the identification. 
 
 
Figure 3.3: Venn diagram showing the overlapping proteins from the 
exponential and stationary phase experiments. 63 proteins were common to 
both global comparisons. 
Total Number of Differentially Expressed Proteins 
Exponential vs. Stationary Phase 
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Exponential Phase: Top Fold Changes 
 
Table 3.4: List of proteins showing the greatest fold changes during exponential phase for each cell line. 
All proteins have ≥2 unique peptides contributing to their identification, and an ANOVA p-value <0.05, 
and a fold change ≥2 between any two cell lines. Full lists are shown in Appendix 8.1. 
Description
Max fold 
change
Highest
Serum albumin 88.0 DLKP SQ
Vitamin D-binding protein 40.7 DLKP SQ
UBX domain-containing protein 1 20.4 DLKP SQ
Lactotransferrin 17.8 DLKP SQ
Hemoglobin subunit alpha 13.5 DLKP SQ
Hyaluronan and proteoglycan link protein 1 9.6 DLKP SQ
D-3-phosphoglycerate dehydrogenase 5.8 DLKP SQ
Collagen alpha-1(XIV) chain 4.6 DLKP SQ
Leucine-rich repeat flightless-interacting protein 1 4.6 DLKP SQ
Shootin-1 4.4 DLKP SQ
Myristoylated alanine-rich C-kinase substrate 51.7 DLKP M
Collagen alpha-1(III) chain 12.5 DLKP M
Bifunctional ATP-dependent dihydroxyacetone kinase 9.3 DLKP M
PDZ and LIM domain protein 5 8.5 DLKP M
Dihydropyrimidinase-related protein 2 5.3 DLKP M
1,4-alpha-glucan-branching enzyme 4.8 DLKP M
3-hydroxyisobutyrate dehydrogenase, mitochondrial 3.7 DLKP M
Transferrin receptor protein 1 3.7 DLKP M
Cysteine and glycine-rich protein 2 3.5 DLKP M
Guanine nucleotide-binding protein G(i) subunit alpha-1 3.4 DLKP M
Desmoglein-3 175.3 DLKP I
Tissue factor pathway inhibitor 2 23.5 DLKP I
CD166 antigen 9.2 DLKP I
Protein S100-A10 8.0 DLKP I
Neurotensin/neuromedin N 7.5 DLKP I
Uridine phosphorylase 1 4.1 DLKP I
Glutaminase kidney isoform, mitochondrial 3.3 DLKP I
Neuroblast differentiation-associated protein AHNAK 3.0 DLKP I
Annexin A1 3.0 DLKP I
Signal transducer and activator of transcription 1-alpha/beta 2.8 DLKP I
Connective tissue growth factor 122.7 DLKP
Protein CYR61 22.6 DLKP
Transgelin 18.5 DLKP
Solute carrier family 2, facilitated glucose transporter member 3 15.3 DLKP
Hepatocyte growth factor 15.0 DLKP
Cathepsin Z 12.2 DLKP
F-box only protein 2 8.2 DLKP
Gamma-enolase 5.7 DLKP
Fascin 4.2 DLKP
Gap junction alpha-1 protein 3.4 DLKP
 100 
 
Stationary Phase: Top Fold Changes 
 
Table 3.5: List of proteins showing the greatest fold changes in the stationary phase for each cell line. 
All proteins have ≥2 unique peptides contributing to their identification, an ANOVA p-value <0.05, and 
a fold change ≥2 between any two cell lines. Full lists are shown in Appendix 8.1. 
Description
Max fold 
change
Highest 
Abundance
D-3-phosphoglycerate dehydrogenase 5.4 DLKP-SQ
Putative helicase MOV-10 4.2 DLKP-SQ
Fumarylacetoacetase 3.9 DLKP-SQ
Shootin-1 3.5 DLKP-SQ
Ataxin-10 3.4 DLKP-SQ
Serum albumin 3.2 DLKP-SQ
Heat shock protein beta-1 2.8 DLKP-SQ
Isoleucine--tRNA ligase, mitochondrial 2.7 DLKP-SQ
Aldose reductase 2.5 DLKP-SQ
E3 ubiquitin/ISG15 ligase TRIM25 2.5 DLKP-SQ
Myristoylated alanine-rich C-kinase substrate 28.4 DLKP-M
Collagen alpha-1(III) chain 20.2 DLKP-M
Histone H4 13.0 DLKP-M
Chromatin target of PRMT1 protein 7.5 DLKP-M
Cysteine and glycine-rich protein 2 6.8 DLKP-M
Insulin-like growth factor 2 mRNA-binding protein 3 6.4 DLKP-M
Protein NipSnap homolog 1 5.9 DLKP-M
Peroxiredoxin-2 5.7 DLKP-M
SH3 domain-binding glutamic acid-rich-like protein 5.5 DLKP-M
1,4-alpha-glucan-branching enzyme 5.3 DLKP-M
Tissue factor pathway inhibitor 2 14.9 DLKP-I
CD166 antigen 7.3 DLKP-I
Ras GTPase-activating-like protein IQGAP1 3.6 DLKP-I
Annexin A1 3.4 DLKP-I
Neuroblast differentiation-associated protein AHNAK 3.2 DLKP-I
Protein PRRC2C 3.2 DLKP-I
Neurotensin/neuromedin N 3.0 DLKP-I
U1 small nuclear ribonucleoprotein 70 kDa 2.9 DLKP-I
Glutaminase kidney isoform, mitochondrial 2.7 DLKP-I
Vasodilator-stimulated phosphoprotein 2.7 DLKP-I
Connective tissue growth factor 28.7 DLKP
Protein CYR61 20.0 DLKP
Transgelin 11.0 DLKP
Hepatocyte growth factor 6.7 DLKP
Heat shock 70 kDa protein 1A/1B 3.5 DLKP
Fascin 3.2 DLKP
B-cell receptor-associated protein 31 3.1 DLKP
Cathepsin Z 3.0 DLKP
Exportin-2 2.7 DLKP
Ubiquitin-like protein ISG15 2.5 DLKP
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In Table 3.4 and Table 3.5, the top 10 proteins which had the greatest abundance 
in each of the cell lines is shown, resulting in a list of 40 proteins. These protein results 
are from the global comparisons which compared DLKP-SQ, DLKP-M, DLKP-I and 
DLKP against each other at exponential and stationary phases of growth separately. 
From these lists, 17 proteins were common to both experiments. Average fold change 
values were quite different between phases of growth. For the top 36 proteins in each 
experiment there was an average maximum fold change of 19.6 for exponential phase, 
and 7.64 for stationary phase. 
To assess which cell line showed the greatest difference from the others at a 
proteomic level, cell lines were ranked based on those containing the largest proportion 
of highest abundance proteins. Results of this are shown in Table 3.6 and Table 3.7 
below. During exponential phase of growth, the largest number of highest abundance 
proteins could be attributed to DLKP-SQ (45 out of 127 proteins). During stationary 
phase, the largest number of highest abundance proteins was attributed to DLKP-M 
(127 out of 203 proteins). In both phases of growth, this observation correlated with the 
PCA analysis on the peptide features in Figure 3.1 and Figure 3.2. 
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Highest Expressed in Exponential Proteins by Number 
DLKP-SQ 45 
DLKP-M 35 
DLKP 26 
DLKP-I 21 
Total 127 
Table 3.6: Displayed is the total number of proteins from the global comparison during 
exponential phase, and how many proteins were the most abundantly expressed in each 
cell line. 
 
 
 
 
Highest Expressed in Stationary Proteins by Number 
DLKP-M 137 
DLKP-SQ 24 
DLKP 26 
DLKP-I 16 
Total 203 
Table 3.7: Displayed is the total number of proteins from the global comparison 
for stationary phase, and how many proteins were the most abundantly expressed 
in each cell line. 
 
 
3.1.3.3. Two-Sample Comparisons: 
 The global comparison experimental designs described above are useful for an 
overall look at how proteins are expressed between all samples as one large set. Using 
that method, it is possible to track the expression profiles of interesting proteins across 
all sample groups. The two-sample analysis method allows the determination on 
intermediary cell line fold changes, and provides detailed differential protein 
information between just two cell lines in each analysis. Cell lines were compared using 
this method e.g. DLKP-M vs. DLKP-I.  This way, the analysis is focused on one sample 
group versus another with the aim of pulling out the maximum number of statistically 
significant proteins for that one comparison.  
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 Individual comparisons were processed by PCA analysis to ensure cell line 
replicates clustered well and groups separated well. A representative PCA graph is 
shown in Figure 3.4. 
 
 
Figure 3.4: Principal component analysis for DLKP-M vs. DLKP-I during exponential phase of 
growth. PCA showed good separation of sample groups with reasonably tight clustering of 
samples. The PCA analysis was performed on statistically significant peptide features (ANOVA   
p <0.05). 
 
The following pages display the top ten highest abundance proteins found for 
each two-sample cell line comparison of DLKP and the clonal subpopulations. Proteins 
are sorted based on fold change, with the proteins showing the largest abundance 
change between any two samples ranked first. All proteins pass the criteria and 
statistical significance requirements, and full lists are shown in Appendix 8.1. From 
these lists, a number of proteins were highlighted as repeatedly highly expressed in a 
single clone for both phases of growth. Shootin-1 can be seen as highly expressed in 
DLKP-SQ during exponential and stationary phases of growth in Table 3.14 and Table 
3.15 respectively for example, as well as others. Myristoylated alanine-rich C-kinase is 
associated with high expression in DLKP-M as seen in Table 3.8 and Table 3.9 during 
both exponential and stationary phases of growth. Desmoglein-3 showed extremely high 
expression in DLKP-I during exponential phase as seen in Table 3.10. These proteins 
were taken forward for further investigation. 
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DLKP-SQ vs. DLKP-M Exponential Phase 
 
Table 3.8: Highest abundance proteins for DLKP-SQ vs. DLKP-M comparison. Top 10 
highest fold changes for each cell line are shown. 
 
 
DLKP-SQ vs. DLKP-M Stationary Phase 
 
Table 3.9: Highest abundance proteins for DLKP-SQ vs. DLKP-M comparison. Top 10 
highest fold changes in each cell line are shown. 
 
Name Fold Change
Highest 
Abundance
Serum albumin 88.0 DLKP-SQ
Vitamin D-binding protein 40.7 DLKP-SQ
UBX domain-containing protein 1 23.4 DLKP-SQ
Lactotransferrin 17.8 DLKP-SQ
MICOS complex subunit MIC19 14.5 DLKP-SQ
Hemoglobin subunit alpha 13.5 DLKP-SQ
Keratin, type I cytoskeletal 16 11.5 DLKP-SQ
Protein CYR61 11.0 DLKP-SQ
Myristoylated alanine-rich C-kinase substrate 20.9 DLKP-M
Collagen alpha-1(III) chain 8.3 DLKP-M
PDZ and LIM domain protein 5 7.3 DLKP-M
Histone H4 4.1 DLKP-M
Gamma-enolase 4.0 DLKP-M
Histone H3.1t 3.4 DLKP-M
Guanine nucleotide-binding protein G(i) subunit alpha-1 3.4 DLKP-M
Tryptophan--tRNA ligase, cytoplasmic 3.1 DLKP-M
Name Fold Change
Highest 
Abundance
Protein CYR61 9.5 DLKP-SQ
Actin, cytoplasmic 1 3.7 DLKP-SQ
D-3-phosphoglycerate dehydrogenase 3.6 DLKP-SQ
Shootin-1 3.5 DLKP-SQ
Serum albumin 3.2 DLKP-SQ
Heat shock 70 kDa protein 1A/1B 3.2 DLKP-SQ
Isoleucine--tRNA ligase, mitochondrial 2.7 DLKP-SQ
Fumarylacetoacetase 2.7 DLKP-SQ
Myristoylated alanine-rich C-kinase substrate 21.0 DLKP-M
Collagen alpha-1(III) chain 15.7 DLKP-M
Histone H4 12.1 DLKP-M
Insulin-like growth factor 2 mRNA-binding protein 3 6.4 DLKP-M
Chromatin target of PRMT1 protein 6.4 DLKP-M
Cysteine and glycine-rich protein 2 5.2 DLKP-M
Histone H2A type 1-B/E 4.9 DLKP-M
Sulfatase-modifying factor 2 4.6 DLKP-M
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DLKP-SQ vs. DLKP-I: Exponential Phase 
 
Table 3.10: Highest abundance proteins for DLKP-SQ vs. DLKP-I comparison. Top 10 
highest fold changes in each cell line are shown. 
 
 
DLKP-SQ vs. DLKP-I: Stationary Phase 
 
Table 3.11: Highest abundance proteins for DLKP-SQ vs. DLKP-I comparison. Top 
10 highest fold changes in each cell line are shown. 
 
Name Fold Change
Highest 
Abundance
Vitamin D-binding protein 22.6 DLKP-SQ
Serum albumin 20.8 DLKP-SQ
Lactotransferrin 13.8 DLKP-SQ
D-3-phosphoglycerate dehydrogenase 5.8 DLKP-SQ
Bifunctional ATP-dependent dihydroxyacetone kinase 5.4 DLKP-SQ
Synaptosomal-associated protein 29 4.7 DLKP-SQ
Keratin, type II cytoskeletal 2 epidermal 4.4 DLKP-SQ
PDZ and LIM domain protein 1 4.4 DLKP-SQ
Desmoglein-3 175.3 DLKP-I
CD166 antigen 9.2 DLKP-I
Myristoylated alanine-rich C-kinase substrate 8.2 DLKP-I
Protein S100-A10 8.0 DLKP-I
40S ribosomal protein S29 5.3 DLKP-I
PDZ and LIM domain protein 5 3.6 DLKP-I
Glutaminase kidney isoform, mitochondrial 3.2 DLKP-I
Neuroblast differentiation-associated protein AHNAK 3.1 DLKP-I
Name Fold Change
Highest 
Abundance
D-3-phosphoglycerate dehydrogenase 5.4 DLKP-SQ
Peroxiredoxin-2 4.4 DLKP-SQ
Putative helicase MOV-10 4.2 DLKP-SQ
1,4-alpha-glucan-branching enzyme 3.6 DLKP-SQ
Fumarylacetoacetase 3.5 DLKP-SQ
Ataxin-10 3.4 DLKP-SQ
Heat shock protein beta-1 2.8 DLKP-SQ
Isoleucine--tRNA ligase, mitochondrial 2.7 DLKP-SQ
Tissue factor pathway inhibitor 2 14.9 DLKP-I
CD166 antigen 7.3 DLKP-I
Myristoylated alanine-rich C-kinase substrate 4.5 DLKP-I
Insulin-like growth factor 2 mRNA-binding protein 3 4.3 DLKP-I
Neuroblast differentiation-associated protein AHNAK 3.2 DLKP-I
Annexin A1 2.8 DLKP-I
Vasodilator-stimulated phosphoprotein 2.7 DLKP-I
Glutaminase kidney isoform, mitochondrial 2.5 DLKP-I
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DLKP-I vs. DLKP-M: Exponential Phase 
 
Table 3.12: Highest abundance proteins for DLKP-I vs. DLKP-M individual comparison. 
Top 10 highest fold changes in each cell line are shown. 
 
 
DLKP-I vs. DLKP-M: Stationary Phase 
 
Table 3.13: Highest abundance proteins for DLKP-I vs. DLKP-M comparison. 
Top 10 highest fold changes in each cell line are shown. 
 
Name Fold Change
Highest 
Abundance
Desmoglein-3 97.3 DLKP-I
Tissue factor pathway inhibitor 2 19.0 DLKP-I
Neurotensin/neuromedin N 5.0 DLKP-I
CD166 antigen 4.6 DLKP-I
Uridine phosphorylase 1 4.1 DLKP-I
Hemoglobin subunit alpha 3.2 DLKP-I
Heat shock 70 kDa protein 1A/1B 2.9 DLKP-I
Protein S100-A10 2.8 DLKP-I
Bifunctional ATP-dependent dihydroxyacetone kinase 8.2 DLKP-M
1,4-alpha-glucan-branching enzyme 4.7 DLKP-M
Transferrin receptor protein 1 3.7 DLKP-M
KDEL motif-containing protein 2 3.4 DLKP-M
Caldesmon 3.3 DLKP-M
3-hydroxyisobutyrate dehydrogenase, mitochondrial 3.0 DLKP-M
Collagen alpha-1(III) chain 3.0 DLKP-M
Dihydropyrimidinase-related protein 2 3.0 DLKP-M
Name Fold Change
Highest 
Abundance
Protein CYR61 9.7 DLKP-I
Tissue factor pathway inhibitor 2 7.8 DLKP-I
CD166 antigen 4.7 DLKP-I
Hepatocyte growth factor 4.4 DLKP-I
Kinectin 3.8 DLKP-I
Hematopoietic progenitor cell antigen CD34 3.6 DLKP-I
Ras GTPase-activating-like protein IQGAP1 3.6 DLKP-I
Protein PRRC2C 3.2 DLKP-I
Histone H4 13.0 DLKP-M
Collagen alpha-1(III) chain 10.7 DLKP-M
Protein NipSnap homolog 1 5.9 DLKP-M
Peroxiredoxin-2 5.7 DLKP-M
1,4-alpha-glucan-branching enzyme 5.2 DLKP-M
Myristoylated alanine-rich C-kinase substrate 5.1 DLKP-M
Sulfatase-modifying factor 2 4.7 DLKP-M
Histone H2A type 1-B/E 4.4 DLKP-M
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DLKP-SQ vs. DLKP-: Exponential Phase 
 
Table 3.14: Highest abundance proteins for DLKP-SQ vs. DLKP comparison. Top 10 
highest fold changes in each cell line are shown 
 
 
DLKP-SQ vs. DLKP-: Stationary Phase 
 
Table 3.15: Highest abundance proteins for DLKP-SQ vs. DLKP comparison. 
Top 10 highest fold changes in each cell line are shown. 
 
Name Fold Change
Highest 
Abundance
Hyaluronan and proteoglycan link protein 1 9.6 DLKP-SQ
Collagen alpha-1(XIV) chain 4.7 DLKP-SQ
Shootin-1 4.3 DLKP-SQ
Neurotensin/neuromedin N 3.8 DLKP-SQ
D-3-phosphoglycerate dehydrogenase 3.0 DLKP-SQ
Four and a half LIM domains protein 1 2.9 DLKP-SQ
Chloride intracellular channel protein 4 2.7 DLKP-SQ
SH3 domain-binding glutamic acid-rich-like protein 2.7 DLKP-SQ
Transgelin 18.5 DLKP
Connective tissue growth factor 16.8 DLKP
Solute carrier family 2, facilitated glucose transporter member 3 15.3 DLKP
Cathepsin Z 12.2 DLKP
Gamma-enolase 5.7 DLKP
Fascin 4.2 DLKP
Hepatocyte growth factor 3.1 DLKP
Integrin beta-1 2.5 DLKP
Name Fold Change
Highest 
Abundance
Fumarylacetoacetase 3.9 DLKP-SQ
Collagen alpha-1(XIV) chain 3.8 DLKP-SQ
Myristoylated alanine-rich C-kinase substrate 3.6 DLKP-SQ
Shootin-1 3.5 DLKP-SQ
D-3-phosphoglycerate dehydrogenase 3.2 DLKP-SQ
Keratin, type II cytoskeletal 2 epidermal 3.1 DLKP-SQ
Keratin, type I cytoskeletal 10 2.8 DLKP-SQ
SH3 domain-binding glutamic acid-rich-like protein 2.6 DLKP-SQ
Connective tissue growth factor 15.6 DLKP
Transgelin 7.0 DLKP
Hematopoietic progenitor cell antigen CD34 4.2 DLKP
Hepatocyte growth factor 3.5 DLKP
Fascin 3.2 DLKP
Cathepsin Z 3.0 DLKP
Serpin H1 2.2 DLKP
Neuroblast differentiation-associated protein AHNAK 2.2 DLKP
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DLKP-M vs. DLKP: Exponential Phase 
  
Table 3.16: Highest abundance proteins for DLKP-M vs. DLKP individual comparison. Top 
10 highest fold changes in each cell line are shown. 
 
 
DLKP-M vs. DLKP: Stationary Phase 
 
Table 3.17: Highest abundance proteins for DLKP-M vs. DLKP comparison. Top 
10 highest fold changes in each cell line are shown. 
 
Name Fold Change
Highest 
Abundance
Myristoylated alanine-rich C-kinase substrate 49.8 DLKP-M
Collagen alpha-1(III) chain 12.5 DLKP-M
Dihydropyrimidinase-related protein 2 5.3 DLKP-M
PDZ and LIM domain protein 5 4.4 DLKP-M
3-hydroxyisobutyrate dehydrogenase, mitochondrial 4.0 DLKP-M
Histone H4 3.6 DLKP-M
Collagen alpha-1(XIV) chain 3.6 DLKP-M
Cysteine and glycine-rich protein 2 3.5 DLKP-M
Connective tissue growth factor 122.7 DLKP
Protein CYR61 22.6 DLKP
Transgelin 18.3 DLKP
Hepatocyte growth factor 15.0 DLKP
Hemoglobin subunit alpha 11.4 DLKP
Solute carrier family 2, facilitated glucose transporter member 3 10.8 DLKP
F-box only protein 2 8.2 DLKP
Cathepsin Z 5.3 DLKP
Name Fold Change
Highest 
Abundance
Myristoylated alanine-rich C-kinase substrate OS 24.5 DLKP-M
Collagen alpha-1(III) chain OS 20.2 DLKP-M
Histone H4 OS 12.3 DLKP-M
Chromatin target of PRMT1 protein OS 7.5 DLKP-M
Cysteine and glycine-rich protein 2 OS 6.8 DLKP-M
SH3 domain-binding glutamic acid-rich-like protein OS 5.5 DLKP-M
Small nuclear ribonucleoprotein Sm D1 OS 4.8 DLKP-M
TATA-binding protein-associated factor 2N OS 4.7 DLKP-M
Connective tissue growth factor OS 28.7 DLKP
Protein CYR61 OS 20.0 DLKP
Hematopoietic progenitor cell antigen CD34 OS 9.7 DLKP
Hepatocyte growth factor OS 6.7 DLKP
Heat shock 70 kDa protein 1A/1B OS 3.5 DLKP
B-cell receptor-associated protein 31 OS 3.1 DLKP
Kinectin OS 3.1 DLKP
Gap junction alpha-1 protein OS 2.8 DLKP
Fascin OS 2.7 DLKP
Protein PRRC2C OS 2.5 DLKP
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DLKP-I vs. DLKP: Exponential Phase 
 
Table 3.18: Highest abundance proteins for DLKP-I vs. DLKP comparison. Top 10 highest 
fold changes in each cell line are shown 
 
 
DLKP-I vs. DLKP: Stationary Phase 
 
Table 3.19: Highest abundance proteins for DLKP-I vs. DLKP individual comparison. Top 
10 highest fold changes in each cell line are shown. 
Name Fold Change
Highest 
Abundance
Desmoglein-3 81.6 DLKP-I
Myristoylated alanine-rich C-kinase substrate 19.7 DLKP-I
Neurotensin/neuromedin N 7.5 DLKP-I
Protein S100-A10 7.1 DLKP-I
CD166 antigen 5.1 DLKP-I
Collagen alpha-1(III) chain 4.2 DLKP-I
PDZ and LIM domain protein 5 4.2 DLKP-I
Glutaminase kidney isoform, mitochondrial 3.3 DLKP-I
Solute carrier family 2, facilitated glucose transporter member 3 14.6 DLKP
Transgelin 14.5 DLKP
Connective tissue growth factor 14.1 DLKP
Cathepsin Z 4.5 DLKP
1,4-alpha-glucan-branching enzyme 4.1 DLKP
Gamma-enolase 4.1 DLKP
Hemoglobin subunit alpha 2.9 DLKP
Peroxiredoxin-2 2.9 DLKP
Name Fold Change
Highest 
Abundance
Tissue factor pathway inhibitor 2 10.8 DLKP-I
CD166 antigen 5.5 DLKP-I
Myristoylated alanine-rich C-kinase substrate 5.3 DLKP-I
PDZ and LIM domain protein 5 3.9 DLKP-I
Annexin A1 3.4 DLKP-I
Neurotensin/neuromedin N 3.0 DLKP-I
Insulin-like growth factor 2 mRNA-binding protein 3 2.8 DLKP-I
Glutaminase kidney isoform, mitochondrial 2.7 DLKP-I
Keratin, type I cytoskeletal 10 2.7 DLKP-I
Transgelin 11.0 DLKP
Connective tissue growth factor 11.0 DLKP
1,4-alpha-glucan-branching enzyme 4.0 DLKP
Peroxiredoxin-2 3.9 DLKP
Hematopoietic progenitor cell antigen CD34 2.7 DLKP
Exportin-2 2.7 DLKP
KDEL motif-containing protein 2 2.7 DLKP
Putative helicase MOV-10 2.6 DLKP
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3.1.3.4. Global Analysis Including the Combination Cell Lines 
In a separate experimental design, the global analysis method was applied 
again, this time incorporating the combination cell lines which were created by 
combining certain proportions of the DLKP clonal subpopulations, as described in 
Section 3.1.1. This was done to allow the assessment of protein expression profiles in 
the combination lines of proteins which showed strong abundance in the individual 
clones. Combining these two analyses together may shed light on how the clones 
interact to enhance or inhibit protein expression in the DLKP cell line.  
 
 
 
 
3.1.4. Expression Patterns of Proteins of Interest 
Proteins which were highlighted as significant by the global and two-sample 
comparison methods show very stark differences in abundance between the DLKP cell 
line and its clonal subpopulations. To assess how each protein was expressed across all 
cell lines, proteins of interest were displayed graphically based on protein abundance 
values. The expression pattern of a protein can be displayed as a graph of these 
abundance values. A selection of proteins which were deemed as significantly 
differentially expressed are displayed in the following pages. Proteins were chosen 
based on the following criteria: i) passing all the stringent statistical criteria described 
previously ii) being very highly abundant in one cell line only iii) appearing in more 
than one of the two-sample comparisons. 
The subset of protein targets showing highest abundance in individual cell lines 
are shown in Figure 3.6-Figure 3.23. These proteins were highlighted by the label-free 
analyses described previously in Section 3.1.3. In the case of DLKP-SQ, Hemoglobin 
subunit alpha (Figure 3.5) showed a maximum fold change of 13.5 between DLKP-SQ 
and DLKP-M (ANOVA, p= 2.73E-04) during exponential phase of growth. D-3-
phosphoglycerate dehydrogenase (Figure 3.8) also showed highest abundance in DLKP-
SQ with a maximum fold change of 5.77 between DLKP-SQ and DLKP-I (ANOVA, p= 
5.58E-10) during exponential phase of growth, and a similar protein abundance profile 
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for stationary phase (Figure 3.9). Shootin-1 (Figure 3.6) was also highlighted and this 
protein was taken forward for further investigation as described in Section 3.1.5. 
Proteins associated with high abundance in DLKP-M were also highlighted by 
the various analyses carried out in this study. Collagen alpha-1 (III) chain showed 
highest abundance in DLKP-M with a maximum fold change of 12.47 between DLKP-
M and DLKP (ANOVA, p= 1.65E-11) during exponential phase of growth (Figure 
3.12). A similar trend was also shown during stationary phase of growth (Figure 3.13) 
with a maximum fold change of 20.16 between DLKP-M and DLKP (ANOVA, p= 
1.94E-10). Histone H4 showed a maximum fold change of 29.23 between DLKP-M and 
SQ+M (ANOVA, p= 1.40E-08) but only was highlighted in the stationary phase 
analyses (Figure 3.14). Myristoylated alanine-rich C-Kinase substrate was also 
highlighted by these analyses and taken forward for further investigation as described in 
Section 3.1.5. 
In the case of DLKP-I, a number of proteins showed high expression in this 
cell line when protein expression profiles were generated. CD166 showed highest 
expression in DLKP-I with a maximum fold change of 9.18 between this cell line and 
DLKP-SQ (ANOVA, p= 1.13E-06) during exponential phase of growth (Figure 3.16). 
Similarly a maximum fold change of 7.3 between DLKP-I and DLKP-SQ (ANOVA, p= 
3.26E-06) was found during stationary phase of growth (Figure 3.17). 
Neurotensin/Neuromedin N also showed highest expression in DLKP-I with a 
maximum fold change of 7.46 and 3.02 between DLKP-I and DLKP for exponential 
(Figure 3.18) and stationary phases (Figure 3.19) of growth respectively (ANOVA, p= 
3.64E-08 and p= 5.31E-04). Desmoglein-3 was also highlighted as specifically highly 
expressed in DLKP-I and taken forward for further investigation as described in Section 
3.1.5. 
A number of proteins showed specifically high expression in the DLKP cell 
line itself, however as the aim of this thesis was to investigate protein expression in the 
clonal subpopulations of DLKP and look for potential marker, these were not pursued. 
Of particular interest however were Connective tissue growth factor, and Transgelin. 
Connective tissue growth factor showed maximum fold change of 122.69 and 28.66 
between DLKP and DLKP-M during both exponential (Figure 3.20) and stationary 
phases (Figure 3.21) of growth respectively (ANOVA, p= 1.85E-07 and p= 3.56E-06). 
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Transgelin showed a maximum fold change between DLKP and DLKP-SQ of 18.46, 
highest in DLKP (Figure 3.22) during exponential phase of growth (ANOVA, p= 
2.22E-06). Transgelin also showed a maximum fold change of 11.38 between DLKP 
and SQ+M, highest in DLKP (Figure 3.23), during stationary phase of growth 
(ANOVA, p= 3.53E-06). 
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Highest in DLKP-SQ 
 
 
Figure 3.5: Protein expression profile for Hemoglobin subunit alpha during 
exponential phase of growth.  
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Highest in DLKP-SQ 
 
Figure 3.6: Protein expression profile for Shootin-1. It is expressed with 
highest abundance in DLKP-SQ during exponential phase of growth.  
 
 
 
 
Figure 3.7: Protein expression profile for Shootin-1. Highest expression is 
seen in DLKP-SQ during stationary phase also.  
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Highest in DLKP-SQ 
 
Figure 3.8: Protein expression profile for D-3-phosphoglycerate 
dehydrogenase during exponential phase of growth.  
 
 
 
 
Figure 3.9: Protein expression profile for D-3-phosphoglycerate 
dehydrogenase during stationary phase of growth.  
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Highest in DLKP-M 
 
Figure 3.10: Protein expression profile for Myristoylated alanine-rich C-
kinase substrate during exponential phase of growth.  
 
 
 
 
Figure 3.11: Protein expression profile for Myristoylated alanine-rich C-kinase 
substrate during stationary phase of growth. 
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Highest in DLKP-M 
 
Figure 3.12: Protein expression profile for Collagen alpha-1(III) chain 
during exponential growth. 
 
 
 
 
Figure 3.13: Protein expression profile for Collagen alpha-1(III) chain during 
stationary phase of growth. 
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Highest in DLKP-M 
 
Figure 3.14: Protein expression profile for Histone H4 during stationary 
phase of growth. 
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Highest in DLKP-I 
 
Figure 3.15: Protein expression profile for Desmoglein-3 during exponential 
phase of growth. 
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Highest in DLKP-I 
 
Figure 3.16: Protein expression profile for CD166 during exponential 
phase of growth. 
 
 
 
 
Figure 3.17: Protein expression profile for CD166 during stationary 
phase. 
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Highest in DLKP-I 
 
Figure 3.18: Protein expression profile for Neurotensin/Neuromedin N 
during exponential phase. 
 
 
 
 
Figure 3.19: Protein expression profile for Neurotensin/Neuromedin N 
during stationary phase. 
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Highest in DLKP 
 
Figure 3.20: Protein expression profile for Connective tissue growth factor 
shows highest expression in DLKP during exponential phase of growth. 
 
 
 
 
Figure 3.21: Protein expression profile for Connective tissue growth 
factor during stationary phase. 
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Highest in DLKP 
 
Figure 3.22: Protein expression profile for Transgelin shows highest 
expression in DLKP during exponential phase. 
 
 
 
 
Figure 3.23: Protein expression profile for Transgelin shows the same 
expression pattern during stationary phase. 
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3.1.5. Selection of Proteins for Further Investigation 
The quantitative label-free proteomic analysis resulted in the discovery of a 
large dataset of differentially expressed proteins between the cell lines. The global 
analysis method allowed the visualisation of the protein expression patterns of these 
proteins across the entire sample set. This enabled the highlighting of proteins which 
showed a high abundance in one clone relative to the other cell lines in the comparison. 
The addition of the combination cell lines into the global method of analysis facilitated 
the expression patterns of proteins to be determined during co-culture conditions. The 
two-sample analysis method supplemented the global method, by providing the 
intermediary fold change values and associated statistical significances for proteins of 
interest. 
These analyses resulted in a number of proteins of interest for further 
investigation (See Section 3.1.4), which showed high fold changes and enriched protein 
expression in individual cell lines. These proteins are shown in Table 3.20. 
Protein DLKP Clone 
Hemoglobin subunit alpha DLKP-SQ 
D-3-phosphoglycerate dehydrogenase DLKP-SQ 
Shootin-1 DLKP-SQ 
Myristoylated alanine-rich C-Kinase substrate DLKP-M 
Collagen alpha-1 (III)-chain DLKP-M 
Histone H4 DLKP-M 
Desmoglein-3 DLKP-I 
CD166 DLKP-I 
Table 3.20: A list of proteins which underwent preliminary investigation to validate their 
expression pattern in the DLKP cell lines. 
 
Details of proteins shown in Table 3.2 can be found in Section 3.1.4 along with 
their protein expression patterns. The majority of these potential targets did not validate 
by western blot analysis, showing protein expression patterns in no way resembling 
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those found by the label-free analysis. For a number of the potential targets, the western 
blot analyses resulted in high background images, or a large number of non-specific 
bands being highlighted which obscured the result. Three proteins however validated 
well with the expression pattern found by western blot matching closely to the label-free 
protein abundance data. The three proteins were chosen for follow-up investigation: 
Shootin-1; MARCKS; and Desmoglein-3.  
Shootin-1 is a relatively novel protein, exclusively studied in neuronal cells to 
date. It is a recently discovered protein thought to play a significant role in Actin-related 
cell motility (Sapir et al. 2013). Very few studies have been carried out on it and it 
represents an opportunity to characterise a novel protein in lung cancer. The protein 
expression profile during both exponential and stationary phases of growth (Figure 3.6 
and Figure 3.7) show highest expression in DLKP-SQ relative to all other cell lines.  
MARCKS is a ubiquitously expressed protein found to be especially abundant 
in the nervous system. It is the major substrate for Protein Kinase-C, and has been 
shown to play roles in cell migration and dendrite branching in neuronal cells (Larsson 
2006). It has also been shown to bind actin, and is little studied in relation to lung 
cancer. This protein was found to be highly expressed in DLKP-M by the quantitative 
label-free proteomic analyses during both exponential and stationary phases of growth 
(Figure 3.10 and Figure 3.11 respectively). 
Desmoglein-3 is a transmembrane protein exclusively expressed in stratified 
epithelium, and is a member of the Cadherin family. It is predominantly associated with 
its role in the desmosome cell-cell adhesion structure, and also plays a significant role in 
the autoimmune disease Pemphigus Vulgaris (Jennings et al. 2011). Little is known 
about its function in cancer, though it has been shown to be involved in cell migration in 
oral squamous cell carcinoma. This protein was found to be specifically highly 
expressed in DLKP-I during stationary phase (Figure 3.15), with very little to potentially 
no expression in the other clones. 
These three proteins were taken forward for validation and further investigation 
into their roles in their respective clones. The relative novelty of Shootin-1 and 
MARCKS expression in lung cancer cells promoted their selection. The highly specific 
expression of Desmoglein-3 as well as the small number of studies in lung cancer 
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facilitated its selection. The following chapters describe the quantitative label-free data 
found for these proteins, and the follow-up investigations into their roles in their 
respective clones. 
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Chapter 4. Shootin-1 
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4.1. Shootin-1: 
Shootin-1 was found to show highest abundance in DLKP-SQ in the 
quantitative label-free proteomic analysis. Shootin-1 was first described as a novel 
protein involved in neuron cell polarization (Toriyama et al. 2006, Sapir et al. 2013). 
This group sought to investigate proteins involved in the formation of axons in 
hippocampal neurons with a view to understanding the mechanism by which neuronal 
cell polarization occours. Shootin-1 was discovered as a key molecule involved in the 
process of neuronal polarization and in axon outgrowth. It was found that Shootin-1 
accumulates at the leading edge of axonal growth cones and mediates the linkage 
between F-Actin Retrograde Flow (ARF) and the cell adhesion molecule L1-CAM 
(Shimada et al. 2008). Linkage between ARF and the CAM family of proteins is 
thought to transmit the force of actin filament polymerisation to extracellular substrates, 
resulting in cell motility. The ability of cancerous cells to migrate allows cells to change 
position within tissues, disseminate into circulation and undergo metastatic growth in 
distant organs. ARF is therefore an important mechanism in relation to the study of 
metastasis in cancer, and Shootin-1 may play an important role in this process. To date 
there are no studies on Shootin-1 in cancer as this protein is little studied, and the focus 
has been on neuronal cells thus far. The DLKP cell line was found to express neuronal 
markers (McBride et al. 1998a), therefore this was a reason to choose this protein for 
follow up. 
 
4.2. Label-free Proteomic Analysis: Shootin-1 
The purpose of the label-free analysis experiment was to highlight 
differentially expressed proteins between DLKP and its clonal subpopulations. 
Interesting targets are screened for using the protein expression pattern view in the 
Progenesis software, with the particular goal of highlighting proteins very highly 
expressed in one of the clones compared to the others. A specifically highly expressed 
protein in a single cell line compared to the others could potentially play a role in its 
known phenotypic characteristics. It could also become a marker for those 
characteristics and warrant further functional investigation. To focus in on potential 
candidate proteins, the data was screened initially using the protein expression profile 
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view shown in Figure 4.1. From an initial look at the data, Shootin-1 stood out as a 
prime candidate due to its high expression in DLKP-SQ compared to the other cell 
lines. 
 
4.2.1. Global Analysis: Shootin-1 
 During exponential phase of growth, Shootin-1 had a maximum fold change of 
4.41 with highest abundance in DLKP-SQ compared to the lowest abundance 
found in DLKP-M. 
 
 During stationary phase of growth the protein had a maximum fold change of 
3.55 with highest abundance in DLKP-SQ and lowest in DLKP. 
 
 
In both experiments, Shootin-1 passed the stringent criteria of: ≥ 2 peptides 
contributing to the protein identification, an abundance change of ≥ 2 fold between two 
experimental groups, an ANOVA p- value of <0.05 for a protein between experimental 
groups. A representative output protein abundance graph from the Progenesis software 
for exponential phase can be seen in Figure 4.1. Peptide sequences which contributed to 
the identification of Shootin-1 are shown in Figure 4.2. This image shows the 
normalised abundance values for Shootin-1 across the DLKP cell line and its clonal 
subpopulations. During both phases of growth, the abundance of Shootin-1 was very 
similar for DLKP-M and DLKP, slightly higher in DLKP-I, and approximately 4 fold 
higher in DLKP-SQ. Next, the expression levels of Shootin-1 were determined using 
experimental designs which compare the cell lines against each other using a two-
sample method: e.g. DLKP-SQ vs. DLKP-M. 
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Figure 4.1: Label-Free normalised abundances for Shootin1 during exponential phase displayed 
by Progenesis software. Highest expression is seen in the DLKP-SQ clone followed by DLKP-I. 
Lowest expression levels are seen in DLKP-M and DLKP. 7 peptides contributed to this protein 
identification, with a max fold change of 4.41 between DLKP-SQ and DLKP-M, (ANOVA, p= 
6.03E-08).  
 
 
 
 
 
 
Figure 4.2: Peptides which contributed to the identification of Shootin-1 are displayed by 
Progenesis software. Each peptide had an ANOVA p < 0.05, and MASCOT scores ≥40. 
 
 
 
 
 
 
 
DLKP-SQ DLKP-M DLKP-I DLKP 
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4.2.2. Two-Sample Experimental Designs: Shootin-1 
Shootin-1 was highlighted as being highly expressed in a single clone when all 
samples were analysed using the global analysis experimental design (See Section 
4.2.1). The expression profile clearly shows the protein as being highly expressed in 
DLKP-SQ compared to DLKP and the other clonal populations. In this analysis, 
Shootin-1 expression is assessed using experimental designs which compare two cell 
lines against each other in a one vs. one approach. This is carried out as described in 
Section 3.1.3.3. The purpose of this analysis is to uncover more detailed information on 
how a protein is expressed between each cell line, resulting in the availability of 
intermediary fold change data between any two samples, information which is not 
available from a group analysis. Results for Shootin-1 are summarised in Table 4.1.  
The analysis was comprised six comparisons for each phase of growth, with 
every permutation accounted for. Each analysis has stringent filtering criteria applied to 
the resulting proteins which are: ≥ 2 peptides contributing to the protein identification, 
an abundance change of ≥ 2 fold between two experimental both groups, an ANOVA p-
value of <0.05 for a protein between both experimental groups.  
In each analysis containing DLKP-SQ in the comparison, Shootin-1 is 
identified as being significantly differentially expressed. Shootin-1 is not highlighted as 
a differentially expressed protein in comparisons which do not include DLKP-SQ in the 
experimental design.  This indicates Shootin-1 is a specifically highly expressed protein 
in DLKP-SQ in both exponential and stationary phases of growth.  
 During exponential phase of growth, Shootin-1 was only highlighted in 
comparisons which included DLKP-SQ, always being the most abundant in that 
cell line by ~4-fold compared to other cell lines. The remaining comparisons did 
not find Shootin-1 to be statistically significantly differentially expressed and 
therefore no fold change data is available.  
 During stationary phase of growth Shootin-1 was found to be most abundant in 
DLKP-SQ each time the cell line was compared to one other. Shootin-1 was also 
found to be statistically significantly differentially expressed between DLKP-I 
vs. DLKP-M (2.07-fold), with highest abundance in DLKP-I. This marked a 
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slight change from exponential phase data, where the clonal subpopulations 
expressed Shootin-1 at a similarly low level.  
 
 
 
Exponential Phase:  
 
 
Stationary Phase: 
 
Table 4.1: Individual comparisons of the DLKP cell line and clonal subpopulations for 
exponential (A) and stationary (B) phases of growth. In each comparison containing DLKP-
SQ, Shootin-1 was highlighted as having the highest expression in that cell line. For each 
comparison, ≥ 2 peptides contributed to the identification, and ANOVA p-values were <0.05 
in the protein abundance comparisons. 
 
 
 
 
Individual Comparison Description
Max fold 
change
Highest 
Abundance
Lowest 
Abundance
DLKP-SQ   vs. DLKP-M Shootin-1 4.41 DLKP-SQ DLKP-M
DLKP-SQ   vs. DLKP-I Shootin-1 3.70 DLKP-SQ DLKP-I
DLKP-I       vs. DLKP-M - - - -
DLKP-SQ  vs. DLKP Shootin-1 4.25 DLKP-SQ DLKP
DLKP-M    vs. DLKP - - - -
DLKP-I      vs. DLKP - - - -
Individual Comparison Description
Max fold 
change
Highest 
Abundance
Lowest 
Abundance
DLKP-SQ   vs. DLKP-M Shootin-1 3.48 DLKP-SQ DLKP-M
DLKP-SQ   vs. DLKP-I Shootin-1 2.31 DLKP-SQ DLKP-I
DLKP-I       vs. DLKP-M Shootin-1 2.07 DLKP-I DLKP-M
DLKP-SQ  vs. DLKP Shootin-1 3.55 DLKP-SQ DLKP
DLKP-M    vs. DLKP - - - -
DLKP-I      vs. DLKP - - - -
(B) 
(A) 
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4.3. Validation of Shootin-1 Expression in DLKP and Clonal Subpopulations 
The expression pattern of Shootin-1 was followed up by Western Blot 
validation using the method as described in Section 2.3. This protein has a predicted 
MW of ~70kDa according to UniProt. However, Shootin-1 was found to have a MW of 
~100kDa in the DLKP cell lines. This unexpected MW for Shootin-1 was later validated 
as accurate by immunoprecipitation which identified Shootin-1 in the 100kDa region of 
a coomassie stained SDS-PAGE gel by mass spectrometry (See Figure 4.20).  
The expression pattern of Shootin-1 found by western blot analysis correlates 
well with the quantitative label-free data. A representative image of the Western Blot 
for Shootin-1 in the DLKP and clonal subpopulations is shown in Figure 4.3 A. Highest 
expression of Shootin-1 is seen in DLKP-SQ. Low level bands are present in all other 
cell lines, with DLKP-I and DLKP-M showing similar abundance levels, and almost 
undetectable bands in DLKP. Normalised abundances from the label-free analysis were 
graphed for Shootin-1 and shown in Figure 4.3 B for comparison. 
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Figure 4.3: (A) Western Blot showing expression levels of Shootin-1 in the DLKP cell 
line and clonal subpopulations, as well as combination lines. Beta-Actin loading control 
included. (B) Label-free abundance values for Shootin-1 in the DLKP cell line and clonal 
subpopulations, as well as combination lines. Standard deviations for biological triplicate 
samples are shown.  
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4.4. Proteomic Comparison of DLKP Compared to the Three Clones and 
Combination Cell Lines 
Shootin-1 was established as being highly expressed in DLKP-SQ when the 
experimental design compared DLKP and the clonal subpopulations against each other 
as a group. One vs. one comparisons showed the fold change of the protein when 
compared to the remaining cell lines. The expression pattern of Shootin-1 is next 
checked against the experimental design which incorporates all samples in the analysis. 
This experimental design includes the ‘combination lines’ which are newly created cell 
lines made up of 50:50 ratios of any two clonal subtypes, as well as a reconstituted 
DLKP based on proportions discovered in previous work (McBride et al. 1998b), as 
detailed in Section 3.1.1. A large global group analysis was created in Progenesis 
software which incorporates all samples into one large experimental design containing 
24 samples (8 conditions with three biological replicates for each). The combination 
lines were included in the analysis to determine if co-culture of the DLKP clones had 
any effect on the expression of proteins of interest. These effects could be inhibition or 
increased expression of protein targets. Shootin-1 is highlighted as a statistically 
significantly differentially expressed protein by this analysis. In addition, the abundance 
levels of Shootin-1 in the combination lines are also readily available from this analysis.  
Peptides which identify as belonging Shootin-1 and have contributed to its 
quantification are grouped together by the Progenesis software and abundances are 
displayed graphically across all samples. 6 peptides passed the filtering criteria 
previously mentioned in Section 3.1.2, and each of these contributed to the 
identification of Shootin-1. These peptides are shown in Figure 4.2. 
 
The expression profile from the analysis which shows Shootin-1 peptide 
abundances are shown in Figure 4.4. Abundance levels for Shootin-1 are significantly 
higher in DLKP-SQ than all other sample groups in the experimental design. 
Additionally, the combination line samples which contain DLKP-SQ as a component 
show higher abundances of Shootin-1 than samples not containing that cell line. 
Interestingly, two of the combination lines containing DLKP-SQ as a component did 
not express Shootin-1 at a similar abundance level as expected. There is a fold change 
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of 1.57 between SQ+M and SQ+I for Shootin-1, with the highest expression found in 
SQ+I. These two combination lines would be expected to express Shootin-1 at a similar 
level based on the data from the clonal subpopulations only. However SQ+M shows a 
significantly lower expression level of the protein. This suggests inhibition of protein 
expression is occurring in co-culture of DLKP-SQ and DLKP-M. 
 
 
 
 
 
Figure 4.4: Peptide expression pattern as displayed by Progenesis software. Peptide abundances for 
Shootin-1 show changes between clonal cell lines as well as combination lines (Exponential phase). 
Highest abundance in DLKP-SQ, lowest in DLKP-M (ANOVA, p= 2.07E-12). 
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4.5. Validation of Shootin-1 Expression in DLKP plus the Clones and Combination 
Cell Lines 
4.5.1. Western Blot 
The DLKP cell lines along with the combination lines were analysed by 
western blot to determine if the expression pattern found by the label-free proteomic 
analysis could be validated. The label-free data shows unexpected abundances of 
Shootin-1 in the combination lines, with a higher expression of the protein in SQ+I 
compared to SQ+M. Western Blot analysis validated the expression pattern in the 
exponential phase samples and can be seen in Figure 4.3 A. The label-free abundance 
values for Shootin-1 are displayed graphically in Figure 4.3 B for comparison.  
 
 
4.5.2. mRNA Expression 
Following on from western blot validation, DLKP samples were analysed 
using quantitative PCR (qPCR) to determine the relative levels of Shootin-1 mRNA 
levels in DLKP, clones and combination cell lines. Relative gene quantification was 
completed on all cell lines and combinations using beta-actin as the endogenous control. 
Biological duplicate samples were analysed and results are combined in Figure 4.5. The 
calculation of relative quantity (RQ) was achieved by normalizing the data to DLKP-
SQ. 
Gene expression of Shootin-1 correlated well with the label-free proteomics 
data in the clones. DLKP-SQ has the highest mRNA abundance out of the entire sample 
set. On average, there is a ~5-fold difference between both DLKP-M and DLKP-I when 
each is compared to DLKP-SQ. This correlates well with the label-free proteomic data 
which showed similar fold changes for the same comparisons. The abundance of 
Shootin-1 in the combinations is much lower than expected given the 1:1 ratio present 
in those samples. Though the mRNA level for Shootin-1 is low in these combination 
cell lines, they do show the same expression profile as was found in the proteomic 
analyses. 
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DLKP and Remade showed very similar levels of Shootin-1 gene expression. 
DLKP also shows higher levels of Shootin-1 gene expression than what is shown by 
label-free profiling data and western blot analysis in relation to the other samples. It is 
possible that the presence of DLKP-M cells in the DLKP cell line inhibit Shootin-1 
expression at a translational level, though further work is required to establish this. 
 
 
 
 
 
 
 
Figure 4.5: qPCR results showing gene expression of Shootin1 in the clones and 
combination lines. Samples analysed are in biological duplicate (n=2). Error bars shown 
are the standard deviations between the two replicate experiments. Data are normalised 
to DLKP-SQ.  
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4.6. Imaging of Shootin-1 in the DLKP Cell Lines: 
Validation studies confirm Shootin-1 as being highly expressed in DLKP-SQ 
compared to other cell types at the protein and mRNA level. In order to investigate the 
localization of Shootin-1 in the DLKP cell lines as well as further validate the 
expression pattern, Shootin-1 was stained using immunocytochemistry and 
immunofluorescence. Staining methods were performed as described in Section 2.6 on 
DLKP and clonal subpopulations fixed to glass slides. 
 
4.6.1. Immunocytochemical Staining of Shootin-1 in DLKP Cell Lines 
The staining intensity for Shootin-1 correlated well with the Label-free results, 
showing high staining levels in DLKP-SQ (See Figure 4.6). The staining in these cells 
is localized to the cytoplasm, with low staining in the nucleus/nuclear envelope. The 
next most intense staining is in DLKP-M. This clone has a morphology which presents 
as being projection rich with many cells showing dendritic-like outgrowths. Many of 
these projections stain positively for Shootin-1 which may lend support to the idea that 
the protein is involved in the formation of these outgrowths (Toriyama et al. 2006).  
DLKP-I has the lowest level of Shootin-1 staining overall, with the majority of 
the cells showing low level staining in the cytoplasm of the cells. In the DLKP line, 
Shootin-1 stains strongly in subpopulations of cells revealing the heterogeneous nature 
of this cell line. Some of the more intensely stained cells may be DLKP-SQ, however 
there are some abnormally large cells present with positive staining for Shootin-1 also. 
These cells may represent a so far uncharacterised clone type. In each clonal 
subpopulation, there are subpopulations which show different intensities of Shootin-1 
staining. This may indicate that each clone is not 100% one cell type only, and may 
support the theory of the inter-conversion properties of the DLKP clones as previously 
described (McBride et al. 1998b). 
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DLKP-SQ DLKP-M 
    
DLKP-I DLKP 
    
Figure 4.6: Immunocytochemical images of DLKP-SQ, DLKP-M, DLKP-I and DLKP stained with 
Shootin-1. Nuclei are stained with Dapi. Negative controls with secondary antibody only did not result 
in staining (images not shown). Original magnification used on all micro-pictographs shown at 200x, 
200μm scale bar. (n=2) 
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4.6.2. Immunofluorescent Staining of Shootin-1 in DLKP Cell Lines 
Immunofluorescence staining of Shootin-1 was carried out in DLKP and each 
of its clonal subpopulations to allow visualization of the distribution of the protein in 
each cell type, as well as a semi-quantitative assessment of protein abundances. Staining 
was carried out using the method described in Section 2.6.3 with resulting images 
shown in Figure 4.7. DLKP-SQ shows the most intense staining for Shootin-1 out of all 
cell lines. The staining is high in the cytoplasm and high areas of Shootin-1 can also be 
seen in what may be the leading edges of lamellipodia in some cells as described in a 
previous study (Shimada et al. 2008). In addition, there appears to be some perinuclear 
staining for Shootin-1 in the DLKP-SQ cells. DLKP-M has the next highest level of 
Shootin-1 staining. The morphology of DLKP-M results in many projecting structures 
similar to dendritic or axonal outgrowths, and staining of Shootin-1 is high in these 
structures. DLKP-I has the least intense staining, showing only diffuse low level 
Shootin-1 expression in the cytoplasm of the cells. DLKP shows intense staining of 
Shootin-1 in some subpopulations and none in others. Some of the stained cells 
resemble DLKP-SQ and DLKP-M as expected, with block like staining and outgrowth 
staining respectively. In addition, there are very large cells present staining very 
strongly for Shootin-1 which do not resemble any of the known clonal subpopulations 
and may represent a so far uncharacterised subpopulation within DLKP. 
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DLKP-SQ DLKP-M 
    
 DLKP-I DLKP 
    
Figure 4.7: Immunofluorescence images staining for Shootin-1 in DLKP-SQ, DLKP-M, DLKP-I 
and DLKP. Nuclei are stained with Dapi. Negative controls with secondary antibody only did not 
result in staining (images not shown). Original magnification used on all micro-pictographs shown 
at 400x, 50μm scale bar. (n=2) 
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4.7. Functional Analysis of Shootin-1 Knockdown by RNAi 
4.7.1. Transfection Optimisation 
To investigate the role Shootin-1 plays in DLKP, RNA interference (RNAi) by 
transfection was chosen as a method to knockdown the expression of Shootin-1 in 
DLKP-SQ. This method is a relatively straightforward way of reducing the expression 
of a target protein and assessing the effects, using a panel of functional assays. 
Functional effects of protein knockdown can be determined by comparing the 
knockdown samples against the negative siRNA control. Here, a standard commercially 
available negative siRNA control is used that does not code for any known target 
sequence. This is used as a control to determine the effects of introducing siRNA into 
the cells. DLKP-SQ was chosen for Shootin-1 RNAi treatment as it has the highest 
expression levels of Shootin-1 at the protein and mRNA level. Before Shootin-1 
knockdown was attempted, DLKP-SQ cells were first tested to determine the optimal 
transfection conditions required: 
 The volume of transfection reagent necessary to effectively transfect DLKP-SQ 
was determined as described below. 
 Next, the optimal concentration of siRNA was determined which significantly 
reduced expression of the target, yet did not over-saturate the cells with 
unnecessary siRNA. 
 
4.7.1.1. Optimisation of Transfection Reagent Volume: 
Transfection reagent is necessary to introduce siRNA into living mammalian 
cells using the method described in Section 2.4.1. In order to determine the most 
effective volume of transfection reagent to use for a particular cell type, a balance must 
be found between maximising transfection efficiency and limiting the toxic effects 
inherently associated with transfection reagent (Lipofectamine 2000). Rigorous 
optimisation is required in order to determine appropriate reagent volume. Transfection 
of DLKP-SQ cells was performed to test different volumes of transfection reagent in 
order to determine the optimal transfection reagent volume required. A proliferation 
assay subsequently performed using the acid phosphatase assay to determine cell 
viability (Section 2.5.1) is shown in Figure 4.8. Results are displayed as a percentage 
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survival value relative to the negative siRNA control (2 μl/well of transfection reagent). 
In all transfection conditions where siRNA is included, a 5 nM concentration is used. 
Four different transfection conditions were assayed in order to assess the optimal 
volume of Lipofectamine reagent to use for RNAi in DLKP-SQ: Cells-only; Lipo-only; 
Negative siRNA; Positive siRNA. 
 
4.7.1.2. Transfection Reagent Optimisation 
In order to focus in on the optimal transfection reagent volume to use for 
DLKP-SQ cells, 1 μl and 2 μl per well volumes of Lipofectamine per well in a 6-well 
plate were tested (after previous optimisation steps). Results are shown in Figure 4.8. A 
positive siRNA control is included which targets Kinesin, a motor protein required for 
the establishing of the bipolar spindle (Rapley et al. 2008)_. Inhibition of this protein 
arrests cells in mitosis, eventually leading to cell death. When compared to Cells-only, 
both 1 μl/well and 2 μl/well of transfection reagent show no effect on the proliferation 
of the Lipo-only control or the negative siRNA control. In contrast, the positive siRNA 
has a huge effect on the cell viability. A volume of 2 μl/well of transfection reagent 
effectively delivers positive control siRNA into the cells, resulting in a 90% reduction 
of cell viability compared to the negative siRNA control. This reagent volume shows no 
negative effects on cell viability and is twice as effective as a transfection reagent 
volume of 1 μl/well. Therefore, a volume was of 2 μl/well chosen as optimal for further 
transfections with DLKP-SQ. 
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Figure 4.8: Proliferation assay performed on DLKP-SQ cells using 1μl/6-well (Blue) 
and 2μl/6-well (Red) of Lipofectamine transfection reagent. Percentage survival values 
are relative to the Negative siRNA control. (1μl /well: P-Value 1.8E-04) (2μl/well P-
Value: 3.1E-05). 
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4.7.1.3. Optimisation of siRNA Concentration: Shootin-1 
The optimization of Shootin-1 RNAi transfection conditions was finalized by 
establishing the optimal siRNA concentration to achieve maximum Shootin-1 protein 
knockdown. A transfection experiment was set up with a range of siRNA concentrations 
for Shootin-1 in DLKP-SQ. Transfection conditions were comprised of: 
 Cell-only, Lipofectamine-only and Negative siRNA controls. 
 5 nM, 10 nM, 20 nM and 30 nM of siRNA were tested for Shootin-1. 
 Two different siRNA molecules were tested in tandem which target Shootin-1. 
 
 
Cell lysates were prepared from each transfection condition 72 hours post 
transfection using the method described in Section 2.3.1. Western blot analysis probed 
for Shootin-1 across all samples and the resulting blot image is shown in Figure 4.9. 
Two independent siRNA molecules were used to knockdown Shootin-1 expression at 
the four different concentrations described above. Bands for Shootin-1 are clearly 
visible at 100 kDa as expected in DLKP. A concentration of 30 nM siRNA was used in 
the negative siRNA sample to represent the maximum siRNA concentration in the 
Shootin-1 test panel. Based on the western blot results, 20 nM was determined as the 
optimal concentration of siRNA to use for Shootin-1 RNAi DLKP-SQ. This 
concentration shows total knockdown of the target, yet does not over-saturate the cells 
with unnecessary siRNA molecules. 
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Figure 4.9: Western Blot probing for Shootin-1 (100kDa). Lanes 1-3 contain: Cells-only, 
Lipofectamine-only and Negative siRNA (30nM). Each Shootin-1 siRNA group (#1 and 
#2) is comprised of four sample lanes which were treated with 5 nM, 10 nM, 20 nM and 30 
nM of siRNA from left to right. Beta-Actin loading control included. 
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4.7.2. Effects of Shootin-1 Knockdown on Proliferation, Migration and Invasion in 
DLKP-SQ 
To investigate the potential role of Shootin-1 in DLKP-SQ, a panel of 
functional assays were carried out following siRNA transfection to knockdown the 
protein. Two individual siRNA molecules were used to knockdown Shootin-1 in 
DLKP-SQ using conditions optimised and described in Section 4.7.1. Proliferation, 
migration and invasion assays were carried out to investigate if a reduction in Shootin-
1 expression resulted in a significant effect on the phenotype of DLKP-SQ. 
 
4.7.2.1. Proliferation of DLKP-SQ after Shootin-1 Knockdown: 
Proliferation of DLKP-SQ cells was measured 72 hours post transfection as 
described in Section 2.2.3. Knockdown of Shootin-1 by RNAi was found to have no 
significant effect on proliferation compared to the negative siRNA Control. Results are 
shown in Figure 4.10. 
 
 
 
Figure 4.10: Proliferation assay on DLKP-SQ 72 hours post-transfection for 
Shootin-1 RNAi. There was no statistically significant difference in proliferation 
between siRNA knockdown samples (#1 and #2) and the Negative siRNA control 
(n=3). (siRNA#1 P-value: 0.23, siRNA#2 P-value: 0.16).  
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4.7.2.2. Migration of DLKP-SQ after Shootin-1 Knockdown: 
Migration assays were performed 72 hours post transfection as described in 
Section 2.5.4. DLKP-SQ cells were allowed to pass through the uncoated membrane for 
24 hours before being fixed and stained with crystal violet. A reduction in the migratory 
ability of DLKP-SQ cells was found when Shootin-1 knockdown samples were 
compared to the negative control. Migration levels are shown in Figure 4.11. Only one 
of the siRNA molecules show a significant reduction in migration; however the second 
molecule follows the same trend. This suggests that knockdown of Shootin-1 reduces 
the migratory ability of DLKP-SQ.  
 
 
 
 
Figure 4.11: Migration assay results for DLKP-SQ cells following Shootin-
1 knockdown with RNAi. Total number of cells which migrated through the 
uncoated membrane is shown (n=3). A statistically significant difference 
was found between knockdown siRNA sample #1 and the negative control. 
SiRNA #2 did not show a significant effect, but did show the same trend in 
reducing migration compared to the negative siRNA control. (siRNA#1 P-
value: 0.04, siRNA#2 P-value: 0.19)  
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4.7.2.3. Invasion of DLKP-SQ after Shootin-1 Knockdown: 
Invasion assays were performed 72 hours post transfection as described in 
Section 2.5.3. Cells which passed through the Matrigel coated membrane were counted 
and total numbers of invading cells per insert were calculated. No significant effect was 
found in the ability of DLKP-SQ to invade following Shootin-1 knockdown by RNAi 
when compared to the negative control. Invasion levels are shown in Figure 4.12. 
 
 
 
 
Figure 4.12: Invasion assay results of DLKP-SQ cells following Shootin-1 
knockdown with RNAi. Total number of cells which invaded through the coated 
membrane is shown (n=3). There was no statistically significant difference between 
knockdown siRNA samples (#1 and #2) and the negative siRNA control (siRNA#1 
P-value: 0.80, siRNA#2 P-value: 0.22).  
 
 
 
 
 
0
500
1000
1500
2000
2500
3000
Cells Only Lipo Neg siRNA siRNA#1 siRNA#2 
To
ta
l N
o.
 o
f 
In
va
di
ng
 C
el
ls
DLKP-SQ Invasion Assay 
Shootin-1 Knockdown
 151 
 
4.7.3. Co-Staining of Shootin-1/F-Actin after Shootin-1 Knockdown by RNAi in 
DLKP-SQ 
 Literature studies have reported an association between Shootin-1 and Actin, 
particularly in the growth cones of neuronal cells. One research group sought to 
investigate the molecular mechanism linking cell adhesion molecules (CAMs) and 
Actin Retrograde Flow (ARF). They found Shootin-1 mediates the linkage between 
L1CAM and ARF in cultured rat hippocampal neurons (Shimada et al. 2008). Shootin-1 
RNAi impaired this linkage, reducing L1CAM dependant axon outgrowth. At present, 
there are no reports of Shootin-1 expression in lung or lymph derived cell lines and 
therefore no links with Actin in these systems either. Due to these reported links 
between Shootin-1 and Actin mentioned above, it was decided to investigate this 
potential link in DLKP-SQ.  
 DLKP-SQ cells were stained simultaneously for Shootin-1 and Actin and 
imaged using confocal microscopy. Staining was performed after Shootin-1 expression 
was knocked down by RNAi. This was done to assess the effect of Shootin-1 reduction 
on Actin localization or staining intensity. In order to image the cells clearly, DLKP-SQ 
were grown on glass coverslips previous to Shootin-1 knockdown. Staining of Shootin-
1 and Actin by confocal microscopy was performed after RNAi transfection. The 
transfection was performed on DLKP-SQ cells using the method as described in Section 
2.4.2. To increase the likelihood of capturing motile cells mid-movement by confocal 
imaging, cells were scratched once with a P1000 tip 48 hours post transfection and 
washed with complete medium. Cells were fixed at 72 hours with 4% Paraformaldehyde 
before the staining process began. DLKP-SQ control and transfection samples were co-
stained with Shootin-1, Actin and Dapi as described in Section 2.6.4. 
 Knockdown samples were compared to the controls: Cells-only, Lipo-only and 
negative siRNA. To rule out the possibility of non-specific staining, negative controls 
using secondary-only antibody treatment were imaged by confocal microscopy also. 
This resulted in no staining in DLKP-SQ cells, confirming that staining in the test 
samples is not due to sticky non-specific secondary binding (Images not shown). This 
experiment was performed in biological duplicate, and resulting images are shown in 
Figure 4.13 to Figure 4.17. Shootin-1 is referred to as ‘Shot1’ in the images. 
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DLKP-SQ: Cells Only 
 
Figure 4.13: DLKP-SQ cells stained for Shootin-1, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are untreated by any RNAi method. Original 
magnification of all photomicrographs, ×400, scale bar = 20 μm. 
 
 
DLKP-SQ: Lipofectamine-only Control 
 
Figure 4.14: DLKP-SQ cells stained for Shootin-1, Actin and Dapi. A 
merged image is shown in the bottom right corner. Cells are treated with 
transfection reagent only (Lipofectamine). Original magnification of all 
photomicrographs, ×400, scale bar = 20 μm. 
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DLKP-SQ: Negative siRNA Control 
 
Figure 4.15: DLKP-SQ cells stained for Shootin-1, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are treated with transfection reagent and 
negative siRNA control. Original magnification of all photomicrographs, ×400, scale 
bar = 20 μm. 
 
 
DLKP-SQ: Shootin-1 Knockdown- siRNA #1 
 
Figure 4.16: DLKP-SQ cells stained for Shootin-1, Actin and Dapi. A 
merged image is shown in the bottom right corner. Cells are treated with 
siRNA#1 for Shootin-1. Original magnification of all photomicrographs, 
×400, scale bar = 20 μm. 
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DLKP-SQ: Shootin-1 Knockdown- siRNA #2 
 
Figure 4.17: DLKP-SQ cells stained for Shootin-1, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are treated with siRNA#2 for Shootin-1. 
Original magnification of all photomicrographs, ×400, scale bar = 20 μm. 
 
 
Negative Control: High Magnification 
 
Figure 4.18: DLKP-SQ cells stained for Shootin-1, Actin and Dapi. A merged image is 
shown in the bottom right corner. DLKP-SQ cells at high magnification showing co-
localization of Shootin-1 and Actin in cell projections. Original magnification of all 
photomicrographs, ×800, scale bar = 5μm. 
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Staining of Shootin-1 in DLKP-SQ (coloured red) shows a similar localization 
of the protein as found in the immunofluorescence work described in Section 4.6 for the 
control group. In the control group cells, there is high level staining of Shootin-1 visible 
throughout the cytoplasm with strong points of intense staining visible at the edges of 
the cells. The Dapi nuclear stain (coloured blue) is still visible in the merged 
photograph, which suggests low level staining for Shootin-1 in the nucleus or nuclear 
envelope of DLKP-SQ cells. Actin staining is high in DLKP-SQ (coloured green) 
showing high cytoplasmic staining throughout the cells as well as at the edges. The 
merged photographs reveal co-localization of Shootin-1 and Actin, particularly in 
Figure 4.14. This image shows most clearly an overlapping staining pattern for both 
proteins, notably in the projections emanating from the cells showing intense staining at 
the tips.  
The confocal imaging of Shootin-1 also shows successful RNAi knockdown of 
the protein expression in Figure 4.16 and Figure 4.17. The two samples were treated 
with siRNA #1 and #2 for Shootin-1 and there is a large reduction in the levels of 
staining for Shootin-1 in both cases. Actin staining seems to be unaffected by this 
treatment, which indicates that Shootin-1 is neither involved in the expression levels of 
actin, nor its localization in DLKP-SQ cells. This finding somewhat corroborated by the 
use of beta-actin as a loading control in the western blot shown in Figure 4.9. Although 
the expression levels of actin were not expected to change upon knockdown of Shootin-
1, it was thought that it could have had an effect on actin localization. The confocal 
imaging suggests that this is not the case in DLKP-SQ. 
Shown in Figure 4.18 is a high magnification image of the negative control 
sample which clearly shows co-localization of Shootin-1 and Actin. This co-localization 
is visible throughout the cell, but especially on the protruding outgrowths which link 
neighbouring cells together. Shootin-1 and Actin can clearly be seen dotted along these 
filamentous outgrowths, suggesting a possible connection between the two proteins in 
DLKP-SQ. 
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4.8. Identification of Potential Binding Partners of Shootin-1 
To shed some light on the role of Shootin-1 in DLKP-SQ, a co-
immunoprecipitation (Co-IP) of Shootin-1 was performed on DLKP-SQ cells with a 
view to extracting potential binding partners with the target. Co-IP uses antibodies 
specific to the target to form an immune complex with the protein of interest which can 
be captured on a beaded support column. Along with the target itself, other 
macromolecules which may be bound to the target by native interactions will also be 
captured. This form of affinity chromatography can be an effective method of 
discovering binding partners of the target protein. Two strategies were attempted to Co-
Immunoprecipitate Shootin-1 and potential binding partners: Cross-linked Co-IP and 
Traditional Co-IP. 
 
4.8.1. Cross Linked Co-Immunoprecipitation: 
Initially, Co-IP employing cross-linked antibody technology was used to 
immunoprecipitate Shootin-1 and any potential binding partners from DLKP-SQ cell 
lysate. This method leaves the antibody specific to the target covalently bound to the 
bead column after elution of the bound protein complexes. Protein elution is carried out 
using a low pH buffer to preserve the activity of the antibody for the protein of interest. 
The advantage of this method is once the eluted proteins are separated using SDS-
PAGE, no antibody fragments (heavy and light chain fragments) co-elute in the sample. 
This results in easier identification of captured proteins in the sample by MS or western 
blot, as they are not masked by the presence of relatively large abundances of antibody 
fragments. Also, the column can be reused for further Co-Immunoprecipitation 
experiments. Rabbit IgG antibody was used as a negative control in parallel to account 
for non-specific binding of protein to the target antibody isotype. Unfortunately this 
method was unsuccessful at purifying Shootin-1 by immunoprecipitation as shown in 
Figure 4.19. 
Western blot analysis of Shootin-1 for the Co-IP sample set is shown in Figure 
4.19. Shootin-1 is visible at 100 kDa in the positive control lysate, showing the protein 
can be detected when DLKP-SQ cells have been lysed using the IP compatible lysis 
buffer. For both Shootin-1 and rabbit IgG control samples, double elutions were 
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performed in order to retrieve the maximum amount of bound protein from each 
column. Elutions of Shootin-1 samples do not contain the protein (Lanes 2 and 3) and 
only heavy chain antibody fragments are visible. Shootin-1 can be clearly seen in the 
unbound fraction (Lane 4), suggesting Shootin-1 was not captured by the cross-linked 
antibody technology. Rabbit IgG control sample elutions (Lanes 5 and 6) show 
extremely strong heavy and light chain antibody fragments as well as high background. 
This is unusual as the same concentration of antibody was used for both test and 
control. Shootin-1 is visible once again in the unbound fraction of this control group 
(Lane 7). These results show the failure of this technique on two fronts. The target 
protein was not captured, and heavy and light chain antibody fragments were eluted 
from the beads even after cross-linking. 
 
 
Figure 4.19: Western Blot probing for Shootin-1 in DLKP-SQ samples after cross 
linked Co-IP. Lane 1: DLKP-SQ lysate control. Lanes 2 and 3: First and second 
elution from Shootin-1 Co-IP. Lane 4: Shootin-1 Co-IP unbound fraction. Lanes 5 
and 6: First and second elution from Rabbit IgG control. Lane 7: Rabbit IgG 
unbound fraction. Shootin-1 is visible at 100kDa. Heavy and light antibody chains 
are prominent. 
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4.8.2. Traditional Co-Immunoprecipitation: Shootin-1 
This method differs from Cross-Linked IP in that the target antibody is not 
covalently bound to the Protein-G bead column. During elution of the target protein and 
any binding partners, the antibody is also released from the bead support. Because of 
this, the heavy and light chains of the denatured antibody are present when the sample is 
separated by SDS-PAGE, and mask the detection of proteins by western blot or MS. 
However, it is an effective and simple method of performing a Co-IP, particularly if the 
protein of interest does not have a similar Mw to the antibody fragments.  
 
Shootin-1 was immunoprecipitated from DLKP-SQ and analysed by western 
blot. This analysis was unable to detect the protein due to huge interference by the 
antibody fragments present in the elution samples. Fragments of antibody were detected 
in the entire length of the lane, thereby masking detection of any specific protein (image 
not shown). However, a coomassie stained gel on which the test and control elutions 
were separated by SDS-PAGE revealed a weak but obvious band at 100 kDa in the 
Shootin-1 elution lane which was not present in the rabbit IgG control elution shown in 
Figure 4.20. Each lane was excised from the gel and sliced into 2 mm fragments along 
its entire length. In-gel digestion was performed on the gel pieces and proteins were 
identified using LC-MS/MS using methods described in Section 2.8.6. MS analysis was 
successful in detecting Shootin-1 and potential binding partners in two independent 
traditional Co-IP experiments with results summarised in Table 4.2.  
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Figure 4.20: Coomassie stained gel of Shootin-1 Co-IP samples. Lane 1: DLKP-SQ 
positive control lysate. Lane 2: Shootin-1 Co-IP elution. Lane 3: Negative control Rb 
IgG to account for non-specific binding events. Shootin-1 band is circled in red at 
100kDa in lane 2. Heavy and light antibody chains are clearly visible. 
 
Proteins identified as present in the negative control (Rabbit IgG) lane were 
eliminated from the list of proteins identified in the Shootin-1 immunoprecipitate. 
Results from both replicate experiments were overlapped and common proteins are 
shown in Table 4.2. The sequence coverage for each protein identified by MS is shown 
for both experiments.  
Shootin-1 was the most abundant unique protein in each experiment, with 
sequence coverage of 54% and 36% respectively. The majority of peptides which 
contributed to this identification were obtained from the gel slice circled in red in Figure 
4.20. This finding confirms Shootin-1 as being expressed at 100kDa in DLKP. Even 
though the western blot detection of Shootin-1 was made impossible by the presence of 
antibody fragments, MS detection was used to show its presence at the expected weight 
in the immunoprecipitation. This indicates that successful immunoprecipitation of 
Shootin-1 and potential binding partners was achieved. 
A number of proteins were found to co-immunoprecipitate with Shootin-1 in 
both replicate experiments. This panel of proteins (Table 4.2) were not present in the 
negative control, ruling out non-specific binding as the reason for their capture. They 
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also passed all the stringent criteria associated with MS analysis in this experiment as 
described in Section 2.7.6.2, and were therefore followed up by western blot analysis. 
 
 
Protein Sequence Coverage 
Exp 1 
Sequence Coverage 
Exp 2 
Shootin-1 54% 36% 
Small nuclear ribonucleoprotein 
Sm D3 
25% 8% 
60S ribosomal protein L12 24% 9% 
Striatin-3 6% 2% 
Src substrate cortactin 6% 2% 
Semenogelin-1 5% 10% 
Table 4.2: Mass spec identifications showing immunoprecipitated Shootin-1 protein, with co-
eluted proteins from two replicate experiments. Percentage of each protein sequence identified by 
MS is shown for each experiment. 
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4.8.3. Western Blot Analysis of Shootin-1 Binding Partners in DLKP 
Western Blot analysis was used to validate the presence of three of the 
potential Shootin-1 binding partners. Unfortunately, this could not be done on the 
Shootin-1 immunoprecipitate elution, as the antibody fragment problem prevents 
detection of specific proteins due to masking effects. The analysis was therefore 
performed on DLKP-SQ cell lysate to ensure the proteins are being expressed by the 
cell line. Alongside this, the protein panel was also analysed by western blot in the 
remaining DLKP cell lines as well as the combination lines in order to establish their 
expression pattern in the DLKP cell line model. This information may correlate with the 
known phenotypes of the clones and shed light on role in this system. The three proteins 
chosen for validations are: Semenogelin-1, Striatin-3 and Src Substrate Cortactin. 
 
4.8.3.1. Semenogelin-1: 
Semenogelin-1 (SEMG1) is a secreted protein usually expressed in the seminal 
vesicles and urinary bladder with little to no expression in other tissues of the body 
(Bjartell et al. 1996). However, it has been shown to be expressed very specifically in 
the cerebellum and only in Purkinje cells located there. Semenogelin1 has been found to 
be ectopically expressed in small cell lung cancer (SCLC) and expression is not limited 
to males in these cases. The protein has been found to be secreted into growth medium 
by SCLC cell lines and was proposed as a useful biomarker for the disease (Rodrigues 
et al. 2001).  
SEMG1 was successfully detected by western blot in all DLKP and subclonal 
cell lines. Looking at DLKP and the clones only (Figure 4.21), highest expression of 
SEMG1 is in DLKP-M which shows a much higher abundance of this protein when 
compared to all other samples. The next highest expression level is in DLKP-I followed 
by DLKP-SQ and DLKP. The combination lines show unexpected expression patterns. 
The abundance of SEMG1 is higher in SQ+M than in I+M, which is not what would be 
the case if the band intensities from the clone constituents are added together. It is 
therefore possible that DLKP-I has an inhibitory effect on the expression of SEMG1. 
The DLKP has a lower abundance of SEMG1 compared to the ‘Remade’ cell line. The 
‘Remade’ cell line was created to reform DLKP in the proportions found previously 
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(McBride et al. 1998b). In the case of SEMG1 the abundance level of the protein is not 
equal between the two, suggesting the presence of other cell types in the DLKP cell 
line. SEMG1 was not found to be a significantly differentially expressed protein in the 
label-free LC-MS proteomic analysis.  
 
 
 
Figure 4.21: Western Blot probing for Semenogelin-1 in DLKP and clonal 
subpopulation lines. Combination lines are included also. Bands are visible at the 
expected weight of ~52kDa. Beta-Actin is used as a loading control. 
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4.8.3.2. Src Substrate Cortactin 
Src Substrate Cortactin (CCTN) is a cytoplasmic protein involved in actin 
polymerization and rearrangement of the actin cytoskeleton (Wei et al. 2014). Cortactin-
assisted actin branching is most prominent around the outside of the cell and occours 
when cortactin has been phosphorylated. The protein then stabilises the ARP2/3 
complex which provides more nucleation sites for actin branching, resulting in 
enhanced formation of lamellipodia and cell spreading (Uruno et al. 2001, Weed and 
Parsons 2001). CCTN has been found to be overexpressed in malignant tumours in 
oesophageal squamous cell carcinoma and has been found to be a prognostic marker for 
poor survival in colorectal adenocarcinoma (Kim et al. 2012, Luo et al. 2006).  
CCTN was validated as being expressed in the DLKP cell line model by 
western blot analysis (Figure 4.22A). DLKP and DLKP-SQ have the highest abundance 
of the protein, followed next by DLKP-M and then DLKP-I. Combination lines showed 
unexpected expression patterns. SQ+M has a lower abundance of CCTN than the two 
individual clones which combine to make it. This suggests an inhibitory effect on the 
expression of CCTN when the two cell types are grown in co-culture. A similar 
inhibitory effect can be seen on the other combinations SQ+I and I+M, which show 
much lower abundances of CCTN that would be expected. DLKP and Remade also 
show different levels of CCTN expression, suggesting an expression difference between 
them. 
CCTN was also discovered by the label-free analysis as a differentially 
expressed protein (Figure 4.22B). It has a maximum fold change of 1.79 between 
DLKP-SQ and DLKP-I (ANOVA, p= 1.73E-05) and 4 peptides contributed to its 
identification. With a fold change <2, it did not meet with the criteria necessary to be 
included in the results described in Section 3.1.2. However, the fold change is still 
significant and the data can be used to assess protein expression patterns in the DLKP 
cell line model. In the case of CTTN, there is a good correlation between the label-free 
data, and that discovered by western blot analysis. In both cases, DLKP-SQ and DLKP 
showed the highest levels of CTTN abundance. CCTN is involved in actin 
polymerisation at the leading edges of cells. Immunofluorescence staining showed 
localization of Shootin-1 at these areas also, which suggests an interaction between the 
two proteins, however further work is necessary to show this. 
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Figure 4.22: (A) Western blot probing for Src Substrate Cortactin. Bands are visible at 
the expected weight of ~61kDa. Beta-actin is used as a loading control. (B) Label-Free 
analysis result for Src Substrate Cortactin. 
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4.8.3.3. Striatin-3 
Striatin-3 (STRN3) is a member of the striatin family of proteins which are 
found to be mostly expressed in the dendritic spines of neurons in the central nervous 
system. They contain multiple protein-binding domains such as caveolin and coiled 
coil-binding domains. They are also known to bind calmodulin and Ca2+ (Bartoli et al. 
1999, Benoist, Gaillard and Castets 2006). Expressed in a variety of cancer cell lines 
and tissues, striatin family members are reported to be involved in cell migration and 
invasion. Knockdown of a striatin family member has been shown to reduce the 
metastatic phenotype of oesophageal and ovarian cancer cell lines (Wong et al. 2014).  
STRN3 was identified as a potential binding partner of Shootin-1 by Co-IP. 
Western blot validation of STRN3 revealed its expression profile in the DLKP cell line 
model (Figure 4.23). Lowest expression of STRN3 is seen in DLKP-SQ (the least 
invasive cell line). Highest expression is in DLKP-M (the most invasive cell line). 
Similar levels are in both DLKP-I and DLKP with the latter showing slightly less 
abundance. In the case of the combination lines, the level of STRN3 expression in both 
of the cell lines containing DLKP-M is higher than expected. Abundance levels for the 
protein remained similar to the undiluted DLKP-M clone. This suggests that STRN3 
expression in DLKP-M is unaffected by co-culture with DLKP-I or DLKP-SQ, with 
abnormally high abundance levels of the protein visible in SQ+M and I+M. Expression 
levels of this protein correlate with the known phenotypes of the DLKP clones with 
regards to invasion and migration. Highest expression is visible in DLKP-M while 
lowest expression is in DLKP-SQ. Further work is needed to determine if STRN-3 is 
involved with the invasive phenotype of DLKP-M. STRN-3 was not found as a 
differentially expressed protein in any of the label-free quantitative analyses. 
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Figure 4.23: Western blot probing for Striatin-3. Bands are visible at the 
expected weight of ~87kDa. Beta-Actin is used as a loading control. 
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4.9. Over-Expression of Shootin-1 in DLKP and Clonal Subpopulations 
To further investigate the role of Shootin-1 in DLKP, it was decided that over-
expression of the protein in the DLKP clones may shed light on its function in the cell 
line model. If successful over-expression was achieved, functional assays could be 
performed to assess the effects of Shootin-1 over-expression. In order to create an over-
expression vector, the approach taken uses cDNA generated from DLKP-SQ RNA as a 
template to amplify the Shootin-1 open reading frame (ORF) sequence. This sequence is 
then ligated into a vector and can be transfected into each clonal subpopulation to 
promote gene over-expression. This method is cost effective and uses the endogenous 
sequence for Shootin-1 being expressed by DLKP-SQ. The first step is to design 
primers which successfully amplify the target sequence for Shootin-1. Next, that 
sequence is cloned into an over-expression vector and transformed into competent 
bacteria for amplification. Following this, the vector is extracted and digested with 
restriction enzymes to ensure the correct size fragment has been incorporated into the 
vector. Finally, the potential Shootin-1 fragment is sequenced to ensure complete 
homology to the known open reading frame sequence.  
 
4.9.1. PCR Amplification of the Shootin-1 Coding Sequence from DLKP-SQ 
Firstly, the DLKP-SQ cell line was used as a basis for acquiring the Shootin-1 
coding sequence as it is expressed at the highest abundance in that cell line at the 
protein and mRNA levels. Primers were designed which flank either end of the Shootin-
1 coding sequence and also incorporate different restriction enzyme sites at their 5 
prime ends. Restriction enzyme sites flanking Shootin-1 were chosen based on their 
presence and position in the vector (pcDNA 3.1 Hygro+) and were designed into the 
primers to ensure the resulting amplicon would be oriented correctly in the vector after 
ligation. Restriction enzyme sites used were KPN1 and XHO1.  
 
Following extensive optimisation, a PCR was carried out to amplify the 
Shootin-1 coding sequence. The starting material for this process was cDNA generated 
from DLKP-SQ RNA. Synthesis of cDNA was carried out using a standard reverse 
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transcription kit with random primers as described in Section 2.9.3. To amplify the 
Shootin-1 sequence by PCR, multiple different annealing temperatures were tested 
using the Shootin-1 primers and resulting DNA fragments were separated by agarose 
gel electrophoresis and visualised using SafeView (Figure 4.24A). In the final panel 
tested, 2 samples resulted in faint bands at the expected weight of ~1950bp PCR 
products were cleaned up using a PCR purification kit to remove small DNA fragments 
(primers) and incompatible buffers from the PCR reaction. Following this, the PCR 
product was digested using KPN1 and XHO1 to create the sticky ends necessary for 
ligation into the pcDNA3.1 vector. In tandem, the vector was also digested with the 
same restriction enzymes to linearize it and prepare it for ligation (Figure 4.24B). 
 
 
Figure 4.24: (A) PCR amplification of the Shootin-1 coding sequence. Five samples at 
different annealing temperatures were attempted (1-5). Samples 1 and 5 show faint 
bands at the expected weight of 1950bp. (B) Samples are separated on an agarose gel 
after digestion by KPN1 and Xho1. The pcDNA3.1 vector has been linearized by the 
digestion process (Lanes 1 and 2), and Shootin-1 sequence can be assumed to be 
digested also (Lanes 3 and 4). 
Shootin-1
Marker 1 2 3 4 5
2000bp
Marker 1 2 3 4
1950bp
~5600bp
(A) 
(B) 
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4.9.2. Ligation of Shootin-1 Fragment and Over-Expression Vector 
The vector and Shootin-1 fragments were ligated together overnight at 16°C 
using a Roche Rapid Ligation kit. The following day, 7 μl of ligation mix was 
transformed into DH5α E. coli and plated on ampicillin LB agar plates. Four colonies 
were picked and miniprepped to extract the vector. Extracted vectors from all picked 
colonies were quantified and digested using KPN1 and Xho1 to determine if any 
contained the insert of expected size (1950 bp). The resulting product was visualized on 
an agarose gel. Four colonies were picked and mini-prepped, and these correspond to 
the last four lanes in Figure 4.25. The image shows that sample 3 has a secondary band 
at the expected size of ~1950bp, which suggests the Shootin-1 fragment has been 
successfully incorporated into the vector backbone.  
Sample 3 was sent for sequencing to ensure the fragment which has been 
inserted is indeed the coding sequence for Shootin-1. Primers were designed to allow 
sequencing of the entire length of the Shootin-1 ORF. Sequencing was completed and 
showed 100% homology to the Shootin-1. Once this step was completed, the vector was 
the midi-prepped to scale it up and remove endo-toxins so it can be used for transfection 
and ultimately, overexpression of Shootin-1.  
 
 
 
Figure 4.25: Digested vectors from positive bacterial colonies. Four were picked and 
digested with KPN1 and XHO1. Sample 3 resulted in the expected weights of 1950 bp 
for Shootin-1 and 5600bp for the vector backbone. 
1950bp
~5600bp
1 2 3 4
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4.9.3. Shootin-1 Overexpression 
 To assess the role Shootin-1 may play in the DLKP cell line model, DLKP-SQ, 
DLKP-M and DLKP-I were transfected with the newly created vector with the goal of 
overexpressing the protein and following up with functional assays. Transfection was 
carried out and cells were placed under antibiotic selection (Hygromycin). Antibiotic 
concentration was determined by setting up a kill curve. Each clone was transfected 
with both the Shootin-1 overexpression vector (O.E), and an empty vector control (E.V) 
to generate cell lines for comparison. Untreated cells which were not transfected at all 
are included as a control. Results of western blot analysis analysing Shootin-1 
expression are shown in Figure 4.26.  
 DLKP-SQ showed no change in expression for Shootin-1 in any of the three 
samples which were analysed by western blot. This suggests the maximum level of 
Shootin-1 is currently being expressed by DLKP-SQ and post translational regulation 
may be prohibiting over-expression. DLKP-M samples showed low level Shootin-1 
expression in each of the three samples. The over-expression sample shows a higher 
level of Shootin-1 expression compared to the empty vector and control samples, 
suggesting over-expression has been achieved. DLKP-I samples showed an increase in 
Shootin-1 expression in the overexpression sample compared to both the empty vector 
and untreated cells control also. This western blot has only been carried out once and 
will need to be repeated to verify the findings.  Functional assays will then be carried 
out to look for phenotypic changes related to the overexpression of Shootin-1. 
Experiments would include investigating the migratory and invasive abilities of each 
clone when Shootin-1 is being overexpressed. A quantitative label-free proteomic 
analysis could also be performed, comparing Shootin-1 overexpressing clones to their 
normal and empty vector counterparts, This could highlight proteins which are affected 
by changes in Shootin-1 expression, potentially revealing new interacting partners. 
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Figure 4.26: Western blot probed for Shootin-1. Each DLKP clone was transfected 
with Shootin-1 over expressing vector (O.E) and an empty vector control (E.V). 
Untreated cells and Beta-actin loading control are included also. 
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4.10. Shootin-1 Expression in a Panel of Cell Lines 
 Western blot analysis was used to determine the presence and expression levels 
of Shootin-1 in a panel of cell lines. Results are shown in Figure 4.27 
 Pancreatic cell lines: PANC-1, AsPC-1, BxPC-3 and MIA PaCa 2. 
 Lung cancer cell lines: A549, SK-LU-1, and NCI-H82. 
 DLKP clones: DLKP-SQ, DLKP-M and DLKP-I. 
 
 Western blot analysis of Shootin-1 shows the expression levels of the protein in 
the panel of pancreatic and lung cancer cell lines mentioned above (Figure 4.27). 
Shootin-1 has its characteristic expression pattern in the DLKP clones, with very high 
abundance in DLKP-SQ compared to the others. In the pancreatic panel, the two with 
the most invasive phenotypes (PANC-1 and BxPC-3) show the highest expression of 
Shootin-1. AsPC-1 has low expression of Shootin-1 while Mia PaCa 2 had very little to 
none at all. Both these cell lines are known to be lowly invasive from preliminary 
studies carried out in the NICB by others. Regarding the lung cancer cell lines, 
expression of Shootin-1 was only found in A549, with no detectable levels of the 
protein in either SK-LU-1, or NCI-H82.  
 
Figure 4.27: Western blot probed for Shootin-1 in a panel of cell lines. Shootin-1 
bands came up at ~100kDa in cell lines where it was present. Alpha Tubulin loading 
control included. 
Alpha-Tubulin
Shootin-1
DLKP-M
DLKP-I
Panc1 Bxpc3
Aspc1 Mia2
A549
Sklu1
H82
DLKP-SQ
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4.11. Summary 
Label-free quantitative LC-MS/MS analysis of the DLKP cell line and its 
clonal subpopulations identified Shootin-1 as a significantly differentially expressed 
protein, with highest expression in DLKP-SQ relative to all other cell lines. This was 
found to be the case for both exponential and stationary phases of growth, indicating a 
strong expression pattern for the protein, conserved across multiple growth phases. 
Follow up experiments validated this expression profile at a protein and mRNA level, 
confirming the high expression in DLKP-SQ. In addition, DLKP-M was found to 
express the next highest abundance of Shootin-1 using the techniques mentioned above. 
In order to further investigate Shootin-1 in the DLKP cell line and clonal 
subpopulations, immunocytochemical and immunofluorescent staining of fixed cells 
was carried out. These analyses highlighted the localisation of Shootin-1 and also 
further validated the expression pattern described in the proteomic analyses. 
Localisation of Shootin-1 in DLKP-SQ was found to be cytoplasmic and also 
concentrated in lamellipodial-like structures at the edges of the cells. In addition, ICC 
staining also revealed Shootin-1 localisation in fine dendritic-like outgrowths extending 
from DLKP-SQ. Staining for Shootin-1 was also found in DLKP-M, and was seen to be 
high in the protrusions which extend from that cell type.  
Transient protein knockdown of Shootin-1 in DLKP-SQ followed by 
functional analyses showed a significant reduction in the migratory ability of the cells. 
No effects on proliferation or the invasive ability of DLKP-SQ were observed upon 
knockdown of Shootin-1. Functional analyses and staining of Shootin-1 performed in 
this study suggest a potential link between Shootin-1 and actin in this lung cancer cell 
line, as actin is known to be intimately involved in the outgrowth of cell protrusions.  
As this link has only been shown in neuronal cells to date, co-staining of Shootin-1 and 
F-actin was therefore carried out using confocal microscopy. This analysis provided 
strong evidence of co-localisation of Shootin-1 and F-actin in DLKP-SQ cells, 
strengthening the possible interaction between the two proteins. Transient RNAi 
knockdown of Shootin-1 did not affect the abundance or localisation of F-Actin as 
assessed by confocal microscopy, suggesting that Shootin-1 does not regulate Actin 
expression or localisation, but may still act as an interacting partner in DLKP-SQ.  
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To investigate this link further, co-immunoprecipitation of Shootin-1 was 
performed on DLKP-SQ cells in order to discover the binding partners of Shootin-1, 
and to determine if actin is among them. Repeated co-IP analyses did not find actin as a 
binding partner of Shootin-1 however a panel of proteins were highlighted which are 
strong potential binding partners. Investigations into a subset of these (Semenogelin-1; 
Src-Substrate Cortactin; and Striatin-3, were found to be expressed in all DLKP cell 
lines by western blot analyses. These proteins have neuronal roles, as well as actin 
binding roles, which suggest Shootin-1 may interact with actin through other proteins in 
DLKP-SQ. In addition, the neuronal role of Semenogelin-1 and Striatin may strengthen 
the neuroendocrine qualities of the DLKP cell line as previously described (McBride et 
al. 1998a).  
To determine the functional role on Shootin-1 in the DLKP clonal 
subpopulations, an overexpression vector was constructed using the endogenous 
sequence for the protein extracted from the DLKP-SQ cell line. The vector was 
successfully constructed and DNA sequencing confirmed the coding sequence for 
Shootin-1 was present on the vector. Following transfection of the vector, 
overexpression of Shootin-1 was achieved in DLKP-M and DLKP-I compared to empty 
vector controls. Unfortunately, time did not allow for subsequent functional analysis of 
the effects of Shootin-1 overexpression. 
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Chapter 5. MARCKS 
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5.1. MARCKS 
Myristoylated alanine-rich C-kinase substrate (MARCKS) was found to be a 
significantly differentially expressed protein by LC-MS/MS analysis, with highest 
expression in DLKP-M. MARCKS is a ubiquitously expressed multi-functional protein 
which has been found to be especially abundant in the nervous system (Albert, Nairn 
and Greengard 1987). Originally identified as a major substrate for Protein Kinase-C 
(PKC), MARCKS is tethered to the plasma membrane via a myristoyl group at its N-
terminus and also by an electrostatic interaction between membrane phospholipids and 
the effector domain (ED) of the protein (Arbuzova, Schmitz and Vergeres 2002). Upon 
phosphorylation by PKC at the ED, MARCKS dissociates from the plasma membrane 
and moves to the cytosol where it has been shown to play roles in cell migration 
through direct binding to actin resulting in cell remodelling (Li et al. 2008a). The ED of 
MARCKS has also been shown to be a target for calcium (Ca2+) activated calmodulin. 
Increased Ca2+ concentration results in calmodulin binding to MARCKS at the ED and 
initiates its reversible dissociation from the plasma membrane (Matsubara et al. 2003). 
The association of MARCKS with actin has shown the protein to be a key regulator of 
dendritic outgrowth in neuronal cells. Knockdown of MARCKS significantly reduced 
dendritic complexity, while over-expression enhanced dendritic development in 
neuronal cells (Calabrese and Halpain 2005, Li et al. 2008a). Thus far, there have only 
been two studies on MARCKS in lung cancer. It has been identified as a potential 
biomarker associated with poor prognosis in human SCC using immunohistochemical 
methods (Hanada et al. 2013). The second study detected high expression of MARCKS 
in highly invasive lung cancer cell lines and found that MARCKS knockdown by 
siRNA significantly reduced cell migration (Chen et al. 2014b).  
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5.2. Label-free Analysis of DLKP Cell Lines: MARCKS 
The label-free profiling experiment sought to highlight differentially expressed 
proteins between the DLKP cell line as well as the clonal subpopulations. A protein 
with a high abundance in one cell line compared to the others may play a role in the 
known phenotypic characteristics of the cell. DLKP-M is characterised by it high 
migratory and invasive abilities relative to the other clonal subpopulations. Therefore, 
protein expression patterns were screened to look for a highly abundant protein in 
DLKP-M. 
MARCKS protein stood out as an interesting candidate due to its high 
abundance in DLKP-M compared to DLKP and clonal subpopulations (Figure 5.1) 
during both exponential and stationary phase of growth. The protein was found as 
strongly expressed in DLKP-M in both the global analysis and the two-sample 
experimental designs. 
 
5.2.1. Global Analysis: MARCKS 
 During exponential phase of growth MARCKS abundance shows a maximum 
fold change of 51.70 with highest abundance in DLKP-M compared to the 
lowest in DLKP. 
 
 During stationary phase of growth, the protein abundance has a maximum fold 
change of 28.37 with highest abundance in DLKP-M and lowest in DLKP. 
 
During both exponential and stationary phases, MARCKS passed the stringent 
criteria of: ≥ 2 peptides contributing to the protein identification, an abundance fold 
change of ≥ 2 between two experiment groups, an ANOVA p-value of < 0.05 for a 
protein between experimental groups. A representative protein abundance graph from 
Progenesis software is shown for exponential phase. This graph displays the normalised 
abundance values for MARCKS across the DLKP cell line and its clonal subpopulations 
(Figure 5.1).  
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MARCKS shows the highest abundance in DLKP-M, followed by DLKP-I. 
The expression levels of MARCKS is at its lowest in DLKP and DLKP-SQ, with both 
cell lines showing the greatest fold change in abundance when compared to DLKP-M. 
Next, the expression level of MARCKS was determined using experimental designs 
which compared each cell line against one other using a one vs. one design: e.g. DLKP-
SQ vs. DLKP-M. Peptides which contributed to the identification of MARCKS are 
shown in Figure 5.2. 
 
 
Figure 5.1: Label-free abundances for MARCKS during exponential phase of growth viewed in 
Progenesis software. Highest expression is in DLKP-M, followed by DLKP-I. 4 peptides 
contributed to this identification with a maximum fold change of 51.70 between DLKP-M and 
DLKP (ANOVA, p= 3.14E-09). 
 
 
 
Figure 5.2: Peptides which contributed to the identification of MARCKS are displayed by 
Progenesis software. Each peptide had an ANOVA p < 0.05, and MASCOT scores ≥40. 
 
 
 
 
 
DLKP-SQ DLKP-M DLKP-I DLKP 
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5.2.2. Two-Sample Experimental Designs 
 MARCKS was highlighted in the global analysis with DLKP-M expressing the 
protein at a much higher abundance than all other cell lines in the comparison. In the 
two-sample analysis, the expression of MARCKS was determined for cell lines showing 
intermediary fold changes for the protein. Results are summarised in Table 5.1. 
The analysis is made up of six comparisons for each phase of growth, with every 
permutation accounted for. Each analysis has stringent filtering criteria applied to the 
resulting proteins which are: ≥ 2 peptides contributing to the protein identification, an 
abundance change of ≥ 2 fold between the two experimental groups, an ANOVA p-
value of <0.05 for a protein between the experimental groups. In each analysis 
containing DLKP-M in the comparison, MARCKS is identified as being the most 
abundant protein. This indicates MARCKS is specifically highly expressed in DLKP-
M. 
 
 During exponential phase of growth, MARCKS is highlighted in every 
comparison as a statistically significantly differentially expressed protein (Table 
5.1A). The data shows that this protein has the highest abundance in DLKP-M 
out of all the cell lines. The largest fold change in this phase of growth is 
between DLKP-M and DLKP at 49.82, with highest MARCKS abundance in 
DLKP-M. In each other comparison, MARCKS consistently is shown as being 
highest in DLKP-M. 
 
 Stationary phase analysis (Table 5.1B) revealed the same trend as exponential 
with expression of MARCKS being highest in DLKP-M in each comparison 
containing that cell line. The highest fold change is once again between DLKP-
M and DLKP at 24.50, highest in DLKP-M. The remaining comparisons 
matched the findings for exponential phase. 
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Exponential Phase:  
 
Stationary Phase: 
 
Table 5.1: Individual comparisons of the DLKP cell line and its subpopulations for exponential (A) and 
stationary (B) phases of growth. In each comparison containing DLKP-M, MARCKS was highlighted 
as being most abundant in that cell line. For each comparison, ≥ 2 peptides contributed to the protein 
identification, and ANOVA p-values were < 0.05 in the protein abundance comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
Individual Comparison Description
Max fold 
change
Highest 
Abundance
Lowest 
Abundance
DLKP-SQ   vs. DLKP-M Myristoylated alanine-rich C-kinase substrate 20.94 DLKP-M DLKP-SQ
DLKP-SQ   vs. DLKP-I Myristoylated alanine-rich C-kinase substrate 8.16 DLKP-I DLKP-SQ
DLKP-I       vs. DLKP-M Myristoylated alanine-rich C-kinase substrate 2.53 DLKP-M DLKP-I
DLKP-SQ   vs. DLKP Myristoylated alanine-rich C-kinase substrate 2.38 DLKP-SQ DLKP
DLKP-M     vs. DLKP Myristoylated alanine-rich C-kinase substrate 49.82 DLKP-M DLKP
DLKP-I        vs. DLKP Myristoylated alanine-rich C-kinase substrate 19.68 DLKP-I DLKP
Individual Comparison Description
Max fold 
change
Highest 
Abundance
Lowest 
Abundance
DLKP-SQ   vs. DLKP-M Myristoylated alanine-rich C-kinase substrate 20.98 DLKP-M DLKP-SQ
DLKP-SQ   vs. DLKP-I Myristoylated alanine-rich C-kinase substrate 4.47 DLKP-I DLKP-SQ
DLKP-I       vs. DLKP-M Myristoylated alanine-rich C-kinase substrate 5.11 DLKP-M DLKP-I
DLKP-SQ   vs. DLKP Myristoylated alanine-rich C-kinase substrate 3.59 DLKP-SQ DLKP
DLKP-M     vs. DLKP Myristoylated alanine-rich C-kinase substrate 24.50 DLKP-M DLKP
DLKP-I        vs. DLKP Myristoylated alanine-rich C-kinase substrate 5.34 DLKP-I DLKP
(A) 
(B) 
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5.3. Validation of MARCKS Expression in DLKP and Clonal Subpopulations 
The expression pattern of MARCKS was validated by western blot using the 
method described in Section 2.3. The protein came up with bands visible at 80 kDa in 
the DLKP cell line model which is the expected molecular weight of MARCKS. The 
expression pattern of MARCKS found by western blot analysis is shown in Figure 
5.3A. MARCKS expression profile was graphed using the label-free normalized 
abundance values. The expression pattern correlated well with label-free data for 
MARCKS, shown in Figure 5.3B for comparison. 
 
 
Figure 5.3:(A) Western blot showing the expression levels of MARCKS in all cell lines. 
Beta-actin was used as a loading control. MARCKS bands are visible at ~80 kDa as 
expected (n=3). (B) Label-free abundance values for MARCKS in all DLKP cell lines 
during exponential phase. Standard deviations are shown. (n=3).  
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5.4. Proteomic Comparison of DLKP Compared to the Three Clones and 
Combination Cell Lines 
 The expression pattern of MARCKS was next analysed using an experimental 
design which incorporated all samples in a global analysis. The design includes the 
combination cell lines, which are 1:1 combinations of the clonal subpopulations and a 
reconstituted version of DLKP made from the clones in proportions described 
previously (McBride et al. 1998b). Details of the creation of these cell lines can be 
found in Section 3.1.1. 
A large global analysis was created in Progenesis software which incorporated 
all samples into one large experimental design, including the combination cell lines. 
were included in the analysis to determine if co-culture of the DLKP clones had any 
effect on the expression of MARCKS. Progenesis software groups together peptides 
which contribute to the identification of MARCKS, and displays their abundance levels 
for each sample group. The standardised normalised abundance values for peptides 
belonging to MARCKS are shown in Figure 5.4, which demonstrates the expression 
profile for each peptide. Peptides which contributed to the identification of MARCKS 
are shown in Figure 5.2. 
Peptides belonging to MARCKS are more abundant in DLKP-M compared to 
all other samples in the global experimental design. In the combination lines which 
contain DLKP-M as a component, the abundances of peptides belonging to MARCKS 
are significantly higher than in all other combination cell lines. In addition, I+M seems 
to show a slightly higher abundance of MARCKS than is shown for SQ+M which is 
most likely due to the higher abundance of the protein in the DLKP-I clone. DLKP-
Remade shows a slightly higher abundance of MARCKS than the DLKP cell line. 
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Figure 5.4: Peptide expression pattern for MARCKS as displayed by Progenesis software. Peptides 
identifying as MARCKS cluster well together showing highest expression of the protein in DLKP-M and 
lowest in DLKP (ANOVA, p= 9.70E-13). 
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5.5. Validation of MARCKS Expression in DLKP plus the Clones and 
Combination Cell Lines 
5.5.1. Western Blot 
The DLKP cell lines along with the combination lines were analysed by 
western blot to determine if the expression pattern found by the label-free analysis could 
be validated. Results of the western blot analysis are shown in Figure 5.3A, showing 
DLKP-M as a cell line containing a relatively high abundance of MARCKS in the 
clones and combination lines. The label-free analysis output for MARCKS (Figure 
5.3B) shows the abundance of MARCKS is also relatively high in the combination lines 
containing the DLKP-M clone as a constituent.  
The combination lines show high expression of MARCKS in the cell lines 
which contain DLKP-M as a constituent. However, SQ+M shows lower abundance of 
MARCKS compared to I+M. This is an expected finding as DLKP-I expresses the 
second highest abundance of MARCKS out of all the DLKP clonal subpopulations. 
Neither DLKP nor DLKP-Remade show detectable levels of MARCKS by Western 
Blot analysis. Label-free proteomic analysis showed DLKP-Remade to express 
MARCKS at a higher abundance than DLKP, however in both cases the abundance was 
very low. Western Blot analysis therefore correlates well with the label-free analysis. 
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5.5.2. mRNA Expression 
Following on from the label-free analysis and western blot validation, DLKP 
samples were analysed using quantitative PCR (qPCR) to determine the relative levels 
of MARCKS mRNA expression between each cell line. Relative quantification was 
performed on all cell lines and combinations using beta-actin as the endogenous control 
gene. Biological duplicate samples were analysed and results are combined in Figure 
5.5. The calculation of relative quantity (RQ) was achieved by normalizing the data to 
DLKP-M. 
mRNA level of MARCKS correlated well with the label-free analysis of the 
DLKP cell lines. DLKP-M shows the highest expression of MARCKS, followed by 
DLKP-I and then DLKP-SQ. Fold changes in the mRNA transcript are comparable to 
those found in the proteomics analysis between highest and lowest expressing cell lines. 
This expression pattern also matches what was found by western blot analysis. In the 
combination cell lines, SQ+M and I+M show the highest expression of MARCKS, with 
lowest expression in SQ+I and Remade. A slightly higher gene expression of MARCKS 
is seen in SQ+M compared to I+M, which contradicts the western blot findings, 
however this is not a statistically significant difference. In addition, DLKP-Remade 
expresses a higher abundance of MARCKS than the DLKP cell line. This expression 
pattern correlates with the findings of the label-free proteomic data. Different 
expression levels of MARCKS between DLKP and DLKP Remade may suggest the 
presence of uncharacterised cell types in DLKP which reduce the expression of 
MARCKS in that cell line. 
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Figure 5.5: qPCR results showing gene expression of MARCKS in the clones and 
combination cell lines. Samples are analysed in biological duplicate. Error bars shown 
are the standard deviations between the two replicate experiments. Data are normalized 
to DLKP-M. 
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5.6. Imaging of MARCKS in the DLKP Cell Lines: 
Validation of MARCKS expression by western blot and mRNA analysis in the 
DLKP cell lines confirmed the pattern shown by the label-free data. In order to 
investigate the localization of MARCKS protein in the DLKP cell lines and further 
validate the expression pattern found by the techniques mentioned above, MARCKS 
was stained using immunocytochemistry (ICC) and immunofluorescence (IF). Staining 
was performed using the method described in Section 2.6 on DLKP and clonal 
subpopulations fixed to glass slides by Paraformaldehyde. Unfortunately, the 
immunocytochemistry staining resulted in high non-specific staining with the IHC 
compatible antibody. Immunofluorescence on the other hand resulted in staining 
specific for MARCKS in the DLKP cell lines.  
 
5.6.1. Immunofluorescent Staining of MARCKS in DLKP Cell Lines 
Immunofluorescence staining of MARCKS was carried out in DLKP and each 
of its clonal subpopulations to allow visualization of the distribution of the protein in 
each cell type, as well as a semi-quantitative assessment of MARCKS abundance. 
Staining was carried out using the method described in Section 2.6.3 with resulting 
images shown in Figure 5.6. MARCKS staining showed very high levels in DLKP-M 
compared to the other cell lines which correlated well with the label-free proteomic 
data. High levels of staining can be seen throughout the cytoplasm of DLKP-M, and in 
many cases the localization of the protein is concentrated in the cell projections which 
are characteristic of this cell type. There is also punctate staining clearly visible in 
DLKP-M cells with intense dots of MARCKS staining throughout the cells.  
DLKP-I had the next highest level of MARCKS staining. In the case of this 
cell type, staining was intense in a subpopulation within DLKP-I, with low level 
staining in the remaining population. Punctate staining for MARCKS is also visible in 
the cytoplasm of DLKP-I as well as accumulation of the protein in the tips of projection 
structures. DLKP itself shows a varied staining pattern also, with some cells in the 
population more intensely stained compared to others. This staining pattern is expected 
as DLKP is made up of the clonal subpopulations, with DLKP-M comprising 
approximately 5% of the total population (McBride et al. 1998b). Similar localization of 
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MARCKS is found in this cell type with projections showing high MARCKS staining 
intensity.  
DLKP-SQ has the lowest level of staining for MARCKS with very low level 
cytoplasmic staining visible in the majority of the population. Similar to the other cell 
types analysed here, a subpopulation within DLKP-SQ shows higher staining for 
MARCKS than the majority of cells. The staining found in subpopulations of the clones 
themselves may support the theory of clone inter-conversion discussed in Section 
1.4.1.4. The staining localization of MARCKS suggests it may play a role in actin 
polymerization, similar to Shootin-1. MARCKS punctate staining is visible in all cell 
types and it is particularly high in DLKP-M. This suggests an additional role for the 
protein in DLKP-M. 
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DLKP-SQ             DLKP-M 
    
DLKP-I      DLKP 
    
Figure 5.6: Immunofluorescence images staining for MARCKS in DLKP-SQ, DLKP-M, DLKP-I and 
DLKP. Nuclei are stained with Dapi. Negative controls with secondary antibody only did not result in 
staining (images not shown). Original magnification used on all micro-pictographs shown at 400x, 
50μm scale bar. (n=2) 
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5.7. Functional Analysis of MARCKS Knockdown by RNAi 
5.7.1. Transfection Optimisation 
To investigate the potential role played by MARCKS in the DLKP model, 
protein knockdown was carried out and followed up by functional analysis in DLKP-M. 
Protein knockdown was performed using RNA interference (RNAi). DLKP-M was 
chosen as the cell line to investigate the functional effects of protein knockdown due to 
the high expression of MARCKS in that cell line at the protein and mRNA level. 
Following knockdown of MARCKS by RNAi, the effects of this were assessed using a 
panel of functional assays. A standard commercially available negative siRNA control 
was used to compare against for the knockdown samples. This negative siRNA is 
homologous to no known sequence and therefore acts as a control to assess the effects 
of introducing siRNA into cells. Before MARCKS knockdown was attempted, DLKP-
M cells underwent rigorous optimisation steps as previously described in Section 4.7.1. 
 
5.7.1.1. Optimisation of Transfection Reagent Volume: 
To optimise the volume of transfection that would effectively deliver siRNA 
into DLKP-M cells, 1 μl and 2 μl per well volumes of Lipofectamine were tested (after 
previous optimisation). Cell viability was analysed using an acid phosphatase 
proliferation assay as described in Section 2.5.1, and results are shown in Figure 5.7. 
Results are displayed as a percentage survival value relative to the negative siRNA 
control (2 μl/well of transfection reagent). In all conditions where siRNA was included, 
a 5 nM concentration was used. Four different transfection conditions were tested in 
order to determine the optimal volume of Lipofectamine reagent to use for RNAi in 
DLKP-M: Cells-only; Lipo-only; Negative siRNA; Positive siRNA (Kinesin siRNA). 
 
Both volumes (1 μl/well and 2 μl/well) of transfection reagent had no effect on 
the Lipo-only control samples compared to the non-transfected Cells-only condition 
(Figure 5.7). Similarly, the negative siRNA control had a negligible effect on viability 
using both volumes of transfection reagent. The positive siRNA control had a large 
effect on the viability of DLKP-M cells at both volumes. This Kinesin siRNA induces 
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cell death by arresting growth during mitosis, preventing formation of the bipolar 
spindle. Using a volume of 1 μl of transfection reagent reduced the cell viability by 
~35%, whereas using 2 μl of transfection reagent reduced the cell viability by ~62%. It 
was determined in previous optimisation experiments that higher volumes of 
transfection reagent had a detrimental effect on the viability of DLKP-M in the Lipo-
only and negative control samples. Therefore, a volume of 2 μl transfection reagent was 
used for all RNAi experiments involving DLKP-M moving forward. 
 
 
 
 
Figure 5.7: Proliferation assay performed on DLKP-M cells using 1μl/6-well (Blue) and 
2μl/6-well (Red) of Lipofectamine transfection reagent. Percentage survival values are 
relative to the negative siRNA control. (1μl /well: P-Value 1.3E-03) (2μl/well: P-Value: 
2.5E-04). 
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5.7.1.2. Optimisation of siRNA Concentration: MARCKS 
 The optimization of MARCKS RNAi transfection conditions was finalized by 
determining the optimal siRNA concentration to achieve maximum MARCKS protein 
knockdown. A transfection experiment was set up with a range of siRNA concentrations 
for MARCKS in DLKP-M: 
 Cell-only, Lipofectamine-only and Negative siRNA controls. 
 5 nM, 10 nM, 20 nM and 30 nM of siRNA were tested for MARCKS. 
 Two different siRNA molecules were tested in tandem which target MARCKS. 
 
Cell lysates were prepared from the various transfection conditions as 
described in Section 2.3.1, 72 hours post transfection. Western blot analysis was 
performed on these samples and probed using an antibody specific for MARCKS. The 
results are shown in Figure 5.8. Untreated cells, Lipofectamine-only and Negative 
siRNA samples take up lanes 1-3 respectively, and bands for MARCKS are clearly 
visible at ~80kDa. A concentration of 30 nM siRNA was used in the negative siRNA 
sample to represent the maximum siRNA concentration in the MARCKS test panel. 
Each concentration tested effectively reduced the expression of MARCKS in DLKP-M 
to near undetectable levels. Based on the Western Blot results, 20 nM of siRNA was 
determined as the optimal concentration to use for MARCKS RNAi before functional 
assessment of the role of the protein in DLKP-M. 
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Figure 5.8: Western blot probing for MARCKS-1 (80kDa). Lanes 1-3 contain: Cells-
only, Lipofectamine-only and Negative siRNA (30 nM). Each MARCKS siRNA group 
(#1 and #2) is comprised of four sample lanes which were treated with 30 nM, 20 nM, 
10 nM and 5 nM of siRNA from left to right. Beta-actin loading control included. 
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5.7.2. Effects of MARCKS Knockdown on Proliferation, Migration and Invasion in 
DLKP-M 
 To study the potential role of MARCKS in DLKP-M, a panel of functional 
assays were carried out following siRNA transfection to knock down the target. Two 
individual siRNA molecules were used to knockdown MARCKS in DLKP-M using 
conditions optimised and described in Section 5.7.1. Proliferation, migration and 
invasion assays were carried out to investigate if a reduction in MARCKS expression 
had a significant effect. 
 
5.7.2.1. Proliferation of DLKP-M Post-MARCKS Knockdown 
Proliferation of DLKP-M cells was measured 72 hours post transfection as 
described in Section 2.2.3. Knockdown of MARCKS by RNAi was found to have no 
significant effect on proliferation compared to the negative control (n=3). Results are 
shown in Figure 5.9. 
 
 
 
Figure 5.9: Proliferation assay on DLKP-M post transfection for MARCKS RNAi. 
There was no statistically significant difference in proliferation between siRNA 
knockdown samples (#1 and #2) and the negative control (n=3). (siRNA#1 P-value: 
0.63, siRNA#2 P-value: 0.56).  
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5.7.2.2. Migration of DLKP-M Post-MARCKS Knockdown 
Migration assays were performed 72 hours post transfection using the method 
as described in Section 2.5.4. Cells were allowed to migrate through the uncoated 
membrane for 24 hours before being fixed and stained by crystal violet. Upon 
comparing the MARCKS RNAi samples to the negative control, a significant inhibitory 
effect on the migratory ability of the cells was found (n=3). Results are shown in Figure 
5.10 
 
 
 
 
Figure 5.10: Migration assay results for DLKP-M cells following MARCKS 
knockdown using RNAi. Total number of cells which migrated through the uncoated 
membrane is shown (n=3). A statistically significant difference between siRNA 
knockdown samples (#1 and #2) and the Negative siRNA control was found. (siRNA#1 
P-value: 8.7E-04, siRNA#2 P-value: 7.7E-04)  
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5.7.2.3. Invasion of DLKP-M Post-MARCKS Knockdown: 
 Invasion assays performed 72 hours post transfection using the method as 
described in Section 2.5.3. Knockdown of MARCKS had a significant effect on the invasive 
ability of DLKP-M cells when compared to the negative control sample (n=3). Results are 
shown in Figure 5.11.  
 
 
 
 
 
 
Figure 5.11: Invasion assay results for DLKP-M cells following MARCKS knockdown 
using RNAi. Total number of cells which migrated through the Matrigel coated 
membrane is shown (n=3). A statistically significant difference between siRNA 
knockdown samples (#1 and #2) and the negative siRNA control was found. (siRNA#1 
P-value: 8.5E-03, siRNA#2 P-value: 1.5E-02)  
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5.7.3. Co-Staining of MARCKS/F-Actin after MARCKS Knockdown by RNAi in 
DLKP-M 
 MARCKS is a membrane bound protein involved in the cross-linking of actin 
filaments. The N-terminus of the protein is attached to the membrane via a myristoyl 
group and anchors the actin network to the inner side of the plasma membrane. Upon 
phosphorylation by protein kinase C (PKC) or binding by calmodulin/actin, MARCKS 
becomes detached from the plasma membrane and its association with actin filaments is 
inhibited, leading to its presence in the cytoplasm (Matsubara et al. 2003). Due to these 
reported links between MARCKS and actin, it was decided to investigate this potential 
link in DLKP-M using confocal microscopy. Cells were treated with RNAi to knock 
down expression of MARCKS to assess the effect on actin, and also localization of 
MARCKS itself. 
 Once RNAi was performed, DLKP-M cells were allowed to grow for 48 hours 
before being scratched with a P1000 tip, washed and had growth media replaced. Cells 
were allowed to grow for a further 24 hours before being fixed with 4% 
paraformaldehyde. Scratching was done to encourage the cells to grow in a particular 
direction to close the created wound. This enables the visualisation of motile cells by 
confocal microscopy once the cells are stained. Resulting images are shown in Figure 
5.12 to Figure 5.16. 
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DLKP-M: Cells Only 
 
Figure 5.12: DLKP-M cells stained for MARCKS, Actin and Dapi. A merged 
image is shown in the bottom right corner. Cells are untreated by any RNAi method. 
Original magnification of all photomicrographs, ×400, scale bar = 20 μm. 
 
 
DLKP-M: Lipofectamine-only Control 
 
Figure 5.13: DLKP-M cells stained for MARCKS, Actin and Dapi. A merged 
image is shown in the bottom right corner. Cells are treated with transfection reagent 
only. Original magnification of all photomicrographs, ×400, scale bar = 20 μm. 
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DLKP-M: Negative siRNA Control 
 
Figure 5.14: DLKP-M cells stained for MARCKS, Actin and Dapi. A merged 
image is shown in the bottom right corner. Cells are treated with transfection reagent 
and negative siRNA control. Original magnification of all photomicrographs, ×400, 
scale bar = 20 μm. 
 
 
DLKP-M: MARCKS Knockdown- siRNA #1 
 
Figure 5.15: DLKP-M cells stained for MARCKS, Actin and Dapi. A merged 
image is shown in the bottom right corner. Cells are treated with siRNA#1 for 
MARCKS. Original magnification of all photomicrographs, ×400, scale bar = 20 
μm. 
 
 
Dapi
Actin Merge  
MARCKS  
Dapi
Actin Merge  
MARCKS  
 200 
 
DLKP-M: MARCKS Knockdown- siRNA #2 
 
Figure 5.16: DLKP-M cells stained for MARCKS, Actin and Dapi. A merged 
image is shown in the bottom right corner. Cells are treated with siRNA#2 for 
MARCKS. Original magnification of all photomicrographs, ×400, scale bar = 20 
μm. 
 
 
Negative siRNA Control: DLKP-M High Magnification 
 
Figure 5.17: DLKP-M cells stained for MARCKS, Actin and Dapi. A merged 
image is shown in the bottom right corner. DLKP-M cells at high magnification 
showing co-localization of MARCKS and Actin in a punctate staining pattern. Cells 
are treated with negative siRNA control. Original magnification of all 
photomicrographs, ×800, scale bar = 5μm. 
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The staining of MARCKS (coloured red) in DLKP-M was followed by 
imaging using confocal microscopy and shows a similar staining pattern to that found 
by the immunofluorescence work described in Section 5.6.1. Strong staining for 
MARCKS is visible throughout the cytoplasm of the cells in the control group: Cells-
only; Lipo-only; Negative siRNA (Figure 5.12 and Figure 5.13), with MARCKS 
expression and localization unaffected by the transfection control conditions. Punctate 
staining is present with intense points of MARCKS protein scattered throughout the 
cytoplasm. This staining pattern potentially represents accumulations of the MARCKS 
protein at distinct cellular locations, and may be indicative of a role as part of a protein 
complex. 
MARCKS can also be seen at the tips of projections emanating from the 
DLKP-M cells. Dapi nuclear staining is clearly visible, and in the merged photograph 
nuclei have a light purple colour upon combining with red MARCKS staining. This 
indicates a low level of MARCKS localization in the nucleus or nuclear envelope. F-
actin staining (coloured green) is very high in the control DLKP-M cells and can be 
seen throughout the cytoplasm as well as at the edges of cells. These may be 
lamellipodia where actin is reported to polymerise aiding in cell movement. Overlap of 
MARCKS and F-actin staining shows strong co-localization of both proteins. Punctate 
staining as well as cell projection staining overlap is particularly apparent for both 
proteins as shown in Figure 5.14. 
RNAi knockdown of MARCKS in DLKP-M revealed an interesting 
development which can be seen in Figure 5.15 and Figure 5.16. Cells here treated with 
siRNA #1 and siRNA #2 for MARCKS, and in both cases there is large reduction in 
MARCKS expression for both siRNA. However, the nuclei in both knockdown samples 
appear to have become enriched with remaining MARCKS once they are treated with 
RNAi targeting the protein. This is clear from the confocal images which show the 
overlap between MARCKS and the nuclear stain Dapi. The nuclei are a rich purple 
colour compared to the control samples, which suggests that knockdown of MARCKS 
triggered the protein to be translocated the nuclei. Localization of MARCKS is visible 
in the nuclei of the control samples at a low level; however RNAi appears to have 
significantly increased staining for MARCKS in this cellular component. F-actin 
staining appears to be reduced in the knockdown samples compared to the control 
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group. Western blot analysis probing for beta-actin in these samples did not show a 
reduction in the expression of actin (Figure 5.8). F-actin was not assayed. 
A high magnification image is shown in Figure 5.17 of the negative siRNA 
control. Punctate cytoplasmic staining of MARCKS is visible, which in many cases 
shows co-localization with actin. Nuclear staining for MARCKS is also visible, but at a 
low level compared to the knockdown samples in. Another control was set up using 
secondary antibody only. This was done to test for the specificity of the target antibody 
and to check for non-specific binding of the secondary. Images remained clear of 
staining (not shown). 
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5.7.4. Over-Expression of MARCKS in DLKP and Clonal Subpopulations 
Functional assays performed on DLKP-M after MARCKS knockdown show 
the protein is highly involved in the phenotypic characteristics of the cell line. 
Knockdown of MARCKS by RNAi results in a significant reduction of both the 
migratory and invasive capabilities of DLKP-M. In order to further illuminate the role 
MARCKS plays in DLKP, over-expression of the protein was next investigated.  
To create an over-expression vector for MARCKS, a similar approach was 
taken as was done for Shootin-1, described in Section 4.9. The open reading frame 
(ORF) the MARCKS nucleotide sequence was isolated using custom designed primers, 
and cDNA generated from DLKP-M RNA was used as a template. Primer sequences 
have restriction enzymes sites incorporated into their design to facilitate the creation of 
sticky ends for ligation further downstream. PCR amplification of the sequence targeted 
by the primers resulted in faint bands at the expected size of ~1000bp when they were 
separated on an agarose gel using electrophoresis. An image of this gel is shown in 
Figure 5.18. 
 
 
 
Figure 5.18: PCR for MARCKS using cDNA reverse transcribed from DLKP-M 
RNA. Bands are visible in the sample set (1-5 lanes) at ~1000bp. MARCKS has a 
predicted size of 1010bp based on primer design. 
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These bands were excised from the gel and digested to create sticky ends in 
preparation for ligation into a previously linearized overexpression vector. The newly 
digested fragment for MARCKS coding sequence was ligated into the pcDNA3.1 
overexpression vector before being amplified by DH5α E. coli. The following day the 
bacteria cultures were miniprepped to extract the amplified vectors. Following this, 
vectors were digested using the restriction enzymes designed into the primers to assess 
if they had incorporated the MARCKS coding sequence of expected size (~1000 bp) 
along with the vector backbone (5600 bp). The resulting products were separated on an 
agarose gel and visualised (Figure 5.19).  
The vector sample from lane 2 was sequenced which confirmed that it has 100% 
homology to the known ORF sequence for MARCKS. Next this vector was midi-
prepped to scale it up and remove endo-toxins in preparation for transfection. In 
tandem, an empty vector was also midi-prepped in the same way to act as a control for 
all future transfections. 
 
 
Figure 5.19: Three bacteria colonies grew successfully on Ampicillin LB agar 
plates, and each was picked and miniprepped. Each was digested with KPN1 and 
XHO1 and products were run on a 0.8% agarose gel. Lane 2 resulted in the expected 
fragment sizes of 5600bp for vector backbone and ~1000bp for MARCKS. 
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To assess the role MARCKS may play in the DLKP cell line model, clonal 
subpopulations: DLKP-SQ, DLKP-M, DLKP-I and DLKP were transfected with the 
newly created vector with the goal of overexpressing the protein. Cells were put under 
antibiotic selection to generate stable over-expressing clones. Each clone was 
transfected with both the MARCKS overexpression vector (O.E), and an empty vector 
control (E.V). Untreated cells which were not transfected at all are included as a control. 
Results of western blot analysis are shown in Figure 5.20.  
 DLKP-SQ showed no expression of MARCKS in any of the three samples 
which were analysed by western blot. This cell line does not express MARCKS as 
shown in Figure 5.3A. DLKP-M samples showed low level MARCKS expression in 
each of the three samples, all at the same level of band intensity. The low level of 
MARCKS expression is unusual and may be as a result of low exposure during the 
imaging of the western blot. DLKP-I samples showed a slight increase in MARCKS 
expression in the overexpression sample compared to both the Empty Vector and 
untreated cells control. This western blot has only been carried out once and will need to 
be repeated to verify the findings, at least in DLKP-I. Functional assays will then be 
carried out to look for phenotypic changes related to the overexpression of MARCKS. 
 
 
Figure 5.20: Western Blot probed for MARCKS. Each DLKP clone was transfected 
with MARCKS over expressing vector (O.E) and an empty vector control (E.V). 
Untreated cells are included also. 
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5.8. Cell Line Panel: MARCKS 
 Western blot analysis was used to determine the presence and expression levels of 
MARCKS in a panel of cell lines. Results are shown in Figure 5.21. 
 Pancreatic cell lines: PANC-1, AsPC-1, BxPC-3 and MIA PaCa 2. 
 Lung cell lines:A549, SK-LU-1, and NCI-H82. 
 DLKP clones: DLKP-SQ, DLKP-M, and DLKP-I. 
 
MARCKS showed its characteristic expression pattern in the DLKP clones, 
being highest in DLKP-M, followed by DLKP-I. Little to no expression was visible in 
DLKP-SQ. The pancreatic cell lines showed expression of MARCKS in BxPC-3 and 
PANC-1 cell lines. Little or no expression was seen in AsPC-1 or MIA PaCa 2. Both 
cell lines expressing MARCKS are known to have an invasive phenotype, whereas the 
cell lines with no expression of MARCKS are considered lowly invasive. The three 
lung cancer cell lines all showed expression of MARCKS. SK-LU-1 had the highest 
expression followed by A549 which showed low levels of expression. NCI-H82 had 
extremely faint bands for MARCKS indicating an extremely low level of expression in 
that cell line. 
 
Western Blot: MARCKS 
 
Figure 5.21: Western Blot probed for MARCKS in a panel of cell lines. Alpha-
Tubulin loading control included. 
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5.9. Summary 
MARCKS was identified as a significantly differentially expressed protein 
when the DLKP cell line and its clonal subpopulations were compared against each 
other using quantitative label-free LC-MS/MS. The DLKP-M cell line was found to 
have the highest abundance of MARCKS for both exponential and stationary phases of 
growth. The difference in fold change was shown to be very high between the highest 
expresser in DLKP-M compared to the lowest in DLKP, at 49.82 during exponential 
phase, and this expression pattern was validated at a protein and mRNA level. 
Immunofluorescent staining of MARCKS in each cell line further validated this 
expression pattern, and found MARCKS to localise to invadopodial-like structures in 
DLKP-M and subpopulations within DLKP, similar to what was found for Shootin-1. 
Punctate staining is also visible for MARCKS in all cell lines, suggesting it may co-
localise with discrete focal contacts in these cell lines as this protein is tethered to the 
plasma membrane in its unphosphorylated form. 
Transient knockdown of MARCKS protein in DLKP-M was found to have a 
significant effect on the migratory and invasive abilities of this cell line. Both of these 
abilities were significantly reduced when MARCKS expression was reduced in DLKP-
M compared to the negative control samples. No effect was found on proliferation upon 
MARCKS knockdown in DLKP-M. Further knockdown studies on MARCKS were 
carried out to look for an effect on the behaviour of F-actin in DLKP-M, as there are 
reported associations between MARCKS and actin in neuronal cells and hepatic stellate 
cells (Li et al. 2008a, Rombouts et al. 2013). Both proteins were co-stained and imaged 
using confocal microscopy. In control cells, co-localisation of MARCKS and F-actin 
were found, with high staining for both proteins throughout the cytoplasm and at the 
edges of cells. Co-localisation of punctate staining is also visible, which may indicate 
both proteins form a complex in DLKP-M cells. Co-staining of MARCKS and F-actin 
in transient knockdown samples revealed a potential translocation of remaining 
MARCKS to the nuclei of DLKP-M cells. The cytoplasmic staining of MARCKS was 
reduced by the knockdown process, however the nuclei of the cells show visibly 
enriched MARCKS expression, suggesting a translocation effect. This observation 
requires further investigations to determine if nuclei are enriched for MARCKS and will 
be completed as future work. In addition, co-staining of MARCKS and F-Actin showed 
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a reduction in F-actin staining intensity in knockdown samples. This reduction is slight 
however, and was not validated by western blot probing for Beta-actin. This will also 
need to be investigated further. 
Overexpression of MARCKS was attempted through the construction of an 
overexpression vector. The coding sequence for MARCKS was successfully extracted 
from DLKP-M cells and amplified. It was ligated into an overexpression vector and 
DNA sequencing confirmed successful construction of the vector. This was transfected 
into the DLKP clones, however western blot analysis did not find successful 
overexpression of MARCKS in DLKP-SQ; DLKP-M; or DLKP-I. Time did not allow 
for further exploration of this side of the MARCKS investigation, however it will be 
performed again in the future, and followed up with functional assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 209 
 
 
 
 
 
 
Chapter 6. Desmoglein-3 
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6.1. Desmoglein-3 
Desmoglein 3 (DSG3) was identified in the quantitative label-free study as a 
very specifically highly expressed protein in DLKP-I. Little or no protein is present in 
the other cell lines, potentially meaning the protein could be a marker for DLKP-I. 
DSG3 is a transmembrane glycoprotein exclusively expressed in stratified epithelium. It 
is member of the desmoglein family of proteins, which in turn are a part of the cadherin 
superfamily of cell adhesion molecules. Expression of DSG3 is limited to the basal and 
supra-basal layers of the skin, however it is expressed homogeneously throughout the 
stratified epithelium in oral mucosa (Amagai et al. 1996, Garrod and Chidgey 2008). 
DSG3 is a major component of the desmosome, which is an adhesive intercellular 
junction critical to the integrity of tissues that experience shear stress. Homophilic 
binding of the DSG3 extracellular domain to adjacent cells leads to cell-cell adhesion, 
while the cytoplasmic tail of DSG3 links to internal keratin intermediate filaments via 
linker proteins such as the armadillo and plakin families (Dehner et al. 2014, Garrod 
and Chidgey 2008, Delva, Tucker and Kowalczyk 2009). DSG3 has been extensively 
studied in relation to the auto-immune disease Pemphigus Vulgaris (PV), in which 
autoantibodies bind to the extracellular domain of DSG3 and cause internalization of 
the protein (Jennings et al. 2011, Sato, Aoyama and Kitajima 2000). This results in a 
signalling cascade which leads to loss of cell-cell adhesion in the basal and immediate 
supra-basal layers of stratified squamous epithelia as well as the oral mucosa, causing 
painful blistering and lesions.  
DSG3 has been found to be overexpressed in head and neck cancer (HNC) by 
PCR analysis in tissue samples when compared to normal keratinocytes and other 
cancer types (bladder, neuron, colon and liver) (Chen et al. 2007). Using 
immunohistochemical staining, DSG3 was found to be redistributed to the cytoplasm 
from the membrane in the majority of ESCC cases (Wang et al. 2007). This paper 
hypothesised that DSG3 may play a role other than functioning as a cell adhesion 
molecule, and may be involved in cell migration and invasion. DSG3 has also been 
studied in lung cancer. Immunohistochemical studies aiming to identify markers for the 
differential diagnosis of non-small-cell carcinomas of the lung identified DSG3 as a 
potentially useful marker for the identification of squamous cell carcinoma (Gomez-
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Morales et al. 2013). No in vitro functional studies have been carried out in lung cancer 
investigating DSG3 to date. 
 
6.2. Label-Free Proteomic Analysis: Desmoglein-3 
 Label-free proteomic profiling was carried out on DLKP and clonal 
subpopulations in order to discover proteins exhibiting significant differentially 
expressed proteins between the cell lines. The resulting proteomics data was screened to 
find proteins showing large abundances in a single clonal subpopulation compared to 
the others using the protein expression profile view shown in Figure 6.1. The purpose of 
highlighting such proteins is discussed previously in Section 4.2. One such protein 
which shows large protein abundance difference in DLKP and clonal subpopulation 
lines is DSG3.  
 
6.2.1. Global Analysis: Desmoglein-3 
DSG3 was highlighted by the label-free profiling work which quantitatively 
analysed the DLKP cell line and its clonal subpopulations and compared the data in one 
large experimental design. This design is termed a ‘Global Analysis’ and compares 
DLKP-SQ, DLKP-M, DLKP-I and DLKP against each other as one large group at both 
exponential and stationary phase of growth. DSG3 stood out as one of the top fold 
change proteins discovered by this analysis during exponential phase of growth only. 
 
 During exponential phase of growth, DSG3 has a maximum fold change of 
175.33 during with highest abundance in DLKP-I and lowest abundance in 
DLKP-SQ. 
 
 Three peptides contributed to the identification of DSG3. 
 
 During stationary phase of growth, DSG3 was not highlighted as a statistically 
significantly differentially expressed protein. 
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DSG3 was positively identified by mass spectrometry by passing the stringent 
criteria of: ≥ 2 peptides contributing to the protein identification, an abundance change 
of ≥ 2 fold between two experimental groups, an ANOVA p-value of <0.05 attributed to 
a protein between experimental groups. A representative protein abundance graph from 
the Progenesis software for DSG3 can be seen below in Figure 6.1. This image shows 
the normalised abundance values for DSG3 across the DLKP cell line and its clonal 
subpopulations. During exponential phase of growth, highest abundance of DSG3 is in 
DLKP-I compared to all other cell lines in the global analysis. Next highest abundance 
is seen in DLKP-M and DLKP, both showing similar levels judging by the protein 
expression profile. Very low level abundance is in DLKP-SQ. Following this initial 
assessment, the levels of DSG3 expression were analysed using experimental designs 
which compare the cell lines against each other using a one vs. one method instead of as 
one group: e.g. DLKP-SQ vs. DLKP-I. Peptides contributing to the identification of 
DSG3 are shown in Figure 6.2. 
 
 
Figure 6.1: Peptide expression profile for DSG3 during exponential phase of growth. Highest 
expression of DSG3 can be seen in DLKP-I, with a 175.33-fold difference between DLKP-I and 
the lowest abundance found in DLKP-SQ (ANOVA, p-value is 5.94E-06).  
 
 
Figure 6.2: Peptides which contributed to the identification of DSG3 as shown by Progenesis 
software. Each peptide had an ANOVA p < 0.05, and MASCOT scores ≥40. 
 
 
DLKP-SQ DLKP-M DLKP-I DLKP 
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6.2.2. Two-Sample Experimental Designs: Desmoglein-3  
 DSG3 was found to be expressed with very high abundance in a single clone 
population when samples were grouped together in a global analysis. The expression 
profile in Figure 6.1 shows DSG3 as being highly expressed in DLKP-I when compared 
to DLKP and the remaining clonal subpopulations. In this analysis, DSG3 expression is 
determined using an approach which compares individual cell lines against each other in 
a one vs. one experimental design. Each cell line is compared to another individually, 
using Progenesis software as described previously in Section 4.2.2. This analysis results 
in the availability of individual fold change data between cell lines with the associated 
statistical information. Intermediary fold change data can be obtained using this 
analysis. The usual strong criteria are applied to the resulting proteins to ensure strong 
identifications with high statistical significance as previously described in Section 3.1.2. 
Results of this analysis for DSG3 are summarised in Table 6.1.  
 Each experimental design which contains DLKP-I in the comparison highlights 
DSG3 as the top fold change result with greatest abundance in DLKP-I. The protein is 
not highlighted as a significantly differentially expressed protein in comparisons which 
do not include DLKP-I in the experimental design. This indicates that DSG3 is a 
specifically highly expressed protein in DLKP-I during exponential phase. DSG3 was 
identified as highly expressed in DLKP-I during stationary phase, however only one 
peptide contributed to this identification and was therefore screened out. 
 
 During exponential phase of growth DSG3 is highlighted only in the 
experimental designs which contain DLKP-I, indicating that the protein is very 
specifically expressed in DLKP-I compared to the other cell lines. 
 
 DSG3 shows the largest abundance difference between DLKP-I and DLKP-SQ 
with a fold change of 175.33, highest in DLKP-I. The next highest abundance is 
in DLKP followed finally by DLKP-M.  
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Exponential Phase: 
 
Table 6.1: Individual comparisons of the DLKP cell line and clonal subpopulations for exponential 
phase of growth. In each comparison containing DLKP-I, DSG3 was highlighted as having the 
highest expression in that cell line. For each comparison, ≥ 2 peptides contributed to the 
identification, and ANOVA p-values were <0.05 in the protein abundance comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individual Comparison Description
Max fold 
change
Highest 
Abundance
Lowest 
Abundance
DLKP-SQ   vs. DLKP-M - - - -
DLKP-SQ   vs. DLKP-I Desmoglein-3 175.33 DLKP-I DLKP-SQ
DLKP-I       vs. DLKP-M Desmoglein-3 97.31 DLKP-I DLKP-M
DLKP-SQ   vs. DLKP - - - -
DLKP-M     vs. DLKP - - - -
DLKP-I        vs. DLKP Desmoglein-3 81.55 DLKP-I DLKP
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6.2.3. Validation of DSG3 Expression in DLKP and Clonal Subpopulations  
To validate the expression pattern for DSG3 found by the label-free analysis 
comparing DLKP and the clonal subpopulations, each cell line was analysed by 
Western Blot. Samples were prepared as described in Section 2.3.1 and probed for 
DSG3 using the appropriate primary antibody. Western Blots analysis revealed bands at 
a MW of 130 kDa which is the expected weight of this protein (Koga et al. 2013).  
Highest expression of DSG3 is in DLKP-I, with no detectable DSG3 in any of 
the other clones. A representative image of the western blot analysis is shown in Figure 
6.3A of DSG3 expression in the DLKP cell lines. For comparative purposes, a graphical 
representation of the label-free abundances for DSG3 is shown in Figure 6.3B. 
 
 
Figure 6.3: (A) Western Blot showing expression levels of DSG3 in all DLKP cell 
lines. Beta-Actin was used as a loading control. DSG3 bands are visible at 
~130kDa in the DLKP model. (n=3). (B) Label-free abundance values for DSG3 
in the DLKP cell line and clonal subpopulations. Standard deviations are shown 
(n=3). 
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6.3. Proteomic Comparison of DLKP Compared to the Three Clones and 
Combination Cell Lines 
 DSG3 was established as highly expressed in the DLKP-I clonal subpopulation 
in an analysis comparing the cell lines together as a group. Further analysis showed the 
individual fold changes between the high expressing DLKP-I clone against the 
remaining cell lines. To further explore the expression pattern of DSG3 using the label-
free profiling data, an experimental design was set up which incorporates all samples 
into the analysis. This design includes the ‘combination lines’ which are newly created 
cell lines made up of 50:50 ratios of any two clonal subtypes, as well as a reconstituted 
version of DLKP based on previous work (McBride et al. 1998b). Details of the 
combination cell lines are described in Section 3.1.1.  
A large global group analysis was created in Progenesis software which 
incorporates all samples into one large experimental design, consisting of 24 individual 
samples representing eight different conditions in biological triplicate. The combination 
lines inclusion into the analysis was done to determine if co-culture of the DLKP clonal 
subpopulations would have any effect on the expression of proteins of interest. Such 
effects include inhibited or increased expression of protein targets. In this analysis, 
DSG3 is highlighted as a statistically significantly differentially expressed protein 
during exponential phase, and its expression in the combination lines is available for 
analysis also. 
Peptides which belong to DSG3 and have contributed to its identification and 
quantification are displayed by Progenesis software (Figure 6.2). Each peptide had an 
ANOVA p-value <0.05, and Mascot scores ≥40. Each peptide showed highest 
abundance in DLKP-I. These peptides are grouped together by the software and 
quantification data is displayed as a peptide expression profile. Label-free data can be 
displayed as a peptide or protein expression pattern. The peptide expression view 
(Figure 6.4) allows for the detection of peptide outliers in the data which may skew the 
results. In the case of DSG3, the peptides cluster together well, indicating a strong 
quantitative analysis for the protein identified. The abundance levels of DSG3 are 
significantly higher in DLKP-I than all other samples in the analysis. Moreover, the 
combination lines which contain DLKP-I as a component show a higher abundance of 
DSG3 when compared to samples which do not contain that cell line. The two 
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combination lines containing DLKP-I as a component are: SQ+I and I+M. The peptide 
expression profile for DSG3 shows that these two samples do not express the same level 
of the protein as would be expected. This is due to the fact both DLKP-SQ and DLKP-
M show little to no expression of DSG3 based on the data described in Section 6.2.1. 
This unusual expression pattern in the combination lines suggests that co-culture of 
DLKP-I with DLKP-M results in decreased expression of DSG3.  
 
 
 
 
Figure 6.4: Peptide expression profile for DSG3 across all DLKP cell lines and combination lines. 
Peptide abundance for DSG3 show clear differences between clonal cell lines, as well as the combination 
lines. Highest abundance is in DLKP-I and lowest in DLKP-SQ (ANOVA p-value= 1.44E-10). 
 
 
 
 
 
 
 
 
 
 
DLKP-SQ DLKP-M DLKP-I DLKP SQ+M SQ+I I+M Remade 
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6.4. Validation of Desmoglein-3 Expression in DLKP plus the Clones and 
Combination Cell Lines 
6.4.1. Western Blot 
Western Blot analysis was performed on the DLKP cell lines along with the 
combination lines to determine if the expression pattern found by the label-free analysis 
could be validated. The label-free analysis had revealed an unexpected abundance 
pattern of DSG3 in the combination line samples. SQ+I and I+M would be expected to 
result in similar abundance levels. However, the label-free data reveals a lower 
abundance of DSG3 in I+M than is found in SQ+I. This suggests an inhibition of DSG3 
expression by the DLKP-M clone when it is in co-culture with DLKP-I. Western blot 
analysis validated this expression pattern and can be seen in Figure 6.3 A, with SQ+I 
showing higher expression of DSG3 than I+M. A graphical representation of the label-
free abundances for DSG3 in DLKP clones and combinations is shown in Figure 6.3B 
for comparison. 
 
 
6.4.2. mRNA Expression 
 Western blot analysis validated the expression of DSG3 found by the label-free 
proteomic profiling. To further investigate this expression pattern, DLKP samples were 
analysed using quantitative PCR (qPCR) to determine the relative levels of DSG3 
mRNA expression in DLKP, clones and combination cell lines. Relative gene 
quantification was performed on all cell lines as one experiment, and beta-actin was 
used as the endogenous control. Biological duplicate samples were analysed and the 
experiment was carried out twice. The calculation of relative quantity (RQ) was 
achieved by normalizing the data to DLKP-I. Results are combined in Figure 6.5. 
mRNA levels of DSG3 correlated well with label-free proteomics data as well as 
the western blot analysis. Highest mRNA level can be seen in DLKP-I, further showing 
the target as a potential marker for this cell type. mRNA for DSG3 in DLKP-SQ and 
DLKP-M is virtually non-existent. There is a low expression level of the target in the 
DLKP cell line, which is expected as DLKP is made up of approximately 25% DLKP-I 
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(McBride et al. 1998b). The mRNA abundance in the combinations correlated well with 
the findings from the proteomic analysis. SQ+M shows no expression of DSG3, while 
both SQ+I and I+M have detectable levels of the target. I+M has approximately half the 
abundance of mRNA levels for DSG3 compared to SQ+I. This further supports the 
hypothesis that co-culture of DLKP-I with DLKP-M has inhibited the expression level 
of DSG3 at the protein, and now mRNA level. 
 
 
Figure 6.5: qPCR results showing mRNA levels of DSG3 in the clones and combination lines. 
Samples are analysed in biological duplicate (n=2). Error bars shown are the standard 
deviations between two replicate experiments. Data are normalized to DLKP-I. 
 
 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
DLKP-SQ DLKP-M DLKP-I DLKP SQ+M SQ+I I+M Remade
R
el
at
iv
e 
Q
u
an
ti
ty
 (R
Q
)
Gene Expression: Desmoglein-3
 220 
 
6.5. Imaging of Desmoglein-3 in the DLKP Cell Lines 
 DSG3 was validated as being a significantly differentially expressed target at the 
protein and mRNA level, showing very high abundance in the DLKP-I clonal 
subpopulation. In order to investigate the localization of this protein in the DLKP cell 
line model, as well as further validate the expression pattern, DSG3 was stained and 
imaged using both immunocytochemistry and immunofluorescence. Staining methods 
were performed as described in Section 2.6 on DLKP and clonal subpopulations fixed 
to glass slides by paraformaldehyde. 
 
6.5.1. Immunocytochemical Staining of Desmoglein-3 in DLKP Cell Lines 
 Expression of DSG3 in the DLKP cell line and clonal subpopulations shows 
drastic differences in protein abundance according to the label-free proteomics data. 
DLKP-I has the highest and only expression of DSG3 with the other clonal 
subpopulations showing no detectable levels of the protein by western blot analysis or 
qPCR analysis. The staining intensity of DSG3 in the DLKP cell lines by 
immunocytochemistry correlated very well with these findings and resulting images are 
shown in Figure 6.6.  
DLKP-I shows extremely high intensity of DSG3 staining compared to the other 
cell lines, further validating its specific expression in DLKP-I. Localization of the 
protein can be clearly seen in the cell-cell junctions of actively dividing DLKP-I cells, 
which is expected due to its known role as a component of the desmosome (Garrod and 
Chidgey 2008). In normal stratified epithelium, DSG3 expression is predominantly in 
the cell membrane. However, strong cytoplasmic and perinuclear staining is clearly 
visible in DLKP-I cells. This cytoplasmic localization has previously been found in oral 
squamous cell carcinoma (OSCC) and in esophageal squamous cell carcinoma (ESCC). 
In both cases, this abnormal cytoplasmic localization correlated with poor prognosis 
(Wang et al. 2007, Fang et al. ). DLKP-SQ and DLKP-M shows no staining for DSG3, 
while the Dapi nuclear stain remains clearly visible. The DLKP cell line itself shows a 
subpopulation of cells which stain positively and strongly for DSG3. This is most likely 
the DLKP-I subpopulation which makes up approximately 25% of the DLKP cell line 
as described in Section 1.4.1.2. 
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DLKP-SQ             DLKP-M 
    
DLKP-I              DLKP 
    
Figure 6.6: Immunocytochemistry staining images of DLKP-SQ, DLKP-M, DLKP-I and DLKP stained 
with DSG3. Nuclei are counterstained with Dapi. Negative controls with secondary antibody only did 
not result in staining (images not shown). Original magnification used on all micro-pictographs shown 
at 200x, 200μm scale bar (n=2). 
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6.5.2. Immunofluorescence Staining of Desmoglein-3 in DLKP Cell Lines 
 Immunofluorescence staining of DSG3 was carried out in DLKP and each of its 
clonal subpopulations to allow visualization of the distribution of the protein in each 
cell type, as well as a semi-quantitative assessment of protein abundances. Staining was 
carried out using the method described in Section 2.6.3, with resulting images shown in 
Figure 6.7.  
 Immunofluorescence staining of DSG3 followed the same trend as was found 
for immunocytochemistry. The DLKP-I cell line has the most intense staining of all the 
samples, and is the only cell line from the clonal subpopulations to stain positively for 
the protein. The localization of DSG3 in this cell line is both membranous and 
cytoplasmic in nature. There is clear enhanced staining for the protein at cell-cell 
junctions which is expected. In addition, there is punctate staining present on the cell 
surface which may be the DSG3 component of the desmosomes dotted across the cell 
membrane. Perinuclear and cytoplasmic staining is also visible, which is an abnormal 
localization for this protein (Chidgey and Dawson 2007). Both the DLKP-M and 
DLKP-SQ cell lines show no detectable levels of DSG3 staining, which correlates well 
with the findings for the protein so far. This stark difference in protein expression is 
quite unusual as the clonal cell lines are derived from the same heterogeneous 
population (DLKP). The DLKP cell line shows positive staining for DSG3 in a small 
subpopulation, which is most likely DLKP-I. However, the morphology of this cell line 
is slightly different from the clonal DLKP-I cell line. This indicates that in the 
heterogeneous population, co-culture conditions play a significant role on the behaviour 
of the cells. Investigating cellular heterogeneity and how subpopulations interact in lung 
cancer may lead to improved treatments and the discovery of useful prognostic markers. 
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DLKP-SQ             DLKP-M 
    
DLKP-I              DLKP 
    
Figure 6.7: Immunofluorescence images stained for DSG3 in DLKP-SQ, DLKP-M, DLKP-I and DLKP. 
Nuclei are counterstained with Dapi. Negative controls with secondary antibody did not result in staining 
(images not shown). Original magnification used on all micro-pictographs shown at 400x, 50μm scale bar 
(n=2). 
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6.6. Functional Analysis of Desmoglein-3 Knockdown by RNAi 
 DSG3 plays an unknown role in the DLKP cell line model. It shows extremely 
high expression in one clonal subpopulation only: DLKP-I. Expression in the remaining 
clonal cell lines is undetectable by both western blot analysis and gene expression 
assays. In order to investigate the role of DSG3 at a functional level, knockdown of the 
protein was carried out using RNA interference (RNAi). DLKP-I was used as the cell 
line to carry out the investigation of this process as it expresses the highest abundance 
of DSG3 in the DLKP cell line model. The effects of DSG3 knockdown were 
determined by a panel of functional assays and comparing test samples against a 
negative siRNA control. In this case a standard commercially available negative siRNA 
was used for this purpose. Previous to the knockdown of DSG3, cells were first tested to 
determine the optimal transfection conditions for DLKP-I. Conditions were optimised 
as described in Section 2.4.1. 
 
6.6.1. Transfection Optimisation 
6.6.1.1. Optimisation of Transfection Reagent Volume: 
 The transfection reagent volume necessary to effectively introduce siRNA in 
cells is an important optimisation step previously described in Section 4.7.1. Prior 
optimisation narrowed down the required transfection reagent volume to 1 μl or 2 μl per 
6-well, and both these volumes are tested here. Post-transfection cell viability was 
measured using an acid phosphatase proliferation assay on a series of controls and tests 
as described previously in Section.4.7.1. Results are shown in Figure 6.8. 
 In the case of DLKP-I, both of the volumes of transfection reagent tested had a 
negligible effect on the Lipo-only control compared to the Cells-only condition. This 
indicates that neither volume is detrimental to the survival of DLKP-I cells. The 
negative siRNA control similarly shows no reduction in cell proliferation or viability 
which indicates that introducing non-coding siRNA into these cells has no effect on 
these conditions. The positive control siRNA is designed to induce cell death by 
targeting kinesin, a protein crucial to proper cell functioning. Both 1 μl or 2 μl volumes 
of transfection reagent effectively delivered the siRNA into DLKP-I cells, resulting in 
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~37% and ~62% cell death respectively. This result led to choosing the 2 μl volume of 
transfection reagent for future transfections with DLKP-I. 
 
 
Figure 6.8: Proliferation assay performed on DLKP-I cells using 1μl/6-well (Blue) and 
2μl/6-well (Red) of Lipofectamine transfection reagent. Percentage survival values are 
relative to the negative siRNA control. (1μl /well: P-Value 7.8E-03) (2μl/well: P-Value: 
9.4E-04) 
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6.6.1.2. Optimisation of siRNA Concentration: Desmoglein-3 
 Optimisation of siRNA concentration for DSG3 is essential to ensure the target 
is being knocked down effectively. In addition, it is important to use the minimum 
concentration of siRNA which achieves this, as over saturating the cells with surplus 
siRNA can have additional effects aside from knockdown of the protein. Optimisation 
was carried out using the following conditions: 
 Cells-only, Lipofectamine-only and Negative siRNA controls. 
 30 nM, 20 nM, 10 nM and 5 nM of siRNA for DSG3. 
 Two different siRNA molecules were tested in tandem which target DSG3. 
 
After transfection using the conditions described above, cell lysates were 
prepared as described in Section 2.3.1. Western blot analysis for DSG3 was carried out 
on the entire sample set and the resulting image is shown in Figure 6.9. In the first three 
lanes containing the control samples, DSG3 can be seen at 130kDa, with expression 
unaffected by the transfection process. Each siRNA group shows no expression of 
DSG3 at any of the concentrations tested. However, the blot is bad quality and has high 
background, therefore the experiment was repeated using the two lowest siRNA 
concentrations: 10 nM and 5 nM (Figure 6.10). 
 
Figure 6.9: Western Blot probing for DSG3 (130 kDa). Lanes 1-3 contain: Cells-only, 
Lipofectamine-only and Negative siRNA (30 nM). Each DSG3 (DSG3) siRNA group 
(#1 and #2) is comprised of four sample lanes which were treated with 30 nM, 20 nM, 
10 nM and 5 nM of siRNA from left to right. Beta-actin loading control included. 
Cells Lipo Neg siRNA#1 siRNA#2
Beta-Actin
DSG3
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 The transfection experiment was repeated once again with the middle 
concentrations of siRNA (20 nM and 10 nM), as these concentrations in the previous 
optimisation experiment seemed to result in complete knockdown of DSG3. A 
concentration of 5 nM was ruled out on the basis of practicability. This concentration 
requires a siRNA volume which is simply too small to be accurately and repeatedly 
pipetted in transfection experiments. The resulting western blot analysis of DSG3 in 
these samples is shown in Figure 6.10. The results show that both concentrations of 
siRNA effectively reduce the expression of DSG3 to undetectable levels. A 
concentration of 10 nM was chosen for future knockdown of DSG3 by RNAi. 
 
 
 
 
Figure 6.10: Western Blot probing for DSG3 (DSG3). Lanes 1-3 contain: Cells-
only, Lipofectamine-only and negative siRNA (30nM). Each DSG3 siRNA 
group (#1 and #2) is comprised of two sample lanes treated with 20 nM and 10 
nM of siRNA in the left and right lane respectively. Beta-Actin loading control 
included. 
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6.6.2. Functional Effects of Desmoglein-3 Knockdown on Proliferation, Migration 
and Invasion in DLKP-I 
 In order to shed light on the role played by DSG3 in DLKP-I, siRNA 
knockdown of the protein was carried out. This was followed up by a panel of 
functional assays. These assays measure proliferation, migration and invasion and 
significance is calculated by comparing the knockdown samples to the negative siRNA 
control. Each assay was carried out as described in Section 2.5. 
 
6.6.2.1. Proliferation of DLKP-I Post-DSG3 Knockdown: 
 Proliferation of DLKP-I was measured 72 hours post transfection as described 
in Section 2.2.3. Knockdown of DSG3 in DLKP-I had no significant effect on the 
proliferation of the cells compared to the negative siRNA control (n=3). Results are 
shown in Figure 6.11. 
 
 
 
Figure 6.11: Proliferation assay on DLKP-I post transfection for DSG3 RNAi. There was 
no statistically significant difference in proliferation between siRNA knockdown samples 
(#1 and #2) and the negative control (n=3). (siRNA#1 P-value: 0.61, siRNA#2 P-value: 
0.68). 
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6.6.2.2. Migration of DLKP-I Post Desmoglein-3 Knockdown: 
 Migration assays on DLKP-I were carried out 72 hours post DSG3 knockdown 
by RNAi. The assay was performed using the method described in Section 2.5.4. 
DLKP-I cells were allowed to migrate through the uncoated membrane for 24 hours 
before being fixed and stained with crystal violet. Knockdown of DSG3 in DLKP-I had 
a significant inhibitory effect on the ability of the cells to migrate when compared to the 
negative siRNA control sample (n=3). Results are shown in Figure 6.12.  
 
 
 
Figure 6.12: Migration assay results for DLKP-I cells following DSG3 knockdown 
using RNAi. Total number of cells which migrated through the uncoated membrane is 
shown (n=3). A statistically significant difference between siRNA knockdown samples 
(#1 and #2) and the negative siRNA control was found. (siRNA#1 P-value: 9.6E-03, 
siRNA#2 P-value: 1.0E-02).  
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6.6.2.3. Invasion of DLKP-I Post-Desmoglein-3 Knockdown: 
 Knockdown of DSG3 was performed 72 hours post transfection as described in 
Section 2.5.3. Cells were allowed to pass through the Matrigel coated membrane for 24 
hours before fixation and staining by crystal violet. DSG3 knockdown had a significant 
inhibitory effect on the ability of DLKP-I cells to invade when they were compared to 
the negative siRNA control sample (n=3). Results are shown in Figure 6.13. 
 
 
 
Figure 6.13: Invasion assay results for DLKP-I cells following DSG3 knockdown using 
RNAi. Total number of cells which migrated through the Matrigel coated membrane is 
shown (n=3). A statistically significant difference between siRNA knockdown samples 
(#1 and #2) and the negative siRNA control was found. (siRNA#1 P-value: 2.7E-02, 
siRNA#2 P-value: 1.5E-02).  
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6.6.3. Co-Staining of Desmoglein-3/F-Actin after Dsemoglein-3 Knockdown by 
RNAi in DLKP-I 
DSG3 is a membrane bound protein which is predominantly found as a 
component of the desmosome. Its importance as a cell adhesion molecule is highlighted 
by its role in the autoimmune disease Pemphigus vulgaris, in which DSG3 has been 
shown to be the target of autoimmune antibodies (Koga et al. 2013). Upon binding of 
these antibodies to DSG3, a signalling cascade leading to the degradation of the protein 
from desmosomes is initiated. This in turn leads to the disorganisation of the actin 
cytoskeleton resulting in a loss of cell-cell adhesion which leads to blistering and 
lesions. In addition, knockdown of DSG3 in epidermoid carcinoma cells caused in a 
significant loss of cortical F-actin bundles, resulting in decreased cell height indicating a 
loss of contractility in cells with DSG3 depletion (Gliem et al. 2010, Tsang et al. 2012). 
These reported links between DSG3 and actin may be relevant to the phenotypic 
characteristics of DLKP-I, as knockdown of the protein has resulted in decreased 
migration and invasion. It was decided to investigate this link by staining both DSG3 
and F-actin in DLKP-I and imaging the proteins by confocal microscopy. DLKP-I cells 
were also treated by RNAi to knockdown the expression of DSG3 and determine if 
there was an effect on F-actin organization, location or abundance. DSG3 expression 
and localization was also assessed. 
DLKP-I cells were prepared as previously described in Section 4.7.3 and were 
co-stained with Dapi nuclear stain. Resulting images are shown in Figure 6.14 to Figure 
6.17. 
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DLKP-I: Cells-Only 
 
Figure 6.14: DLKP-I cells stained for DSG3, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are untreated by any RNAi method. Original 
magnification of all photomicrographs, ×400, scale bar = 20μm. 
 
 
DLKP-I: Lipofectamine-Only Control 
 
Figure 6.15: DLKP-I cells stained for DSG3, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are treated with transfection reagent only 
(Lipofectamine). Original magnification of all photomicrographs, ×400, scale bar = 
20μm. 
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DLKP-I: Negative siRNA Control 
 
Figure 6.16: DLKP-I cells stained for DSG3, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are treated with transfection reagent and 
negative siRNA control. Original magnification of all photomicrographs, ×400, scale 
bar = 20μm. 
 
 
DLKP-I: DSG3 Knockdown-siRNA #1 
 
Figure 6.17: DLKP-I cells stained for DSG3, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are treated with siRNA#1 for DSG3. Original 
magnification of all photomicrographs, ×400, scale bar = 20μm. 
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DLKP-I: DSG3 Knockdown-siRNA #2 
 
Figure 6.18: DLKP-I cells stained for DSG3, Actin and Dapi. A merged image is 
shown in the bottom right corner. Cells are treated with siRNA#2 for DSG3. Original 
magnification of all photomicrographs, ×400, scale bar = 20μm. 
 
 
 
Figure 6.19: DLKP-I treated with negative siRNA control. Cells are stained for DSG3, 
Actin and Dapi. A merged image is shown in the bottom right corner. Intense staining 
of DSG3 can be seen at cell-cell junctions as well as punctate staining throughout the 
cytoplasm. Original magnification of all photomicrographs, ×800, scale bar = 5μm. 
 
 Confocal imaging of DLKP-I cells resulted in highly specific staining for both 
DSG3 and F-actin. This cell line clearly expresses a high abundance of DSG3 which 
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can be seen in the control group of images: Cells-only, Lipofectamine-only and 
Negative siRNA (Figure 6.14-Figure 6.16). In these groups, staining for DSG3 is visible 
throughout the cell. However, increased staining intensity can be seen at the periphery 
of many cells and at cell-cell junctions. This junction localization of the protein is 
presumably desmosomal bound DSG3 acting in its role as a cell adhesion molecule. 
There is also a significant amount of punctate staining of DSG3 present in the control 
group images which vary in size. Some are small and may be membrane bound 
desmosomal structures. Others are relatively large and are unlikely to be desmosomes, 
and therefore are possibly larger cell structures containing DSG3 as a component. F-
Actin staining is high in the control group also, in many cases showing its characteristic 
filamentous expression pattern. Co-localization of F-actin and DSG3 can be seen where 
intense staining for DSG3 is present. The negative siRNA control image Figure 6.16 
shows overlapping staining for both F-actin and DSG3 at cell-cell junctions and at 
fillopodial outgrowths.  
DSG3 knockdown by RNAi (Figure 6.17 and Figure 6.18) resulted in a 
significant loss of staining intensity for the protein when compared to the control group. 
Faint perinuclear staining and potentially desmosomal punctate staining remains in the 
knockdown samples, but overall DSG3 expression is drastically reduced. F-actin 
expression seems to have been affected and shows reduced staining intensity in 
response to DSG3 knockdown for both siRNA molecules. This is evident especially in 
Figure 6.18, where relatively high DSG3 expression remains in a subpopulation of the 
cells in the field of view, and F-actin shows relatively high staining in the same 
subpopulation. This supports the findings of a previous study where overexpression of 
DSG3 was found to increase the rate of actin turnover while knockdown had the 
opposite effect (Tsang et al. 2012).  
A high magnification image of the Cells-only control is shown in Figure 6.19 
displaying DSG3/F-actin staining. Co-localization of DSG3 and F-actin is clearly 
visible in this example, with intense staining of both proteins at the cell periphery and at 
cell-cell junctions. Co-staining is also visible in fillopodial protrusions and membrane 
ruffles, suggesting that both proteins may interact at these locations in DLKP-I. This 
interaction is investigated in Section 6.7 where DSG3 binding partners were determined 
using co-immunoprecipitation.  
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6.7. Identification of Potential Binding Partners of Desmoglien-3 in DLKP-I 
In order to further investigate the role of DSG3 in DLKP-I, co-
immunoprecipitation analysis was performed to pull the protein out the cell lysate along 
with any binding partners which may be complexed to it. The basis behind Co-
immunoprecipitation is discussed in Section 2.8. The two methods described previously 
in Section 4.8 were used in an attempt the Immunoprecipitation of DSG3 and its 
binding partners: Cross Linked Co-IP and Traditional Co-IP. 
 
 
 
6.7.1. Cross-Linked Co-Immunoprecipitation 
 Cross-linked Immunoprecipitation technology was used initially as a method to 
pull DSG3 and its binding partners out of DLKP-I cell lysate. Within this, two different 
systems were used. The first used a magnetic Co-IP kit which cross-links the antibody 
for the target protein to Protein A/G magnetic beads permanently. Beads are separated 
from the cell lysate and during wash steps by magnetism in place of centrifugation. The 
second method uses a standard Cross-Linked Co-IP kit in which the target antibody is 
covalently bound to Protein A/G bead column using amide bonds. In both cases, the 
target antibody and binding partners are eluted from the beads by a low pH buffer which 
dissociates the bound complex from the beads without disrupting the activity of the 
target antibody. Unfortunately, neither of these cross-linked techniques was in any way 
successful in achieving immunoprecipitation of the target. Western Blot analysis from 
both techniques shows that the immunoprecipitation of DSG3 and recovery was not 
achieved. Results of the standard Cross-Linked Co-IP technique are shown in Figure 
6.20. 
 Lane-1 shows DSG3 being successfully detected at 130kDa when DLKP-I cells 
have been lysed using the IP compatible gentle lysis buffer. Lane-2 containing the 
elution of immunoprecipitated DSG3 has not detected the protein, indicating that the 
protein was not pulled out of the lysate and bound to the Protein A/G beads via the 
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primary antibody. Lane-3 contains the unbound fraction in which a faint band for DSG3 
can be seen, as well as faint antibody heavy and light chains. Lane-5 and 6 contain the 
negative control mouse IgG samples. DSG3 was not detected in the elution, but was 
detected in the unbound fraction as expected. Each sample run on this western Blot has 
an equal concentration of protein. Therefore, these results suggest that DSG3 was 
depleted from the cell lysate as the intensity of the band in Lane-3 is much lower than in 
Lane-1 or Lane-5. However, as the protein is not detected in the elution, it was either 
lost during wash steps, or remains bound to the beads even after the elution step. 
Antibody heavy and light chains in the elutions for both test and control groups further 
solidify the failure of this technique. Both the Magnetic and Cross-Linked kits were 
tried multiple times with various optimisation steps with no success. Therefore the 
Traditional IP method was employed. 
 
 
 
Figure 6.20: Western Blot analysis of DSG3 on cross-linked Co-IP samples. Lane 
1: DLKP-I control lysate. Lane 2: DSG3 immunoprecipitate elution. Lane 3: DSG3 
unbound fraction. Lane 4: Mouse IgG immunoprecipitate elution. Lane 5: Mouse 
IgG unbound fraction. DSG3 is visible at 130kDa in the control lysate and the 
mouse IgG unbound fraction. 
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6.7.2. Traditional Co-Immunoprecipitation: DSG3 
DLKP-I cells were lysed using a gentle IP compatible lysis buffer and DSG3 
was immunoprecipitated along with potential binding partners using the method 
outlined in Section 4.8.2. Elutions from the DSG3 test, and IgG negative control were 
analysed by western blot.  
 Western blot analysis of DSG3 was successful at detecting the protein in the test 
elution sample. Lane-1 contains the DLKP-I lysate control and DSG3 is visible at 
130kDa as expected. Lane-2 contains the elution of immunoprecipitated DSG3 along 
with the heavy and light antibody chains. Lane-3 contains the elution of the control 
mouse IgG. An enriched band for DSG3 can be clearly seen in Lane-2, indicating 
successful immunoprecipitation of the target. This experiment was repeated twice and a 
representative blot is shown in Figure 6.21. 
 
 
 
Figure 6.21: Western Blot analysis of DSG3 on Co- IP elution samples. Lane 
1: DLKP-I lysate positive control. Lane 2: DSG3 Co-IP elution. Lane 3: 
Mouse IgG Negative Control elution. DSG3 is visible at 130kDa in positive 
control and DSG3 Co-IP elution (circled in Red). Heavy and light antibody 
chains are visible in both elutions. 
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6.7.3. Identification of Immunoprecipitated Proteins by Mass Spectrometry 
 Two independent Co-IP experiments were performed using the Traditional IP 
method with the goal of achieving co-immunoprecipitation of DSG3 and its binding 
partners in DLKP-I. Positive lysate control, DSG3 elution and negative control mouse 
IgG elution samples were separated on a polyacrylamide gel by SDS-PAGE (Section 
2.3.3) and stained using Coomassie Blue (Figure 6.22). Staining revealed a faint band in 
the DSG3 elution (Lane-2) at 130 kDa which was not present in the mouse IgG control 
lane (Lane-3). Each lane was excised from the gel and sliced into 2 mm fragments from 
top to bottom. In-gel digestion of each gel piece was performed and proteins were 
identified using LC-MS/MS analysis using methods described in Section 2.8.6. MS 
analysis was successful in detecting DSG3 in two independent Co-IP experiments, and 
results are summarised in Table 6.2. 
 
 
 
 
Figure 6.22: Coomassie stained gel of DSG3 Co-IP samples. Lane 1: DLKP-I 
positive control lysate. Lane 2: DSG3 Co-IP elution. Lane 3: Negative control Ms 
IgG to account for non-specific binding events. DSG3 band is circled in red at 130 
kDa in lane-2. Heavy and light antibody chains are clearly visible. 
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6.7.3.1. Proteins Identified by Mass Spectrometry: Desmoglein-3 Co-IP 
 Immunoprecipitation elutions were analysed by LC-MS/MS after in-gel 
digestion as described in Section 2.7.5. Proteins identified in the negative control 
(mouse IgG) were eliminated from the list of proteins identified in the DSG3 
immunoprecipitate. Results from both independent experiments were overlapped and 
proteins identified as common to both are shown in Table 6.2. The peptides numbers 
contributing to protein identifications are shown for each experiment (Expt 1 and Expt 
2). DSG3 was found to have the most peptides contributing to its identification, 28 and 
29 peptides respectively. The majority of the peptides contributing to the identification 
of DSG3 came from the gel slice circled in red in Figure 6.22. 
 Potential binding partners of DSG3 are shown in Table 6.2. A subset of these 
proteins were followed up by western blot analysis to see if they could be detected in 
the DSG3 immunoprecipitation elution, as well as to validate their expression in the 
DLKP cell line model and ascertain their expression patterns. 
Protein Peptide 
Number 
Expt 1 
Peptide 
Number 
Expt 2 
DSG3 
28 29 
Junction plakoglobin 
4 6 
Pyruvate dehydrogenase E1 component subunit alpha, 
mitochondrial 
12 13 
Pyruvate dehydrogenase E1 component subunit beta, 
mitochondrial 
11 10 
Dihydrolipoyllysine-residue acetyltransferase 
component of pyruvate dehydrogenase complex, 
mitochondrial 
15 11 
Tubulin alpha-1C chain 
7 5 
Pyruvate dehydrogenase protein X component, 
mitochondrial 
5 7 
ADP/ATP translocase 2 
3 4 
ADP-ribosylation factor 4 
4 5 
Table 6.2: Mass spectrometry results showing Immunoprecipitated DSG3 protein, with co-eluted 
proteins from two replicate experiments. Number of peptides identified by MS is shown for each 
experiment. 
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6.7.4. Western Blot Analysis of Desmoglein-3 Binding Partners in DLKP 
 The co-IP of DSG3 in DLKP-I resulted in a panel of proteins which were 
repeatedly found to co-elute with the target protein. A large proportion of these proteins 
are associated with the mitochondria, which is unexpected for a cell adhesion protein. A 
subset of proteins was chosen for further validation by western blot analysis:  
 Junction Plakoglobin 
 Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial 
 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
 
6.7.4.1. Junction Plakoglobin: 
 Junction plakoglobin (PG) is a member of the armadillo family of proteins and 
has been identified as a component of the desmosome (Andl and Stanley 2001). PG has 
been found to interact directly with the cytoplasmic domain of desmogleins and 
desmocollins, tethering these proteins to desmoplakin (DP). This large protein links the 
cytoskeleton to the plasma membrane, and integrates actin, microtubules and keratin 
intermediate filaments (KIF) (Delva, Tucker and Kowalczyk 2009). It has been shown 
that PG is weakly expressed or absent in several NSCLC cell lines and that restoration 
of protein expression in these cell lines had anti-proliferative effects (Winn et al. 2002). 
In addition, over-expression of PG in SCC-9 squamous carcinoma cells induced a 
mesenchymal to epidermoid phenotype (Parker et al. 1998).  
 
 PG was analysed by Western Blot in the DSG3 elution and negative control 
sample from the co-IP experiment to see if MS analysis had correctly detected its 
presence as a binding partner of DSG3, and results are shown in Figure 6.23. PG can be 
detected in the DSG3 co-IP elution (Lane-2), indicating that it is a binding partner of 
DSG3 in DLKP-I. No PG is present in the negative control, ruling out non-specific 
binding of the protein. This DSG3/PG interaction is not a novel discovery has been long 
reported in reported extensively in the literature (Chitaev et al. 1996). However, the 
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finding is a good validation of the method employed here to discover binding partners 
of DSG3 by co-IP using the traditional IP protocol. 
 
Western Blot of Junction Plakoglobin on Desmoglein-3 Co-IP Samples: 
 
Figure 6.23: Western Blot probing for Junction Plakoglobin (PG) on Co-IP samples 
which targeted DSG3 and its binding partners. Lane-1: DLKP-I control lysate. Lane 
2: DSG3 Elution. Lane 3: Mouse IgG Negative Control elution. PG is visible at 
~80kda in Lane-1 and Lane-2 (circled in red). 
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6.7.4.2. Expression of Junction Plakoglobin in DLKP plus the Clones and 
Combination Cell Lines 
 Further investigation into the expression of PG was carried out by determining 
its expression in the DLKP cell lines as well as the combination lines by western blot, 
and results are shown in Figure 6.24A. The expression pattern of PG followed the same 
trend as was previously found for DSG3. Western blot for DSG3 is reproduced here in 
Figure 6.24B for comparison.  
 DLKP-I shows the highest expression of PG out of all the samples. DLKP-M 
has the next highest expression in the clones with a faint band visible at the expected 
MW. Neither DLKP-SQ nor DLKP show any expression of PG. Each of the 
combination cell lines shows expression of PG, with similar and highest abundance in 
DLKP-I containing cell lines: SQ+I and I+M. The Remade cell line has the next highest 
abundance (25% DLKP-I) and SQ+M has extremely faint expression levels. The 
expression pattern in co-culture therefore correlates well with the finding that PG is 
predominantly expressed in DLKP-I. It does not seem to be affected by any of the 
inhibitory effects experienced by DSG3 in co-culture, as described in Section 6.4. 
 
 
Figure 6.24: (A) Western Blot analysis of Junction Plakoglobin in the DLKP cell 
lines and combination lines. Bands are visible at ~80kDa and beta-actin loading 
control is included. (B) Western Blot analysis of DSG3 reproduced from Fig 5A for 
comparative purposes. 
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6.7.4.3. The Pyruvate Dehydrogenase Complex: 
 Co-IP of DSG3 resulted in a panel of proteins which repeated were pulled out of 
DLKP-I with the target protein in two independent experiments and results are shown in 
Table 6.2. Eight proteins were found as potential binding partners of DSG3, and five of 
these are mitochondrial associated proteins: 
 Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial 
 (PDHE1-A). 
 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial  
(PDHE1-B). 
 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial (DLAT). 
 Pyruvate dehydrogenase protein X component, mitochondrial (PDHX). 
 ADP/ATP translocase 2 (ANT2). 
 
The first four proteins shown above (PDHEA1-A; PDHE1-B; DLAT; PDHX) 
are each a component of the Pyruvate Dehydrogenase Complex (PDC), which is a 
multi-enzyme complex located in the mitochondrial matrix.  
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6.7.4.4. Western Blot of PDHE1-A on Desmoglein-3 Co-IP Samples: 
PDHE1-A was analysed by western blot to determine if the protein is present in 
the DSG3 co-IP elution. Positive and negative control samples were analysed in tandem 
and results are shown in Figure 6.25. PDHE1-A was successfully detected in the 
positive control DLKP-I lysate as well as the DSG3 elution sample. The protein was not 
detected in the negative mouse IgG control ruling out non-specific binding of the 
PDHE1-A to Protein-G. Bands for PG are visible on the blot as it had been used 
previously to detect that protein.  
 
 
Figure 6.25: Western blot probing for pyruvate dehydrogenase E1 component subunit 
alpha, mitochondrial (Pyruvate E1/PDHE1-A) on Co-IP samples which targeted 
DSG3 and its binding partners. Lane-1: DLKP-I control lysate. Lane 2: DSG3 
Elution. Lane 3: Mouse IgG Negative Control elution. PDHE1-A is visible at ~43kda 
in Lane-1 and Lane-2. PG is also visible from the previous western blot analysis. 
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6.7.4.5. Expression of PDHE1-A in DLKP plus the Clones and Combination Cell 
Lines 
 Further investigation into the expression of PDHE1-A was performed by 
western blot analysis of the protein in the DLKP cell lines as well as the combination 
lines. This was carried out to validate the expression of the protein in the DLKP cell 
lines, and to determine its expression pattern. Results are shown in Figure 6.26.  
 PDHE1-A shows highest expression levels in both DLKP-SQ and DLKP-M at a 
similar abundance. DLKP-I has the lowest expression of the protein and DLKP shows 
intermediate expression compared to the clonal subpopulations. The combination lines 
showed an unexpected expression pattern with SQ+I having a higher abundance of 
PDHE1-A than SQ+M. Considering DLKP-SQ and DLKP-M were found to express the 
protein the most, it is unusual that their co-culture has resulted in decreased protein 
abundance. In the same vein, SQ+I shows higher than expected expression of PDHE1-A 
despite the DLKP-I clone showing the lowest abundance. This further implicates the co-
culture and heterogeneous nature of the DLKP cell line as a critical factor to consider 
when analysing the behaviour of these cells. 
 
 
 
Figure 6.26: Western Blot probing for Pyruvate dehydrogenase E1 component subunit 
alpha, mitochondrial (Pyruvate E1/PDHE1-A) in the DLKP cell lines and combination 
lines. Bands are visible at ~43kDa and beta-actin loading control is included. 
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6.7.4.6. Expression of DLAT in DLKP plus the Clones and Combination Cell Lines 
 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial (DLAT) is another major component of the 
PDC and is therefore also localized to the mitochondrial matrix. Its function is to 
finalise the conversion of Pyruvate to Acetyl-CoA in conjunction with the other proteins 
of the PDC (PDHE1-A, DLD).  
 Western blot analysis of DLAT in the DLKP cell lines and combinations 
validates the expression of the protein as present in the DLKP samples Figure 6.27. In 
addition, it shows the expression pattern across all the cell lines. Similar to PDHE1-A, 
highest expression was found in DLKP-SQ and DLKP-M. Both DLKP-I and DLKP 
show low expression of DLAT and at a similar level. Based on these findings, it is 
possible that both DLKP-SQ and DLKP-M have a higher proportion of mitochondria 
than DLKP-I or DLKP. Further work would be required to show this however. In the 
combination lines, SQ+M showed an unexpectedly low expression of DLAT 
considering both of its clonal constituents have the highest expression level of the 
protein. This suggests a possible inhibition of protein expression when the cells are in 
co-culture, and a similar effect was found for PDHE1-A (Figure 6.26). 
 
 
Figure 6.27: Western blot probing for DLAT (Pyruvate E2) in the DLKP cell lines and 
combination lines. Bands are visible at ~68kDa and beta-actin loading control is included. 
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6.8. Desmoglein-3 Expression in a Panel of Cell Lines 
 Western blot analysis was used to determine the presence and expression levels 
of DSG3 in a panel of cell lines. Results are shown in Figure 6.28. 
 Pancreatic cell lines: PANC-1, AsPC-1, BxPC-3 and MIA PaCa 2. 
 Lung cancer cell lines: A549, SK-LU-1, and NCI-H82. 
 DLKP clones: DLKP-SQ, DLKP-M and DLKP-I. 
 
The expression of DSG3 in the DLKP clones follow the expression pattern 
determined previously, with high abundance in DLKP-I and no detectable levels in 
DLKP-SQ or DLKP-M. From the panel outlined above, only two other cell lines show 
detectable levels of DSG3. These are AsPC-1 and BxPC-3, both pancreatic 
adenocarcinoma cell lines. AsPC-1 is derived from ascites and shows low level DSG3 
expression. BxPC-3 is an epithelial derived cell line, and has a higher abundance of 
DSG3 than AsPC-1. Neither PANC1 nor MIA PaCa 2 expressed DSG3 and the protein 
was not detected in any of the lung cancer cell lines either. 
 
 
 
 
Figure 6.28: Western Blot probed for DSG3 in a panel of cell lines. DSG3 bands came 
up at ~130kDa in cell lines where it was present. alpha tubulin loading control included. 
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6.9. Summary 
Desmoglein-3 was highlighted as a highly differentially expressed protein 
when the DLKP cell line and its subpopulations were compared against each other using 
quantitative label-free LC-MS/MS during exponential phase of growth. Highest 
expression was found in DLKP-I, with a 175.33-fold change between this cell line and 
the lowest expresser in DLKP-SQ. The other cell lines (DLKP-M and DLKP) also 
showed very low to no expression of Desmoglein-3 in this analysis, suggesting the 
protein may be a specific marker for DLKP-I. This expression pattern was validated at a 
protein and mRNA level, with DLKP-I showing the highest expression of Desmoglein-
3, with no expression in the other clones. The DLKP cell line itself was found to 
express a low abundance of Desmoglein-3 protein and mRNA, as expected.  
Immunocytochemical and immunofluorescent staining of Desmoglein-3 further 
validated the expression pattern already found, with only DLKP-I positively staining for 
the protein out of all the clones. Staining was found at cell-cell junctions as expected, 
however abnormal cytoplasmic staining is also visible. For both staining methods, clear 
staining for Desmoglein-3 is visible in a subpopulation with the DLKP, most likely 
representing DLKP-I. This further strengthened the potential of Desmoglein-3 as a 
potential specific marker for DLKP-I.  
Transient knockdown of Desmoglein-3 protein expression was investigated by 
functional analyses, and this revealed a role for the protein in migration and invasion. 
Both of these phenotypic traits were significantly reduced when Desmoglein-3 protein 
expression was knocked down, suggesting additional roles for the protein in lung cancer 
other than its known role in cell-cell adhesion as previously reported (Delva, Tucker and 
Kowalczyk 2009). The literature also reports associations between Desmoglein-3 and 
the actin cytoskeleton, which may be how invasion and migration is affected by 
Desmoglein-3 knockdown, so this link was also investigated. 
Confocal imaging of co-stained Desmoglein-3 and F-actin showed high 
staining for Desmoglein-3 in cell-cell junctions, and this overlapped with F-actin 
staining in many cases. Punctate staining is also visible for Desmoglein-3 which may be 
an indicator of its role in desmosomes, complexing with these structures at focal 
adhesions. Knockdown samples showed a visible decrease in Desmoglein-3 expression, 
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further validating the successful knockdown of the protein in DLKP-I. In addition, there 
seems to be a decrease in the staining intensity for F-actin in the Desmoglein-3 
knockdown samples, though this finding requires further investigation.  
Co-immunoprecipitation studies on Desmoglein-3 repeatedly found the 
majority of potential binding partners for the protein to be associated with the 
mitochondria. One of these, Junction Plakoglobin, is a known binding partner of DSG3 
from the literature (Chitaev et al. 1996), and western blot analysis in our study found it 
shows the same expression pattern as Desmoglein-3 in these cell lines. The 
mitochondrial proteins found as potential binding partners are components of the 
Pyruvate Dehydrogenase Complex, and two of the members validated in our study as 
expressed in the DLKP cell line and its subpopulations by western blot analysis also 
(PDHE1-A and DLAT).  
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Chapter 7. Discussion 
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Tumour heterogeneity refers to the observation that multiple cell types can be 
found within individual tumours, and that each subpopulation can show distinct 
morphological and phenotypic characteristics. These can include cellular morphology, 
gene expression, protein expression, metabolism, and metastatic potential (Marusyk and 
Polyak 2010). Tumour heterogeneity in lung cancer presents major challenges for the 
determination of appropriate treatments and indeed the diagnosis of the disease. 
Subpopulations within a tumour can survive through therapeutic intervention and cause 
re-growth of the tumour, severely compromising attempts at treatment. Despite the 
evidence for intratumour heterogeneity, the subject remains relatively poorly explored. 
It is thought that a more systematic approach is required to characterise the extent of 
heterogeneity within tumours. An important factor to consider is to distinguish between 
cellular heterogeneity and clonal heterogeneity (Marusyk and Polyak 2010).  
The DLKP cell line represents a heterogeneous lung cancer derived cell line 
which was found to be comprised of at least three clonal subpopulations, each with 
specific morphologies and phenotypic characteristics (McBride et al. 1998a, Keenan et 
al. 2012). This distinctive cell line model represents a unique opportunity to study 
tumour heterogeneity in vitro. In this study, we undertook to investigate the clonal 
subpopulations of DLKP using quantitative label-free proteomic analysis. It was hoped 
that proteins could be identified which are highly expressed in each of the clonal 
subpopulations relative to the others. These could be related to their phenotypes or 
potentially even act as markers for particular clones. In addition, these clones were co-
cultured and included in the proteomic analysis to look for effects on highly abundant 
proteins representing the clones. This may provide insight into how the clones behave in 
their heterogeneous environment, inhibiting or enhancing protein expression stimulated 
by neighbouring cells. 
A simplistic view of tumours as homogenous entities is not a true 
representation of the reality in the majority of lung cancers or cancers in general. 
Intratumour heterogeneity is a significant hurdle in the development of effective 
treatments, as undetected subclonal cancer cells can develop drug resistance rendering 
the treatment ineffective (Gerlinger and Swanton 2010). It can also lead to the false 
diagnosis of cancer subtypes based on single biopsy methods which underestimate the 
genetic and proteomic heterogeneity present in individual tumours. A number of 
approaches can be taken to investigate the tumour heterogeneity. Our study aimed to 
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increase the knowledge of the roles of specific proteins in a heterogeneous lung cancer 
cell line, and investigate the roles of these proteins in its clonal subpopulations. An 
alternative or even supplementary strategy could use next generation sequencing 
techniques to investigate genetic aberrations which give rise to lung cancer. 
Developments in next generation sequencing techniques have been employed to identify 
extensive genetic heterogeneity in individual tumours (Cancer Genome Atlas Research 
Network et al. 2013). These studies have shown the wide variety of aberrant gene 
fusions, dysfunctional transcriptomes with single-nucleotide variants, and alternative 
splice variants which contribute to tumour heterogeneity. 
One such study investigated intratumour heterogeneity in clear-cell renal 
carcinomas (ccRCC) where multiple biopsies were taken from each of 10 ccRCC 
tumours and analysed using multi-region exome sequencing (Gerlinger et al. 2014). The 
analysis revealed a heterogeneous genomic profile within each of the 10 ccRCCs with 
spatially separated subclones present in each. The spatial separation can give the 
illusion of a dominant clone when the tumour is assessed by a single biopsy resulting in 
ineffective targeted therapies. They also screened for the known genetic drivers of 
ccRCC and found that 73-75% of genetic driver events were subclonal. The presence of 
these subclonal driver events may explain the inevitable acquisition of resistance to 
targeted therapeutic treatment.  
Studies such as the one carried out by Gerlinger et al highlight the importance 
of understanding cancer at the genetic and transcriptomic levels, however it is equally 
important to include the proteomic level in order to achieve a greater understanding of 
the mechanisms involved in cancer. Proteins are central to the normal function of cells 
and aberrant protein expression can initiate tumour development, drive the development 
of heterogeneous subclones, and ultimately dictate treatment options. High throughput 
options for analysing the proteome of cancers are critical to allow the identification of 
changes in signalling pathways and protein expression, which themselves may become 
therapeutic targets. A mass spectrometry based study using a method such as the one 
presented in this thesis represents such an option, which would be greatly enhanced by 
using fresh frozen tumour tissue as the starting material. Such a proteomic study could 
be complemented by a genetic study which would allow the correlation between mRNA 
and protein expression to be investigated on a large scale. There is only a partial 
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correlation between mRNA levels and protein expression, therefore integrating both 
disciplines into a proteogenomic approach may shed light on how the information flow 
from genome to proteome is altered in tumours.  
One of the main aims of this thesis was to use quantitative proteomic profiling 
to identify proteins highly expressed each of the DLKP clonal subpopulations. The 
identification of such proteins may lead a greater understanding of the heterogeneous 
nature of lung cancer. These proteins can be exploited to investigate the phenotypic 
differences of the clones as found in previous work (Joyce H, PhD 2015), and may 
serve to characterise their known phenotypic properties.  
In order to highlight proteins which may be potential markers for each clonal 
subpopulation, samples were first analysed in a ‘global analysis’ experimental design 
method using Progenesis software. The global analyses resulted in the identification of 
127 proteins during exponential phase, and 203 proteins during stationary phase of 
growth (See Section 3.1.3.2). These proteins showed high fold changes and strong, 
statistically significant changes in expression levels between at least two samples. 
Within the two growth-phase datasets, 63 proteins overlapped, indicating conservation 
of expression for a subgroup of proteins across multiple growth phases. 
Cell lines were then compared against each other in two-sample experimental 
designs to elucidate the fold changes for a protein between individual cell lines in a 
comparison, along with their associated statistical significance. This method was 
referred to as the two-sample analysis. The data generated from this analysis was used 
to re-enforce the findings of the global analysis, and to provide the intermediary fold 
changes and associated statistical significances. A protein found to have an interesting 
expression pattern in the global analysis, i.e. showing highest abundance in one of the 
clones relative to all the other cell lines, could be re-enforced using data available from 
the two-sample analysis. This strengthens the protein discovery and provides extra fold 
change information.   
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7.1. Proteins of Interest 
Protein expression patterns across the whole sample set were screened to look 
for proteins showing interesting expression patterns. An interesting expression pattern 
was assigned to proteins where high expression was visible in one clone only or at least 
significantly highly expressed in one clone. This may indicate a potential clone marker, 
or a protein associated with the known phenotype of that cell line. A number of proteins 
showed these patterns are shown in Section 3.1.4. We followed up Shootin-1, 
MARCKS, and Desmoglein-3 due to their relative novelty in lung cancer studies, and 
the role of Desmoglein-3 in particular as a potential marker for DLKP-I. Table 7.1 
shows a summary of the findings of this study for each protein investigated. 
 
Protein 
Target 
Highly 
Expressed In 
Cellular 
Localisation 
Functional 
Effect after 
RNAi 
Potential 
Binding 
Partners 
Shootin-1 DLKP-SQ Cytoplasmic 
staining with 
enrichment in 
projecting 
structures. 
Slight reduction 
in migration 
Semenogelin-1 
Src-Substrate 
Cortactin 
Striatin-3 
MARCKS DLKP-M Punctate staining 
throughout the 
cytoplasm with 
enrichment in the 
tips of projecting 
structures. 
Reduction in 
migration 
No data 
Reduction in 
invasion 
Desmoglein-3 DLKP-I Cytoplasmic and 
nuclear staining. 
Intense staining 
at cell-cell 
junctions. 
Reduction in 
migration 
Junction 
plakoglobin 
Reduction in 
invasion 
Pyruvate 
dehydrogenase 
E1 
DLAT 
Table 7.1: Summary table of the three main proteins investigated in this study. Main findings 
are displayed. 
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7.2. Shootin-1 
Shootin-1 was highlighted as a highly expressed protein in DLKP-SQ as 
discussed in Section 4.2. Shootin-1 is a recently discovered protein which has been 
exclusively studied in neuronal cells to date. It was originally discovered in a study 
which identified it as a protein involved in the polarization of rat hippocampal neurons 
(Toriyama et al. 2006), and is described as a brain-specific protein. This group was 
investigating the formation of axons in vitro using rat hippocampal neuronal cells, and 
found Shootin-1 to be involved in the generation of internal asymmetric signals required 
for neuronal polarization and neurite outgrowth, strongly localising to the tips of 
outgrowing axons. They identified the protein as a potential mediator of axon outgrowth 
in these cells, and found that overexpression of Shootin-1 leads to the generation of 
surplus axons, while siRNA knockdown reduces axon formation.  
Follow up work found that Shootin-1 interacts with actin retrograde flow 
(ARF), a process integral to providing the force required for axon outgrowth in neuronal 
cells (Shimada et al. 2008, Van Goor et al. 2012). They concluded that Shootin-1 acts as 
a mediator or ‘clutch molecule’, linking filamentous actin and the cell adhesion 
molecule L1-CAM. Impairing this link impairs axon outgrowth, while enhancing the 
link promotes outgrowth. Another recent study showed that p21-activated kinase 1 
(Pak1) mediates the phosphorylation of Shootin-1, promoting the clutch engagement 
and transmission of traction forces at axonal growth cones through ARF (Toriyama et 
al. 2013). They also found the chemo-attractant Netrin1 positively regulated the Pak1 
mediated phosphorylation of Shootin-1, resulting in increased axon outgrowth. In 
addition, Shootin1 was also shown to co-localise with active pools of phosphoinositide 
3-kinase (PI3K) and inhibition of PI3K activity reduces the ability of shootin1 to induce 
surplus axons. A separate study found Shootin-1 to be a novel cargo of the motor 
protein Kif20B, and the interaction with this member of the kinesin superfamily 
localises Shootin-1 to the tip of elongating axons by transport along microtubules (Sapir 
et al. 2013). Taken together, these studies suggest Shootin-1 is a protein involved in cell 
motility, however this has not yet been investigated in cancer cell lines. 
The Shootin-1 protein does not show significant homology to previously 
known proteins, which suggests that it is a member of a novel class of proteins. 
Invertebrate homologues of Shootin-1 were not found in the databases, therefore is 
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thought that Shootin-1 is probably a late addition to the genome during the evolution of 
animals (Toriyama et al. 2006). The work carried out by Toriyama et al. investigated the 
expression of Shootin-1 in a range of rat tissues: brain; heart; lung; liver; spleen; 
kidney; muscle; and placenta, and they determined that Shootin-1 is a brain specific 
protein not expressed in the other tissues tested. Shootin-1 has not been studied at length 
in any type of cancer as of yet and has only been studied in neuronal cells. One group 
investigating single nucleotide polymorphisms (SNPs) associated Shootin-1 with breast 
cancer risk as part of a large dataset (Higginbotham et al. 2012), therefore Shootin-1 
remains un-researched in cancer or explored in any other cells than neuronal types.  
In our study we wanted to determine if Shootin-1 is highly expressed in DLKP-
SQ compared to the other clones. Therefore validation studies were performed on all 
DLKP cell lines using western blot analysis. Label-free proteomic analysis had found 
Shootin-1 to be expressed at ~4-fold higher abundance in DLKP-SQ compared to 
DLKP-M, DLKP-I and DLKP, each of which expressed the protein at a similarly low 
level. The findings from the western blot analysis of Shootin-1 across the sample set 
correlates well with the label-free proteomics data. Expression of Shootin-1 is 
significantly higher in DLKP-SQ relative to DLKP-M, DLKP-I and DLKP. A minor 
discrepancy was found in that DLKP-M shows higher expression of Shootin-1 than 
DLKP-I, the opposite of the quantitative proteomic analysis findings. However, both 
cell lines express Shootin-1 at a similarly low level and the expression pattern as a 
whole remains unchanged.  
The expression pattern for Shootin-1 in the combination lines highlighted 
unexpected protein abundances from label-free proteomic analysis. The combination of 
SQ+M shows a much lower abundance of Shootin-1 than SQ+I. Given that both DLKP-
M and DLKP-I express Shootin-1 at similar levels, this expression pattern is surprising. 
Western blot analysis of the combination lines agrees with the finding that Shootin-1 
expression is higher in SQ+I compared to SQ+M. This result suggests there may be an 
inhibitory effect on the expression of Shootin-1 in DLKP-SQ by co culture with DLKP-
M. The interaction between mesenchymal and squamous cells has been previously 
found to directly affect protein expression as well as the phenotypes of cells in 
heterogeneous cell populations. Cancer associated fibroblasts have been shown to exert 
significant paracrine effects on squamous tumour cells by excreting IL-6 which in turn 
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affected protein expression and promoted tumour growth in NSCLS (Vicent et al. 
2012). The heterogeneous nature of DLKP may function in a similar way, with cells 
interacting with each other through paracrine effects, regulating protein expression and 
altering phenotypes to adapt to the tumour microenvironment. 
The comparison of DLKP and DLKP-Remade shows a significant difference in 
Shootin-1 abundance by both proteomic analysis methods described above. Abundance 
levels for Shootin-1 are higher in the DLKP-Remade with low levels of the protein 
detectable in DLKP. This suggests that DLKP-Remade is not an exact reconstitution of 
the original DLKP cell line as described previously (McBride et al. 1998a). It is 
possible DLKP-Remade requires a longer time in culture than 5 passages to fully mimic 
the protein expression patterns of DLKP, or there are as of yet undescribed cell types 
present in DLKP affecting Shootin-1 expression. Further work is needed to establish 
this. 
Following on from the western blot analysis, quantitative PCR was performed 
to determine the relative levels of Shootin-1 gene expression across the sample set. The 
abundance of Shootin-1 mRNA in the sample set may highlight post transcriptional 
regulation factors in certain cell lines, and shed light on how co-culture influences the 
expression of the protein. The results from the gene expression assays show a direct 
relationship between protein expression abundance as determined by the label-free and 
western blot proteomic analyses. On average, DLKP-SQ shows a ~4 fold increase in 
Shootin-1 protein abundance when compared to DLKP, DLKP-M and DLKP-I. The 
mRNA assay results show a similar abundance change with DLKP-SQ showing ~5-fold 
higher Shootin-1 mRNA abundance compared to DLKP-M and DLKP-I. This further 
solidifies Shootin-1 as a marker for DLKP-SQ at both the protein and mRNA level. 
The quantitative PCR analysis on combination cell lines shows Shootin-1 
mRNA is significantly decreased when the clonal subpopulations are co-cultured. This 
is especially evident in the combination lines which contain DLKP-SQ as a constituent. 
Using the mRNA abundances in the clones as a guide, it was expected that co-culture of 
DLKP-SQ with either DLKP-M or DLKP-I would reduce Shootin-1 mRNA expression 
by ~60%, due to the diluting effect of co-culture. However qPCR analysis reveals the 
mRNA abundance levels for Shootin-1 to reduce sharply by ~80% relative to DLKP-SQ 
levels. This suggests that inhibition of Shootin-1 expression is occurring at the 
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transcriptional level when the clones are in co-culture conditions. In addition, the 
mRNA abundances in DLKP and DLKP-Remade show similar expression at the mRNA 
level, whereas they differ at the protein level. Taken together, it is possible that an 
undiscovered cell line in the DLKP cell population inhibits the expression of Shootin-1 
at the post-transcriptional level which is not present in DLKP-Remade. This may 
support the theory that DLKP parental cell line contains cell populations which have yet 
to been discovered, again outlining the heterogeneity of this cell line. 
 
Shootin-1 is a highly expressed protein in DLKP-SQ relative to the other 
clones as shown by this work so far, at the protein and mRNA level. The evidence 
shows Shootin-1 is expressed at a significantly higher abundance in DLKP-SQ relative 
to DLKP-M, DLKP-I, or DLKP. In order to further validate the expression pattern of 
Shootin-1, and elucidate the role it may play in the DLKP cell line model, staining of 
Shootin-1 was performed by immunocytochemistry and immunofluorescence in the four 
cell lines (DLKP and its clonal subpopulations). Each of the DLKP cell lines were 
expected to stain positively for Shootin-1 as the protein is detectable by the proteomic 
analyses already discussed. Visualisation of Shootin-1 in the four cell lines shows the 
protein staining pattern correlates well with the expected staining pattern. DLKP-SQ 
has the most intense staining for Shootin-1 out of all the cell lines in the analysis. The 
next most intense staining is in DLKP-M, followed by DLKP and finally DLKP-I.  
In the case of DLKP-SQ, Shootin-1 localization is evident in the cytoplasm 
with little or no staining in the nucleus or nuclear envelope. The immunocytochemical 
analysis shows Shootin-1 staining positively in small filopodial outgrowths in DLKP-
SQ. These outgrowths are not usually visible in day to day cell culture of DLKP-SQ due 
to its tightly packed block-like morphology in monolayer (See Figure 1.2), however 
immunocytochemical staining of Shootin-1 allows them to be visualized. In addition, 
immunofluorescence staining shows high levels of Shootin-1 in the cytoplasm, and high 
intensity areas of staining can be seen at the edges of the cytoplasm in DLKP-SQ cells.  
DLKP-M stains positively for Shootin-1, but at a lower intensity than DLKP-
SQ. The DLKP-M clone has a morphology which can be described as mesenchymal-
like, with an elongated cytoplasm and long neurite-like outgrowths. 
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Immunocytochemical staining of Shootin-1 is high in these outgrowths and in some 
cases staining can only be seen in the protrusions emanating from the cell. 
Immunofluorescent staining demonstrates this staining pattern very clearly, cell 
protrusions staining strongly for Shootin-1. The immunocytochemical and 
immunofluorescent staining in DLKP-I shows the lowest intensity of Shootin-1 relative 
to the other cell types. Diffuse cytoplasmic localization of Shootin-1 can be seen in both 
techniques with no remarkable staining pattern visible in DLKP-I. 
DLKP shows a very diverse staining pattern for Shootin-1. This finding is 
expected due to the heterogeneous nature of the cell line. The most intense staining for 
Shootin-1 is visible in block-like cells with thin filopodial protrusions. These cells are 
assumed to be DLKP-SQ as they have the highest Shootin-1 staining intensity as well as 
the distinctive DLKP-SQ morphology. What are assumed to be the remaining two 
clones are visible in the DLKP cell line; however it is difficult to distinguish these from 
each other by using Shootin-1 staining intensity as a guide. The DLKP cell line also 
contains abnormally large cells which stain positively for Shootin-1. These cells do not 
match the characteristics of any of the known clonal subpopulations of DLKP.  
This imaging of Shootin-1 in the DLKP cell lines revealed a common 
characteristic in staining patterns which correlates with previous finding from the 
literature. The high staining of Shootin-1 in the cell outgrowths was previously 
described in studies originally performed on the protein in neuronal cells. Shootin-1 was 
first described in a study which investigated the formation of axons in rat hippocampal 
cells (Toriyama et al. 2006). In this study, rat hippocampal neurons were cultured and 
then dissected to separate the axon networks from the cell bodies. A proteomic 
comparison of axons vs. the cell bodies found Shootin-1 to be significantly highly 
expressed in the axons, and this study resulted the first charaterisation of the protein. 
This description of Shootin-1 localization in neuronal cells found by Toriyama et al. 
closely matches what was found in our study for DLKP cell lines. This discovery of 
Shootin-1 in the DLKP cell line model with its previously described role in neuronal 
cells suggests it may act as a neuroendcrine marker. 
Shootin-1 is highly expressed in DLKP-SQ, at both the protein and mRNA level 
relative to all the other DLKP cell lines. Co-culture has a significant effect on the 
expression of Shootin-1, and it is hypothesised that DLKP-M plays an inhibitory role in 
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this regard. Immunocytochemical and Immunofluorescent imaging techniques confirm 
DLKP-SQ as having the highest Shootin-1 abundance out of all the DLKP clonal 
subpopulations, further validating the expression pattern established by other 
techniques. In addition, evidence of other cell types in DLKP has been found. This may 
support the hypothesis that the DLKP cell line contains as of yet uncharacterised 
subpopulations. Literature studies show that Shootin-1 plays a role in the outgrowth of 
axons in neuronal cells. Staining of the protein in DLKP revealed a similar staining 
pattern, with highest localization of the protein found in cell outgrowths.  
 
To investigate the role Shootin-1 plays in DLKP-SQ in vitro, the protein was 
knocked down using RNAi and follow up functional assays were performed. Shootin-1 
knockdown had been verified by western blot analysis before functional assays were 
pursued. These assays measure proliferation, migration and invasion of the cells to 
assess if knockdown of Shootin-1 has any effect on these phenotypic characteristics. 
DLKP-SQ was chosen as the subject for the follow up functional analyses as the 
abundance of the Shootin-1 is significantly higher in this cell line relative to the other 
clonal subpopulations at the protein and mRNA level. 
Transient siRNA knockdown of Shootin-1 by RNAi has no effect on 
proliferation of DLKP-SQ. This finding is unsurprising as there is no evidence in the 
literature that Shootin-1 plays any role in the proliferation or viability of the neuronal 
cells in which it has been studied. The migratory ability of DLKP-SQ is significantly 
decreased upon knockdown of Shootin-1 in DLKP-SQ. This significant effect is present 
in only one of the siRNA molecules used in the experiments when compared to the 
negative control. The second siRNA molecule which targets Shootin-1 does not have a 
significant effect on migration, but it follows the same trend tending towards a 
reduction in migration also. Knockdown of Shootin-1 in DLKP-SQ has no effect on 
invasion for either siRNA molecule tested, indicating that knockdown of Shootin-1 does 
not reduce or increase the invasive ability of this cell line.  
The original studies on Shootin-1 found the protein to interact with F-actin and 
as a result actively promote axon outgrowth (Toriyama et al. 2006, Shimada et al. 
2008). Overexpression of the protein was found to enhance axon outgrowth, while 
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interference by RNAi was found to have the opposite effect and inhibit the formation of 
outgrowths. For our study, it was hypothesised based on the literature that a reduction in 
Shootin-1 expression may have a similar effect on actin related phenotypes such as cell 
spreading, motility or cell shape in DLKP-SQ. The findings in our study suggest that 
this potentially is the case for cell migration. 
The reduction in migration of DLKP-SQ by Shootin-1 knockdown may be 
explained by its known associations with actin retrograde flow (ARF) investigated in 
neuronal cells by Shimada et al. 2008. They found that Shootin-1 is involved in ARF 
which is an instrumental process in wound healing, cell migration and tumour 
metastasis (Zimmermann et al. 2012). ARF describes the process by which actin 
filaments polymerize in the lamellipodium, which is a flat projection structure at the 
leading edge of a migrating cell. The retrograde polymerization of actin (back towards 
the cell body) in the leading edge of this structure pushes against the plasma membrane, 
conferring movement to the cell. However, in order for the cell to gain traction by using 
ARF, the meshwork of actin must be mechanically coupled to cell adhesion molecules 
(CAMs) attached to extracellular substrates thereby providing the mechanical tension 
required for movement (Suter and Forscher 2000, Yamashiro and Watanabe 2014). The 
study by Shimada et al. found evidence that Shootin-1 mediates the link between actin 
and the cell adhesion molecule L1-CAM, acting as a ‘clutch molecule’, regulating the 
effects of ARF on neuronal axon outgrowth. They concluded that Shootin-1 plays a 
significant role in cell motility through ARF. It is therefore possible that the role found 
by these studies Shootin-1 as a mediator between the Actin cytoskeleton and CAMs 
may also be the case in DLKP-SQ in our study, though further work would be required 
to establish this link. 
Our study represents the first investigation of Shootin-1 at a functional level in 
cells other than neuronal cells. In addition, this is the first study to investigate the role of 
Shootin-1 in a lung cancer cell line, and to have found a functional role for the protein 
in relation to cell migration. No studies link Shootin-1 with a functional cancer 
phenotype, however its binding partner L1-CAM, as described in Shimada et al. 2008, 
has been found to be expressed in a variety of cancer types. L1-CAM is a 
transmembrane protein predominantly expressed in developing neurons where it plays 
important roles in the developing nervous system mediating neuron adhesion, migration 
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and axon guidance (Kleene et al. 2001, Hortsch 2000). In addition to its physiological 
role in neural development, recent studies indicate that L1-CAM also plays a role in the 
pathology of a diverse variety of cancers types. Its expression has been detected in 
colon, breast, ovarian and pancreatic cancers (Gavert et al. 2005, Fogel et al. 2003, Ben 
et al. 2010) and high expression has been found to correlate with poor prognosis. Its 
localization in human tumours is exclusively found at the invasive front, suggesting that 
L1-CAM may have an active role in the migratory and invasive processes.  
The functional assays carried out in this study found while Shootin-1 has no 
effect on proliferation or invasion, a significant effect was found on cell migration. 
Knockdown of Shootin-1 in DLKP-SQ reduces the migratory ability of the cells. Our 
study shows for the first time that Shootin-1 knockdown significantly reduces cell 
migration in a lung cancer cell line. 
With both siRNA molecules inducing a reduction in the migratory ability of 
DLKP-SQ upon knockdown, it was concluded that Shootin-1 potentially plays a role in 
the motility of DLKP-SQ. Literature studies implicate a strong link between F-Actin 
and Shootin-1 in neuronal cells. It has been found to mediate the linkage between actin 
retrograde flow and CAMs, working as a ‘clutch molecule’ to increase mechanical 
tension depending on its phosphorylation state by Pak1 (Shimada et al. 2008, Toriyama 
et al. 2013). To investigate the mechanism by which Shootin-1 is involved in the 
migratory ability of DLKP-SQ, the studies mentioned above were taken into account, 
and the expression and localisation of F-actin were investigated relative to Shootin-1. 
Using RNAi, Shootin-1 was knocked down and co-stained with F-actin as described in 
Section 4.7.3. 
Co-staining of Shootin-1 and F-actin revealed an overlapping staining pattern 
in the control group samples (Cell-only; Lipo-only; Negative siRNA control). This 
overlap is most clearly visible in the thin filopodial protrusions which can be seen 
extending from the cytoplasmic membrane of DLKP-SQ.  In addition, the leading edge 
of lamellipodial-like structures also shows enrichment of Shootin-1, and similar 
findings were reported by Toriyama et al. in their investigations into Shootin-1 in 
neuronal cells. These structures were visible in our immunofluorescence work (Section 
4.6.2) and it was thought these may be associated with actin also due to the strong links 
reported in the literature. Combined with the knowledge that Shootin-1 knockdown 
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reduces the migratory ability of DLKP-SQ, it can be hypothesised that a similar 
mechanism involving Shootin-1/F-actin coupling may be involved in the migratory 
ability of this lung cancer cell line. 
The confocal imaging of DLKP-SQ was also used to further validate the 
transient knockdown of Shootin-1by RNAi. There was a visible decrease in the 
expression of Shootin-1 in the majority of the cells in each field of view, with the 
largest reduction of the protein visible in the cytoplasm of the cells. Some minor 
perinuclear as well as focused cytoplasmic staining remains after RNAi knockdown. 
Our results also show that F-actin staining is unaffected by the knockdown of Shootin-
1, with the protein showing a similar staining intensity and localisation when compared 
to control group samples. This implies that Shootin-1 is not critical to the expression 
and localisation of F-actin in DLKP-SQ, but it may still act as a mediator molecule 
similar to its role in neuronal cells. The work carried out by Shimada et al. shows that 
Shootin-1 acts as a mediator between F-actin and CAMs, but does not enhance or 
inhibit F-actin levels. Therefore, we hypothesise that Shootin-1 does not affect the 
expression, localisation, or rate of actin polymerisation in DLKP-SQ. However it may 
increase or decrease the coupling of F-actin filaments to CAMs and in so doing, 
regulate cell migratory ability of DLKP-SQ.  
 
Shootin-1 was successfully co-immunoprecipitated from DLKP-SQ whole cell 
lysate along with a panel of 5 other proteins. This protein panel was reproducibly co-
immunoprecipitated with Shootin-1 from the lysate of DLKP-SQ cells and identified 
using LC-MS/MS. These are Semenogelin-1, Src-Substrate Cortactin, Striatin-3, Small 
Nuclear Ribonucleoprotein Sm D3, and 60s Ribosomal Protein L12. For the purposes of 
this discussion, the focus will be on the first three proteins in the list, as no follow up 
work was carried out on the last two proteins. 
Semenogelin-1 was identified in our study as a potential binding partner of 
Shootin-1 in DLKP-SQ. The semenogelin proteins (SEMG1 and SEMG2) are mainly 
expressed and secreted by the seminal vesicles, and are the main structural component 
proteins which make up human semen. They both originate from the glandular 
epithelium of the seminal vesicles and are secreted in high concentrations. SEMG1 
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plays a specific role in the gel-like formation of semen, and is readily cleaved by 
prostate-specific antigen (PSA) into small peptides which are thought to have functions 
of their own such as self-assembling to form a hydrogel (Frohm et al. 2015), and 
binding to HIV-virions resulting in enhanced HIV infection (Roan et al. 2014).  
We found SEMG1 to be expressed in a human lung cancer cell line using co-IP 
as a potential binding partner of Shootin-1. Neither of these two proteins have been 
reported to be expressed in healthy lung tissue. SEMG1 is normally a very highly 
specifically expressed protein, and is only found in the seminal vesicles and urinary 
bladder, with little or no expression in other tissues of the body. Interestingly, low levels 
of SEMG1 have been found to be expressed in neuronal cells of the brain, specifically 
the Purkinje cells of the cerebellum (Human protein atlas). These neuronal cells are 
characterised by their elaborate and high number of dendritic outgrowths, and suggests 
that SEMG1 may have a neuronal role, in addition to its established role from which it 
acquired its name. This may strengthen the role of SEMG1 as a potential binding 
partner of Shootin-1 in our study, as the latter protein is highly associated with dendritic 
and axonal outgrowths in neuronal cells (Sapir et al. 2013, Toriyama et al. 2013).  
We found SEMG1 to be expressed by the DLKP cell line and its 
subpopulations using western blot analysis (see Figure 4.21). DLKP-M showed the 
highest levels of SEMG1 expression, while DLKP-SQ had the lowest. DLKP-M cells 
are characterised by their prominent outgrowths and cell protrusions, most closely 
resembling neuronal cell morphology, and they also express the second highest levels of 
Shootin-1 out of all the DLKP clones as determined by the quantitative label-free and 
western blot analyses. It is therefore possible that SEMG1 and Shootin-1 have neuronal 
roles in the DLKP cell lines. Further work is required to validate SEMG1 as a binding 
partner of Shootin-1 using reverse co-IP experiments. The other DLKP clones, 
particularly DLKP-M, will be investigated to assess the same binding partners of 
Shootin-1 are found across all cell lines and to discover new binding partners. 
SEMG1 has been described in one other study to be expressed in SCLC and 
was found to be associated with adhesion complexes in lung cancer cell lines 
(Rodrigues et al. 2001). In the context of the potential interaction of SEMG1 and 
Shootin-1 found by our study, the association of SEMG1 with adhesion complexes ties 
in with previous literature reports which linked Shootin-1 to CAMs in neuronal cells 
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(Shimada et al. 2008). This strengthens our findings that SEMG1 may be a binding 
partner of Shootin-1 in the DLKP-SQ cell line. The study by Rodrigues et al. also found 
SEMG1 to be a secreted protein, and concluded that it may be potentially used as a 
biomarker for the presence of SCLC. Further work will need to be carried out to 
determine if SEMG1 is secreted by DLKP-SQ, or any other the other DLKP cell lines. 
Src-Substrate Cortactin (CCTN) was another protein identified in our study as 
a potential binding partner of Shootin-1 in DLKP-SQ. It is a multi-domain, ubiquitously 
expressed protein that was first identified as a major substrate of the Src oncogene (Wu 
et al. 1991). It is localized to the cytoplasm and is highly associated with F-actin. It has 
been shown to play a role in many actin based cellular processes such as migration and 
invasion (Yamaguchi and Condeelis 2007) as well as axon guidance (Knoll and 
Drescher 2004). CCTN is activated by phosphorylation events, and once this occours it 
binds directly to the Arp2/3 complex and F-actin through its Proline-rich domain. This 
activates the Arp2/3 complex to promote nucleation of actin filaments and induces 
rearrangements of the actin cytoskeleton such as the formation of filopodia and 
lamellipodia (Uruno et al. 2001). It is highly associated with the formation and 
maintenance of invadopodial structures by stabilising the ARP 2/3 complex on 
filamentous actin, and has also been shown to be essential for the trafficking of the key 
invadopodia proteases, MT1-MMP, MMP2, and MMP9 in head and neck squamous 
carcinoma cells (Clark and Weaver 2008, Clark et al. 2007). 
Our study found CTTN to be a potential binding partner of Shootin-1 in 
DLKP-SQ cells by co-IP in repeatable experiments. In addition, CTTN was also 
identified as a differentially expressed protein in our quantitative label-free study on the 
DLKP cell line and its clonal subpopulations, showing highest expression in DLKP-SQ. 
Follow up by western blot analysis for CTTN validated the expression pattern found in 
the label-free study as shown in Figure 4.22. CTTN has been shown to be 
overexpressed in a variety of cancers such as colorectal, laryngeal and esophageal 
squamous cell carcinoma (Cai et al. 2010, Rodrigo et al. 2011, Luo et al. 2006). 
Immunohistochemical analysis of CTTN expression in colorectal carcinoma found that 
staining scores were significantly higher in well, moderately, and poorly differentiated 
colorectal adenocarcinomas compared to normal colorectal epithelia (Lee et al. 2009). 
In a subset of in vitro studies, CTTN over-expression induced tumour invasion and 
metastasis in esophageal and head/neck squamous cell carcinoma (Luo et al. 2006). 
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Reports on investigations of the role of CTTN in lung cancer are rare, however in 
NSCLC it was found to be associated with poor prognosis and lymph node metastasis 
by immunohistochemical analysis. It was concluded that CTTN is involved in the 
progression of NSCLC (Noh et al. 2013). 
CTTN clearly plays a role in migration and invasion in different systems. We 
hypothesise that this protein may serve a similar function in the DLKP cell lines. In our 
study, transient knockdown of Shootin-1 expression resulted in a significant reduction 
in the migratory ability DLKP-SQ. As a potential binding partner of Shootin-1, it is 
possible CTTN was affected, and was unable to fulfil its role as an F-actin/Arp 2/3 
binding protein, resulting in reduced migration. Shootin-1 has been shown to be a 
mediator of F-actin-CAM interactions, so our discovery of CTTN as a potential binding 
partner of Shootin-1 represents a novel finding in lung cancer. The potential of Shootin-
1 and CTTN acting as binding partners is strengthened by a very recent study which 
found a direct interaction between them in rat hippocampal neurons (Kubo et al. 2015). 
 
Striatin-3 (STRN3) was investigated as a prospective binding partner of 
Shootin-1 after co-IP experiments in our study repeatedly found it to be potentially 
complexed with Shootin-1 in DLKP-SQ. STRN3 is described as a quantitatively minor, 
Ca2+/Calmodulin binding protein, and is mostly expressed in neurons of the motor and 
olfactory structures of the central nervous system (Bartoli, Monneron and Ladant 1998). 
It is exclusively expressed in the somatodendritic compartment of neurons, at the 
exclusion of axons, and is localised mostly to dendritic spines. Striatin family members 
contain several protein–protein association domains: from the N- to the C-terminus, a 
putative Caveolin-binding motif, a coiled-coil structure, a Ca2+/Calmodulin-binding site 
and a large WD-repeat domain (Castets et al. 1996, Bartoli et al. 1999). Due to its 
potential for bind many different protein types, Striatin is thought to be a scaffolding 
protein which functions in a Ca2+dependent manner. Down-regulation of Striatin in 
cultured rat spinal motor-neurons was found to impair the growth of dendrites, 
indicating the protein has a potential role in the formation of cell protrusions (Bartoli et 
al. 1999).  
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We analysed the expression of STRN3 in the DLKP cell line and its clonal 
subpopulations using western blot analysis. All cell lines showed detectable levels of 
STRN3 expression, with highest expression in DLKP-M. Our study is not the first to 
detect the expression of Striatin family members in cancer cell lines, as Striatin-4 has 
been found to be expressed in pancreatic; esophageal; colorectal; lung; and ovarian 
carcinomas (Wong et al. 2014). However our study is the first to specifically detect 
STRN3 in a lung cancer cell line, and demonstrate heterogeneous expression between 
subpopulations of that cell line. Similar to SEMG1, STRN3 is thought to have a specific 
neuronal role, and both proteins show highest expression in DLKP-M. As mentioned 
before, DLKP-M has the most neuron-like morphology, with protruding dendritic-like 
outgrowths. It is therefore possible STRN3 in combination with Shootin-1 may play a 
role in the formation of these structures, which may have a concomitant effect on the 
migratory ability of the DLKP cell lines, particularly DLKP-SQ and DLKP-M.  
Shootin-1 was previously found to be highly expressed in DLKP-SQ in a 
preliminary label-free experiment carried out by Michael Henry and Dr Joanne Keenan 
in the NICB on whole cell lysates of DLKP and its clonal subpopulations. This work 
was not followed up; however the preliminary findings strengthen the discovery of 
Shootin-1 as associated with high expression in the DLKP-SQ clonal subpopulation. In 
addition, microarray analysis carried out by Dr Helena Joyce on the DLKP clones found 
the Shootin-1 gene to be expressed highly in DLKP-SQ relative to both DLKP-M and 
DLKP-I (Joyce H, PhD 2015, data not published). Taken together, these findings 
increased confidence in Shootin-1 being a target associated with high expression in 
DLKP-SQ.  
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In order to shed light on the clinical relevance of Shootin-1 with respect to lung 
cancer, a Kaplan Meier plot was created using KM plotter to determine if the target is a 
potential biomarker or target for lung cancer treatment. The Kaplan Meier plotter is a 
bioinformatics tool capable of assessing the effect of 54,675 genes on survival using 
10,188 cancer samples (www.kmplot.com). These include 4,142 breast, 1,648 ovarian, 
2,437 lung and 1,065 gastric cancer patients. The resulting plot can be used to estimate 
survival function from lifetime data, with respect to proteins of interest in the case of 
our study presented here.  
The resulting plot is shown in Figure 7.1 and shows the overall survival data 
based on 1926 patients. The plot suggests that Shootin-1 may be a good prognosis 
indicator, as high levels of protein expression are associated with a better outcome and 
prolonged survival. This suggests that Shootin-1 may not be very useful as a therapeutic 
target as low levels are associated with poorer outcome; however it may still be useful 
as a prognostic biomarker. Highest levels of Shootin-1 were found to be expressed in 
DLKP-SQ which is the least migratory and invasive clone as determined by previous 
work and also this study. These findings fit in with the results of the Kaplan-Meier plot 
shown in Figure 7.1 as better prognosis is associated with high levels of Shootin-1 
expression, suggesting Shootin-1 is associated with a less aggressive metastatic 
phenotype. 
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Figure 7.1: Kaplan Meier plot for Shootin-1 showing 
overall survival data regarding lung cancer patients. 
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7.3. MARCKS 
Label-free proteomic analyses highlighted MARCKS as highly expressed in 
DLKP-M. The protein expression pattern suggests MARCKS expression is significantly 
higher in DLKP-M compared to the remaining clonal subpopulations and the DLKP cell 
line. The combination lines also show relatively high expression of MARCKS in the 
samples which contain DLKP-M as a component.  
Myristoylated alanine-rich C-kinase substrate is a ubiquitously expressed heat-
stable protein localized to the plasma membrane. It is reversibly tethered to the plasma 
membrane via a myristoyl group located at its N-terminus, and also by ionic interactions 
between membrane phospholipids and the MARCKS effector domain (ED) (Albert, 
Nairn and Greengard 1987, Arbuzova, Schmitz and Vergeres 2002). MARCKS is 
phosphorylated by Protein Kinase C (PKC) and depending on its phosphorylation 
status, the protein shuttles between the plasma membrane and the cytosol. This 
translocation to the cytoplasm is also induced by the binding of Calmodulin (CAM) in a 
Calcium (Ca2+) dependant manner to the ED (Hartwig et al. 1992, Yarmola et al. 2001). 
At the plasma membrane, MARCKS cross-links Actin filaments into bundles, 
significantly altering the Actin cytoskeleton.  
MARCKS has been reported to be highly expressed in a wide range of cancers 
such as breast, melanoma, and cholangiocarcinoma (Jonsdottir et al. 2012, Micallef et 
al. 2009, Techasen et al. 2010). MARCKS has been directly linked to motility, where it 
was found that phosphorylation of MARCKS directly promotes motility of melanoma 
cells (Chen and Rotenberg 2010). MARCKS has been extensively studied in the lungs 
in relation to its role in regulating the secretions of granules in goblet cells (Haddock et 
al. 2014); however, it has only been the subject of two studies to date in lung cancer. It 
has been identified as a potential biomarker associated with poor prognosis in human 
SCC using immunohistochemical methods (Hanada et al. 2013). The second study 
detected high expression of MARCKS in highly invasive lung cancer cell lines and 
found that MARCKS knockdown by siRNA significantly reduced cell migration (Chen 
et al. 2014b). 
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In order to validate the expression pattern found for MARCKS by quantitative 
label-free LC-MS/MS, all cell line samples were analysed by western blot to determine 
the protein expression pattern for MARCKS using a second proteomic technique. The 
western blot analysis results correlate well with the label-free proteomic data, validating 
the protein expression pattern for MARCKS. DLKP-M shows the highest abundance of 
MARCKS with strong bands visible at the expected MW of 80kDa. DLKP-I shows the 
next highest abundance as expected, with weak bands visible. Both DLKP-SQ and 
DLKP show no detectable expression of MARCKS in either cell line. 
Analysis of the combination lines by western blot show MARCKS abundance 
range from highest to lowest as follows: I+M; SQ+M; SQ+I; DLKP-Remade. These are 
the expected abundance levels for the combinations based on the data generated from 
the clones. The combination lines are made up in a 1:1 ratio, therefore these findings 
show that MARCKS expression is not significantly affected by co-culture in DLKP-SQ 
and DLKP-M. The western blot findings also clarify the unexpectedly low MARCKS 
abundance value found by label-free proteomic analysis in the I+M cell line described 
in Section 5.5.1. This cell line now shows an expression level for MARCKS by western 
blot at the expected higher abundance. It is likely that instead of DLKP-I inhibiting 
MARCKS, the low abundance value is most likely down to the large standard deviation 
found for that sample, skewing the levels downward. This is somewhat corroborated by 
the peptide expression profile for MARCKS in Figure 5.4 which shows a peptide outlier 
bringing the value down. Finally, both DLKP and DLKP-Remade show similarly low 
MARCKS abundances by label-free proteomic and western blot analyses methods, both 
being undetectable in the latter cell line. This is unsurprising as DLKP-M constitutes 
approximately 5% of the cell population in both cell lines.  
 Overall, western blot analysis correlates well with the label-free proteomic 
analyses, validating the expression pattern found for MARCKS by the global analysis, 
and also by the two-sample experimental designs. MARCKS is shown to be 
significantly highly expressed in DLKP-M relative to all other samples denoting the 
protein as a strongly abundant in DLKP-M relative to the other cell lines. Following on 
from this, MARCKS was analysed at an mRNA level using qPCR. 
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Quantitative PCR was carried out across the sample set to assess the mRNA 
level of MARCKS in the DLKP cell lines as well as the combinations. Analysing the 
abundance of MARCKS mRNA in relation to its known protein expression abundances 
may highlight post-transcriptional processes which are known to play key roles in the 
final synthesis of a protein. The findings from the MARCKS gene expression assay 
strongly correlate with the label-free proteomics data in that they show the same 
expression profile in both datasets. DLKP-M shows significantly high expression of 
MARCKS in DLKP-M at both mRNA and protein levels. Protein analysis showed a 
fold change of 49.42 between DLKP-M and DLKP, and at the mRNA level this figure 
is increased to a fold change of 66.66. This shows that DLKP-M is the strongest 
expresser of MARCKS at both the protein and mRNA level by a significant margin. 
DLKP-I expression of MARCKS mRNA is lower than expected, with a fold change of 
3.78 between DLKP-M and DLKP-I. This further separates DLKP-M from DLKP-I in 
relation to MARCKS expression, reinforcing MARCKS expression as being associated 
strongly with DLKP-M. Both DLKP and DLKP-SQ show very low levels of MARCKS 
mRNA expression, similar to the finding of the proteomic analyses, with DLKP-SQ 
being the slightly higher expresser.  
The combination cell lines show the same expression profile for MARCKS at 
the mRNA level as they show at a protein level. The mRNA abundances for MARCKS 
are slightly higher than expected in the cell lines SQ+M and I+M relative to DLKP-M 
when the data is compared with the protein abundance findings. High expression of 
mRNA relative to the known protein expression may suggest that MARCKS mRNA has 
a long half-life, and does not degrade quickly. It has been shown previously that 
MARCKS mRNA has a long half-life in murine fibroblast cells (Wein et al. 2003). This 
may explain the high mRNA levels relative to protein levels in our combination cell 
lines, indicating that post transcriptional factors keep the protein level lower than the 
mRNA level. 
 
Validation studies in this work so far have shown MARCKS to be a highly 
expressed in the DLKP-M cell line compared to the other cell lines. With this in mind, 
MARCKS was stained using immunofluorescence in each of the four cell lines: DLKP-
SQ, DLKP-M, DLKP-I and DLKP. This was carried out to further validate the 
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expression pattern as found by the methods previously discussed, and to establish the 
localization of MARCKS in the DLKP cell lines, with a focus on DLKP-M. It was 
expected that DLKP-M would show the strongest staining for MARCKS based on the 
previous findings, with the next most intense staining in DLKP-I, and lowest in both 
DLKP-SQ and DLKP. Visualisation of MARCKS by immunofluorescence correlates 
with the proteomic analyses in general. 
Immunofluorescence analysis shows that DLKP-M has the strongest staining 
for MARCKS out of all the cell lines analysed. This cell line is characterized as 
mesenchymal-like, and has morphology rich in outgrowths and extended cytoplasmic 
formations. Interestingly, extremely strong staining for MARCKS shows localization in 
these protruding outgrowths. The protein has previously been implicated in Actin 
dynamics and cellular outgrowths in neuronal cells (Calabrese and Halpain 2005, 
Larsson 2006). This suggests that MARCKS may play a role in cell motility in the 
DLKP cell lines also. In DLKP-M, MARCKS also shows localization to the plasma 
membrane/cytoplasm, with high punctate staining patterns visible here, and it is absent 
from the nuclear area. Punctate staining patterns indicate that MARCKS accumulates in 
highly concentrated forms in DLKP-M. Previous work has found MARCKS to show a 
similar punctate staining pattern in macrophages (Rosen et al. 1990), and it was 
determined that MARCKS was localized to the substrate-adherent surface in the 
filopodia of these cells. Subsequent phosphorylation of MARCKS by PKC liberates 
MARCKS from these punctate structures and induces its translocation to the cytosol 
(Green et al. 2012). 
DLKP-I has the second strongest staining intensity for MARCKS as 
determined by Immunofluorescence imaging. This correlates with the proteomic 
analyses findings which show DLKP-I as the second highest MARCKS expresser. 
However, the positive staining in DLKP-I for MARCKS is found in subpopulations 
within the DLKP-I cell line. The presence of this subpopulation may be explained by 
the plastic nature of DLKP-I as previously described (McBride et al. 1998b). This work 
found that DLKP-I may be an intermediate cell line capable of inter-converting to either 
DLKP-M or DLKP-SQ. It was hypothesised that DLKP-I acts as a stemcell-like 
population which can give rise to either of the other two clones depending on growth 
conditions. Therefore, it is possible that subpopulations of the cells within DLKP-I are 
tending towards converting to DLKP-M morphology, indicated by the strong expression 
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of MARCKS in these cells. This hypothesis is strengthened by the presence of 
outgrowths in the DLKP-I cells expressing MARCKS, showing them tending towards 
established DLKP-M morphology. 
The DLKP-SQ cell line shows no staining for MARCKS in ~90% of the cell 
population. However, the protein does stain positive in a small subpopulation of cells 
within DLKP-SQ. The presence of these cells expressing MARCKS helps shed light on 
the unexpected finding that DLKP-SQ expresses a higher abundance of MARCKS than 
the DLKP cell line as found by our proteomic analyses. It is surprising DLKP-SQ 
expresses MARCKS at a higher level than DLKP once proportions of each clone 
present in DLKP is considered:  5% DLKP-M and 25% DLKP-I and 70% DLKP-SQ as 
was reported by McBride et al. 1998. It would be expected that the presence of DLKP-
M and DLKP-I in the DLKP cell line would boost the abundance of the protein in the 
DLKP cell line as they both express MARCKS. The abundance is so unexpectedly low 
in DLKP that it is likely an inhibitory effect is occurring. This strengthens the 
hypothesis that there may be other uncharacterised cell types present in the DLKP cell 
line which reduce MARCKS expression by inhibitory processes.  
The staining of MARCKS in DLKP results in varied intensities which can be 
explained by the heterogeneous nature of the cell line. Clear staining for MARCKS can 
be seen in cellular outgrowths and, similar to Shootin-1, localization is strong in the tips 
of these outgrowths. This increases the likelihood of MARCKS as being involved in 
cell motility processes in the DLKP cell line model as has previously been found in 
mouse melanoma cells, vascular smooth muscle cells, and neuronal cells (Chen and 
Rotenberg 2010, Yu et al. 2015, Li et al. 2008b).  
DLKP-M is known to show the highest cell motility out of all the clonal 
subpopulations (Joyce H, PhD 2015). These phenotypic differences are stark, and 
DLKP-M is associated with very high migration and invasion relative to the other 
DLKP clones. Though MARCKS has been shown to be over-expressed in a variety of 
aggressive cancers such as pancreatic and breast cancer (Gardner-Thorpe et al. 2002, 
Jonsdottir et al. 2012), there have been limited studies on MARCKS in cancer 
metastasis. MARCKS has however been shown to be involved in the migration and 
invasion of melanoma cells (Chen and Rotenberg 2010). They found that MARCKS is a 
major determinant in the motility of mouse melanoma cells in vitro. Weakly metastatic 
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melanoma cells show undetectable levels of phosphorylated MARCKS, whereas 
aggressively metastatic cells show abundant expression of the same protein. 
Knockdown and overexpression studies confirmed MARCKS as being a key 
determinant in the metastatic process, and also elucidated a role for phospho-MARCKS 
which was previously unclear. The high staining of MARCKS in the outgrowths of cells 
in DLKP-M and DLKP suggest the protein may play a role in cell motility in the DLKP 
cell line model. Therefore it is hypothesised that MARCKS may play a role in both 
migration and possibly invasion, promoting these phenotypes. This was investigated by 
functional analysis assays after siRNA knockdown of MARCKS in DLKP-M. 
 
To investigate the functional role played by MARCKS in DLKP-M, the protein 
was knocked down using RNAi and the effects of this process were subsequently 
determined using a panel of functional assays. The effects of MARCKS RNAi were 
verified by western blot analysis to ensure the protein was effectively knocked down 
prior to the functional analyses being carried out. DLKP-M was chosen as the cell line 
to investigate due to its significantly high expression of MARCKS in this cell type. 
Functional assays measured proliferation, migration and invasion of the DLKP-M cell 
line 
The functional analysis of MARCKS after RNAi knockdown shows that 
MARCKS plays a significant role in the motility of DLKP-M for both migration and 
invasion. Firstly, RNAi of MARCKS in DLKP-M significantly reduces the migratory 
ability of the cell line. The effect is observable in both siRNA molecules which are used 
to knockdown the MARCKS protein and in both cases the effect is highly significant. 
Migration of DLKP-M in knockdown samples is reduced by an average of 70% 
compared to the negative control. This finding is consistent with our hypothesis that 
MARCKS is involved in the motility of the DLKP-M cell line. In addition, knockdown 
of MARCKS also reduces the invasive ability of DLKP-M with high significance. 
Invasive ability is reduced by an average of 71% when knockdown samples are 
compared to the negative control. These findings demonstrate that MARCKS is 
intimately involved in the motility of DLKP-M as suggested in Section 5.6.1. 
Previous studies shed light on the mechanisms by which MARCKS may be 
involved in cell migration. As discussed earlier, MARCKS has been shown to shuttle 
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between the plasma membrane and the cytoplasm depending on its phosphorylation 
state (Hartwig et al. 1992, Larsson 2006). Unphosphorylated MARCKS is located to the 
plasma membrane and cross-links actin filaments to the cytoplasmic side which results 
in alterations to the actin cytoskeleton. The translocation of MARCKS to the cytoplasm 
upon phosphorylation promotes cell spreading by releasing actin-membrane cross links, 
resulting in cytoskeletal plasticity which in turn promotes the ability of cells to spread. 
De-phosphorylation of MARCKS causes its re-localisation to the plasma membrane, 
induces actin cross-linking and causes cytoskeletal conformational changes once more. 
These transient interactions with the actin cytoskeleton are thought to regulate the 
dynamics of F-actin which in turn impacts cell motility (Chen and Rotenberg 2010).  
This reversible localization of MARCKS is controlled by phosphorylation of 
the protein, mainly by PKC. This mechanism may be a key system which regulates cell 
motility, and this seems to be the case for DLKP-M. This cell line has been shown to be 
highly motile and a reduction in the abundance of MARCKS by RNAi has significantly 
reduced the ability of the cells to migrate.  
Knockdown of MARCKS in DLKP-M was found to have no effect on cell 
proliferation when compared to the negative control sample. Previous studies have 
found conflicting results on the role MARCKS plays in proliferation. One group 
studying glioblastoma multiforme (GBM) found that RNAi knockdown of MARCKS 
promoted proliferation of the cells, and over-expression of the protein greatly reduced 
the growth rate and induced senescence (Jarboe et al. 2012). This suggested that high 
MARCKS expression reduces cell proliferation.  A different study found that treatment 
of fibroblasts by a cell permeable peptide which inhibits the function of MARCKS had 
no effect on the proliferation of the cells (Chen et al. 2014b). Therefore, the finding that 
MARCKS knockdown has no effect on the proliferation rate of DLKP-M is 
unsurprising. 
In our study so far, MARCKS has been shown to significantly reduce 
migration and invasion in the DLKP-M cell line. Immunofluorescence studies have 
shown the localization of MARCKS to be at both the cytoplasm and at plasma 
membrane in concentrated punctate structures. MARCKS also has particularly strong 
localization in cell projections. Literature studies reveal that MARCKS is highly 
associated with F-actin, and is involved with cross linking this protein to the plasma 
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membrane through the two binding sites located in the effector domain of MARCKS 
(Yarmola et al. 2001). The association between MARCKS and F-Actin has not been 
studied as of yet in lung cancer. It was therefore decided to knockdown MARCKS by 
RNAi, and co-stain both F-actin and MARCKS using confocal laser microscopy. It was 
hoped this investigation would clarify the relationship between F-actin and MARCKS 
in DLKP-M as we hypothesise both proteins interact. This hypothesis is based on the 
staining pattern found by our immunofluorescence in combination with what is known 
from the literature (Larsson 2006, Rombouts et al. 2013). These studies found 
MARCKS to be an F-actin binding protein in neuronal and hepatic stellate cells 
involved in the dynamic reorganisation of the actin cytoskeleton. 
Our results from the confocal imaging of MARCKS and F-actin in the DLKP-
M cell line show strong staining for both proteins in the control conditions where 
MARCKS was not knocked down. Similar to the immunofluorescence findings, 
MARCKS shows localization to the cytoplasm and plasma membrane and intense 
staining in cellular protrusions characteristic of DLKP-M. MARCKS also shows strong 
punctate staining patterns which suggest high concentrations of the protein localize to 
particular regions of the cell. There is faint nuclear staining in some samples within the 
control groups, but it is weak. These findings corroborate the results from the 
immunofluorescence work which show the same staining patterns for MARCKS. The 
imaging of both proteins shows that co-localisation for MARCKS and F-actin is present 
in DLKP-M. This is particularly apparent in the cellular outgrowths and punctate 
staining regions, and both proteins show strong overlap in these cases. This strengthens 
the hypothesis that MARCKS and F-actin interact in DLKP-M, and this may be one of 
the key processes which is interrupted upon RNAi, resulting in decreased migration and 
invasion of the cell line. 
Confocal imaging of DLKP-M treated with MARCKS RNAi results in a 
decrease of MARCKS staining for both siRNA molecules used. This is accompanied by 
a visible decrease in the staining strength of F-actin. In the control group (Cell-only, 
Lipofectamine-only and Negative control), F-actin staining is moderately high, and 
localisation is present in cell protrusions and punctate structures similar to MARCKS. 
F-actin staining is also strong in cell-cell junctions and at the edges of cells, which seem 
to be the leading edges, or lamellipodia, of the DLKP-M cells. MARCKS knockdown 
samples show a marked decrease in staining of F-actin, particularly in the areas 
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overlapping with MARCKS staining. However low abundance staining remains in some 
of the lamellipodial structures, indicating knockdown of MARCKS does not strongly 
affect the expression of F-actin at these regions. There is a visible decrease in punctate 
and cell protrusion staining for F-actin in the MARCKS knockdown samples, which 
suggests that a reduction in MARCKS expression has resulted in a concomitant 
reduction in F-actin localisation to these areas of the cell. These results show that 
MARCKS is very likely an actin interacting partner in DLKP-M. To further investigate 
this link, and establish if the interaction is direct or indirect, immunoprecipitation 
studies were attempted which aimed to pull out MARCKS from DLKP-M and any 
binding partners which came with it. Unfortunately, repeated attempts using two 
independent MARCKS antibodies failed as the protein was not immunoprecipitated 
using the antibodies available. This will be pursued in the future if suitable antibodies 
for immunoprecipitation can be sourced. 
Confocal imaging of MARCKS in the knockdown samples by RNAi resulted 
in an unusual localisation of the protein. Firstly, the knockdown samples show 
decreased staining for MARCKS overall, with markedly reduced cytoplasmic and 
membrane staining, as expected. Additionally, there is also a decrease in cellular 
protrusions visible in the knockdown samples compared to the control group, which 
suggests MARCKS is involved in the morphology of the DLKP-M cell line. This 
finding is in-line with the effect of knockdown of MARCKS on cell migration and 
invasion, decreasing them both significantly. However, imaging of MARCKS in the 
knockdown samples shows that the MARCKS protein which remains in the cells 
potentially shows significant re-localisation to the nuclear area. This striking 
translocation of MARCKS to the nucleus is clearly visible in the confocal images for 
both siRNA molecules which were used to reduce the expression of the protein.  
Western blot analysis of DLKP-M cells treated by MARCKS RNAi show that 
the highest concentration of siRNA results in almost complete knockdown of the 
protein as seen in Figure 5.8. Remaining protein can be seen for both siRNAs used, and 
is more abundant in siRNA#2. It is this remaining protein which may be translocated to 
the nucleus of the cells after RNAi treatment. MARCKS which remains after RNAi is 
much more visible in the confocal images compared to the western blot images. This 
may be due to the much higher concentration of MARCKS primary antibody (25 times 
more) used in the cell staining method compared to the western blot analysis, as per the 
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manufacturers antibody usage guidelines. MARCKS translocation is not a certainty, and 
further work is required to confirm this finding by the use of nuclear isolation and 
MARCKS quantification. If it is the case, translocation of MARCKS to the nucleus of 
DLKP-M is an unexpected effect of the protein being knocked down by RNAi. 
Translocation of MARCKS to the nucleus is not completely unheard of, and literature 
studies show three papers which previously described MARCKS behaving in this 
manner, though not after RNAi.  
One study found MARCKS to translocate to the nucleus from the cytoplasm 
upon over-expression in HEK 293 cells (Spizz and Blackshear 2001). Following this, a 
separate group (Rohrbach et al. 2015) investigated the mechanism by which MARCKS 
translocates to the nucleus upon overexpression in glioblastoma cell lines. They induced 
mutations into various domains of MARCKS to determine if it resulted in the inhibition 
of nuclear localisation. Mutations in the myristoyl tail and other regions of MARCKS 
did not inhibit translocation to the nucleus, therefore these protein domains were 
deemed as having no relation to the translocation of MARCKS. However, mutations in 
the Effector Domain (ED) of MARCKS effectively prevented translocation of 
MARCKS to the nucleus, an indication that this domain is involved in the process. In 
addition, they determined the ED of MARCKS contains homologous sequences to 
known nuclear localisation sequences (NLS). Therefore, Rohrbach et al. 2015 
determined that the ED of MARCKS is the critical domain that regulates nuclear 
localization of MARCKS upon over-expression.  
A third study focused on the expression of MARCKS in cholangiocarcinoma 
(CCA), where it had been found to be over-expressed by immunohistochemical analysis 
of paraffin embedded liver tissue samples (Techasen et al. 2010). They followed up this 
discovery by investigating the effects of MARCKS phosphorylation on CCA cell lines 
and assayed these effects by confocal microscopy, migration and invasion assays. 
Induced phosphorylation of MARCKS in this case was stimulated by the use of a PKC 
activator called TPA. Confocal microscopy revealed that upon stimulation of MARCKS 
using TPA induced phosphorylation by PKC, MARCKS visibly translocated to the 
nucleus. This process also resulted in a significant increase in the migratory and 
invasive abilities of the CCA cell lines tested (Techasen et al. 2010).  
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Our study is the first to report nuclear translocation of MARCKS in a lung 
cancer cell line. In addition, our study found this translocation to the nucleus to be 
stimulated by knockdown of the protein, rather than over expression or induced 
phosphorylation as previously reported (Rohrbach et al. 2015, Techasen et al. 2010). 
Further work is required to validate this observation, and phosphorylated MARCKS 
will also need to be investigated to determine whether it is MARCKS or phospho-
MARCKS which undergoes translocation. The association of MARCKS with high 
expression is strengthened by unpublished work carried out by Dr Helena Joyce (Joyce 
H, PhD 2015). DNA microarray analysis showed the MARCKS gene to be highly 
expressed in the DLKP-M clone relative to both DLKP-SQ and DLKP-I. Lowest 
expression was found in DLKP-SQ and MARCKS expression in DLKP-I was 
approximately half that found in DLKP-M. This correlates with the expression pattern 
in our study, further strengthening this expression pattern. 
Examination of the clinical relevance of MARCKS in to lung cancer 
progression was carried out using KM plotter to generate a Kaplan-Meier plot showing 
overall survival of lung cancer patients with respect to MARCKS expression (Figure 
7.2). From the plot, MARCKS appears to be a marker of poor prognosis. High 
expression of the protein is associated with a lower probability of prolonged survival in 
lung cancer. Our study found MARCKS to be highly expressed in the DLKP-M clonal 
subpopulation relative to the other cell lines, and it is DLKP-M which has been shown 
to have the highest metastatic phenotypes. It has the highest levels of both migration 
and invasion relative to the other clones, and these finding correlate with the Kaplan-
Meier plot showing high expression of MARCKS associated with poor outcome. The 
two papers which investigated MARCKS expression in lung cancer also corroborate 
this finding. A study by (Hanada et al. 2013) compared a cohort of primary SCC tissue 
samples against non-cancerous adjacent tissues using mass spectrometry and 
immunohistochemical analyses found that MARCKS was upregulated by ~2 fold in the 
SCC samples. Subsequent immunohistochemical evaluation in another set of SCC 
patients found high expression of MARCKS to be associated with poor outcome, 
suggesting the protein could be a useful biomarker for outcome in SCC. A separate 
study by (Chen et al. 2014a) found that higher levels of phospho-MARCKS were 
associated with shorter overall survival of lung cancer patients. Blocking the 
phosphorylation site of MARCKS with a peptide synthesised in the lab resulted in a 
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reduction in MARCKS phosphorylation and a concomitant reduction in tumour growth 
and metastasis in vivo. Taken together, these studies suggest MARCKS may play an 
important role in the clinical setting as both a biomarker for poor outcome in SCC and 
also as a therapeutic target. 
 
 
 
Figure 7.2: Kaplan Meier plot for MARCKS showing 
overall survival data for lung cancer patients. 
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7.4. Desmoglein-3 
DSG3 is shown to be a strong candidate marker for DLKP-I by label-free 
proteomic analyses. Desmoglein 3 (DSG3) is a transmembrane glycoprotein exclusively 
expressed in stratified epithelium. It is member of the desmoglein family of proteins, 
which in turn are a part of the cadherin superfamily of cell adhesion molecules. 
Expression of DSG3 is limited to the basal and supra-basal layers of the skin, however 
it is expressed homogeneously throughout the stratified epithelium in oral mucosa 
(Amagai et al. 1996, Garrod and Chidgey 2008). DSG3 is a major component of the 
desmosome, which is an adhesive intercellular junction critical to the integrity of tissues 
that experience shear stress. Homophilic binding of the DSG3 extracellular domain to 
adjacent cells leads to cell-cell adhesion, while the cytoplasmic tail of DSG3 links to 
internal keratin intermediate filaments via linker proteins such as the Armadillo and 
Plakin families (Dehner et al. 2014, Garrod and Chidgey 2008, Delva, Tucker and 
Kowalczyk 2009). DSG3 has been extensively studied in relation to the auto-immune 
disease Pemphigus Vulgaris (PV), in which autoantibodies bind to the extracellular 
domain of DSG3 and cause internalization of the protein (Jennings et al. 2011, Sato, 
Aoyama and Kitajima 2000). This results in a signalling cascade which leads to loss of 
cell-cell adhesion in the basal and immediate supra-basal layers of stratified squamous 
epithelia as well as the oral mucosa, causing painful blistering and lesions.  
DSG3 has been found to be overexpressed in head and neck cancer (HNC) by 
PCR analysis in tissue samples when compared to normal keratinocytes and other 
cancer types (bladder, neuron, colon and liver) (Chen et al. 2007). DSG3 was also found 
to exhibit upregulation and abnormal localization in esophageal squamous cell 
carcinoma (ESCC). Using immunohistochemical staining, DSG3 was found to be 
redistributed to the cytoplasm from the membrane in the majority of ESCC cases (Wang 
et al. 2007). This paper hypothesised that DSG3 may play a role other than functioning 
as a cell adhesion molecule, and may be involved in cell migration and invasion.  
The quantitative proteomic analyses performed on DLKP and its clonal 
subpopulations highlight DSG3 as specifically and highly expressed in DLKP-I, with 
little or no expression of the protein in the other three cell lines (DLKP-SQ; DLKP-M; 
DLKP). To investigate these findings and validate the expression pattern found by the 
label-free proteomic analyses, validation studies were carried out using western blot 
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analysis. Furthermore, qPCR analysis was carried out on the sample set to determine the 
relative abundance of DSG3 mRNA in all the cell lines. 
The expression pattern for DSG3 by WB analysis correlates very well with the 
label-free quantitative proteomics findings. Analysis of DSG3 by WB shows up bands 
at the expected weight of 130kDa in all samples analysed. DLKP-I has the highest 
abundance of DSG3 out of the four DLKP cell lines. DSG3 expression in the remaining 
cell lines (DLKP-SQ; DLKP-M; DLKP) is not detectable by WB and suggests the 
protein is extremely low or absent in these cell lines. The WB analysis clarifies the 
expression levels found by label-free proteomic analyses of DSG3 in these cell lines. 
Results suggest that these cell lines most likely do not express DSG3, at least to levels 
which are detectable by Western Blot. This strengthens the position of DSG3 as a 
marker for DLKP-I 
WB analysis for DSG3 also supports the differential expression found between 
SQ+I and I+M with higher abundance validating in the former cell line. These findings 
suggest that the co-culture cell line I+M has resulted in an inhibition of DSG3 
expression in DLKP-I by the presence of DLKP-M. It is unlikely that the DSG3 
abundance difference between these two combination lines is due to one population 
outgrowing another. This can be deduced from the label-free proteomic analysis where 
standard deviations for these combination lines show little variation across the three 
biological replicates which make them up (Figure 6.3B). This effect may be induced by 
paracrine signalling from DLKP-M resulting in inhibited DSG3 expression. The finding 
highlights the effects of cellular heterogeneity in the tumour microenvironment with 
regard to protein expression and potentially cell phenotypic characteristics.  
Another surprising finding from the proteomic analysis on the combination cell 
lines was that the abundance of DSG3 in DLKP-Remade is higher than what is found 
for the DLKP cell line. This protein expression pattern was also subsequently validated 
by WB. The difference in DSG3 abundance levels between DLKP and DLKP-Remade 
strengthens the ‘undiscovered subpopulation’ hypothesis which was formulated upon 
finding similar results for MARCKS and Shootin-1. This hypothesis suggests that the 
DLKP cell line may contain as of yet undiscovered and uncharacterised cell populations 
which interfere with the expression of some proteins. If DLKP is made up of only 
DLKP-SQ, DLKP-M and DLKP-I in proportions which mimic DLKP, one would 
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expect the protein expression patterns of both cell lines to match each other. As this is 
not the case, the possibility of undiscovered clonal subpopulation remains. The 
difference in DSG3 abundance between DLKP-Remade and the parental cell line could 
also be due to cross-talk between the known DLKP subpopulations, resulting in altered 
protein expression. Further work is needed to establish these hypotheses. 
Quantitative PCR analysis was performed on the sample set to measure the 
relative gene expression level of DSG3 in the DLKP cell lines as well as the 
combinations. The findings of the gene expression assay correlate closely with both the 
label-free and WB proteomic analyses. DLKP-I shows significantly high expression of 
DSG3 mRNA levels relative to all other samples in the analysis. Proteomic data had 
shown a maximum fold change of 175.33 for DSG3 between DLKP-I and DLKP-SQ. 
Quantitative PCR analysis shows a fold change of 6288 between the same two cell lines 
indicating that DSG3 is highly expressed in DLKP-I. The analysis also suggests that 
DSG3 is expressed at extremely low or absent levels in DLKP-SQ and DLKP-M at the 
mRNA level as the relative quantity abundance levels between these cell lines and 
DLKP-I are very high.  
The qPCR analysis on the combination cell lines shows the same expression 
pattern as is found in the proteomic analyses. The cell line SQ+I shows a 2.6 higher 
DSG3 mRNA level than is found for I+M. This suggests that inhibition of DSG3 
expression in DLKP-I by DLKP-M is occurring at a post-transcriptional level, 
preventing or interfering with the synthesis of DSG3 mRNA in co-culture conditions. 
This further highlights the range of interacting effects heterogeneity in the tumour 
microenvironment can have on cell populations at both the protein and mRNA levels.  
The difference in DSG3 protein abundance between DLKP and DLKP-Remade 
has also been corroborated by the gene expression analysis. This finding supports the 
idea that there are uncharacterised cell populations remaining in DLKP which have yet 
to be discovered. The existence of such populations may be the reason why DLKP and 
DLKP-Remade do not behave the same at the protein and mRNA level. This data also 
shows that DSG3 is expressed at an mRNA level, whereas the proteomic analyses 
suggest extremely low or absent expression of DSG3. The mRNA expression pattern 
correlates well with the cDNA microarray analysis carried out by Dr Helena Joyce 
where each clone was compared to each other as a group (Joyce H, PhD 2015) in 
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unpublished work. DSG3 was found to be essentially absent from both DLKP-M and 
DLKP-SQ, which is what has been found in the current study also. This strengthens 
DSG3 as a potential marker for DLKP-I. Combination cell lines also showed high 
expression of DSG3 in the DLKP-I containing cell lines. These findings were validated 
at the protein and mRNA levels.  
 
Thus far, this work has shown DSG3 to be specifically highly expressed in 
DLKP-I compared to the other clones. The various assays performed on the sample set 
suggest that the high abundance of DSG3 is specific to DLKP-I and is either very low 
or absent from the other clonal subpopulations. To investigate this expression pattern 
further, Immunocytochemical and Immunofluorescent staining of DSG3 were 
performed on the DLKP cell line and its clonal subpopulations. This was carried out to 
validate the expression pattern found by this work so far, and to establish the 
localisation of DSG3 in the DLKP cell lines. It was expected that DLKP-I would show 
the most intense staining for DSG3, with little or no staining in the other clones. In 
addition, it was uncertain whether the DLKP cell line would show positive staining for 
DSG3, as this target shows detectable levels at an mRNA level, but extremely low to 
undetectable protein levels in this cell line. 
Immunocytochemical staining of DSG3 shows DLKP-I as having very high 
expression relative to DLKP-SQ; DLKP-M; and DLKP. This correlates well with the 
previous proteomic analyses which established this same expression pattern. Staining is 
highest in DLKP-I and essentially absent from the other two clonal subpopulations. The 
DLKP cell line shows positive staining for DSG3, where it seems to be expressed very 
specifically by a subpopulation within the cell line. This could be reasonably 
hypothesised to represent the DLKP-I component within DLKP. The stark staining 
contrast between the DLKP-I subpopulation and the surrounding cells in DLKP suggest 
that expression of DSG3 is highly specifically expressed, and supports its role as a 
potential marker of this clonal subpopulation.  
Localisation of DSG3 in DLKP-I shows high intensity at cell-cell junctions as 
would be expected due to the known role of the protein as a desmosomal component 
(Dusek and Attardi 2011). However, our study found that DSG3 shows abnormal 
cytoplasmic and perinuclear staining in a large proportion of the DLKP-I cells. 
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Uncharacteristic localisation of DSG3 has been previously reported in relation to 
esophageal squamous-cell carcinoma (Fang et al. 2014). They reported that abnormal 
cytoplasmic localisation of DSG3 correlated with regional lymph node metastasis in 
esophageal squamous-cell carcinoma, and in patients without lymph node metastasis the 
cytoplasmic localisation of DSG3 correlated with poor prognosis. They also refer to a 
previous study which investigated a panel of desmosomal proteins and found DSG2, a 
Cadherin family member homologous to DSG3, showed cytoplasmic localisation 
correlated with poor tumour differentiation in esophageal squamous-cell carcinoma also 
(Fang et al. 2010). A study by a different group reported on the localisation of DSG3 in 
oral squamous-cell carcinoma, and found that perinuclear staining for the protein as 
well as other Cadherin proteins significantly correlated with disease progression (Wang 
et al. 2007).  
Immunofluorescent staining of DSG3 in the DLKP cell lines shows the same 
trend as was found using the previous staining method; however this higher resolution 
technique detected additional DSG3 localisation not visible by immunocytochemistry. 
Where DSG3 staining is present, it is strong in the cell-cell interactions as was 
previously found. In addition, a punctate staining pattern is visible which is not visible 
by ICC. Highly specific dots of DSG3 are visible in distinct points in the DLKP-I cells. 
These may be desmosomal-bound DSG3 dotted across the cell membrane. High nuclear 
staining can also be seen in some of the cells, and these add to what was shown in the 
previous staining method.  
In our study, cytoplasmic and perinuclear staining of DSG3 is visible in 
DLKP-I. This suggests that DSG3 functions as more than merely a cell-cell adhesion 
molecule and may play a significant role in the metastatic characteristics of DLKP-I. 
Previous studies have suggested that DSG3 may serve as a signalling centre which 
extends the role of the protein beyond just cell-cell adhesion, and a study has implicated 
the protein to be an upstream regulator of Src activity in epithelial cell lines (Chidgey 
and Dawson 2007, Tsang et al. 2010). A recent study found that overexpression of 
DSG3 increased the motility of an oral squamous carcinoma cell line by causing 
enhanced phosphorylation of Ezrin by PKC(Brown et al. 2014). They found DSG3 
forms a complex with Ezrin at the plasma membrane in OCC which is required for the 
proper formation of the Ezrin-F-actin interaction, and knockdown of DSG3 impaired 
this interaction. Taken together, these reports implicate DSG3 as having a wide range of 
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potential roles in addition to its function in the desmosome as a cell adhesion molecule. 
The abnormal localisation of DSG3 in DLKP-I may involve some of the pathways 
described above, and the protein may play a role in the motility of the DLKP-I cell line. 
The subpopulation of DLKP cells staining positive for DSG3 in our ICC and IF 
analyses also shows localisation of the protein at the edges of these cells. Intense 
staining can be seen at lamellipodial-like structures where the cells appear to be 
spreading outwards. This suggests DSG3 may co-localise with F-Actin in DLKP-I as 
was found by Brown et al. 2014, and may be involved in the regulation of cell motility 
in this role. A previous study found DSG3 to interact with Actin in human epithelial cell 
lines and showed overexpression of DSG3 promotes Actin dynamics leading to 
enhanced formation of lamellipodial and filopodial protrusions (Tsang et al. 2012). This 
supports the idea that DSG3 may be involved in cell motility in the DLKP-I clonal cell 
line and the DLKP lung cancer cell line model. 
To investigate the role of DSG3, a panel of functional analyses were carried 
out on the DLKP-I cell line after knockdown of DSG3 by RNAi. DLKP-I was chosen as 
the subject for analysis as DSG3 is potentially a marker for this cell type, and it is also 
the only DLKP clone to express DSG3 protein. The effects of DSG3 RNAi were 
verified by Western Blot analysis to ensure the protein was effectively knocked down 
prior to functional analyses. The assays which were performed on DLKP-I measured 
proliferation, migration and invasion. 
The functional analyses of DSG3 shows the protein to play a major role in the 
motility of DLKP-I. Both the migratory and invasive abilities of DLKP-I show a 
significant reduction upon knockdown of DSG3, with invasion being more strongly 
affected than migration. The migratory ability of DLKP-I shows an average of 28% 
reduction in the siRNA treated samples compared to the Negative control, and both 
siRNA molecules have the same effect. Invasiveness of DLKP-I is reduced by 50% in 
knockdown samples compared to the negative control. These findings suggest that 
DSG3 plays a key role in the motility of DLKP-I. No effect on proliferation was found 
upon DSG3 knockdown. This finding marks the first time knockdown of DSG3 has 
reduced cell motility in a lung cancer cell line. 
 289 
 
This finding that DSG3 knockdown reduces cell motility is supported by 
previous studies which have shown the protein to be involved in the metastatic 
phenotype of other cancer types. Previous studies have found overexpression of DSG3 
to be associated with the metastatic phenotype of Inverted Papilloma SCC and also 
lymph node metastasis in HNSCC (Huang et al. 2010, Patel et al. 2013). Another study 
compared normal epithelial tissue against tissue samples from head and neck cancer 
(HNC) patients with a view to finding targets which could serve as therapeutic markers 
of the disease (Chen et al. 2007). They found DSG3 to be overexpressed in the HNC 
samples at the protein and mRNA levels, and knockdown of the protein significantly 
reduced both migration and invasion of HNC cell lines.  
The mechanisms by which DSG3 may play a role in the motility of DLKP-I are 
unclear, however previous work may provide an insight the role played by the protein in 
these phenotypes. As discussed earlier, DSG3 was investigated in oral squamous- cell 
carcinoma cell lines (Brown et al. 2014). It was found that DSG3 forms a complex with 
Ezrin, another protein known to be involved in metastatic phenotypes in cancers such as 
osteosarcoma and hepatocellular carcinoma (Ren et al. 2009, Chen et al. 2011). This 
complex is necessary for the interaction between Ezrin and F-actin to induce 
cytoskeletal remodelling. The study by Brown et al. 2014 identified DSG3 is an 
upstream cell surface activator of the PKC/Ezrin pathway and showed it to be a 
regulating factor of cell motility and invasion in OCC. They demonstrated that 
DSG3/Ezrin complex forms at the plasma membrane and regulates Ezrin 
phosphorylation by PKC. The phosphorylation of Ezrin is a prerequisite for proper 
interaction with F-Actin and cytoskeletal remodelling leading to cell migration and 
invasion. Overexpression of DSG3 resulted in enhanced phosphorylation of Ezrin which 
resulted in increased filopodial protrusions, cell spreading and invasive phenotype.  
DSG3 was also found by this study to regulate the activity of AP-1, a known proto-
oncogene which is show to be a regulator of cancer cell metastasis (Ozanne et al. 2007). 
The reduction in invasion of DLKP-I cells upon knockdown of DSG3 may be 
supported by the findings of a previous work in which the effects of DSG3 knockdown 
in invasive HNCC cell lines were investigated (Chen et al. 2013). They found that 
silencing of DSG3 in these cell lines reduced the interaction between DSG3 and its 
known binding partner Plakoglobin (PG) (Hu et al. 2003), resulting in the translocation 
of PG from the plasma membrane to the nucleus of the cells. In the nucleus, they found 
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PG to bind to TCF/LEF transcription factors which suppress the transcriptional activity 
normally associated with this Wnt-signalling pathway (Hoppler and Kavanagh 2007). 
The effect of this disruption among others things was an inhibition of MMP7 and a 
concomitant reduction in the invasive ability of the HNCC cells.  
Literature studies show that DSG3 is implicated in the metastatic phenotypes 
of a number of cancer cell lines, however our study is the first to show that knockdown 
of DSG3 results in decreased migration and invasion in a lung cancer cell line. It is 
unclear how DSG3 plays a role in these phenotypes, however the literature suggests a 
number of possibilities that require further investigation in DLKP-I. The interaction of 
DSG3 with Ezrin and the effects on F-Actin found in literature studies present a 
potential avenue of investigation, and it is possible that F-Actin plays an important role 
in cell motility in DLKP-I. 
Co-staining of DSG3 and F-Actin was carried out on DLKP-I cells and imaged 
using confocal microscopy. A number of conditions were included in this experiment as 
described in Section 6.6.3 In short, both proteins were co-stained to assess if co-
localisation was occurring in this cell line. In addition, the effect of DSG3 knockdown 
was investigated to determine if loss of the protein had an effect on F-Actin expression 
or cell morphology. F-actin has been found to be an interacting partner of DSG3 in 
other cancer cell lines such as ESCC (Brown et al. 2014), so this potential link was 
investigated in our lung cancer cell line using a co-staining method. 
It was found that both DSG3 and F-Actin show strong staining in the DLKP-I 
cell line. DSG3 shows localisation to cell-cell junctions as well as punctate staining 
patterns throughout the cytoplasm, similar to what was found in the IF work discussed 
in Section 6.5.2. In addition, strong staining for DSG3 can be seen around the periphery 
of the DLKP-I cells. F-actin staining shows a localisation pattern which is similar to that 
found for DSG3. Strong accumulations of F-actin can be seen in cell-cell junctions also 
and around the cell peripheries. This may be cortical Actin as this protein has been 
shown to be enriched around the cell periphery where it interacts with the inner side of 
the plasma membrane (Cosen-Binker and Kapus 2006). In the control group, co-
localisation of DSG3 and F-actin is visible. This is particularly noticeable in the cell-
cell junctions and cell peripheries. In addition, where the cells show filopodial 
outgrowths, strong co-staining of both proteins can be seen. This concurs with the 
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findings of Brown et al. 2014 where DSG3, Ezrin and F-Actin were found to co-localise 
and promote cytoskeletal remodelling. 
RNAi of DSG3 resulted in a visible reduction of staining for the protein in the 
knockdown samples compared to the negative siRNA control. This did not result in a 
change in the morphology of the DLKP-I cells; however it did seem to affect the 
intensity of F-Actin staining by noticeably reducing it. F-Actin staining is still present 
and it has not been reduced to the same degree as DSG3, but the reduction is strong. It 
is possible that the knockdown of DSG3 has interfered with actin polymerization, 
resulting in the decreased staining intensity of F-actin. Western blot analysis probing for 
Beta-actin (Figure 6.10) in DSG3 knockdown samples did not show a reduction in 
expression of the protein. However, F-actin staining highlights the protein in its 
filamentous form, and it is possible that the knockdown of DSG3 has affected actin 
polymerisation rather than the expression of the protein itself. This hypothesis 
contributes to explaining the reduction in cell motility which was also found in DLKP-I 
upon transient DSG3 knockdown by this study. Interfering with actin polymerisation 
may inhibit cytoskeletal dynamics and reduce the ability of the affected cells to migrate 
through ARF. 
 
Thus far, this work has shown DSG3 to play a role in migration and invasion in 
the DLKP-I cell line. The involvement of DSG3 in these phenotypic characteristics is 
unclear; however co-staining studies have shown that there is a potential interaction 
between DSG3 and F-Actin, a protein known to be involved in cell motility. In order to 
investigate this link further, Co-Immunoprecipitation (Co-IP) of DSG3 was carried out 
using the method described in Section 2.8.1. It was hoped that this study would validate 
the potential interaction between DSG3 and F-actin, and also discover other binding 
partners of DSG3 in DLKP-I which could shed light on the role of the protein in this 
cell line. 
This co-IP study was successful in extracting DSG3 protein from DLKP-I cell 
lysate. In addition, the technique reproducibly co-immunoprecipitated a small panel of 
proteins which were deemed as potential interacting partners of DSG3 in the DLKP-I 
cell line. F-Actin was not found to be a binding partner of DSG3 in this study. It was 
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pulled out along with DSG3 repeatedly; however it also was present in the negative 
control sample suggesting it non-specifically bound to the Protein-G bead-antibody 
complex. Of the panel of proteins which are potentially binding partners of DSG3, a 
subset were deemed the most interesting based on their known function in combination 
with what is known from the literature. These are: 
 Junction Plakoglobin (PG). 
 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial     
(PDHE1-A).  
 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial     
(PDHE1-B). 
 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex (DLAT). 
 Pyruvate dehydrogenase protein X component, mitochondrial (PDHX). 
 
Junction Plakoglobin is a member of the Armadillo family of proteins and has 
been previously identified as a component of the desmosome. This protein links the 
cytoskeleton to the plasma membrane and integrates actin, microtubules and keratin 
intermediate filaments (Delva, Tucker and Kowalczyk 2009). Junction plakoglobin is a 
known direct binding partner of DSG3 in cultured keratinocytes and has been 
extensively studied along with DSG3 in the Pemphigus Vulgaris disease (Aoyama et al. 
2009). Knockdown of DSG3 has been shown to result in the translocation of this protein 
to the nucleus in HNCC cell lines resulting in decreased expression of MMP7 (Hoppler 
and Kavanagh 2007).  
The presence of this protein in our co-IP of DSG3 has not been described 
before in a lung cancer cell line. However, the interaction of DSG3 and PG in general is 
not a novel discovery. This finding also represents a validation of the method for 
discovering binding partners of DSG3 in DLKP-I. PG was validated as expressed in the 
DLKP cell lines with the same expression pattern as was found for DSG3. This 
indicates that both these proteins are strongly linked in this cell line model and confirms 
their interacting dynamic. 
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Co-IP of DSG3 in DLKP-I resulted in a surprising high proportion of 
mitochondrial related proteins being found as potential binding partners of DSG3. Eight 
proteins were found as potential binding partners of DSG3, and four of these are 
mitochondrial associated proteins: PDHE1-A; PDHE1-B; DLAT; PDHX 
These proteins are each a component of the Pyruvate Dehydrogenase Complex 
(PDC), which is a multi-enzyme complex located in the mitochondrial matrix. This 
complex is a key component in aerobic energy metabolism which functions to convert 
Pyruvate to Acetyl-CoA by Pyruvate decarboxylation. The resulting Acetyl-CoA may 
then be used for cellular respiration as part of the citric acid cycle (Sun et al. 2015).  The 
primary enzymes which form this complex are PDHEA1-A; PDHE1-B; DLAT and 
Dihydrolipoyl dehydrogenase, mitochondria (DLD) which was not identified here.  
Direct links between DSG3 and mitochondria are sparse in the literature. A 
number of studies in the 1980’s found mitochondria attached to the cytoplasmic sides of 
desmosomes in a panel of ciliary epithelia and diseased liver biopsies (Freddo 1988, 
Rassat, Robenek and Themann 1981). More recently a study has found an association 
between the autoimmune disease Pemphigus Vulgaris (PV) and damage to 
mitochondria. Exposure of keratinocytes to the sera of patients suffering PV resulted in 
damage to mitochondria and release of anti-mitochondrial antibodies (AMAs). A 
protein microarray study of auto-antibodies in patients with PV identified a number of 
mitochondrial associated proteins targeted by these antibodies including PDHE1-A 
(Chen et al. 2015, Kalantari-Dehaghi et al. 2013). Mitochondrial damage is a symptom 
of PV and AMA screening is currently used as a diagnostic test for the disease. PDHE1-
A/B and DLAT are the primary proteins (of three) which comprise the PDC and are 
expressed exclusively in the mitochondria. 
 Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial (DLAT) is another major component of the 
PDC and is therefore also localized to the mitochondrial matrix. Its function is to 
finalise the conversion of Pyruvate to Acetyl-CoA in conjunction with the other proteins 
of the PDC (PDHE1-A, DLD). In addition, DLAT is also the primary antigen targeted 
in the autoimmune disease known as Primary Biliary Cirrhosis (PBC) in which the 
small bile ducts of the liver are degraded to the point of rendering the liver seriously 
damaged. The primary cause of the disease is thought to be as a result of AMAs 
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targeting DLAT and causing an immune response, destroying the cells (Lindor et al. 
2009). Disease diagnosis is performed by screening for the AMAs, and it has been 
found that >95% of patients with the disease test positive for antibodies against DLAT. 
 
DSG3 appears to be a relatively poor prognosis biomarker as shown in the 
Kaplan-Meier plot in Figure 7.3. High expression of DSG3 can be seen to be associated 
with a poorer outcome for lung cancer patients. This finding is reflected in previous 
research carried out on DSG3 in other cancer types. A study comparing  tissues from 
head and neck cancer (HNC) against normal epithelial tissue found that high expression 
of DSG3 correlated highly with T-stage and extracapsular spread of the cancer (Chen et 
al. 2007). From this they concluded that DSG3 takes part in carcinogenesis, and in vitro 
follow up work found that knockdown of DSG3 in HNC cell lines significantly 
inhibited their migratory and invasive abilities. A separate study investigating DSG3 
expression in oesophageal squamous cell carcinoma (ESCC) found the protein to be 
significantly upregulated in tumour samples relative to normal epithelial tissue and 
concluded that it contributes to the aggressive features of ESCC (Fang et al. 2014). 
Studies of DSG3 in lung cancer are few, with only a handful investigating the role of 
DSG3 in the disease.  
One group carried out an immunohistochemical analysis comparing 300 
surgical non-small cell lung cancer and neuroendocrine tumours (Fukuoka et al. 2007). 
They found positive immunohistochemical staining of DSG3 to be correlated with 
favourable prognosis in non-small cell lung cancer and carcinoid tumours, and could be 
useful as a prognostic marker. This contrasts with the findings of the role of DSG3 in 
other cancer types where high expression of the protein was associated with poorer 
outcome. A second study of DSG3 in lung cancer did not provide survival data, but 
investigated DSG3 as a potential diagnostic marker (Savci-Heijink et al. 2009). They 
found that staining for DSG3 had a sensitivity of 99% and specificity of 87% for SQCC, 
and concluded that DSG3 may be useful as a diagnostic marker to distinguish SQCC 
from other subtypes of lung cancer when included in a panel of markers. Further studies 
are required in lung cancer to determine the role of DSG3 in the disease. If DSG3 
proves to be a therapeutic target, it has a natural advantage as a transmembrane protein 
expressed on the cell surface which would make it potentially susceptible to antibody-
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targeting therapies as is being currently explored in relation to its known role in 
Pemphigus Vulgaris (Koga et al. 2013). 
 
 
 
Figure 7.3: Kaplan Meier plot for Desmoglein-3 showing overall 
survival for lung cancer patients. 
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7.5. Conclusions: 
Proteomic profiling using quantitative LC-MS/MS was carried out on a lung 
carcinoma cell line comprised of three distinct subpopulations with known phenotypic 
differences with regard to their migratory and invasive ability. Comparative proteomic 
analyses of the cell lines facilitated the discovery of highly abundant proteins enriched 
in each subpopulation. These markers confirm the phenotypic and proteomic variations 
between the clonal subpopulations which underlie the heterogeneous nature of this cell 
line. Conclusions drawn from this work are as follows: 
 
 
1. LC-MS/MS comparative proteomic analyses were used to identify differentially 
expressed proteins between clonal subpopulations in a heterogeneous lung cancer 
cell line model. High stringency filtering criteria identified 127 and 203 
significantly differentially expressed proteins during exponential and stationary 
phases of growth respectively. The analysis allowed for the identification of highly 
abundant proteins associated with each of the clones, providing candidates to 
potentially represent each one. The technology is an effective method for 
characterising the different proteomic profiles in a sample set. 
 
 
2. DLKP and its clonal subpopulations are proteomically distinct cell lines, as found 
by the LC-MS/MS comparative analyses. Individual protein profiles were 
determined for each cell line using the quantitative proteomic analysis software. 
Myristoylated Alanine-Rich C-Kinase Substrate, Desmoglein-3 and Shootin-1 were 
each found to be differentially expressed between the three clonal subpopulations 
with highest abundance in DLKP-M, DLKP-I and DLKP-SQ respectively. Each 
protein was significantly more highly expressed in its associated clonal cell line. 
Desmoglein-3 in particular serves as a potential marker for DLKP-I as it is highly 
expressed in DLKP-I relative to DLKP-SQ and DLKP-M, with little or no 
expression in the latter two cell lines. The proteins representing each of the clonal 
subpopulations were taken forward for further investigation. 
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3. Shootin-1 was found to be highly expressed in DLKP-SQ. This protein is relatively 
uncharacterised and has little research carried out on it to date, with no functional 
studies carried out in cancer to date. 
 Shootin-1 shows a significantly higher protein expression in DLKP-SQ 
compared to DLKP and the other clonal subpopulations. Western Blot and qPCR 
analyses confirmed this finding at the protein and gene level. 
 Immunocytochemistry and Immunofluorescence staining of Shootin-1 supported 
the expression pattern found by LC-MS/MS. In addition, Shootin-1 localization 
was found to be high in cell projections, supporting the research done to date 
which characterizes the protein as involved with actin polymerization in 
dendritic outgrowths.  
 Co-immunoprecipitation studies found potential binding partners of Shootin-1 
which to date have not yet been described. Of particular interest was the 
discovery of Semenogelin-1 (SEMG1) as a novel binding partner of Shootin-1. 
SEMG1 expression is very limited in the body, and its ectopic expression in lung 
cancer was an unusual finding. SMG proteins are secreted, and therefore may be 
useful as a biomarker for lung cancer, though further work would need to be 
carried out to support this hypothesis. 
 
4. Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) was determined to be 
highly expressed in DLKP-M relative to the other clones: 
 MARCKS is abundantly expressed in the DLKP-M clone relative to all the other 
cell lines. Western Blot and qPCR analyses confirmed the expression pattern 
found by the LC-MS/MS analysis at the protein and mRNA level. 
 
 Immunofluorescence staining of MARCKS in each of the cell lines further 
validated the expression pattern found in the initial comparative proteomic 
study. In addition, this analysis showed the protein as localised to the cytoplasm 
with higher concentrations in structures projecting from the cells, such as 
filopodia and dendritic-like outgrowths.  
 Transient siRNA knockdown of MARCKS expression resulted in a significant 
reduction in the ability of DLKP-M cells to migrate and invade in vitro. DLKP-
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M is the most invasive and migratory clonal subpopulation of DLKP, and these 
findings show that MARCKS plays an important role in this phenotype.  
 Confocal imaging of MARCKS and F-actin was carried on DLKP-M cells to 
assess the effects of MARCKS knockdown on both proteins. The remaining 
MARCKS showed translocation from the cytoplasm to the nucleus of the cells. 
This suggests that MARCKS potentially becomes localized to the nucleus when 
the protein expression is reduced and may play a role in gene expression as a 
result; however further work is needed to confirm this. In addition, the intensity 
of F-Actin staining was decreased after MARCKS RNAi.  
 Both Shootin-1 and MARCKS are known to interact with actin. Reduction in the 
expression of each target protein resulted in a significant reduction in cell 
migration in their respective clones. These findings may be as a result of their 
interaction with actin, with reduced expression of Shootin-1 and MARCKS 
causing reduced actin-mediated cell motility. 
 
5. Desmoglein-3 (DSG3) was found to be abundantly expressed in DLKP-I only and 
can therefore be used as a marker for that cell line: 
 DSG3 shows significantly high expression in DLKP-I with no detectable levels 
of the protein in the other clonal subpopulations. Western Blot and qPCR 
analysis confirmed the high expression of DSG3 at the protein and mRNA level. 
 Immunocytochemistry and immunofluorescent staining of DSG3 in DLKP and 
the clonal subpopulations confirmed the high specificity of expression in DLKP-
I only. These techniques confirmed the specific expression DSG3, especially in 
the heterogeneous DLKP cell line where stark differences in protein expression 
between the cells were observed. 
 Transient siRNA knockdown of DSG3 expression in DLKP-I results in a 
significant reduction in the ability of the cells to migrate and invade. This 
finding represents the first report of DSG3 knockdown reducing migration and 
invasion in a lung cancer cell line. 
 Co-immunoprecipitation of Desmoglein-3 in DLKP-I resulted in the discovery 
of a panel of potential binding partners which were identified using LC-MS/MS. 
One protein in the panel, Junction Plakoglobin, is a known binding partner of 
Desmoglein-3 and therefore helped to validate the method. A subpanel of 
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mitochondrial proteins were detected as potential binding partners of 
Desmoglein-3. This suggests DSG3 has additional roles relating to 
mitochondria, which so far remain little studied. Reciprocal Co-IP experiments 
are required to validate these potential binding partner interactions. 
 Co-culture of DLKP-I with DLKP-M reduced expression levels of DSG3. This 
shows that in the heterogeneous population of DLKP, cell-cell interactions 
significantly alter the protein expression profiles of the clonal subpopulations. 
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7.6. Future Work: 
1. MARCKS was found as a highly expressed protein in DLKP-M and has been shown 
to play a functional role in this cell line. There are a number of follow on studies 
which would need to be performed to clarify the role of this protein in the DLKP 
cell line model: 
 
 Functional analyses of MARCKS knockdown will need be carried out in both 
DLKP-SQ and DLKP-I. Though expression of the MARCKS is lower in these 
cell lines, it may play a similar role in cell migration and invasion. This could 
strengthen the findings of this study, and also potentially highlight new roles for 
MARCKS. 
 Confocal analysis revealed a potential translocation of MARCKS to the nucleus 
of DLKP-M upon transient knockdown of the protein using RNAi. This will 
require further investigation to validate the finding. A nuclear extraction will be 
performed on knockdown and control cells, and these will be compared by 
Western Blot analysis to determine if there is enrichment for the protein in 
knockdown samples. A protein segment within MARCKS (the effector domain) 
has been shown to have a homologous sequence to known nuclear localisation 
sequences. This could be investigated in DLKP-M to assess if it is responsible 
for nuclear localisation of MARCKS, and what specifically stimulated this 
response. 
 Co-Immunoprecipitation studies were unsuccessful for MARCKS due to a lack 
of good quality antibodies. In the future, this avenue of investigation will be 
reopened to look for MARCKS binding partners; for example alternative 
suitable antibodies for Co-IP will be sourced. This may shed light on its role in 
the DLKP cell line model, and elucidate the mechanism behind its functional 
roles in migration and invasion. In addition, Co-IP could be carried out on 
MARCKS after it has translocated to the nucleus upon knockdown, to determine 
what binding partners differ depending on its localisation within the cell. 
 Though an overexpression vector was successfully constructed, preliminary 
attempts at inducing a high expression of MARCKS in the DLKP clones were 
unsuccessful. This will be explored again and if overexpression is achieved, 
functional assays will be carried out to determine the effects of this process. It 
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would be hoped that overexpression of MARCKS in DLKP-SQ could induce a 
highly invasive phenotype for example.  
 MARCKS has not been extensively studied in lung cancer. It would be 
interesting to carry out immunohistochemical staining on lung cancer tissue with 
varying invasive and migratory properties to assess if there is a correlation with 
MARCKS expression. 
 
2. Desmoglein-3 was identified as a potential marker for DLKP-I with high specific 
expression in this cell line. This protein target requires additional investigation to 
clarify its role in the DLKP cell line model: 
 
 Further work will need to be carried out to determine how useful Desmoglein-3 
is as a marker for DLKP-I. This protein could potentially be used to re-clone 
DLKP-I from the parent DLKP cell line using Fluorescently-Activated Cell 
Sorting (FACS), and compared to the original DLKP-I. Following on from this, 
Desmogelin-3 could then be used as a potential marker for inter-conversion 
events which these cells are hypothesised to do through DLKP-I (McBride et al. 
1998a). 
 Co-Immunoprecipitation studies found Desmoglein-3 to be potentially 
associated with mitochondrial proteins. Reverse Co-IPs will need to be 
performed in order to validate these interactions. Mitochondrial extractions 
could also be performed from DLKP-I cells and analysed by Western Blot to 
look for the presence of Desmoglein-3, or desmosomal proteins in general. 
 Co-localisation of F-Actin and Desmoglein-3 was found in DLKP-I, and 
knockdown of Desmoglein-3 resulted in a potential reduction of F-Actin 
abundance. This link will need to be investigated further, as well as the potential 
effects of Desmogelin-3 Actin cytoskeletal dynamics. 
 Construction of an overexpression vector for Desmoglein-3 was unsuccessful. A 
synthesised version has been purchased, and this will be transfected into the 
DLKP clonal subpopulations to look for effects on the phenotypic characteristics 
of the cells. This is particularly interesting as expression of Desmoglein-3 is 
specific to DLKP-I, and overexpression may lead to inter-conversion events in 
DLKP-SQ or DLKP-M. In addition, if overexpression is successful, it may be 
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worth investigating if Co-Immunoprecipitation extracts mitochondrial proteins 
in the other DLKP clones also.  
 
3. Shootin-1 was found to be highly expressed protein in DLKP-SQ relative to the 
other cell lines. It requires further work to explore the findings of this study. 
 Transient siRNA knockdown of Shootin-1 was found to reduce the migratory 
ability of DLKP-SQ. It would be worth carrying out the same process in the 
other DLKP clones to assess the functional role of Shootin-1 in these cell lines. 
DLKP-SQ is an anoikis resistant cell line, and the mechanism behind this 
phenotypic trait has not yet been established. Shootin-1, being relatively highly 
abundant in DLKP-SQ, may represent a possible role in this process. 
Preliminary attempts at Anoikis assays were unsuccessful, however once a 
reproducible method is established, this phenotypic trait should be explored with 
regard to Shootin-1. 
 Co-Immunoprecipitation studies found a number of potential Shootin-1 binding 
partners require validation by reverse Co-IP methods. Functional analyses of 
these targets, in particular Semenogelin-1, are required to elucidate the role of 
these proteins in a lung cancer cell line such as DLKP-SQ. They should also be 
explored in the other DLKP clones. 
 Our study found a potential interaction between Shootin-1 and F-Actin, which is 
also reported in the literature in neuronal cells. This link was not validated by 
Co-IP, however it would still be worth investigating if Shootin-1 is involved 
with cell motility in its role as a mediator in Actin retrograde flow in the DLKP 
cell line model.  
 Overexpression of Shootin-1 was achieved by the construction of a vector, and 
this was successfully transfected into the DLKP clones. Both DLKP-M and 
DLKP-I show overexpression of Shootin-1 relative to empty vector controls. In 
the future, functional analyses of the effects of this overexpression will be 
explored. 
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4. Knockdown of each protein target by RNAi induced phenotypic changes in the 
behaviour of their respective cell lines. It would be interesting to assess if similar 
effects are observed when each target is knocked out using a different method such 
as the CRISPR/Cas9 system. This would effectively knockout a target at the 
molecular level and the phenotypic changes associated with this could be assessed. 
Evaluation of the effects of target knockdown at the molecular level could be carried 
by functional analysis of the migratory and invasive abilities of the cells.  
 
5. Co-culture of the DLKP clones resulted in changes in expression of target proteins. 
It would be interesting to determine if the targets explored in this study are secreted, 
and assess the effects of this on the clones which do not express the proteins at high 
levels. Studies could also be carried out to assess the effects of conditioned medium 
from one clone on the growth and phenotypic characteristics of another, and effects 
on targets of interest could be determined also. 
 
6. The quantitative label-free data contains a wealth of protein expression information 
which has yet to be explored. This study looked at high abundance proteins from 
each DLKP clone, however there are many more targets which are yet be explored. 
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Chapter 8.  
 
Bibliography: 
Abedi-Ardekani, B., Kamangar, F., Sotoudeh, M., Villar, S., Islami, F., Aghcheli, K., 
Nasrollahzadeh, D., Taghavi, N., Dawsey, S.M., Abnet, C.C., Hewitt, S.M., Fahimi, S., Saidi, 
F., Brennan, P., Boffetta, P., Malekzadeh, R. and Hainaut, P. 2011. Extremely high Tp53 
mutation load in esophageal squamous cell carcinoma in golestan province, iran. PloS One, 
6(12), pp.e29488.  
Aebersold, R. and Mann, M. 2003. Mass spectrometry-based proteomics. Nature, 422(6928), 
pp.198-207.  
Aguayo, S.M., Schuyler, W.E., Murtagh, J.J.,Jr and Roman, J. 1994. Regulation of lung 
branching morphogenesis by bombesin-like peptides and neutral endopeptidase. American 
Journal of Respiratory Cell and Molecular Biology, 10(6), pp.635-642.  
Aguda, A.H., Burtnick, L.D. and Robinson, R.C. 2005. The state of the filament. EMBO 
Reports, 6(3), pp.220-226.  
Al Alam, D., El Agha, E., Sakurai, R., Kheirollahi, V., Moiseenko, A., Danopoulos, S., 
Shrestha, A., Schmoldt, C., Quantius, J., Herold, S., Chao, C.M., Tiozzo, C., De Langhe, S., 
Plikus, M.V., Thornton, M., Grubbs, B., Minoo, P., Rehan, V.K. and Bellusci, S. 2015. 
Evidence for the involvement of fibroblast growth factor 10 in lipofibroblast formation during 
embryonic lung development. Development (Cambridge, England), 142(23), pp.4139-4150.  
Alban, A., David, S.O., Bjorkesten, L., Andersson, C., Sloge, E., Lewis, S. and Currie, I. 2003. 
A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional 
difference gel electrophoresis incorporating a pooled internal standard. Proteomics, 3(1), pp.36-
44.  
Albert, K.A., Nairn, A.C. and Greengard, P. 1987. The 87-kDa protein, a major specific 
substrate for protein kinase C: Purification from bovine brain and characterization. Proceedings 
of the National Academy of Sciences of the United States of America, 84(20), pp.7046-7050.  
Albini, A., Bruno, A., Gallo, C., Pajardi, G., Noonan, D.M. and Dallaglio, K. 2015. Cancer stem 
cells and the tumor microenvironment: Interplay in tumor heterogeneity. Connective Tissue 
Research, 56(5), pp.414-425.  
Alexander, R.W., Upp, J.R.,Jr, Poston, G.J., Gupta, V., Townsend, C.M.,Jr and Thompson, J.C. 
1988. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer 
Research, 48(6), pp.1439-1441.  
Amagai, M., Koch, P.J., Nishikawa, T. and Stanley, J.R. 1996. Pemphigus vulgaris antigen 
(desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. The 
Journal of Investigative Dermatology, 106(2), pp.351-355.  
Andl, C.D. and Stanley, J.R. 2001. Central role of the plakoglobin-binding domain for 
desmoglein 3 incorporation into desmosomes. The Journal of Investigative Dermatology, 
117(5), pp.1068-1074.  
 305 
 
Aoyama, Y., Yamamoto, Y., Yamaguchi, F. and Kitajima, Y. 2009. Low to high Ca2+ -switch 
causes phosphorylation and association of desmocollin 3 with plakoglobin and desmoglein 3 in 
cultured keratinocytes. Experimental Dermatology, 18(4), pp.404-408.  
Arbuzova, A., Schmitz, A.A. and Vergeres, G. 2002. Cross-talk unfolded: MARCKS proteins. 
The Biochemical Journal, 362(Pt 1), pp.1-12.  
Armirotti, A. and Damonte, G. 2010. Achievements and perspectives of top-down proteomics. 
Proteomics, 10(20), pp.3566-3576.  
Artym, V.V., Zhang, Y., Seillier-Moiseiwitsch, F., Yamada, K.M. and Mueller, S.C. 2006. 
Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at 
invadopodia: Defining the stages of invadopodia formation and function. Cancer Research, 
66(6), pp.3034-3043.  
Baldassarre, M., Pompeo, A., Beznoussenko, G., Castaldi, C., Cortellino, S., McNiven, M.A., 
Luini, A. and Buccione, R. 2003. Dynamin participates in focal extracellular matrix degradation 
by invasive cells. Molecular Biology of the Cell, 14(3), pp.1074-1084.  
Bartoli, M., Monneron, A. and Ladant, D. 1998. Interaction of calmodulin with striatin, a WD-
repeat protein present in neuronal dendritic spines. The Journal of Biological Chemistry, 
273(35), pp.22248-22253.  
Bartoli, M., Ternaux, J.P., Forni, C., Portalier, P., Salin, P., Amalric, M. and Monneron, A. 
1999. Down-regulation of striatin, a neuronal calmodulin-binding protein, impairs rat locomotor 
activity. Journal of Neurobiology, 40(2), pp.234-243.  
Ben, Q.W., Wang, J.C., Liu, J., Zhu, Y., Yuan, F., Yao, W.Y. and Yuan, Y.Z. 2010. Positive 
expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic 
ductal adenocarcinoma. Annals of Surgical Oncology, 17(8), pp.2213-2221.  
Benoist, M., Gaillard, S. and Castets, F. 2006. The striatin family: A new signaling platform in 
dendritic spines. Journal of Physiology, Paris, 99(2-3), pp.146-153.  
Bergh, J.C. 1990. Gene amplification in human lung cancer. the myc family genes and other 
proto-oncogenes and growth factor genes. The American Review of Respiratory Disease, 142(6 
Pt 2), pp.S20-6.  
Beynon, R.J. and Pratt, J.M. 2005. Metabolic labeling of proteins for proteomics. Molecular & 
Cellular Proteomics : MCP, 4(7), pp.857-872.  
Bjartell, A., Malm, J., Moller, C., Gunnarsson, M., Lundwall, A. and H, L. 1996. Distribution 
and tissue expression of semenogelin I and II in man as demonstrated by in situ hybridization 
and immunocytochemistry. Journal of Andrology, 17(1), pp.17-26.  
Bowden, E.T., Barth, M., Thomas, D., Glazer, R.I. and Mueller, S.C. 1999. An invasion-related 
complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular 
matrix degradation. Oncogene, 18(31), pp.4440-4449.  
Brown, L., Waseem, A., Cruz, I.N., Szary, J., Gunic, E., Mannan, T., Unadkat, M., Yang, M., 
Valderrama, F., O Toole, E.A. and Wan, H. 2014. Desmoglein 3 promotes cancer cell migration 
and invasion by regulating activator protein 1 and protein kinase C-dependent-ezrin activation. 
Oncogene, 33(18), pp.2363-2374.  
 306 
 
Bunn, P.A.,Jr and Franklin, W. 2002. Epidermal growth factor receptor expression, signal 
pathway, and inhibitors in non-small cell lung cancer. Seminars in Oncology, 29(5 Suppl 14), 
pp.38-44.  
Cai, J.H., Zhao, R., Zhu, J.W., Jin, X.L., Wan, F.J., Liu, K., Ji, X.P., Zhu, Y.B. and Zhu, Z.G. 
2010. Expression of cortactin correlates with a poor prognosis in patients with stages II-III 
colorectal adenocarcinoma. Journal of Gastrointestinal Surgery : Official Journal of the Society 
for Surgery of the Alimentary Tract, 14(8), pp.1248-1257.  
Calabrese, B. and Halpain, S. 2005. Essential role for the PKC target MARCKS in maintaining 
dendritic spine morphology. Neuron, 48(1), pp.77-90.  
Campos-Parra, A.D., Zuloaga, C., Manriquez, M.E., Aviles, A., Borbolla-Escoboza, J., 
Cardona, A., Meneses, A. and Arrieta, O. 2015. KRAS mutation as the biomarker of response to 
chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: Clues for 
its potential use in second-line therapy decision making. American Journal of Clinical 
Oncology, 38(1), pp.33-40.  
Canas, B., Lopez-Ferrer, D., Ramos-Fernandez, A., Camafeita, E. and Calvo, E. 2006. Mass 
spectrometry technologies for proteomics. Briefings in Functional Genomics & Proteomics, 
4(4), pp.295-320.  
Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, 
K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C. and Stuart, J.M. 2013. The 
cancer genome atlas pan-cancer analysis project. Nature Genetics, 45(10), pp.1113-1120.  
Carney, D.N., Gazdar, A.F., Bunn, P.A.,Jr and Guccion, J.G. 1982. Demonstration of the stem 
cell nature of clonogenic tumor cells from lung cancer patients. Stem Cells, 1(3), pp.149-164.  
Castets, F., Bartoli, M., Barnier, J.V., Baillat, G., Salin, P., Moqrich, A., Bourgeois, J.P., 
Denizot, F., Rougon, G., Calothy, G. and Monneron, A. 1996. A novel calmodulin-binding 
protein, belonging to the WD-repeat family, is localized in dendrites of a subset of CNS 
neurons. The Journal of Cell Biology, 134(4), pp.1051-1062.  
Chambers, A.F., Groom, A.C. and MacDonald, I.C. 2002. Dissemination and growth of cancer 
cells in metastatic sites. Nature Reviews.Cancer, 2(8), pp.563-572.  
Chansky, K., Sculier, J.P., Crowley, J.J., Giroux, D., Van Meerbeeck, J., Goldstraw, P. and 
International Staging Committee and Participating Institutions. 2009. The international 
association for the study of lung cancer staging project: Prognostic factors and pathologic TNM 
stage in surgically managed non-small cell lung cancer. Journal of Thoracic Oncology : Official 
Publication of the International Association for the Study of Lung Cancer, 4(7), pp.792-801.  
Chen, C.H., Statt, S., Chiu, C.L., Thai, P., Arif, M., Adler, K.B. and Wu, R. 2014a. Targeting 
myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. 
mechanisms and therapeutic implications. American Journal of Respiratory and Critical Care 
Medicine, 190(10), pp.1127-1138.  
Chen, C.H., Thai, P., Yoneda, K., Adler, K.B., Yang, P.C. and Wu, R. 2014b. A peptide that 
inhibits function of myristoylated alanine-rich C kinase substrate (MARCKS) reduces lung 
cancer metastasis. Oncogene, 33(28), pp.3696-3706.  
 307 
 
Chen, G., Gharib, T.G., Huang, C.C., Taylor, J.M., Misek, D.E., Kardia, S.L., Giordano, T.J., 
Iannettoni, M.D., Orringer, M.B., Hanash, S.M. and Beer, D.G. 2002. Discordant protein and 
mRNA expression in lung adenocarcinomas. Molecular & Cellular Proteomics : MCP, 1(4), 
pp.304-313.  
Chen, X. and Rotenberg, S.A. 2010. PhosphoMARCKS drives motility of mouse melanoma 
cells. Cellular Signalling, 22(7), pp.1097-1103.  
Chen, Y., Chernyavsky, A., Webber, R.J., Grando, S.A. and Wang, P.H. 2015. Critical role of 
the neonatal fc receptor (FcRn) in the pathogenic action of antimitochondrial autoantibodies 
synergizing with anti-desmoglein autoantibodies in pemphigus vulgaris. The Journal of 
Biological Chemistry, 290(39), pp.23826-23837.  
Chen, Y., Wang, D., Guo, Z., Zhao, J., Wu, B., Deng, H., Zhou, T., Xiang, H., Gao, F., Yu, X., 
Liao, J., Ward, T., Xia, P., Emenari, C., Ding, X., Thompson, W., Ma, K., Zhu, J., Aikhionbare, 
F., Dou, K., Cheng, S.Y. and Yao, X. 2011. Rho kinase phosphorylation promotes ezrin-
mediated metastasis in hepatocellular carcinoma. Cancer Research, 71(5), pp.1721-1729.  
Chen, Y.J., Chang, J.T., Lee, L., Wang, H.M., Liao, C.T., Chiu, C.C., Chen, P.J. and Cheng, 
A.J. 2007. DSG3 is overexpressed in head neck cancer and is a potential molecular target for 
inhibition of oncogenesis. Oncogene, 26(3), pp.467-476.  
Chen, Y.J., Lee, L.Y., Chao, Y.K., Chang, J.T., Lu, Y.C., Li, H.F., Chiu, C.C., Li, Y.C., Li, 
Y.L., Chiou, J.F. and Cheng, A.J. 2013. DSG3 facilitates cancer cell growth and invasion 
through the DSG3-plakoglobin-TCF/LEF-myc/cyclin D1/MMP signaling pathway. PloS One, 
8(5), pp.e64088.  
Chidgey, M. and Dawson, C. 2007. Desmosomes: A role in cancer? British Journal of Cancer, 
96(12), pp.1783-1787.  
Chitaev, N.A., Leube, R.E., Troyanovsky, R.B., Eshkind, L.G., Franke, W.W. and 
Troyanovsky, S.M. 1996. The binding of plakoglobin to desmosomal cadherins: Patterns of 
binding sites and topogenic potential. The Journal of Cell Biology, 133(2), pp.359-369.  
Choe, L., D'Ascenzo, M., Relkin, N.R., Pappin, D., Ross, P., Williamson, B., Guertin, S., Pribil, 
P. and Lee, K.H. 2007. 8-plex quantitation of changes in cerebrospinal fluid protein expression 
in subjects undergoing intravenous immunoglobulin treatment for alzheimer's disease. 
Proteomics, 7(20), pp.3651-3660.  
Choi, H. and Mazzone, P. 2014. Radon and lung cancer: Assessing and mitigating the risk. 
Cleveland Clinic Journal of Medicine, 81(9), pp.567-575.  
Christin, C., Bischoff, R. and Horvatovich, P. 2011. Data processing pipelines for 
comprehensive profiling of proteomics samples by label-free LC-MS for biomarker discovery. 
Talanta, 83(4), pp.1209-1224.  
Clark, E.S. and Weaver, A.M. 2008. A new role for cortactin in invadopodia: Regulation of 
protease secretion. European Journal of Cell Biology, 87(8-9), pp.581-590.  
Clark, E.S., Whigham, A.S., Yarbrough, W.G. and Weaver, A.M. 2007. Cortactin is an essential 
regulator of matrix metalloproteinase secretion and extracellular matrix degradation in 
invadopodia. Cancer Research, 67(9), pp.4227-4235.  
 308 
 
Cosen-Binker, L.I. and Kapus, A. 2006. Cortactin: The gray eminence of the cytoskeleton. 
Physiology (Bethesda, Md.), 21pp.352-361.  
Cottrell, J.S. 2011. Protein identification using MS/MS data. Journal of Proteomics, 74(10), 
pp.1842-1851.  
Dang, C.V. 2012. MYC on the path to cancer. Cell, 149(1), pp.22-35.  
Dehner, C., Rotzer, V., Waschke, J. and Spindler, V. 2014. A desmoplakin point mutation with 
enhanced keratin association ameliorates pemphigus vulgaris autoantibody-mediated loss of cell 
cohesion. The American Journal of Pathology, 184(9), pp.2528-2536.  
Delva, E., Tucker, D.K. and Kowalczyk, A.P. 2009. The desmosome. Cold Spring Harbor 
Perspectives in Biology, 1(2), pp.a002543.  
Desai, T.J., Brownfield, D.G. and Krasnow, M.A. 2014. Alveolar progenitor and stem cells in 
lung development, renewal and cancer. Nature, 507(7491), pp.190-194.  
Duru, N., Fan, M., Candas, D., Menaa, C., Liu, H.C., Nantajit, D., Wen, Y., Xiao, K., Eldridge, 
A., Chromy, B.A., Li, S., Spitz, D.R., Lam, K.S., Wicha, M.S. and Li, J.J. 2012. HER2-
associated radioresistance of breast cancer stem cells isolated from HER2-negative breast 
cancer cells. Clinical Cancer Research : An Official Journal of the American Association for 
Cancer Research, 18(24), pp.6634-6647.  
Dusek, R.L. and Attardi, L.D. 2011. Desmosomes: New perpetrators in tumour suppression. 
Nature Reviews.Cancer, 11(5), pp.317-323.  
Engelsberger, W.R., Erban, A., Kopka, J. and Schulze, W.X. 2006. Metabolic labeling of plant 
cell cultures with K(15)NO3 as a tool for quantitative analysis of proteins and metabolites. 
Plant Methods, 2pp.14.  
Evans, M.J. and Plopper, C.G. 1988. The role of basal cells in adhesion of columnar epithelium 
to airway basement membrane. The American Review of Respiratory Disease, 138(2), pp.481-
483.  
Fang, W.K., Chen, B., Xu, X.E., Liao, L.D., Wu, Z.Y., Wu, J.Y., Shen, J., Xu, L.Y. and Li, 
E.M. 2014. Altered expression and localization of desmoglein 3 in esophageal squamous cell 
carcinoma. Acta Histochemica, 116(5), pp.803-809.  
Fang, W.K., Gu, W., Li, E.M., Wu, Z.Y., Shen, Z.Y., Shen, J.H., Wu, J.Y., Pan, F., Lv, Z., Xu, 
X.E., Huang, Q. and Xu, L.Y. 2010. Reduced membranous and ectopic cytoplasmic expression 
of DSC2 in esophageal squamous cell carcinoma: An independent prognostic factor. Human 
Pathology, 41(10), pp.1456-1465.  
Fang, W., Chen, B., Xu, X., Liao, L., Wu, Z., Wu, J., Shen, J., Xu, L. and Li, E. Altered 
expression and localization of desmoglein 3 in esophageal squamous cell carcinoma. Acta 
Histochemica, (0),  
Fernandez, F.G. and Battafarano, R.J. 2006. Large-cell neuroendocrine carcinoma of the lung. 
Cancer Control : Journal of the Moffitt Cancer Center, 13(4), pp.270-275.  
Fogel, M., Gutwein, P., Mechtersheimer, S., Riedle, S., Stoeck, A., Smirnov, A., Edler, L., Ben-
Arie, A., Huszar, M. and Altevogt, P. 2003. L1 expression as a predictor of progression and 
 309 
 
survival in patients with uterine and ovarian carcinomas. Lancet (London, England), 362(9387), 
pp.869-875.  
Freddo, T.F. 1988. Mitochondria attached to desmosomes in the ciliary epithelia of human, 
monkey, and rabbit eyes. Cell and Tissue Research, 251(3), pp.671-675.  
Freed-Pastor, W.A. and Prives, C. 2012. Mutant p53: One name, many proteins. Genes & 
Development, 26(12), pp.1268-1286.  
Frohm, B., DeNizio, J.E., Lee, D.S., Gentile, L., Olsson, U., Malm, J., Akerfeldt, K.S. and 
Linse, S. 2015. A peptide from human semenogelin I self-assembles into a pH-responsive 
hydrogel. Soft Matter, 11(2), pp.414-421.  
Fukuoka, J., Dracheva, T., Shih, J.H., Hewitt, S.M., Fujii, T., Kishor, A., Mann, F., Shilo, K., 
Franks, T.J., Travis, W.D. and Jen, J. 2007. Desmoglein 3 as a prognostic factor in lung cancer. 
Human Pathology, 38(2), pp.276-283.  
Fuller, H.R., Man, N.T., Lam le, T., Shamanin, V.A., Androphy, E.J. and Morris, G.E. 2010. 
Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and 
osteonectin in SMA cells. Journal of Proteome Research, 9(8), pp.4228-4233.  
Gainor, J.F. and Shaw, A.T. 2013. Emerging paradigms in the development of resistance to 
tyrosine kinase inhibitors in lung cancer. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, 31(31), pp.3987-3996.  
Gardner-Thorpe, J., Ito, H., Ashley, S.W. and Whang, E.E. 2002. Differential display of 
expressed genes in pancreatic cancer cells. Biochemical and Biophysical Research 
Communications, 293(1), pp.391-395.  
Garrod, D. and Chidgey, M. 2008. Desmosome structure, composition and function. Biochimica 
Et Biophysica Acta, 1778(3), pp.572-587.  
Gaspari, M. and Cuda, G. 2011. Nano LC-MS/MS: A robust setup for proteomic analysis. 
Methods in Molecular Biology (Clifton, N.J.), 790pp.115-126.  
Gavert, N., Conacci-Sorrell, M., Gast, D., Schneider, A., Altevogt, P., Brabletz, T. and Ben-
Ze'ev, A. 2005. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at 
the invasive front of colon cancers. The Journal of Cell Biology, 168(4), pp.633-642.  
Gerlinger, M., Horswell, S., Larkin, J., Rowan, A.J., Salm, M.P., Varela, I., Fisher, R., 
McGranahan, N., Matthews, N., Santos, C.R., Martinez, P., Phillimore, B., Begum, S., 
Rabinowitz, A., Spencer-Dene, B., Gulati, S., Bates, P.A., Stamp, G., Pickering, L., Gore, M., 
Nicol, D.L., Hazell, S., Futreal, P.A., Stewart, A. and Swanton, C. 2014. Genomic architecture 
and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature 
Genetics, 46(3), pp.225-233.  
Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, 
P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, 
N.Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., 
Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., 
Futreal, P.A. and Swanton, C. 2012. Intratumor heterogeneity and branched evolution revealed 
by multiregion sequencing. The New England Journal of Medicine, 366(10), pp.883-892.  
 310 
 
Gerlinger, M. and Swanton, C. 2010. How darwinian models inform therapeutic failure initiated 
by clonal heterogeneity in cancer medicine. British Journal of Cancer, 103(8), pp.1139-1143.  
Gill, J.H., Kirwan, I.G., Seargent, J.M., Martin, S.W., Tijani, S., Anikin, V.A., Mearns, A.J., 
Bibby, M.C., Anthoney, A. and Loadman, P.M. 2004. MMP-10 is overexpressed, 
proteolytically active, and a potential target for therapeutic intervention in human lung 
carcinomas. Neoplasia (New York, N.Y.), 6(6), pp.777-785.  
Gliem, M., Heupel, W.M., Spindler, V., Harms, G.S. and Waschke, J. 2010. Actin 
reorganization contributes to loss of cell adhesion in pemphigus vulgaris. American Journal of 
Physiology.Cell Physiology, 299(3), pp.C606-13.  
Gomez-Morales, M., Camara-Pulido, M., Miranda-Leon, M.T., Sanchez-Palencia, A., Boyero, 
L., Gomez-Capilla, J.A. and Farez-Vidal, M.E. 2013. Differential immunohistochemical 
localization of desmosomal plaque-related proteins in non-small-cell lung cancer. 
Histopathology, 63(1), pp.103-113.  
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N.D., Kanchi, K.L., Maher, C.A., 
Fulton, R., Fulton, L., Wallis, J., Chen, K., Walker, J., McDonald, S., Bose, R., Ornitz, D., 
Xiong, D., You, M., Dooling, D.J., Watson, M., Mardis, E.R. and Wilson, R.K. 2012. Genomic 
landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 150(6), pp.1121-
1134.  
Green, T.D., Park, J., Yin, Q., Fang, S., Crews, A.L., Jones, S.L. and Adler, K.B. 2012. Directed 
migration of mouse macrophages in vitro involves myristoylated alanine-rich C-kinase substrate 
(MARCKS) protein. Journal of Leukocyte Biology, 92(3), pp.633-639.  
Gruhler, S. and Kratchmarova, I. 2008. Stable isotope labeling by amino acids in cell culture 
(SILAC). Methods in Molecular Biology (Clifton, N.J.), 424pp.101-111.  
Gu, X., Karp, P.H., Brody, S.L., Pierce, R.A., Welsh, M.J., Holtzman, M.J. and Ben-Shahar, Y. 
2014. Chemosensory functions for pulmonary neuroendocrine cells. American Journal of 
Respiratory Cell and Molecular Biology, 50(3), pp.637-646.  
Gulcicek, E.E., Colangelo, C.M., McMurray, W., Stone, K., Williams, K., Wu, T., Zhao, H., 
Spratt, H., Kurosky, A. and Wu, B. 2005. Proteomics and the analysis of proteomic data: An 
overview of current protein-profiling technologies. Current Protocols in Bioinformatics / 
Editoral Board, Andreas D.Baxevanis ...[Et Al.], Chapter 13pp.Unit 13.1.  
Gygi, S.P., Rist, B., Griffin, T.J., Eng, J. and Aebersold, R. 2002. Proteome analysis of low-
abundance proteins using multidimensional chromatography and isotope-coded affinity tags. 
Journal of Proteome Research, 1(1), pp.47-54.  
Haddock, B.J., Zhu, Y., Doyle, S.P., Abdullah, L.H. and Davis, C.W. 2014. Role of MARCKS 
in regulated secretion from mast cells and airway goblet cells. American Journal of 
Physiology.Lung Cellular and Molecular Physiology, 306(10), pp.L925-36.  
Hage, R., Elbers, J.R., Brutel de la Riviere, A. and van den Bosch, J.M. 1998. Surgery for 
combined type small cell lung carcinoma. Thorax, 53(6), pp.450-453.  
Hajj, R., Baranek, T., Le Naour, R., Lesimple, P., Puchelle, E. and Coraux, C. 2007. Basal cells 
of the human adult airway surface epithelium retain transit-amplifying cell properties. Stem 
Cells (Dayton, Ohio), 25(1), pp.139-148.  
 311 
 
Hanada, S., Kakehashi, A., Nishiyama, N., Wei, M., Yamano, S., Chung, K., Komatsu, H., 
Inoue, H., Suehiro, S. and Wanibuchi, H. 2013. Myristoylated alanine-rich C-kinase substrate as 
a prognostic biomarker in human primary lung squamous cell carcinoma. Cancer Biomarkers : 
Section A of Disease Markers, 13(4), pp.289-298.  
Hanahan, D. and Weinberg, R.A. 2011. Hallmarks of cancer: The next generation. Cell, 144(5), 
pp.646-674.  
Hartwig, J.H., Thelen, M., Rosen, A., Janmey, P.A., Nairn, A.C. and Aderem, A. 1992. 
MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-
calmodulin. Nature, 356(6370), pp.618-622.  
Higginbotham, K.S., Breyer, J.P., McReynolds, K.M., Bradley, K.M., Schuyler, P.A., Plummer, 
W.D., Freudenthal, M.E., Trentham-Dietz, A., Newcomb, P.A., Parl, F.F., Sanders, M.E., Page, 
D.L., Egan, K.M., Dupont, W.D. and Smith, J.R. 2012. A multistage genetic association study 
identifies breast cancer risk loci at 10q25 and 16q24. Cancer Epidemiology, Biomarkers & 
Prevention : A Publication of the American Association for Cancer Research, Cosponsored by 
the American Society of Preventive Oncology, 21(9), pp.1565-1573.  
Hiley, C., de Bruin, E.C., McGranahan, N. and Swanton, C. 2014. Deciphering intratumor 
heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome 
Biology, 15(8), pp.453-014-0453-8.  
Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. 1991. P53 mutations in human 
cancers. Science (New York, N.Y.), 253(5015), pp.49-53.  
Hoppler, S. and Kavanagh, C.L. 2007. Wnt signalling: Variety at the core. Journal of Cell 
Science, 120(Pt 3), pp.385-393.  
Hortsch, M. 2000. Structural and functional evolution of the L1 family: Are four adhesion 
molecules better than one? Molecular and Cellular Neurosciences, 15(1), pp.1-10.  
Hu, P., Berkowitz, P., O'Keefe, E.J. and Rubenstein, D.S. 2003. Keratinocyte adherens junctions 
initiate nuclear signaling by translocation of plakoglobin from the membrane to the nucleus. The 
Journal of Investigative Dermatology, 121(2), pp.242-251.  
Huang, C.C., Lee, T.J., Chang, P.H., Lee, Y.S., Chuang, C.C., Jhang, Y.J., Chen, Y.W., Chen, 
C.W. and Tsai, C.N. 2010. Desmoglein 3 is overexpressed in inverted papilloma and squamous 
cell carcinoma of sinonasal cavity. The Laryngoscope, 120(1), pp.26-29.  
Humphries, J.D., Byron, A. and Humphries, M.J. 2006. Integrin ligands at a glance. Journal of 
Cell Science, 119(Pt 19), pp.3901-3903.  
Hynes, R.O. 2002. Integrins: Bidirectional, allosteric signaling machines. Cell, 110(6), pp.673-
687.  
Ihde, D.C. 1984. Current status of therapy for small cell carcinoma of the lung. Cancer, 54(11 
Suppl), pp.2722-2728.  
Illman, S.A., Lehti, K., Keski-Oja, J. and Lohi, J. 2006. Epilysin (MMP-28) induces TGF-beta 
mediated epithelial to mesenchymal transition in lung carcinoma cells. Journal of Cell Science, 
119(Pt 18), pp.3856-3865.  
 312 
 
Jackman, D.M., Miller, V.A., Cioffredi, L.A., Yeap, B.Y., Janne, P.A., Riely, G.J., Ruiz, M.G., 
Giaccone, G., Sequist, L.V. and Johnson, B.E. 2009. Impact of epidermal growth factor receptor 
and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer 
patients: Results of an online tumor registry of clinical trials. Clinical Cancer Research : An 
Official Journal of the American Association for Cancer Research, 15(16), pp.5267-5273.  
Jarboe, J.S., Anderson, J.C., Duarte, C.W., Mehta, T., Nowsheen, S., Hicks, P.H., Whitley, 
A.C., Rohrbach, T.D., McCubrey, R.O., Chiu, S., Burleson, T.M., Bonner, J.A., Gillespie, G.Y., 
Yang, E.S. and Willey, C.D. 2012. MARCKS regulates growth and radiation sensitivity and is a 
novel prognostic factor for glioma. Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research, 18(11), pp.3030-3041.  
Jarmalaite, S., Kannio, A., Anttila, S., Lazutka, J.R. and Husgafvel-Pursiainen, K. 2003. 
Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung 
cancer. International Journal of Cancer.Journal International Du Cancer, 106(6), pp.913-918.  
Jemal, A., Siegel, R., Xu, J. and Ward, E. 2010. Cancer statistics, 2010. CA: A Cancer Journal 
for Clinicians, 60(5), pp.277-300.  
Jennings, J.M., Tucker, D.K., Kottke, M.D., Saito, M., Delva, E., Hanakawa, Y., Amagai, M. 
and Kowalczyk, A.P. 2011. Desmosome disassembly in response to pemphigus vulgaris IgG 
occurs in distinct phases and can be reversed by expression of exogenous Dsg3. The Journal of 
Investigative Dermatology, 131(3), pp.706-718.  
Ji, L., Lim, J. and Danuser, G. 2008. Fluctuations of intracellular forces during cell protrusion. 
Nature Cell Biology, 10(12), pp.1393-1400.  
Jonsdottir, K., Zhang, H., Jhagroe, D., Skaland, I., Slewa, A., Bjorkblom, B., Coffey, E.T., 
Gudlaugsson, E., Smaaland, R., Janssen, E.A. and Baak, J.P. 2012. The prognostic value of 
MARCKS-like 1 in lymph node-negative breast cancer. Breast Cancer Research and 
Treatment, 135(2), pp.381-390.  
Kalantari-Dehaghi, M., Chen, Y., Deng, W., Chernyavsky, A., Marchenko, S., Wang, P.H. and 
Grando, S.A. 2013. Mechanisms of mitochondrial damage in keratinocytes by pemphigus 
vulgaris antibodies. The Journal of Biological Chemistry, 288(23), pp.16916-16925.  
Kalluri, R. and Weinberg, R.A. 2009. The basics of epithelial-mesenchymal transition. The 
Journal of Clinical Investigation, 119(6), pp.1420-1428.  
Kang, Y., Lu, S., Ren, P., Huo, B. and Long, M. 2012. Molecular dynamics simulation of shear- 
and stretch-induced dissociation of P-selectin/PSGL-1 complex. Biophysical Journal, 102(1), 
pp.112-120.  
Kannagi, R., Izawa, M., Koike, T., Miyazaki, K. and Kimura, N. 2004. Carbohydrate-mediated 
cell adhesion in cancer metastasis and angiogenesis. Cancer Science, 95(5), pp.377-384.  
Kansas, G.S. 1996. Selectins and their ligands: Current concepts and controversies. Blood, 
88(9), pp.3259-3287.  
Keenan, J., Joyce, H., Aherne, S., O'Dea, S., Doolan, P., Lynch, V. and Clynes, M. 2012. 
Olfactomedin III expression contributes to anoikis-resistance in clonal variants of a human lung 
squamous carcinoma cell line. Experimental Cell Research, 318(5), pp.593-602.  
 313 
 
Kelley, M.J., Nakagawa, K., Steinberg, S.M., Mulshine, J.L., Kamb, A. and Johnson, B.E. 1995. 
Differential inactivation of CDKN2 and rb protein in non-small-cell and small-cell lung cancer 
cell lines. Journal of the National Cancer Institute, 87(10), pp.756-761.  
Kenfield, S.A., Wei, E.K., Stampfer, M.J., Rosner, B.A. and Colditz, G.A. 2008. Comparison of 
aspects of smoking among the four histological types of lung cancer. Tobacco Control, 17(3), 
pp.198-204.  
Kim, C.F., Jackson, E.L., Woolfenden, A.E., Lawrence, S., Babar, I., Vogel, S., Crowley, D., 
Bronson, R.T. and Jacks, T. 2005. Identification of bronchioalveolar stem cells in normal lung 
and lung cancer. Cell, 121(6), pp.823-835.  
Kim, Y.N., Choi, J.E., Bae, J.S., Jang, K.Y., Chung, M.J., Moon, W.S., Kang, M.J., Lee, D.G. 
and Park, H.S. 2012. Expression of cortactin and focal adhesion kinase in colorectal 
adenocarcinoma: Correlation with clinicopathologic parameters and their prognostic 
implication. Korean Journal of Pathology, 46(5), pp.454-462.  
Kinzler, K.W. and Vogelstein, B. 1997. Cancer-susceptibility genes. gatekeepers and caretakers. 
Nature, 386(6627), pp.761, 763.  
Kleene, R., Yang, H., Kutsche, M. and Schachner, M. 2001. The neural recognition molecule 
L1 is a sialic acid-binding lectin for CD24, which induces promotion and inhibition of neurite 
outgrowth. The Journal of Biological Chemistry, 276(24), pp.21656-21663.  
Knoll, B. and Drescher, U. 2004. Src family kinases are involved in EphA receptor-mediated 
retinal axon guidance. The Journal of Neuroscience : The Official Journal of the Society for 
Neuroscience, 24(28), pp.6248-6257.  
Knudson, A.G.,Jr. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proceedings 
of the National Academy of Sciences of the United States of America, 68(4), pp.820-823.  
Koga, H., Tsuruta, D., Ohyama, B., Ishii, N., Hamada, T., Ohata, C., Furumura, M. and 
Hashimoto, T. 2013. Desmoglein 3, its pathogenecity and a possibility for therapeutic target in 
pemphigus vulgaris. Expert Opinion on Therapeutic Targets, 17(3), pp.293-306.  
Kong, D., Li, Y., Wang, Z. and Sarkar, F.H. 2011. Cancer stem cells and epithelial-to-
mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers, 3(1), 
pp.716-729.  
Kubo, Y., Baba, K., Toriyama, M., Minegishi, T., Sugiura, T., Kozawa, S., Ikeda, K. and 
Inagaki, N. 2015. Shootin1-cortactin interaction mediates signal-force transduction for axon 
outgrowth. The Journal of Cell Biology, 210(4), pp.663-676.  
Larsson, C. 2006. Protein kinase C and the regulation of the actin cytoskeleton. Cellular 
Signalling, 18(3), pp.276-284.  
Law, E., Gilvarry, U., Lynch, V., Gregory, B., Grant, G. and Clynes, M. 1992. Cytogenetic 
comparison of two poorly differentiated human lung squamous cell carcinoma lines. Cancer 
Genetics and Cytogenetics, 59(2), pp.111-118.  
Lee, Y.Y., Yu, C.P., Lin, C.K., Nieh, S., Hsu, K.F., Chiang, H. and Jin, J.S. 2009. Expression of 
survivin and cortactin in colorectal adenocarcinoma: Association with clinicopathological 
parameters. Disease Markers, 26(1), pp.9-18.  
 314 
 
Lemjabbar-Alaoui, H., Dasari, V., Sidhu, S.S., Mengistab, A., Finkbeiner, W., Gallup, M. and 
Basbaum, C. 2006. Wnt and hedgehog are critical mediators of cigarette smoke-induced lung 
cancer. PloS One, 1pp.e93.  
Li, H., Chen, G., Zhou, B. and Duan, S. 2008a. Actin filament assembly by myristoylated 
alanine-rich C kinase substrate-phosphatidylinositol-4,5-diphosphate signaling is critical for 
dendrite branching. Molecular Biology of the Cell, 19(11), pp.4804-4813.  
Li, H., Chen, G., Zhou, B. and Duan, S. 2008b. Actin filament assembly by myristoylated 
alanine-rich C kinase substrate-phosphatidylinositol-4,5-diphosphate signaling is critical for 
dendrite branching. Molecular Biology of the Cell, 19(11), pp.4804-4813.  
Lindor, K.D., Gershwin, M.E., Poupon, R., Kaplan, M., Bergasa, N.V., Heathcote, E.J. and 
American Association for Study of Liver Diseases. 2009. Primary biliary cirrhosis. Hepatology 
(Baltimore, Md.), 50(1), pp.291-308.  
Linnoila, R.I. 2006. Functional facets of the pulmonary neuroendocrine system. Laboratory 
Investigation; a Journal of Technical Methods and Pathology, 86(5), pp.425-444.  
Luo, M.L., Shen, X.M., Zhang, Y., Wei, F., Xu, X., Cai, Y., Zhang, X., Sun, Y.T., Zhan, Q.M., 
Wu, M. and Wang, M.R. 2006. Amplification and overexpression of CTTN (EMS1) contribute 
to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and 
anoikis resistance. Cancer Research, 66(24), pp.11690-11699.  
MacCoss, M.J., Wu, C.C. and Yates, J.R.,3rd. 2002. Probability-based validation of protein 
identifications using a modified SEQUEST algorithm. Analytical Chemistry, 74(21), pp.5593-
5599.  
Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, B., 
Hartmann, D. and Saftig, P. 2005. ADAM10 mediates E-cadherin shedding and regulates 
epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proceedings of the 
National Academy of Sciences of the United States of America, 102(26), pp.9182-9187.  
Margadant, C. and Sonnenberg, A. 2010. Integrin-TGF-beta crosstalk in fibrosis, cancer and 
wound healing. EMBO Reports, 11(2), pp.97-105.  
Marouga, R., David, S. and Hawkins, E. 2005. The development of the DIGE system: 2D 
fluorescence difference gel analysis technology. Analytical and Bioanalytical Chemistry, 
382(3), pp.669-678.  
Marte, B. 2013. Tumour heterogeneity. Nature, 501(7467), pp.327.  
Marusyk, A. and Polyak, K. 2010. Tumor heterogeneity: Causes and consequences. Biochimica 
Et Biophysica Acta, 1805(1), pp.105-117.  
Matsubara, M., Titani, K., Taniguchi, H. and Hayashi, N. 2003. Direct involvement of protein 
myristoylation in myristoylated alanine-rich C kinase substrate (MARCKS)-calmodulin 
interaction. The Journal of Biological Chemistry, 278(49), pp.48898-48902.  
McBride, S., Meleady, P., Baird, A., Dinsdale, D. and Clynes, M. 1998a. Human lung 
carcinoma cell line DLKP contains 3 distinct subpopulations with different growth and 
attachment properties. Tumour Biology : The Journal of the International Society for 
Oncodevelopmental Biology and Medicine, 19(2), pp.88-103.  
 315 
 
McBride, S., Meleady, P., Baird, A., Dinsdale, D. and Clynes, M. 1998b. Human lung 
carcinoma cell line DLKP contains 3 distinct subpopulations with different growth and 
attachment properties. Tumour Biology : The Journal of the International Society for 
Oncodevelopmental Biology and Medicine, 19(2), pp.88-103.  
Micallef, J., Taccone, M., Mukherjee, J., Croul, S., Busby, J., Moran, M.F. and Guha, A. 2009. 
Epidermal growth factor receptor variant III-induced glioma invasion is mediated through 
myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Research, 69(19), 
pp.7548-7556.  
Michalovitz, D., Halevy, O. and Oren, M. 1990. Conditional inhibition of transformation and of 
cell proliferation by a temperature-sensitive mutant of p53. Cell, 62(4), pp.671-680.  
Miskovic, J., Brekalo, Z., Vukojevic, K., Miskovic, H.R., Kraljevic, D., Todorovic, J. and 
Soljic, V. 2015. Co-expression of TTF-1 and neuroendocrine markers in the human fetal lung 
and pulmonary neuroendocrine tumors. Acta Histochemica, 117(4-5), pp.451-459.  
Miyazaki, H., Goto, A., Hino, R., Ota, S., Okudaira, R., Murakawa, T., Nakajima, J. and 
Fukayama, M. 2011. Pleural cavity angiosarcoma arising in chronic expanding hematoma after 
pneumonectomy. Human Pathology, 42(10), pp.1576-1579.  
Mok, T.S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., 
Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., 
Jiang, H., Duffield, E.L., Watkins, C.L., Armour, A.A. and Fukuoka, M. 2009. Gefitinib or 
carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 
361(10), pp.947-957.  
Monteoliva, L. and Albar, J.P. 2004. Differential proteomics: An overview of gel and non-gel 
based approaches. Briefings in Functional Genomics & Proteomics, 3(3), pp.220-239.  
Mori, N., Yokota, J., Akiyama, T., Sameshima, Y., Okamoto, A., Mizoguchi, H., Toyoshima, 
K., Sugimura, T. and Terada, M. 1990. Variable mutations of the RB gene in small-cell lung 
carcinoma. Oncogene, 5(11), pp.1713-1717.  
Murphy, J.P., Everley, R.A., Coloff, J.L. and Gygi, S.P. 2014. Combining amine metabolomics 
and quantitative proteomics of cancer cells using derivatization with isobaric tags. Analytical 
Chemistry, 86(7), pp.3585-3593.  
Nakajima, S., Doi, R., Toyoda, E., Tsuji, S., Wada, M., Koizumi, M., Tulachan, S.S., Ito, D., 
Kami, K., Mori, T., Kawaguchi, Y., Fujimoto, K., Hosotani, R. and Imamura, M. 2004. N-
cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clinical 
Cancer Research : An Official Journal of the American Association for Cancer Research, 10(12 
Pt 1), pp.4125-4133.  
Nakamura, T., Matsumoto, K., Kiritoshi, A., Tano, Y. and Nakamura, T. 1997. Induction of 
hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of 
tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Research, 57(15), pp.3305-
3313.  
Nakazawa, K., Kurishima, K., Tamura, T., Kagohashi, K., Ishikawa, H., Satoh, H. and Hizawa, 
N. 2012. Specific organ metastases and survival in small cell lung cancer. Oncology Letters, 
4(4), pp.617-620.  
 316 
 
Neilson, K.A., Ali, N.A., Muralidharan, S., Mirzaei, M., Mariani, M., Assadourian, G., Lee, A., 
van Sluyter, S.C. and Haynes, P.A. 2011. Less label, more free: Approaches in label-free 
quantitative mass spectrometry. Proteomics, 11(4), pp.535-553.  
Nishino, K., Imamura, F., Kumagai, T., Uchida, J., Akazawa, Y., Okuyama, T. and Tomita, Y. 
2011. Small-cell lung carcinoma with long-term survival: A case report. Oncology Letters, 2(5), 
pp.827-830.  
Noh, S.J., Baek, H.A., Park, H.S., Jang, K.Y., Moon, W.S., Kang, M.J., Lee, D.G., Kim, M.H., 
Lee, J.H. and Chung, M.J. 2013. Expression of SIRT1 and cortactin is associated with 
progression of non-small cell lung cancer. Pathology, Research and Practice, 209(6), pp.365-
370.  
O'Farrell, P.H. 1975. High resolution two-dimensional electrophoresis of proteins. The Journal 
of Biological Chemistry, 250(10), pp.4007-4021.  
Oft, M., Heider, K.H. and Beug, H. 1998. TGFbeta signaling is necessary for carcinoma cell 
invasiveness and metastasis. Current Biology : CB, 8(23), pp.1243-1252.  
Okamoto, A., Hussain, S.P., Hagiwara, K., Spillare, E.A., Rusin, M.R., Demetrick, D.J., 
Serrano, M., Hannon, G.J., Shiseki, M. and Zariwala, M. 1995. Mutations in the 
p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung 
cancer. Cancer Research, 55(7), pp.1448-1451.  
Ong, S.E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A. and Mann, M. 
2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate 
approach to expression proteomics. Molecular & Cellular Proteomics : MCP, 1(5), pp.376-386.  
Osada, H., Tatematsu, Y., Yatabe, Y., Horio, Y. and Takahashi, T. 2005. ASH1 gene is a 
specific therapeutic target for lung cancers with neuroendocrine features. Cancer Research, 
65(23), pp.10680-10685.  
Otsubo, T., Iwaya, K., Mukai, Y., Mizokami, Y., Serizawa, H., Matsuoka, T. and Mukai, K. 
2004. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Modern 
Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc, 
17(4), pp.461-467.  
Ozanne, B.W., Spence, H.J., McGarry, L.C. and Hennigan, R.F. 2007. Transcription factors 
control invasion: AP-1 the first among equals. Oncogene, 26(1), pp.1-10.  
Pailler, E., Auger, N., Lindsay, C.R., Vielh, P., Islas-Morris-Hernandez, A., Borget, I., Ngo-
Camus, M., Planchard, D., Soria, J.C., Besse, B. and Farace, F. 2015. High level of 
chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung 
cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / 
ESMO, 26(7), pp.1408-1415.  
Parker, H.R., Li, Z., Sheinin, H., Lauzon, G. and Pasdar, M. 1998. Plakoglobin induces 
desmosome formation and epidermoid phenotype in N-cadherin-expressing squamous 
carcinoma cells deficient in plakoglobin and E-cadherin. Cell Motility and the Cytoskeleton, 
40(1), pp.87-100.  
 317 
 
Paschos, K.A., Canovas, D. and Bird, N.C. 2009. The role of cell adhesion molecules in the 
progression of colorectal cancer and the development of liver metastasis. Cellular Signalling, 
21(5), pp.665-674.  
Patel, V., Martin, D., Malhotra, R., Marsh, C.A., Doci, C.L., Veenstra, T.D., Nathan, C.A., 
Sinha, U.K., Singh, B., Molinolo, A.A., Rusling, J.F. and Gutkind, J.S. 2013. DSG3 as a 
biomarker for the ultrasensitive detection of occult lymph node metastasis in oral cancer using 
nanostructured immunoarrays. Oral Oncology, 49(2), pp.93-101.  
Perez-Moreno, P., Brambilla, E., Thomas, R. and Soria, J.C. 2012. Squamous cell carcinoma of 
the lung: Molecular subtypes and therapeutic opportunities. Clinical Cancer Research : An 
Official Journal of the American Association for Cancer Research, 18(9), pp.2443-2451.  
Qian, W.J., Jacobs, J.M., Liu, T., Camp, D.G.,2nd and Smith, R.D. 2006. Advances and 
challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical 
applications. Molecular & Cellular Proteomics : MCP, 5(10), pp.1727-1744.  
Randell, S.H., Comment, C.E., Ramaekers, F.C. and Nettesheim, P. 1991. Properties of rat 
tracheal epithelial cells separated based on expression of cell surface alpha-galactosyl end 
groups. American Journal of Respiratory Cell and Molecular Biology, 4(6), pp.544-554.  
Rapley, J., Nicolas, M., Groen, A., Regue, L., Bertran, M.T., Caelles, C., Avruch, J. and Roig, J. 
2008. The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary 
for mitotic spindle formation. Journal of Cell Science, 121(Pt 23), pp.3912-3921.  
Rassat, J., Robenek, H. and Themann, H. 1981. Structural relationship between desmosomes 
and mitochondria in human livers exhibiting a wide range of diseases. The American Journal of 
Pathology, 105(3), pp.207-211.  
Ren, L., Hong, S.H., Cassavaugh, J., Osborne, T., Chou, A.J., Kim, S.Y., Gorlick, R., Hewitt, 
S.M. and Khanna, C. 2009. The actin-cytoskeleton linker protein ezrin is regulated during 
osteosarcoma metastasis by PKC. Oncogene, 28(6), pp.792-802.  
Reya, T., Morrison, S.J., Clarke, M.F. and Weissman, I.L. 2001. Stem cells, cancer, and cancer 
stem cells. Nature, 414(6859), pp.105-111.  
Reynolds, S.D., Giangreco, A., Power, J.H. and Stripp, B.R. 2000a. Neuroepithelial bodies of 
pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration. 
The American Journal of Pathology, 156(1), pp.269-278.  
Reynolds, S.D., Hong, K.U., Giangreco, A., Mango, G.W., Guron, C., Morimoto, Y. and Stripp, 
B.R. 2000b. Conditional clara cell ablation reveals a self-renewing progenitor function of 
pulmonary neuroendocrine cells. American Journal of Physiology.Lung Cellular and Molecular 
Physiology, 278(6), pp.L1256-63.  
Roan, N.R., Liu, H., Usmani, S.M., Neidleman, J., Muller, J.A., Avila-Herrera, A., Gawanbacht, 
A., Zirafi, O., Chu, S., Dong, M., Kumar, S.T., Smith, J.F., Pollard, K.S., Fandrich, M., 
Kirchhoff, F., Munch, J., Witkowska, H.E. and Greene, W.C. 2014. Liquefaction of semen 
generates and later degrades a conserved semenogelin peptide that enhances HIV infection. 
Journal of Virology, 88(13), pp.7221-7234.  
 318 
 
Rock, J.R., Randell, S.H. and Hogan, B.L. 2010. Airway basal stem cells: A perspective on their 
roles in epithelial homeostasis and remodeling. Disease Models & Mechanisms, 3(9-10), 
pp.545-556.  
Rodrigo, J.P., Alvarez-Alija, G., Menendez, S.T., Mancebo, G., Allonca, E., Garcia-Carracedo, 
D., Fresno, M.F., Suarez, C. and Garcia-Pedrero, J.M. 2011. Cortactin and focal adhesion kinase 
as predictors of cancer risk in patients with laryngeal premalignancy. Cancer Prevention 
Research (Philadelphia, Pa.), 4(8), pp.1333-1341.  
Rodrigues, R.G., Panizo-Santos, A., Cashel, J.A., Krutzsch, H.C., Merino, M.J. and Roberts, 
D.D. 2001. Semenogelins are ectopically expressed in small cell lung carcinoma. Clinical 
Cancer Research : An Official Journal of the American Association for Cancer Research, 7(4), 
pp.854-860.  
Rohrbach, T.D., Shah, N., Jackson, W.P., Feeney, E.V., Scanlon, S., Gish, R., Khodadadi, R., 
Hyde, S.O., Hicks, P.H., Anderson, J.C., Jarboe, J.S. and Willey, C.D. 2015. The effector 
domain of MARCKS is a nuclear localization signal that regulates cellular PIP2 levels and 
nuclear PIP2 localization. PloS One, 10(10), pp.e0140870.  
Rombouts, K., Carloni, V., Mello, T., Omenetti, S., Galastri, S., Madiai, S., Galli, A. and 
Pinzani, M. 2013. Myristoylated alanine-rich protein kinase C substrate (MARCKS) expression 
modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. 
Cancer Letters, 333(2), pp.244-252.  
Rosen, A., Keenan, K.F., Thelen, M., Nairn, A.C. and Aderem, A. 1990. Activation of protein 
kinase C results in the displacement of its myristoylated, alanine-rich substrate from punctate 
structures in macrophage filopodia. The Journal of Experimental Medicine, 172(4), pp.1211-
1215.  
Sapir, T., Levy, T., Sakakibara, A., Rabinkov, A., Miyata, T. and Reiner, O. 2013. Shootin1 acts 
in concert with KIF20B to promote polarization of migrating neurons. The Journal of 
Neuroscience : The Official Journal of the Society for Neuroscience, 33(29), pp.11932-11948.  
Sato, M., Aoyama, Y. and Kitajima, Y. 2000. Assembly pathway of desmoglein 3 to 
desmosomes and its perturbation by pemphigus vulgaris-IgG in cultured keratinocytes, as 
revealed by time-lapsed labeling immunoelectron microscopy. Laboratory Investigation; a 
Journal of Technical Methods and Pathology, 80(10), pp.1583-1592.  
Savci-Heijink, C.D., Kosari, F., Aubry, M.C., Caron, B.L., Sun, Z., Yang, P. and Vasmatzis, G. 
2009. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. The 
American Journal of Pathology, 174(5), pp.1629-1637.  
Savitski, M.M., Nielsen, M.L. and Zubarev, R.A. 2005. New data base-independent, sequence 
tag-based scoring of peptide MS/MS data validates mowse scores, recovers below threshold 
data, singles out modified peptides, and assesses the quality of MS/MS techniques. Molecular & 
Cellular Proteomics : MCP, 4(8), pp.1180-1188.  
Semba, S., Iwaya, K., Matsubayashi, J., Serizawa, H., Kataba, H., Hirano, T., Kato, H., 
Matsuoka, T. and Mukai, K. 2006. Coexpression of actin-related protein 2 and wiskott-aldrich 
syndrome family verproline-homologous protein 2 in adenocarcinoma of the lung. Clinical 
Cancer Research : An Official Journal of the American Association for Cancer Research, 12(8), 
pp.2449-2454.  
 319 
 
Shaw, A.T., Winslow, M.M., Magendantz, M., Ouyang, C., Dowdle, J., Subramanian, A., 
Lewis, T.A., Maglathin, R.L., Tolliday, N. and Jacks, T. 2011. Selective killing of K-ras mutant 
cancer cells by small molecule inducers of oxidative stress. Proceedings of the National 
Academy of Sciences of the United States of America, 108(21), pp.8773-8778.  
Shimada, T., Toriyama, M., Uemura, K., Kamiguchi, H., Sugiura, T., Watanabe, N. and Inagaki, 
N. 2008. Shootin1 interacts with actin retrograde flow and L1-CAM to promote axon 
outgrowth. The Journal of Cell Biology, 181(5), pp.817-829.  
Song, H., Yao, E., Lin, C., Gacayan, R., Chen, M.H. and Chuang, P.T. 2012. Functional 
characterization of pulmonary neuroendocrine cells in lung development, injury, and 
tumorigenesis. Proceedings of the National Academy of Sciences of the United States of 
America, 109(43), pp.17531-17536.  
Song, J. 2007. EMT or apoptosis: A decision for TGF-beta. Cell Research, 17(4), pp.289-290.  
Souchelnytskyi, S. 2005. Bridging proteomics and systems biology: What are the roads to be 
traveled? Proteomics, 5(16), pp.4123-4137.  
Spizz, G. and Blackshear, P.J. 2001. Overexpression of the myristoylated alanine-rich C-kinase 
substrate inhibits cell adhesion to extracellular matrix components. The Journal of Biological 
Chemistry, 276(34), pp.32264-32273.  
Stannard, W. and O'Callaghan, C. 2006. Ciliary function and the role of cilia in clearance. 
Journal of Aerosol Medicine : The Official Journal of the International Society for Aerosols in 
Medicine, 19(1), pp.110-115.  
Suda, K., Tomizawa, K. and Mitsudomi, T. 2010. Biological and clinical significance of KRAS 
mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer 
Metastasis Reviews, 29(1), pp.49-60.  
Sun, W., Liu, Q., Leng, J., Zheng, Y. and Li, J. 2015. The role of pyruvate dehydrogenase 
complex in cardiovascular diseases. Life Sciences, 121pp.97-103.  
Suter, D.M. and Forscher, P. 2000. Substrate-cytoskeletal coupling as a mechanism for the 
regulation of growth cone motility and guidance. Journal of Neurobiology, 44(2), pp.97-113.  
Talmadge, J.E. and Fidler, I.J. 2010. AACR centennial series: The biology of cancer metastasis: 
Historical perspective. Cancer Research, 70(14), pp.5649-5669.  
Techasen, A., Loilome, W., Namwat, N., Takahashi, E., Sugihara, E., Puapairoj, A., Miwa, M., 
Saya, H. and Yongvanit, P. 2010. Myristoylated alanine-rich C kinase substrate phosphorylation 
promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent 
pathway. Cancer Science, 101(3), pp.658-665.  
Toriyama, M., Kozawa, S., Sakumura, Y. and Inagaki, N. 2013. Conversion of a signal into 
forces for axon outgrowth through Pak1-mediated shootin1 phosphorylation. Current Biology : 
CB, 23(6), pp.529-534.  
Toriyama, M., Shimada, T., Kim, K.B., Mitsuba, M., Nomura, E., Katsuta, K., Sakumura, Y., 
Roepstorff, P. and Inagaki, N. 2006. Shootin1: A protein involved in the organization of an 
asymmetric signal for neuronal polarization. The Journal of Cell Biology, 175(1), pp.147-157.  
 320 
 
Toyooka, S., Tsuda, T. and Gazdar, A.F. 2003. The TP53 gene, tobacco exposure, and lung 
cancer. Human Mutation, 21(3), pp.229-239.  
Travis, W.D., Brambilla, E., Noguchi, M., Nicholson, A.G., Geisinger, K., Yatabe, Y., 
Ishikawa, Y., Wistuba, I., Flieder, D.B., Franklin, W., Gazdar, A., Hasleton, P.S., Henderson, 
D.W., Kerr, K.M., Petersen, I., Roggli, V., Thunnissen, E. and Tsao, M. 2013. Diagnosis of lung 
cancer in small biopsies and cytology: Implications of the 2011 international association for the 
study of lung cancer/american thoracic society/european respiratory society classification. 
Archives of Pathology & Laboratory Medicine, 137(5), pp.668-684.  
Tsang, S.M., Brown, L., Gadmor, H., Gammon, L., Fortune, F., Wheeler, A. and Wan, H. 2012. 
Desmoglein 3 acting as an upstream regulator of rho GTPases, rac-1/Cdc42 in the regulation of 
actin organisation and dynamics. Experimental Cell Research, 318(18), pp.2269-2283.  
Tsang, S.M., Liu, L., Teh, M.T., Wheeler, A., Grose, R., Hart, I.R., Garrod, D.R., Fortune, F. 
and Wan, H. 2010. Desmoglein 3, via an interaction with E-cadherin, is associated with 
activation of src. PloS One, 5(12), pp.e14211.  
Tuli, L. and Ressom, H.W. 2009. LC-MS based detection of differential protein expression. 
Journal of Proteomics & Bioinformatics, 2pp.416-438.  
Unwin, R.D. 2010. Quantification of proteins by iTRAQ. Methods in Molecular Biology 
(Clifton, N.J.), 658pp.205-215.  
Uruno, T., Liu, J., Zhang, P., Fan, Y., Egile, C., Li, R., Mueller, S.C. and Zhan, X. 2001. 
Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nature Cell Biology, 
3(3), pp.259-266.  
Van Goor, D., Hyland, C., Schaefer, A.W. and Forscher, P. 2012. The role of actin turnover in 
retrograde actin network flow in neuronal growth cones. PloS One, 7(2), pp.e30959.  
Van Lommel, A. 2001. Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies 
(NEB): Chemoreceptors and regulators of lung development. Paediatric Respiratory Reviews, 
2(2), pp.171-176.  
van Zijl, F., Krupitza, G. and Mikulits, W. 2011. Initial steps of metastasis: Cell invasion and 
endothelial transmigration. Mutation Research, 728(1-2), pp.23-34.  
Veltman, D.M. and Insall, R.H. 2010. WASP family proteins: Their evolution and its 
physiological implications. Molecular Biology of the Cell, 21(16), pp.2880-2893.  
Voyksner, R.D. and Lee, H. 1999. Investigating the use of an octupole ion guide for ion storage 
and high-pass mass filtering to improve the quantitative performance of electrospray ion trap 
mass spectrometry. Rapid Communications in Mass Spectrometry : RCM, 13(14), pp.1427-
1437.  
Wagner, P.L., Kitabayashi, N., Chen, Y.T. and Saqi, A. 2009. Combined small cell lung 
carcinomas: Genotypic and immunophenotypic analysis of the separate morphologic 
components. American Journal of Clinical Pathology, 131(3), pp.376-382.  
Walenkamp, A.M., Sonke, G.S. and Sleijfer, D.T. 2009. Clinical and therapeutic aspects of 
extrapulmonary small cell carcinoma. Cancer Treatment Reviews, 35(3), pp.228-236.  
 321 
 
Wang, L., Liu, T., Wang, Y., Cao, L., Nishioka, M., Aguirre, R.L., Ishikawa, A., Geng, L. and 
Okada, N. 2007. Altered expression of desmocollin 3, desmoglein 3, and beta-catenin in oral 
squamous cell carcinoma: Correlation with lymph node metastasis and cell proliferation. 
Virchows Archiv : An International Journal of Pathology, 451(5), pp.959-966.  
Weaver, A.M. 2006. Invadopodia: Specialized cell structures for cancer invasion. Clinical & 
Experimental Metastasis, 23(2), pp.97-105.  
Weed, S.A. and Parsons, J.T. 2001. Cortactin: Coupling membrane dynamics to cortical actin 
assembly. Oncogene, 20(44), pp.6418-6434.  
Wei, J., Zhao, Z.X., Li, Y., Zhou, Z.Q. and You, T.G. 2014. Cortactin expression confers a 
more malignant phenotype to gastric cancer SGC-7901 cells. World Journal of 
Gastroenterology : WJG, 20(12), pp.3287-3300.  
Wein, G., Rossler, M., Klug, R. and Herget, T. 2003. The 3'-UTR of the mRNA coding for the 
major protein kinase C substrate MARCKS contains a novel CU-rich element interacting with 
the mRNA stabilizing factors HuD and HuR. European Journal of Biochemistry / FEBS, 
270(2), pp.350-365.  
Weinstein, I.B. 2002. Cancer. addiction to oncogenes--the achilles heal of cancer. Science (New 
York, N.Y.), 297(5578), pp.63-64.  
Weinstein, I.B. and Joe, A. 2008. Oncogene addiction. Cancer Research, 68(9), pp.3077-80; 
discussion 3080.  
Westerman, B.A., Neijenhuis, S., Poutsma, A., Steenbergen, R.D., Breuer, R.H., Egging, M., 
van Wijk, I.J. and Oudejans, C.B. 2002. Quantitative reverse transcription-polymerase chain 
reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with 
neuroendocrine features. Clinical Cancer Research : An Official Journal of the American 
Association for Cancer Research, 8(4), pp.1082-1086.  
Winn, R.A., Bremnes, R.M., Bemis, L., Franklin, W.A., Miller, Y.E., Cool, C. and Heasley, 
L.E. 2002. Gamma-catenin expression is reduced or absent in a subset of human lung cancers 
and re-expression inhibits transformed cell growth. Oncogene, 21(49), pp.7497-7506.  
Wirtz, D., Konstantopoulos, K. and Searson, P.C. 2011. The physics of cancer: The role of 
physical interactions and mechanical forces in metastasis. Nature Reviews.Cancer, 11(7), 
pp.512-522.  
Wong, M., Hyodo, T., Asano, E., Funasaka, K., Miyahara, R., Hirooka, Y., Goto, H., 
Hamaguchi, M. and Senga, T. 2014. Silencing of STRN4 suppresses the malignant 
characteristics of cancer cells. Cancer Science, 105(12), pp.1526-1532.  
Wright, J.R. 2004. Host defense functions of pulmonary surfactant. Biology of the Neonate, 
85(4), pp.326-332.  
Wu, H., Reynolds, A.B., Kanner, S.B., Vines, R.R. and Parsons, J.T. 1991. Identification and 
characterization of a novel cytoskeleton-associated pp60src substrate. Molecular and Cellular 
Biology, 11(10), pp.5113-5124.  
 322 
 
Xiao, H., Zhang, L., Zhou, H., Lee, J.M., Garon, E.B. and Wong, D.T. 2012. Proteomic analysis 
of human saliva from lung cancer patients using two-dimensional difference gel electrophoresis 
and mass spectrometry. Molecular & Cellular Proteomics : MCP, 11(2), pp.M111.012112.  
Yamaguchi, H. and Condeelis, J. 2007. Regulation of the actin cytoskeleton in cancer cell 
migration and invasion. Biochimica Et Biophysica Acta, 1773(5), pp.642-652.  
Yamaguchi, H., Lorenz, M., Kempiak, S., Sarmiento, C., Coniglio, S., Symons, M., Segall, J., 
Eddy, R., Miki, H., Takenawa, T. and Condeelis, J. 2005. Molecular mechanisms of 
invadopodium formation: The role of the N-WASP-Arp2/3 complex pathway and cofilin. The 
Journal of Cell Biology, 168(3), pp.441-452.  
Yamaguchi, H., Wyckoff, J. and Condeelis, J. 2005. Cell migration in tumors. Current Opinion 
in Cell Biology, 17(5), pp.559-564.  
Yamashiro, S. and Watanabe, N. 2014. A new link between the retrograde actin flow and focal 
adhesions. Journal of Biochemistry, 156(5), pp.239-248.  
Yang, L., Lin, C. and Liu, Z.R. 2006. P68 RNA helicase mediates PDGF-induced epithelial 
mesenchymal transition by displacing axin from beta-catenin. Cell, 127(1), pp.139-155.  
Yarmola, E.G., Edison, A.S., Lenox, R.H. and Bubb, M.R. 2001. Actin filament cross-linking 
by MARCKS: Characterization of two actin-binding sites within the phosphorylation site 
domain. The Journal of Biological Chemistry, 276(25), pp.22351-22358.  
Yates, J.R., Ruse, C.I. and Nakorchevsky, A. 2009. Proteomics by mass spectrometry: 
Approaches, advances, and applications. Annual Review of Biomedical Engineering, 11pp.49-
79.  
Yu, D., Makkar, G., Strickland, D.K., Blanpied, T.A., Stumpo, D.J., Blackshear, P.J., Sarkar, R. 
and Monahan, T.S. 2015. Myristoylated alanine-rich protein kinase substrate (MARCKS) 
regulates small GTPase Rac1 and Cdc42 activity and is a critical mediator of vascular smooth 
muscle cell migration in intimal hyperplasia formation. Journal of the American Heart 
Association, 4(10), pp.e002255.  
Zhang, S., Li, Y., Wu, Y., Shi, K., Bing, L. and Hao, J. 2012. Wnt/beta-catenin signaling 
pathway upregulates c-myc expression to promote cell proliferation of P19 teratocarcinoma 
cells. Anatomical Record (Hoboken, N.J.: 2007), 295(12), pp.2104-2113.  
Zhu, W., Smith, J.W. and Huang, C.M. 2010. Mass spectrometry-based label-free quantitative 
proteomics. Journal of Biomedicine & Biotechnology, 2010pp.840518.  
Zimmermann, J., Brunner, C., Enculescu, M., Goegler, M., Ehrlicher, A., Kas, J. and Falcke, M. 
2012. Actin filament elasticity and retrograde flow shape the force-velocity relation of motile 
cells. Biophysical Journal, 102(2), pp.287-295.  
  
 
 
 
 323 
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